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 Intermittent fevers caused by Plasmodium parasites have been known for 
millennia, and have caused untold human suffering.  Today, millions of people are 
afflicted by malaria each year, and hundreds of thousands die.  Historically, the most 
successful synthetic antimalarial drug was chloroquine, as it was safe, inexpensive, and 
highly efficacious.  However, plasmodial resistance to chloroquine now greatly limits its 
utility.  Previously in our laboratories it has been shown that attachment of a “reversal 
agent moiety” to the side chain of chloroquine can result in the restoration of activity 
against chloroquine-resistant strains of P. falciparum malaria.  In the first part of the 
work presented here, a study has been made of the importance of the quinoline ring 
substitution pattern to the activity of such reversed chloroquines.  The compounds 
presented here include those bearing a substituent in the 2-, 5, 6-, 7-, and/or 8- position, 
and include those with chloro, bromo, iodo, fluoro, nitro, trifluoromethyl, methyl, and 
methoxy substituents.  For reversed chloroquines, 2-, 5-, and 8- substituents have been 
found to decrease in vitro antiplasmodial activity against P. falciparum relative to 7-
chloro substitution, whereas 6- and 7- substituted compunds with various substituents 
have in many cases similar activity to that of 7-chloro substituted compounds.  Little 
difference has been observed between 6- and 7- substitution, or between chlorine and a 
methyl group in position 6.  In most cases these effects on activity are directionally 
similar to those observed for chloroquine analogs without an attached reversal agent, but 




chloroquines are less affected by modifications to the quinoline ring system than is true 
for chloroquine analogs without an attached reversal agent. 
 The second portion of this work presents an asymmetrical bis-quinoline (PL241) 
that is highly active against P. falciparum malaria, with an IC50 of less than 0.1 nM for all 
strains tested.  Mechanistic studies have been performed in which the substitution 
patterns of the two quinoline rings of PL241 are modified in ways that indicate that either 
ring system is equally capable of participating in the antimalarial activity of these 
compounds.  The excellent in vitro antiplasmodial activity of PL241 makes this a 
compound of great interest for further development as a potential antimalarial drug. 
 In the third part of this work, a survey has been made of antimalarial treatments 
recommended in the European medical literature from the time of Pliny the Elder (active 
in the first century A.D.) through the advent of modern malaria chemotherapy in the early 
twentieth century.  In the fifteen primary sources utilized in this study, 251 distinct 
substances – primarily plants – were identified as having likely been used in the treatment 
of malaria.  Of the 38 substances that were described in three or more sources, at least 
fifteen have been examined by other workers for antiplasmodial activity; in many cases, 
they were found to have antiplasmodial activity in vitro or in vivo.  However, the 
majority of the phytotherapies for malaria identified in this project have not yet been 
tested against Plasmodium species, and may provide valuable leads in the search for new 























Let the fields and the gliding streams in the valleys delight me.   
Inglorious, let me court the rivers and forests.1 
                                                
1 Virgil: …rura mihi et rigui placeant in vallibus amnes, flumina amem silvasque 
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But who could revere enough the diligent research of the ancients? 
 




 Intermittent fevers caused by Plasmodium parasites have been known for 
millennia.  Examination of Egyptian mummies dating from periods as early as the 1400s 
B.C. has revealed Plasmodium parasites (Hawass, 2010; Lalremruata, 2013), and 
infection by Plasmodium is believed that to have afflicted mankind for far longer 
(Hoeppli, 1959; Hay, 2004; Tanabe, 2010; Prugnolle, 2011).  Although the causative 
agents and underlying physiological basis of malaria’s effects were only discovered in the 
19th and early 20th century (Gilles, 2002), the Ebers Papyrus (ca. 1550 B.C.) refers to 
fever with swollen spleen, and malaria symptoms are described in detail in The Yellow 
Emperor’s Classic of Internal Medicine (China, age unknown but certainly prior to 400 
B.C.; Veith, 1972), in the Atharvaveda (India, ca. 450 B.C.), and by the Greek and Latin 
authors (Hippocrates, ca. 400 B.C.; Celsus, 25 B.C. - 50 A.D.; Jones, 1909).  Today it is 
                                                





known that protozoa of the genus Plasmodium cause intermittent fevers, and the resulting 
disease is called malaria.  At least six Plasmodium species parasitize human beings, 
including P. falciparum, P. vivax, P. ovale, P. malariae, P. knowlesi (Strydom, 2014); 
recently, an infection by P. cynomologi has also been reported (Ta, 2014). Most malaria 
cases are caused by P. falciparum and P. vivax.  Although P. falciparum causes the most 
fatalities, P. vivax is also a severe problem (Baird, 2014; Quispe, 2014; Price, 2014).  In 
addition to loss of life, the impact of malaria upon the economic and social welfare of 
malaria-endemic nations can scarcely be underestimated (Jones, 1909; WHO, 2013).   
 Malaria infection is spread between human hosts by the bite of infected female 
mosquitoes of the genus Anopheles.  In the human host, the parasite initially resides in 
the liver, followed by a blood stage.  The classical symptom of untreated malaria is the 
febrile paroxysm, a dramatic series of chills followed by fever followed by afebrile 
periods, although not all victims experience this.  The length of time between paroxysms 
varies with the species and strain of malaria.  In the case of P. falciparum, vivax, and 
ovale, the cycle typically lasts 48 hours, while for P. malariae it typically lasts 72 hours 
(Warrell, 2002; Schlitzer, 2007; WHO Malaria Report 2013).  These are often referred to 
in the older literature as tertian and quartan fevers, with fits occurring on the first and 
third day (tertian) and on the first and fourth day (quartan; Hoeppli, 1959).  Comparison 
of genetic analysis of historical materials with historical medical records has provided 
additional confirmation that the terms tertian and quartan fever do indeed refer to malaria 
(Fornaciari, 2010).  If parasitemia is not completely cleared by drug therapy, 




persist in dormant form so that relapses continue to occur at intervals of months or years 
(Warrell, 2002; Schlitzer, 2007). 
 Malaria today is most prevalent in Africa, Southeast Asia, and South America, but 
was formerly common over an even larger range, including much of Europe, Russia, and 
North America (Taylor, 1945; Nuttall, Cobbet, and Strangeways-Pigg, 1901; Gilles, 
2002).  In 2012, the World Health Organization (WHO) estimates that there were 207 
million cases, of which an estimated 627,000 were fatal (WHO, 2013).  However, the 
number of cases and deaths may be higher than estimated by the WHO (Cibulskis, 2011). 
 Our primary defenses against malaria include control of its vector, the Anopheles 
mosquito, and chemotherapy that targets the parasite directly.  Work is also underway on 
malaria vaccines (Thera, 2012).  Antimalarial drugs are used not only to treat cases of 
malaria (chemotherapy) but also to prevent them (chemoprophylaxis).  Drug resistance is 
a severe problem, and there currently exists no class of antimalarial drugs for which 
resistance has not been reported.  For this reason, the only drug therapies currently 
recommended by the WHO in most malaria-endemic regions are combinations of two 
drugs from different classes (WHO, 2013). 
 
 
1.2:  The early history of quinoline antimalarials: How chloroquine came to be 
 
 In China, treatment of intermittent fevers with quinghao (sweet wormwood, 




but it is often stated that prior to the discovery of cinchona bark in the 16th century, the 
West had no really effective cure.  Cinchona bark comes from a group of species of 
evergreen tree of the genus Cinchona.  The trees are native to the western side of South 
America and grow there at high altitudes, 5,000-8,000 feet above sea level on average 
(Flückiger and Hanbury, 1874; Geerlings, 1999).  Different species and varieties contain 
widely varying amounts of alkaloids.  The most valued species was formerly Cinchona 
ledgeriana, also known as Cinchona officinalis 'Ledgeriana', which contains up to 15% 
quinine in its bark (Taylor, 1945, Geerlings, 1999).  Although the native people may not 
have used cinchona bark to treat malaria (and in fact it is generally thought that malaria 
did not exist in the New World before the arrival of the Spaniards, although this has been 
debated (Guerra, 1977; Yalcindag 2012; de Calda, 2005)), it is said that they were aware 
that the bark of the cinchona tree had medicinal properties (Greenwood, 1992).  Gaspar 
Caldera de Heredia wrote in 1663 that the Spanish Jesuit priests had observed miners in 
the province of Quito using an infusion of the bark in water to treat chills resulting from 
low temperatures (Guerra, 1977; Jarcho, 1993).  The Jesuits are said to have discovered 
the antimalarial efficacy of cinchona bark after using it to relieve the chills of intermittent 
fevers.  The bark was soon imported to Europe.  Although the new treatment did not meet 
at once with universal acceptance, it gradually became the accepted remedy for 
intermittent fevers (Guerra, 1977; Jarcho, 1993).  For this and other purposes, huge 
quantities were exported to Europe from the South American colonies and later from the 
independent South American countries, to the extent that the trees were almost eliminated 




cultivated successfully outside of their native habitat on a large scale by the British in 
India and by the Dutch in the East Indies.   By the early twentieth century, the Dutch 
plantations in Java produced the bulk of the world's cinchona bark (Flückiger and 
Hanbury, 1874; Taylor, 1945; Greenwood, 1992). 
 Of the constituents found in cinchona bark, those to which antimalarial activity is 
usually ascribed are the crystallizable alkaloids occurring in the largest quantity - quinine, 

















Figure 1: Cinchona alkaloids.
 
Figure 1: Cinchona alkaloids 
 
Of these very closely related compounds, quinine has the best ratio of antimalarial 
activity to toxicity (quinidine is more active than quinine but may also be more dangerous 
to administer; Chopra, 1938; Wesche, 1990; Warhurst, 2003; White, 2007).  Evidence 
has also been found that the four alkaloids above act synergistically, and that there may 




Druilhe,1988; Merkus, 1988; Wesche, 1990; Rasoanaivo, 2011).  Quinine was isolated 
from cinchona bark in 1820 by Pierre-Joseph Pelletier and Joseph Bienaimé Caventou 
(although possibly also earlier), and its chemical formula was determined by Adolph 
Strecker in 1854 (Pelletier and Caventou, 1820; Strecker, 1854; Kaufman, 2005).  The 
structure was elucidated piecewise by Zdenko Hans Skraup (1879), W. Königs (1894), 
and Heinrich Hörlein and Paul Rabe (1907) (see Figure 2; Schulemann, 1932):   
 











Figure 2: Elucidation of quinine's structure (adapted from Schulemann, 1932) 
 
Administration of purified quinine allowed for better dosage control (since amounts of 
alkaloids vary in crude bark) and also may have reduced side effects (nausea, blurred 
vision, and depression of the heart were reportedly caused to a greater extent by 
cinchonine and quinidine than by quinine (Chopra, 1938)).  The bark of C. ledgeriana 
contains mostly quinine, while another species, C. succirubra, contains relatively more 
quinidine, cinchonin, and cinchonidine, and for a long time continued to be grown in 
order to provide supplies of these compounds (Taylor, 1945).  Although total synthesis of 
quinine has been achieved (Rabe and Kindler, 1918, Woodward and Doering, 1944 and 
1945 (see also Smith and Williams, 2008); stereoselective synthesis by Stork, 2001), a 




has never been found. 
 Despite quinine's value, it had disadvantages.  Firstly, the supply of a natural 
product - especially one that could grow only under a fairly narrow range of conditions - 
might be threatened (as was feared with the over harvesting of cinchona trees in South 
America, and as was experienced by the Germans during World War I and by the Allies 
during World War II).  Secondly, because of the Dutch monopoly, it was desirable for 
other powers to find a replacement for quinine for economic reasons (Greenwood, 1992 
and 1995; Slater, 2009). Thirdly, to be really effective, quinine needed be taken several 
times per day, and was not without side effects (nausea, tinnitus, reduction in hearing 
ability, vertigo, and vision disturbances; Goodman and Gilman, 1985; Mühlens, 1937).  
The development of synthetic organic chemistry led to hope of a synthetic substitute for 
natural quinine.  Synthetic medicaments effective in lowering fevers had already been 
discovered by the end of the 19th century - notably, the analgesics and antipyretics, 
including Antifebrin (1886) and Phenacetin (1887; Hückel, 1962).  However, these were 
not effective treatments for malaria (Guttmann and Ehrlich, 1891). 
 The first encouraging result came in 1891 with the histological stain methylene 






Figure 3: Methylene blue
 





Histological stains were of interest as possible medicines both because of their known 
bacteriocidal activity and because of their selective and specific affinity to certain cell 
groups and parts of cells (Guttmann and Ehrlich, 1891; Mietzsch, 1951).  Methylene blue 
was known to have an affinity for the cells of Plasmodium and was already used in 
malaria diagnosis.  Paul Ehrlich and Paul Guttmann used methylene blue to treat two 
malaria patients with apparent success and no serious side effects (Guttmann and Ehrlich, 
1891).  In subsequent trials by other researchers, the administration of methylene blue 
often failed to give the same encouraging results and in at least one study was invariably 
attended by unpleasant side effects (severe stomach pain and vomiting); meanwhile other 
researchers confirmed Guttmann and Ehrlich's findings and found no serious side effects 
(Lava, 1891; Mya, 1892; and Thayer, 1892, results summarized in Supplement to the 
British Medical Journal, 1891 and 1892).  The difference in side effects observed 
possibly could have been due to the purity of the dye used, in light of the fact that 
Guttmann and Ehrlich specify the use of chemically pure methylene blue, whereas 
historically the dye has often been used for staining applications at relatively low purity.  
Methylene blue was sometimes recommended for treatment of malaria during the early 
20th century (Potter's Therapeutics, Materia Medica, and Pharmacy, 1917, contains the 
following recommendation:  "Methylene blue, next to quinine, has been considered as the 
most valuable drug.  It is given in 2-grain doses every 4 hours”).  More recently, the 
clinical efficacy of methylene blue against malaria has been reëxamined (Akoachere, 
2005; Meissner, 2006). 




1924/5), quinacrine (Atebrin, Atabrine, Mepacrine, 1932), chloroquine (Resochin, 1934), 
and sontoquine (Sontochin, Nivaquine, 1936), were all developed between the World 
Wars by researchers at Farbenfabrik Bayer, Elberfeld (then part of I.G. Farbenindustrie).  













Chloroquine (Resochin) Sontoquine (Sontochin, Nivaquine)
Figure 4: Synthetic antimalarials from the Bayer research team at Elberfeld.
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The research team at Elberfeld embarked on structure activity relationship studies having 
first quinine and then methylene blue as starting points, with the goal of finding a 
synthetic antimalarial with an improved ratio of activity to toxicity.  Advances in 
techniques of animal testing by Elberfeld's Wilhelm Roehl - a former student of Paul 
Ehrlich - allowed the reliable screening of thousands of candidate compounds, and 
techniques developed by his successor, Walter Kikuth, together with Lilly Mudrow-




asexual stages of the parasite (Kikuth, 1942; Andersag, 1948; Slater, 2009).  Compounds 
successful in animal models (the Plasmodium relictum infection of canaries) were then 
tested against human infection.  Germany had no colonies at that time and no body of 
soldiers and staff in malaria endemic regions, and domestic cases of malaria were by then 
rare.  Bayer's human testing was therefore contracted to Franz Sioli at the Düsseldorf-
Grafenberg psychiatric hospital, who was able to administer the drug candidates to 
neurosyphilis patients during the normal course of malaria therapy (Slater, 2009).3 
 The first of the successes to emerge from the Elberfeld malaria project was 
pamaquine (Figure 4), synthesized in 1924 (Schulemann, 1932, Andersag, 1948).  The 
drug was the first successful application of a principle called by its developers "basic 
alkylation" (basische Alkylierung; Mauss and Mietzsch, 1933; Schönhöfer, 1965), that 
would then be applied successfully in quinacrine, chloroquine, and sontoquine. Extension 
of the dimethylamino substituent of methylene blue into a basic side chain - synthesized 
by Fritz Schönhöfer and August Wingler - had led to improved activity, but had also 
increased toxicity.  Attachment of a basic side chain to the quinoline nucleus of quinine 
was next attempted by Fritz Schönhöfer.  It was initially planned to put the aminoalkyl 
                                                
3 Malaria therapy, developed by the Austrian doctor Julius Wagner Ritter von Jauregg, was the 
only known method of curing late stage syphilis at the time.  The patient was infected with 
malaria and the high fever was allowed to kill the trypanosomes (although this mechanism of 
action has been disputed); the patient was then cured of their malaria with quinine.  This 
treatment for syphilis was widely practiced in Europe and the United States, and Wagner Ritter 
von Jauregg won the 1927 Nobel Prize for his discovery.  In addition to saving thousands of lives, 
malaria therapy provided scientists in many countries with an invaluable opportunity to test new 
medicines for malaria (Covell & Nicol, 1951; Chernin, 1984; Freitas, 2014).  Interestingly, the 
induction of a high body temperature for the treatment for syphilis, together with guaiacum 
therapy, was used at least as early as 1519 (Forrester, 2005), and the disappearance of late stage 
syphilis after incidental infection with quartan fever was noted by Jean Fernel in his great work of 




group at the 6-position (replacing the methoxy group of quinine; see Figure 5 for the 
numbering system of quinoline compounds); however, when this compound proved too 
difficult to purify, Schönhöfer synthesized the 8-amino derivative instead (which could 









Figure 5: Quinoline ring numbering system
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The resulting compound had an activity far superior to quinine in bird malaria.  A 6-
methoxy substituent was then introduced by the project leader, Werner Schulemann, by 
analogy to quinine; this, too led to a jump in activity, yet the results against human 
malaria were disappointing (Schönhöfer, 1965).  Further variation of the basic side chain 
- to that which would later be used in chloroquine - led at last to Pamaquine (then called 






















Figure 6: Development of pamaquine (Plasmochin).
 





It was moreover reported that the drug was active against the gametocyte stage of 
Plasmodium (unlike other known antimalarials), and therefore offered hope that perhaps 
malaria could not only be treated, but eradicated by blocking transmission (Schulemann, 
1932; Kikuth, 1942).  The new compound was also active against the liver stage of P. 
vivax malaria and therefore offered a permanent cure to sufferers from relapsing malaria 
(Schulemann, 1932; Burrows, 2011).  Unfortunately, it had significant toxic side effects, 
rendering it less than ideal for long-term administration as a prophylactic.  Although it is 
often implied today that pamaquine never came into common use due to its toxicity, this 
is not entirely true; for instance, in 1942 the drug was manufactured by ICI in Great 
Britain in amounts "sufficient for 32 million tablets" (Greenwood, 1995, Slater, 2009).   
Researchers at Bayer appreciated that the toxicity of pamaquine was a drawback and later 
launched Certuna (also known as Cilional), a related compound discovered by 




Figure 7: Certuna (Cilional).
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Certuna was less toxic, but also less effective than Plasmochin (Chopra, 1938; Slater, 
2009), and was never a great success.  Plasmochin and Certuna remained the only drugs 




toxic des-diethyl pamaquine derivative, Primaquine, following World War II (Figure 8; 
Slater, 2009, Burrows, 2011).  Primaquine was synthesized by Robert C. Elderfield and 






Figure 8: Primaquine. 
 
 In addition to quinolines, acridines - their close chemical relatives - were also of 
interest as potential antimalarials.  Their development would ultimately lead to the 
development of chloroquine, a drug that would save more lives than any other synthetic 
antimalarial.  Acridine compounds with antibacterial properties were already known.  At 
Elberfeld, Fritz Mietzsch and Hans Mauss carried over the principle of basic alkylation to 
the acridine nucleus (along with a variety of other heterocycles), and discovered 
quinacrine (then called Atebrin or Atabrine, also called mepacrine or Italchina).  
Quinacrine shared with quinine the point of attachment of its alkylamine residue, and 
shared with pamaquine a methoxy group para to the ring nitrogen (Mauss and Mietzsch, 
1933) as well as the identical aminoalkylamino side chain.  In the third fused ring, meta 




Figure 9: Quinacrine (Atebrin, Atabrine, Mepacrine).
 




   
 That introduction of a chlorine atom might lead to active compounds was 
discovered accidentally.  During synthetic work on 8-aminoquinolines, Schönhöfer had 
used tin (II) hydrochloride reduction to reduce a 6-alkyl-8-nitroquinoline, unaware that 
this had sometimes been found to introduce a chlorine atom into the quinoline ring 
system.  The resulting compound had excellent activity, but turned out to contain 
chlorine.  This inspired Mauss and Mietzsch to introduce halogens into their acridine 
compounds (Schönhöfer, 1965).   
 Quinacrine was highly successful as an antimalarial, being more active than 
quinine and having fewer side effects.  Its tolerability made it suitable for prophylactic 
use, and it was used extensively for this purpose, although long term use tended to turn 
the skin yellow (Mietzsch, 1933, Kikuth, 1942, Greenwood, 1995, Slater, 2009).  It was 
manufactured in the United States as well as Germany (having been jointly licensed to 
Bayer and to its American partner, the Winthrop Chemical Company), although in the 
United States there were reports of quinacrine-related psychosis, similar to that later 
observed for mefloquine (Slater, 2009).  During the Second World War, it was 
manufactured by both sides on a large scale (Greenwood, 1995). 
 During quinacrine’s development, it was observed that the presence or absence of 
a 7-chloro substituent had greater influence upon antimalarial activity than did that of the 
methoxy group (Andersag, 1948).  If one imagines removing the 6-methoxy containing 
ring from the structure of quinacrine, one obtains a quinoline compound with the 











Figure 10: Development of chloroquine (Resochin) from quinacrine (Atebrin).
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Thus, by analogy to quinacrine, quinoline compounds with the aminoalkyl substituent 
opposite the ring nitrogen were made (Andersag and Breitner, 1956).  Initially however, 
these 4-aminoquinoline compounds could not be made without a substituent in the 2-
position, and such compounds were inactive against malaria.  However, the clever 
adaptation of a newly patented synthetic route to kynurenic acid (2-carboxy-4-quinoline, 
see Figure 11 below) allowed Hans Andersag to make 4-aminoquinolines with the 2-
















































Figure 11: Hans Andersag's synthetic route to 2-unsubstituted 4-aminoquinolines. 
 
Among these he made the 7-chloro-substituted chloroquine (then called Resochin), and 
together with Stefan Breitner and Heinrich Jung he made sontoquine shortly thereafter 
(Sontochin in German, later also called Nivaquine, Figure 12; Andersag, 1948, Mietzsch, 




Figure 12: Sontoquine (Sontochin, Nivaquine).
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Yet chloroquine was abandoned by Bayer in favor of sontoquine, either because Roehl's 
tests found toxicity in animal subjects, or because human toxicity was observed by Sioli 
(Slater, 2009; it has been suggested that since the human test subjects were in the late 
stages of syphilis, it is possible that unusual physical symptoms would occur that might 




However, chloroquine would soon be rediscovered. 
 In 1939, the National Research Council of the United States launched an 
antimalarial research initiative that by the end of the Second World War had grown into a 
massive screening and development program involving industry, government, and 
academic research labs alike.  The program collaborated with researchers in Britain and 
Australia, and screened over 14,000 compounds against malaria, initially identifying 
quinacrine as the best compound but later fixing upon chloroquine (Wiselogle, 1946; 
Coatney, 1952; Greenwood, 1992; Slater, 2004 and 2009).  Both chloroquine and 
sontoquine had been patented in the United States by Winthrop, but they were not 
included in the screening program until sontoquine was found in the possession of troops 
captured at Tunis in 1943.  Field trials, conducted by the Australian medical officer Neil 
Hamilton Fairley, demonstrated that chloroquine was even more effective than 
sontoquine (Greenwood, 1995; Slater, 2009).  Chloroquine entered clinical use in 1947.  
Because of its efficacy and lack of toxicity - even when administered to pregnant women 
and children - chloroquine was the standard antimalarial therapy for decades (Schlitzer, 
2007; Slater, 2009). 
 
1.3: Chloroquine resistance 
 
 There is substantial evidence that chloroquine acts by interference with the heme 
detoxification mechanism of Plasmodium species (Sullivan, 1996; Egan, 2005; Martin, 




digestion of hemoglobin (Kirk, 2014).  During the blood stage of P. falciparum malaria, 
the concentration of parasites in the blood has been estimated to be as high as millions of 
organisms per milliliter of blood (Dondorp, 2005, Pisciotta, 2007), which can consume 
60-80% of the body’s hemoglobin (Francis, 1997).  Although the parasite utilizes the 
amino acid portion of hemoglobin as a food source, it does not utilize the central oxygen-
binding porphyrin of hemoglobin, heme (Slater, 1991).  In the acidic, aqueous 
environment of the food vacuole, pairs of heme molecules link together into heme dimers 
in which the propionate side chain of one molecule coördinates to the iron atom of the 
other (Slater, 1991, Egan, 2008).  Both free heme and heme dimers are toxic to the 
parasite and if allowed to accumulate, would lead to its death by oxidative or osmotic 
stress (Francis, 1997, Pisciotta, 2007).  To avoid this, the parasite is able to initiate the 
crystallization of the heme dimers into an aggregated structure, hemozoin, which is 
insoluble in the digestive vacuole and is thus rendered non-toxic (Fitch, 1987, Slater, 
1991).  The structure of hemozoin is thought to be a large crystal in which the heme 
dimers associate by hydrogen bonding (Hänscheid, 2007, Egan, 2008).  The process by 
which hemozoin formation is initiated, as well as the exact location of its formation, are a 
matter of debate, but the process may occur at the surface of lipid droplets within the 
acidic, aqueous environment of the digestive vacuole (Jackson, 2004, Oliveira, 2005 (for 
other protozoal diseases), 2007, Egan, 2007; Pisciotta, 2007).  Once heme has 
crystallized, it remains within the digestive vacuole, where it may be stored within lipid 
droplets (Pisciotta, 2007).  Microscopy of malaria parasites reveals large, dark masses of 




the blood of patients with fever has been used since the nineteenth century to diagnose 
malaria (Sullivan, 2002).  Malaria pigment accumulates in the brain, spleen, and blood 
vessels of malaria victims and can be observed upon autopsy without a microscope – the 
earliest existing written description of malaria pigment dates to 1771, although its 
presence was not connected with malaria until 1849 (Sullivan, 2002, Hänscheid, 2007).  
 When chloroquine is present in the bloodstream, it passively diffuses into the red 
blood corpuscle, into the parasite, and thence into the parasite’s digestive vacuole (Kirk, 
2013).  Chloroquine’s accumulation in the digestive vacuole has been estimated as one 
thousand to several thousand times greater than the concentration in uninfected 
erythrocytes (Foley, 1997, Kelly, 2002, Sullivan, 2002).  Once inside the vacuole, the 
quinoline ring system of chloroquine is thought to bind to the heme dimer, preventing the 
formation of hemozoin (Dorn, 1998; Roepe, 2002).  The continued presence and 
accumulation of drug-bound heme dimers then leads to the parasite's death, possibly by 
oxidative and osmotic stress (Sullivan, 1996; Lakshmanan, 2005; Egan, 2005; Martin, 







Figure 13: Putative mechanism of chloroquine. 
 
 
 Inhibition of hemozoin formation is not the only possible mechanism of action for 
chloroquine, but it is the mechanism for which there is the most evidence.  Other 
possibilities that have been explored include DNA intercalation, interference with 
polyamine biosynthesis, or interference with enzyme activity due to a change in the pH of 
the digestive vacuole (Hahn, 1966, Bolte, 1979, Yayon, 1985, Krogstad, 1987, 
Schlesinger, 1988).  It is quite possible that chloroquine may act by more than one 
pathway.  In this work, however, it has been assumed that chloroquine’s primary mode of 




 The heavy and widespread use of chloroquine and other antimalarials, as well as 
the increased size, density, and mobility of the world's population, gave rise to concern 
early on that drug resistant strains of malaria would emerge.  By the end of the 1940s, 
resistance to the antimalarial proguanil (Figure 14), pamaquine, and even quinine had 
been artificially induced in the laboratory, and proguanil resistance had been observed in 












Figure 14: Proguanil. 
 
In the 1950s, chloroquine resistant strains of P. falciparum were reported in Southeast 
Asia and South America (Young, 1961; Rathore, 2005; Packard, 2014).  Since that time, 
resistance has become widespread (WHO, 2013).  Chloroquine resistant parasites exhibit 
reduced accumulation of chloroquine within the digestive vacuole (Krogstad, 1987).  
Chloroquine resistance in P. falciparum has been linked to one or more mutations 
(importantly, K76T) in the transporter PfCRT (Plasmodium falciparum chloroquine 
resistance transporter), present in the membrane of the parasite’s digestive vacuole.  It is 
thought that this mutated transporter is able to export chloroquine out of the vacuole, thus 
allowing the heme detoxification process to proceed normally (Fidock, 1996; 
Lakshmanan, 2005; Martin, 2009; Roepe, 2011).  Additional mutations in other 
transporters, such as PfMDR1 (Plasmodium falciparum Multidrug Resistance 




have been linked with chloroquine resistance in some strains of chloroquine resistant 
parasites (Kirk, 2013).  
 
1.4: A strategy to overcome chloroquine resistance 
  
  An attractive strategy to find new antimalarial compounds is the modification of 
existing drugs to which resistance exists in a way that restores their activity against drug 
resistant strains.  Among other approaches, this can be done by the attachment of a 
reversal agent.  Reversal agents are drugs that are able to restore the activity of a drug to 
which resistance exists, when co-administered.  When given together with chloroquine, 
the calcium channel blocker Verapamil (normally used to treat high blood pressure, 
angina, and cardiac arrhythmia) and the tricyclic antidepressant Desipramine (among 
others) have been observed to have this effect (Figure 15; Martin, 1987; Krogstad, 1987; 











Figure 15: Two known reversal agents for chloroquine resistance in P. falciparum malaria. 
 
 
Reversal agents appear to work by reducing efflux of chloroquine from the food vacuole 
in some manner, perhaps by blocking the chloroquine resistance transporter, PfCRT 
(Bray, 2005; Martin, 2009).  However, if such a reversal agent were to be co-




which has therapeutic activity of its own, might have undesirable effects at the 
concentration needed for it to accumulate in the parasite's digestive vacuole.  In Dr. 
Peyton’s laboratory, it has previously been shown that the combination of a chloroquine-
like moiety with a reversal agent-like moiety in a single molecule – which was named a 
"reversed chloroquine" (RCQ) compound – may be an effective approach through the 
initial compound PL01 (Figure 16), which links a chloroquine-like structure with that of 













IC50 = 2.9 nMD6, 5.3 nMDd2
 
 
Figure 16: The reversed chloroquine-type compound PL01 combined features of chloroquine and 
imipramine.  In vitro antiplasmodial activity is shown as IC50, the concentration required to inhibit 
plasmodial growth by 50%. 
 
 
The hybrid compound had roughly equal activity in vitro against both chloroquine 
sensitive and chloroquine resistant strains of P. falciparum,4 and its activity was not at all 
                                                
4 Antiplasmodial activity is given herein as IC50, the concentration required to inhibit plasmodial 
growth by 50%.  The strains of P. falciparum used in this work for in vitro testing were D6, a 
chloroquine sensitive strain, and Dd2 and 7G8, two chloroquine resistant strains originally 
isolated in southeast Asia and Brazil, respectively.  In quoting results from other research groups, 
when IC50 values are given for compound activity against other P. falciparum strains, it is noted 




diminished relative to that of chloroquine (Burgess, 2006).  A structure-activity 
relationship study was then performed in which the reversal agent moiety attached to the 
4-amino side chain of the 7-chloroquinoline nucleus was varied (see Figure 17 for 
representative compounds; Andrews, 2006, Burgess, 2008, Burgess, 2010, Andrews, 





Figure 17: Representative compounds from the initial structure-activity relationship study during which 
reversed chloroquine-type compounds were developed. 
 
 
 We believe that reversed chloroquine-type compounds act against P. falciparum 
by the same mechanism as chloroquine (i.e. by inhibition of the detoxification of heme by 
conversion to hemozoin).  This is supported by in vitro studies in which it has been 
shown that 7-substituted reversed-chloroquines are able to bind heme, to inhibit the 
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parasites in vitro (Burgess, 2010).  However, it is possible that this may not be the correct 
or only mechanism of these compounds.    
During this work it was assumed initially that changes in substitution pattern of 
the quinoline ring moiety of the reversed chloroquines would only lead to a decrease in 
activity relative to the 4-amino-7-chloro substitution pattern seen in chloroquine, since it 
has previously been shown for other 4-aminoquinoline antimalarials that the 7-chloro 
substitution pattern confers optimal activity (see below).  However, as part of a 
mechanistic investigation of the reversed chloroquine analogue PL06, the des-chloro 























IC50 = 90 nMD6, >250 nMDd2IC50 = 6.9 nMD6, 102 nMDd2  
 
Figure 18: PL06, chloroquine, and their des-chloro analogues 
 
Contrary to what was expected based on the known low activity of des-chloro 
chloroquine (PL127, Figure 18), this compound had excellent antiplasmodial activity 




parasites.  This indicated that modification of the quinoline ring substitution pattern of 
reversed chloroquine-type compounds might, in fact, be a useful line of inquiry (Burgess, 
2010). 
 
1.5: The effect of the quinoline ring system substitution patterns on the antimalarial 
activity of chloroquine-like compounds 
 
 During the original development of chloroquine and sontoquine during the 1930s 
and 1940s by researchers at Farbenfabrik Bayer, Elberfeld,  4-aminoquinolines with a 
large number of different quinoline ring substitution patterns were tested, but much of the 
data on the relative antimalarial efficacy of these compounds was never made public.  
The following information may be gleaned from the patent literature and various 
publications: 
 
1) From the patent literature, 4-aminoquinolines may have been made and tested with 
at least the following substitution patterns (see also Figure 19): 
 
-  2-methyl-6-methoxy (Schulemann, 1929; and Schulemann, 1930) 
-  2-methyl (Ibid) 
-  7-halo, alkyl, hydroxyl, thiol, alkoxy, alkylmercapto, cyano, thiocyano, amino, 
alkylamino, and trifluoromethyl (Andersag, 1939) 
-  In the 3 position of the above 7-substituted quinolines, alkyl, aryl, aralkyl (Ibid) 
-  In the 2 position of the above 7- substituted quinolines, an unknown alkyl 
substituent, probably methyl (Ibid) 
-  7-chloroquinolines with additional substituents from the above in one or more 












R2: H or CH3
R3: H or alkyl, aryl or aralkyl
R5: H or Cl, Br, I, alkyl, OH, SH, OR, SR, CN, SCN, NH2, NHR or NR2, CF3
R6: H or Cl, Br, I, OR
R7: H or Cl, Br, I, alkyl, OH, SH, OR, SR, CN, SCN, NH2, NHR or NR2, CF3, benzyl
Figure 19: Some substituents of 4-aminoquinolines used by the Bayer research team at Elberfeld
 




2) Of these, the most effective compounds contained a halogen atom in the 7-
position.  The halogens used included fluorine, chlorine, bromine, and iodine.  
Amongst chlorine, bromine, and iodine, roughly equal antimalarial activity was 
observed, whereas substitution with fluorine decreased activity.  Many other 7-
substituted compounds were also active. 
 
3) The presence of a methyl group in the 3-position of 7-haloquinolines apparently 
did not reduce the efficacy of these compounds.  Larger 3-alkyl groups resulted in 
reduced efficacy.  For other 7-substituted compounds, 3-substitution did not always 
result in reduced efficacy and sometimes increased efficacy. 
 
4) An alkyl group in the 2-position resulted in a compound with lowered activity 
regardless of any other substituents. 
 
 In monographs published by Frederick Y. Wiselogle (1946) and G. Robert 
Coatney (1952) on the results of the American-British-Australian wartime screening 




Coatney also states that the activity of compounds with a relatively short 
aminoalkylamino chain is more susceptible to variation upon modification of the 
quinoline ring system substituents than is the activity of compounds with a longer chain. 
 The advent of chloroquine resistance has inspired research on the effect of 
varying quinoline ring substitution of 4-aminoquinolines upon activity against 
chloroquine resistant strains (De, 1996; De, 1998; Vippagunta, 1999; Bhattacharjee, 
2001; Stocks, 2002; Kaschula, 2002; Madrid, 2005; Hocart, 2011; Pou, 2012; Nsumiwa, 
2013).  The results of this research can be summarized as follows (see also Figure 20, 























Figure 20: Effect of quinoline ring substitution pattern on chloroquine analogs 
without an attached reversal agent 
 
As for the position of substituents, 7-substitution is optimal whereas moving the 




Vippagunta, 1999; Hocart, 2011; Pou, 2012).  Substitution in the 2- or 8-position 
invariably gives poor efficacy (De, 1996; Madrid, 2005; Hocart, 2011).  This is also true 
for 5- substitution, but to a lesser extent (Madrid, 2005).  With only hydrogen, very poor 
efficacy is observed (De, 1996; Vippagunta, 1999; Hocart, 2011).  As to the nature of the 
substituent, among the halogens some workers have found that chlorine is optimal, while 
other workers have found that there is little difference between iodine, bromine, and 
chlorine (De, 1998; Vippagunta, 1999; Kaschula, 2002; Hocart, 2011).  Fluorine gives 
lowered efficacy (De, 1998; Kaschula, 2002; Pou, 2012).  Electron-donating groups 
(amino, hydroxy, methoxy) in the 7-position generally reduce efficacy, often 
dramatically, and a strong electron-withdrawing group (nitro or trifluoromethyl) 
frequently reduces efficacy as well.  In the case of the 7-trifluoromethyl group, the effect 
is not as dramatic and there are notable exceptions (De, 1998; Vippagunta, 1999; Stocks, 
2002; Kaschula, 2002; Madrid, 2005; Hocart, 2011; Pou, 2012).  Finally, there is some 
evidence for resistance reversal relative to chloroquine in the case of 7-iodo substitution, 
7-trifluoromethyl substitution, 7-nitro substitution, or simultaneous 3-methyl and 7-
chloro substitution (the substitution pattern of sontoquine, see Figure 12; De, 1998; 
Vippagunta, 1999; Stocks, 2002; Pou, 2012).  Additionally, there is evidence that a bulky 
substituent in position 7 (phenoxy, Madrid, 2005) or in position 3 (trifluoromethoxy 
phenyl, Pou, 2012) may enhance activity against resistant parasites. 
 
 The research described above concerns chloroquine analogues without an 




with reversal agent attached may be affected differently by changes to the quinoline ring 
system substitution pattern.  Particularly in light of the results described above for 
resistant parasites, a study of the effects of quinoline ring substitution pattern on the 







Quinoline Ring-Modified Analogues of Reversed Chloroquine-type Compounds 
 
 In the present work, a study has been made of the effect of the quinoline ring 
substititution pattern upon the activity of chloroquine analogs with a reversal agent 
attached.  The 53 compounds synthesized in this work include those bearing a substituent 
in the 2-, 5-, 6-, 7-, or 8- position, as well as some disubstituted compounds, and include 
those with chloro, bromo, iodo, fluoro, nitro-, trifluoromethyl, methyl, and methoxy 
substituents, in addition to unsubstituted compounds (see Appendix B, Table B1 for 
structures). 
 In vitro testing of the new compounds has revealed a wide range of activity 
against P. falciparum malaria.  The bar graph in Figure 21, below, shows the in vitro 
antiplasmodial activities of a selection of the compounds tested against two strains of P. 
falciparum (D6, a chloroquine sensitive strain, and Dd2, a chloroquine resistant strain).  
As above, antiplasmodial activity is given as IC50, the concentration required to inhibit 
plasmodial growth by 50%.  For comparison, chloroquine (CQ, far left) is also included.  
For methods used to obtain these results, see Experimental Methods, Chapter 5.  For 
antiplasmodial activities of all ring-modified reversed chloroquine compounds made in 





Figure 21: In vitro antiplasmodial activities of a selection of the compounds in the present work against 
chloroquine sensitive and chloroquine resistant strains of Plasmodium falciparum.  Chloroquine (CQ) is 
shown at the far left. 
 
Some of the study compounds performed at least as well as chloroquine, and as well as 
the original 7-chloro reversed chloroquine-type compounds, while others had greatly 
diminished activity (see Figure 21, and Figure 22, below).  The following is a summary 






2.1.1: Effect of a substituent in the 2-, 5-, or 8- position 
 
 Compounds with a predominantly electron-withdrawing substituent in the 2- or 8- 
position (either chlorine or a trifluoromethyl group, see PL302 and PL149, figure 22, 
below, and others in Table B1, Appendix B) had little activity in the IC50 range tested, in 
accord with the findings described above for chloroquine analogues without an attached 
reversal agent (Chapter 1, section 1.5).  It was not clear however whether this was due to 
the lack of a substituent in the 7- position, or to the presence of a substituent in the 2- or 
8- position as such.  Therefore, compounds were synthesized with 2,7- and 7,8- 
disubstitution (PL398 and PL305). These were also found to have little activity, and so it 
seems that it might be the presence of the substituent in these positions that is responsible 
for the decrease in activity for 2- and 8- substituted compounds relative to those 



















IC50 > 250 nMD6, >250 nMDd2 IC50 108 nMD6, 491 nMDd2
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Since only electron-withdrawing substituents were tested initially, it was not 
known whether the trend of reduced activity for 2- and 8- substituted compounds would 
also be observed for compounds with an electron-donating group in the 2- or 8- position.  
Therefore, an 8-methoxy substituted compound (PL390) and two 8-methyl substituted 
compounds (PL393 and PL394) were synthesized and tested.  Two of these (PL390 and 
393) proved to have equally low activity when compared to their analogue containing an 
electron-withdrawing group (PL284), while a third molecule with a larger reversal agent 
moiety (PL394) had somewhat improved activity, although still far lower than its 7-
chloro analogue, PL271 (see Figure 23, below and Table B1, Appendix B).  Thus, based 
on this limited sample, the reduction of activity observed with electron-withdrawing 2- 
and 8- groups seems to extend to electron-donating groups as well, but perhaps to a lesser 











IC50 350 nMD6, 1830 nMDd2
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A 7-chloro-2-methyl substituted compound was also tested (PL399).  It proved to 
have much lower activity than that of its 7-chloro-substituted analogue (PL106), but its 
activity was much increased relative to that of the 7-chloro-2-trifluoromethyl- substituted 
analogue, PL398 (Figure 24, below, and Table B1, Appendix B).  For chloroquine 
analogues without an attached reversal agent, a 2-methyl substituent in addition to a 7-
chloro substituent is also known to lower activity (Andersag, 1948; Wiselogle, 1948; 






Cl PL 106 
(Gunsaru, 2010)












IC50 = 660 nMD6, 540 nMDd2  
 
Figure 24: In a series of 7-chloro substituted compounds, an added 2-methyl substituent decreased activity, 
but to a smaller extent than an added 2-trifluoromethyl substituent. 
 
It also was thought desirable to produce 5-substituted compounds for study.  
However, a synthetic challenge was presented by the production of a 4-aminoquinoline 
compound with a substituent in position 5 alone.  In the course of synthesis of the 7-
substituted 4-chloroquinolines needed to produce the compounds under study, a small 
quantity of the 5-substituted regioisomer was usually (but not always) produced during 



























Figure 25: The cyclization step of the Gould Jacobs reaction, a representative quinoline ring-forming 
reaction. 
 
However, the isolation of a sufficient quantity of pure 5-regioisomer – which was nearly 
always produced in a much smaller quantity than the 7-regioisomer – proved difficult 
upon being attempted with several compounds, such as 5- and 7-bromo-4-
chloroquinoline and 5- and 7-fluoro-4-chloroquinoline, since neither crystallization nor 
chromatography provided the 5-regioisomer in pure form (although both methods were 
effective in producing the pure 7-regioisomer; see Appendix A).  Two 5,7-dichloro 
substituted compounds (PL367 and 379, see Table B1, Appendix B, and Figure 26, 
below) were therefore produced under the presumption that the results obtained would 
give some indication of the impact on activity of the 5- substituent when compared to the 
compound with the 7-chloro substituent alone.  When tested in vitro, these compounds 
proved to have somewhat diminished activity compared to their 7-chloro analogues.  
However, the reduction in activity was not nearly as strong as was observed for the 7,8-
























IC50 = 2.7 nMD6, 1.8 nMDd2
IC50 = 217 nMD6, 990 nMDd2IC50 = 33 nMD6, 67 nMDd2  
 
Figure 26: Example of the effect of 5,7-disubstitution compared to 7-substitution and 7,8-disubstitution 
 
These results are in agreement with results obtained by Madrid et al. for 5-substituted 
chloroquine analogues with no attached reversal agent and with and without an additional 
substituent in position 6 or 7 (Madrid, 2005). 
A 2,5-disubstituted compound (PL303) was inadvertantly made during the 
attempted synthesis of PL398 (Figure 24 and Table B1, Appendix B).  In vitro testing of 
this compound revealed that its activity was extremely low, even lower than that of its 2-













IC50 = 690 nMD6, 1250 nMDd2 IC50 = 402 nMD6, 639 nMDd2  
 





Interestingly, the 4-chloroquinoline intermediate to this compound, 4,5-dichloro-2-
(trifluoromethyl)quinoline, was the only 5-regioisomer more readily isolated (by 
recrystallization) than its 7- substituted analogue (4,7-dichloro-2-
(trifuoromethyl)quinoline).  These two quinolines proved to be the only 4-
chloroquinoline intermediates synthesized in the course of this study that had not been 
reported and characterized previously in the literature (Figure 28): 
 




Figure 28: Two previously uncharacterized quinolines were made during the course of this work. 
 
2.1.2: Effect of 6- versus 7-substitution 
 
 Compounds with a substituent in the 6- position had good activity, in some cases 
equal to that of their 7- substituted analogues and in others somewhat diminished (see 
Figure 29, below, and Table B2, Appendix B).  The former is in contrast to most of the 














Cl PL 106 
(Gunsaru, 2010)





IC50 = 6.9 nMD6, 102 nMDd2 (Burgess, 2010)




IC50 = 170 nMNF54 (CQS), 4900 nMK1(CQR) (Vippagunta, 1999)
Cl
IC50 = 30 nMHaiti 135 (CQS), 250 nMIndochina I (CQR) (De, 1996)













Figure 29: 6- versus 7-substituted chloroquine analogs with and without an attached reversal agent. 
 
Additionally, a 6,7- dichloro substituted compound (PL307) showed no diminuition of 
activity relative to its 7-substituted analogue (PL106), but had improved activity relative 




























Figure 30: The effect of 6,7-disubstitution compared to 6- and 7-monosubstitution. 
 
An interesting feature of the results is that for halogen-substituted analogues of PL106 
(bearing a single pyridyl ring in their reversal agent moiety), a change in substituent 
position from 7 to 6 resulted in a noticeable decrease in activity in the case of chloro- and 
bromo-substituted compounds, but this was much less marked in the case of iodo-
substituted compounds (Figure 31 and Table B2, Appendix B).  This effect was observed 
only in the case of PL106 analogues, and not in the case of the PL06 analogues (bearing 
the larger diphenylmethyl group in their reversal agent moiety).  The latter showed 





























IC50 = 2.6 nMD6, 5.2 nMDd2
I












IC50 <2.5 nMD6, <2.5 nMDd2  
 
Figure 31: The effect of 6- versus 7- substitution for chloro, bromo, and iodo-substituted analogues of 
PL106. 
 
2.1.3: Effect of halogen substituents 
 With regard to the halogen series (Table B3, Appendix B), substitution of 
bromine or iodine for chlorine in a given position (6- or 7-) did not appear to result in any 
significant change in in vitro activity within the limits of the assay, although some 
bromo- and iodo-substituted compounds had activity too high for the range in which they 












































Figure 32: Representative bromo- and iodo- substituted compounds 
 
These results are similar to those obtained from much of the previous work on 
compounds without an attached reversal agent (Vippagunta, 1999, Kaschula, 2002, 
Hocart, 2011, Nsumiwa, 2013).  As mentioned previously, substitution with iodine is of 
particular interest because there is some evidence for resistance reversal in 7-iodo 
analogues of chloroquine (De, 1998).   
Compounds with 6-fluoro substitution had somewhat diminished activity relative 
















IC50 = 3.4 nMD6, 7.9 nMDd2











IC50 = 10 nMD6, 16 nMDd2
 
 
Figure 33: The effect of 6-chloro versus 6-fluoro substitution 
 
The above results are in agreement with those obtained from work on chloroquine-like 
compounds (De, 1998, Hocart, 2011, Nsumiwa, 2013), in which the effects of 7-chloro- 
versus 7-fluoro-substitution are compared.  In this work, the synthesis of compounds with 
7-fluoro substitution proved more challenging than expected, since the 7-fluoroquinolines 
appear to undergo nucleophilic aromatic substitution easily in the presence of amines 
(this has been observed previously by Snyder, Freier, Kovacic, and Van Heyningen, 
1947).  On the basis of the results obtained by other researchers for 7-fluoro substituted 
chloroquine analogues without an attached reversal agent, and on the basis of the results 
obtained in this study for 6-fluoro substituted compounds, it appeared likely that the 
activity of a 7-fluoro-substituted compound would be lower than that observed for the 7-





2.1.4: Effect of strongly electron-withdrawing groups in position 6 or 7: nitro and 
trifluoromethyl substituents 
   
 Compounds with strongly electron-withdrawing groups in positions 6 or 7 were 
also made and tested (Table B4, Appendix B).  Only one nitro-substituted compound was 
made (PL282).  This compound did not have significantly diminished activity relative to 
its 6-chloro analog, PL283.  The activity of this compound was also far higher than has 
been observed for short-chain 7-nitro-substituted chloroquine analogs without an attached 
reversal agent, but similar to that observed for 7-nitro substituted chloroquine analogs 
with the side chain of chloroquine (Figure 34 and Table B4, Appendix B).  These 
compounds cannot be compared directly, since the chloroquine analogues without an 
attached reversal agent attached are substituted in the 7-position.  On the basis of other 
results described herein for 6- and 7-substituted compounds of this type, it seems 
probable that a 7-nitro-substituted chloroquine analog with an attached reversal agent 



























IC50 = 15 nMNF54 (CQS), 68 nMK1(CQR) (Vippagunta, 1999)  
 
Figure 34: The effect of nitro substitution on chloroquine analogues with and without an attached reversal 
agent. 
 
  Of the trifluoromethyl-substituted compounds, in most cases the activity was not 
significantly different from that of the chloro-substituted analogues (although in a few 
cases the activity was somewhat lower).  This is in contrast to many of the findings for 
chloroquine analogues without an attached reversal agent (De, 1996, Kaschula, 2002), 

















IC50 1.5 nMD6, 3.9 nMDd2









Cl PL 106 
(Gunsaru, 2010)









IC50 = 16 nMHaiti 135 (CQS), 45 nMIndochina I (CQR) (De, 1996)


































2.1.5: Unsubstituted compounds and those with an electron-donating group in 
position 6 or 7 
 
 As mentioned in the introduction, a des-chloro analogue of PL06 (PL64) had been 
made previously by Steven Burgess and was the catalyst for this study.  During the 
course of this study, a des-chloro analog of another compound made by Steven Burgess, 
PL69, was also made (PL375).  This proved to have unexpectedly low in vitro activity 
against P. falciparum compared to that observed for PL64, particularly against the 
chloroquine resistant strains, Dd2 and 7G8 (Figure 36, below and Table B5, Appendix 
B).  HPLC revealed that this compound may have been less pure than had been believed 
when this compound was tested in vitro, but this alone seems insufficient to account for 
the difference in activity observed, particularly against the chloroquine resistant strains.  
However, this compound would need to be re-synthesized, further purified, and re-tested 





























IC50 = 28 nMD6, 789 nMDd2  
 





 A 6-methyl substituted compound (PL383) proved to have similar activity to that 
of the 6-chloro analog, PL270, and to that of the des-chloro analog, PL64 (Figure 37, 
below; see also Figure 31, above and Table B5, Appendix B).  This is in contrast to 
reported activity for chloroquine analogues with a 7-methyl group and without an 






















Figure 37: A 6-methyl substituted compound compared to 7-chloro and 7-hydro analogues. 
 
A compound with an electron-donating 7-methoxy substituent (PL391) had diminished 
activity relative to that of its 7-choro analog (PL106).  However, the decrease in activity 
was not so great as has been reported in the literature for chloroquine analogues without 








NCl PL 106 
(Gunsaru, 2010)
















IC50 = 55 nMHaiti 135 (CQS), 3000 nMIndochina I (CQR) (De, 1996)













Figure 38: The effect of 7-methoxy substitution on chloroquine analogs with and without an attached 
reversal agent. 
 
2.2: Significance of the findings 
 
The above results show that the antiplasmodial activity of reversed chloroquine-
type compounds is significantly affected by the substitution pattern of the quinoline ring 
system.  These effects upon activity are directionally similar to those observed for 
chloroquine analogs without an attached reversal agent, but are generally smaller, except 
in the case of 2- and 8- substituted compounds.  In an attempt to understand why the 
substitution pattern of the quinoline ring system should affect the antiplasmodial activity 
of chloroquine analogues, and to understand why the effect on reversed chloroquine-type 




reversal agent, several possibilities should be considered.  Firstly, the quinoline ring 
system substitution may affect accumulation of the drug at its site of action, and this 
effect may be smaller for compounds with an attached reversal agent.  Secondly, the 
quinoline ring system substitution may affect the activity of the drug, and this effect may 
be smaller for compounds with an attached reversal agent.  Thirdly, in the case of 
chloroquine resistant parasites, the substitution pattern of the quinoline ring system may 
have an impact on drug efflux from the digestive vacuole.  Each of these possibilities will 
be discussed in turn.  
 
2.2.1 Effect of the quinoline ring system substitution on accumulation of 
chloroquine-like drugs in the digestive vacuole by pH trapping 
 
As mentioned previously, the concentration of chloroquine at its site of action, the 
parasite’s digestive vacuole, has been estimated to be one thousand to several thousand 
times greater than the concentration in uninfected erythrocytes, based on uptake 
experiments (Kelly, 2002; Sullivan, 2002).  This extraordinary degree of accumulation 
has been postulated to occur primarily for two reasons: firstly, because the lower pH of 
the digestive vacuole compared to that of the cytosol favors the accumulation of the 
weakly basic chloroquine within the digestive vacuole, and secondly, because 
chloroquine binds to heme dimers that are present within the vacuole (Yayon, 1985; 
Schlesinger, 1988; Bray, 1998; Bray, 1999; Kaschula, 2002).  Additionally, although 
chloroquine’s entry into the vacuole is generally thought to occur primarily by passive 




drug is not inconceivable (Kaschula, 2002).  It is further possible that there may be active 
transport of some kind, which would constitute a third mechanism of accumulation.  
However, if such a mechanism exists, it has not been identified with certainty (Kirk, 
2013).  
Chloroquine is considered to have two protonatable nitrogens.  One is in the 
quinoline ring system itself (pKa = 8.1), and the other is the tertiary nitrogen of the side 









Figure 39: pKas of chloroquine 
 
The nitrogen in position 4 of the quinoline ring system is thought to be less basic for 
reasons that will be explored during the discussion of bis-quinolines.  Neutral 
chloroquine is able to diffuse freely through the vacuolar membrane, but it is generally 
assumed that little diffusion of diprotonated chloroquine through the membrane occurs 
(Kaschula, 2002; Warhurst, 2007; Kirk, 2013).  The relatively lower pH of the digestive 
vacuole as compared to the cytosol therefore favors the accumulation of diprotonated 
chloroquine within the vacuole (a mechanism referred to as pH trapping).  Prediction of 
the extent of accumulation by pH trapping depends upon the pKa values that are used for 
chloroquine’s protonatable nitrogens, and upon the difference between the values used 




The pH outside of the vacuole is often given as approximately 7.4, whereas the interior of 
the vacuole has been estimated to be between pH 4.5 and 5.9 (Martin, 2009; Kirk, 2013).   
Based on a vacuolar pH of ~5 and a cytosolic pH of 7.4, Martin et al. calculate that 
approximately 83% of the drug outside the vacuole should be present in the diprotonated 
form, with approximately 17% monoprotonated, in contrast to approximately 100% 
diprotonoated inside of the vacuole (Martin, 2009).  On the basis of these values, the drug 
would be predicted to accumulate within the digestive vacuole to a small extent by the 
mechanism of pH trapping; however, pH trapping alone is insufficient to account for 
chloroquine’s remarkable accumulation in the digestive vacuole (Krogstad, 1987; 
Sullivan, 2002; Martin, 2009). 
The primary cause of chloroquine’s accumulation is thought to be binding to 
heme dimers (Krogstad, 1987; Bray, 1998; Bray, 1999). This mechanism of accumulation 
is intimately associated with the drug’s mode of action, which is thought to begin with 
reversible binding to heme (Dorn, 1998).  
The quinoline ring system substitution pattern is postulated to have an impact on 
drug accumulation both through pH trapping and through binding to heme (the effect on 
heme binding will be discussed together with antiplasmodial activity, below; Egan, 2000; 
Kaschula, 2002). As stated above, accumulation of chloroquine by pH trapping would be 
significantly affected by the pKas of chloroquine’s protonatable nitrogens.  It has been 
shown that the substitution pattern of the quinoline ring system strongly affects the pKa 
of the ring nitrogen (pKa1), as well as the nitrogen of the alkylamino side chain (pKa 2; 




compounds have been determined experimentally by Kaschula et al. (2002), and vary by 
as much as two pKa units from molecule to molecule, depending on the ring substituent.  
It is interesting that the quinoline ring substituent should have an effect not only upon the 
pKa of the quinoline ring nitrogen, but upon the side chain nitrogen as well.  The effect 
on the side chain nitrogen evidently occurs through space rather than through bonds.  
Kaschula et al. (2002) have speculated that for shorter-chain chloroquine analogues, this 
effect would be more pronounced than for chloroquine analogues with longer and bulkier 
chains.  Longer side chains may spend more time away from the quinoline ring system 
and may even be sterically prevented from approaching the ring system or its substituent.  
It has been pointed out by Kaschula et al. (2002) that this may account for the 
observation that the antiplasmodial activity of 4-aminoquinolines with a shorter alkyl 
chain is more vulnerable to modification of the quinoline ring system than that of 4-
aminoquinolines with a longer chain (Coatney, 1953, Kaschula, 2002, Nsumiwa, 2013).  
By extension, this may be the explanation for the observation in this work that for 
chloroquine analogs with an attached reversal agent, many modifications of the quinoline 
ring system substitution pattern have relatively little impact on activity as compared to 
that observed for chloroquine analogues without an attached reversal agent.  The long and 
bulky reversal agent side chain may hold the protonatable nitrogen of the side chain far 
enough away from the quinoline ring system to negate an effect of the latter upon side 
chain nitrogen pKa.  However, because the impact of pH trapping on accumulation is 
believed to be relatively small, the importance of quinoline ring system substitution to 




probable that the differences in pKa between compounds with certain substitution 
patterns in the present study are less than would be predicted on the basis of their activity, 
if differences in accumulation due to pH trapping were the only cause of the variations in 
activity observed.  For the compounds under study, however, pKa values have not been 
determined.  
 
2.2.2.  Effect of quinoline ring system substitution on heme binding and β-hematin 
inhibition 
 
For chloroquine and chloroquine-like drugs, the binding site of the heme dimer is 
believed to be the quinoline ring system itself (Egan, 2000).  The structure of the bound 
drug-heme complex in vivo is not known, but it is often envisioned as a π-π stacking 
interaction between the aromatic ring systems of the porphyrin and the quinoline (Leed, 
2002; Stocks, 2002; Crespo, 2010).  The side chain is thought to have little involvement 
in this binding, for reasons that will be discussed later.  Binding of the drug to heme is 
thought to be an important step in inhibition of the formation of hemozoin and hence, the 
antimalarial activity of quinoline drugs (Dorn, 1998).   In vitro models have been 
extensively studied both for heme binding (either as the heme monomer or as the heme 
dimer) and for inhibition of the formation of hemozoin (as inhibition of the formation of 
β-hematin, the chemically identical in vitro analogue of the biomineral hemozoin; Fitch, 
1987; Slater, 1991; Dorn, 1998; Egan, 2000).  In the course of these studies it has been 
found that heme binding strength does not always correlate to β-hematin inhibition – 




ability, but heme binding ability alone does not predict whether a compound will inhibit 
the formation of β-hematin (Egan, 2000; Kaschula, 2002).  Quinoline compounds with a 
wide variety of substitution patterns have been shown to bind to heme in aqueous 
solution (Vippagunta, 1999; Egan, 2000; Kaschula, 2002), but there is a much greater 
variation in ability to inhibit the formation of β-hematin (Egan, 2000; Kaschula, 2002).  
Thus, it has been proposed by Egan (2000) that while the quinoline ring system itself is 
responsible for binding to heme, the inhibition of formation of hemozoin is modulated by 
the substitution pattern of the ring system.  If the quinoline ring system always binds to 
the heme dimer in a similar position, regardless of its substituents, this effect could be 
due to the ability of the substituent to block the site at which the association between 
dimers occurs, preventing hemozoin from forming.  The large effects on antiplasmodial 
activity observed upon variation of the nature of the quinoline ring substituent 
(electronegativity, lipophilicity, steric bulk) or variation of its position on the quinoline 
ring would make sense if such a substituent-specific blocking were occurring.  Another 
explanation might be that the positioning of the quinoline ring system with respect to 
heme is changed by altering the position and nature of the substituent.   Perhaps the 7-
choro substituent is correctly placed and has the right stereoelectronic character to stop 
the biomineralization from occurring (Vippagunta, 1999; Kaschula, 2002).   
 
2.2.3 Effect of the side chain on activity: beyond pH trapping? 
 




binding and inhibition of hemozoin formation.  In the case of chloroquine it has been 
suggested previously that the side chain is involved in binding to the heme dimer by 
association of the protonated side chain nitrogen of chloroquine with the propionate 
moieties of heme (O’Neill, 1997).  In the case of quinoline methanols (quinine and 
mefloquine), which are thought to work similarly to 4-aminoquinolines (at least in part), 
portions of the side chain are thought to be important for heme binding (Alumasa, 2011).  
Additionally, it has been observed that chloroquine associates more strongly with heme 
in vitro as compared to chloroquine analogs with the same quinoline ring substitution 
pattern, but a shorter side chain (Egan, 2000).  In the context of the observation that the 
antiplasmodial activity of chloroquine-like compounds with longer side chains is less 
vulnerable to modification of the quinoline ring system substitution pattern, and in the 
context of the present work in which it is shown that chloroquine analogues with an 
attached reversal agent are even less vulnerable to side chain modification, it is worth 
considering that a longer side chain may have a relatively larger impact on heme binding 
and perhaps on inhibition of hemozoin formation.  Conceivably, the larger side chain 
might alter the binding geometry of the quinoline ring system to heme, affecting 
inhibition of hemozoin formation, or the chain itself might block the site of hemozoin 
formation.   However, because of the extreme variations in side chain structure that are 
possible without affecting antiplasmodial activity, it is thought that the side chain is not 
directly involved in these compounds’ mechanism of action.  This is true both for the 
alkylamine side chain of chloroquine analogues and for the reversal agent moeity of 




by others in our group (Burgess, 2008; Andrews, 2010; Burgess, 2010; Gunsaru, 2010) it 
has been observed that the reversal agent moiety of reversed chloroquine-type 
compounds can be widely varied without affecting in vitro antiplasmodial activity 
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IC50 <2.5 nMD6,<2.5 nMDd2
IC50 = 0.9 nMD6, 1.6 nMDd2
 
 
Figure 40: Variability of the reversal agent moeity of reversed chloroquine-type compounds 
 
A structurally-related molecule with similarly high in vitro potency against chloroquine 










IC50 = 0.9 nMFcB1 (CQR)  
 
Figure 41: A chloroquine analogue closely related to the above reversed chloroquine-type compounds, also 
with high activity against chloroquine resistant parasites. 
 
On the other hand, the above reversed chloroquine-type compounds all bear a lipophilic 
group on their alkylamino side chain, whether aromatic or saturated.  As there is 
substantial evidence that hemozoin formation occurs at the interface of lipid droplets 
within the digestive vacuole (Jackson, 2004; Oliveira, 2005 (for other protozoal 
diseases); Pisciotta, 2007; Egan, 2007), it is possible that in addition to any reversal agent 
activity that these groups may have, they also favor the presence of the reversed 
chloroquine compound at the lipid droplet interface.  Conceivably, the protonated side 
chain might stand outside of the lipid droplet, while the lipophilic group might stand 
inside.  Alternatively, deprotonated molecules might accumulate inside of the lipid 
droplet, constituting an additional mechanism of accumulation (this may be true for 
chloroquine analogues without an attached reversal agent as well; Warhurst, 2007).   In 
any case, whether or not the side chain is involved in the mechanism of action of 






2.2.4: The relationship between accumulation and inhibition of hemozoin formation 
 
It has been observed repeatedly in the literature that the ability of a 4-
aminoquinoline compound to inhibit the formation of β-hematin formation in vitro does 
not unequivocally predict in vitro antiplasmodial activity (Vippagunta, 1999; Egan, 2000; 
Kaschula, 2002).  Chloroquine analogues with high in vitro antiplasmodial activity have a 
high ability to inhibit the formation of β-hematin, but not all compounds that inhibit the 
formation of β-hematin have high in vitro antiplasmodial activity.   This lack of 
correlation has been explained by invoking the variation in accumulation by pH trapping 
of the various compounds involved.  In a study by Kaschula et al. (2002), β-hematin 
inhibitory activity, and in vitro antiplasmodial activity were determined for a series of 
variously substituted short-chain chloroquine analogs.  Among others, the series of 
compounds in that study included those in which the quinoline ring system was 
substituted in the 7-position with a halogen, with a nitro group, with hydrogen, and with a 
methoxy group.  It was observed that compounds with a halogen substituent (chlorine, 
bromine, or iodine) had good β-hematin inhibitory activity and good in vivo activity.  
Compounds bearing a strong electron-withdrawing group (nitro or trifluoromethyl) had 
excellent β-hematin inhibitory activity, but poor in vitro antiplasmodial activity.  
Compounds with an electron-donating methoxy group, as well as those without an 
attached substituent, had much lower β-hematin inhibitory activity, and their in vitro 
antiplasmodial activity was low as well.  However, their antiplasmodial activity was not 




inhibition and antiplasmodial activity were directly correlated.  Side chain and quinoline 
ring nitrogen pKa for the study compounds were determined experimentally, and were 
used to estimate accumulation due to pH trapping relative to that of chloroquine (as 
described above in the discussion of pH trapping, section 4.3.1).  Upon adjusting the in 
vitro β-hematin inhibitory activity of the study compounds for accumulation, a good 
correlation was obtained between accumulation-corrected β-hematin inhibitory activity 
and in vitro antiplasmodial activity.  It therefore appeared to the authors of that study that 
the halogen-substituted compounds presented the best compromise between accumulation 
and β-hematin inhibitory properties, leading to their superior activity relative to 
compounds with other substituents.  As mentioned above (section 4.3.1), accumulation of 
chloroquine at its site of action may occur largely due to heme binding, with 
accumulation due to pH trapping playing a relatively minor role.  Yet in contrast to β-
hematin inhibitory activity, heme binding ability (as determined in vitro) varies 
comparatively little amongst variously substituted chloroquine analogues.   If the 
conclusions of Kaschula and coworkers are correct, and the differences in in vitro 
antiplasmodial activity are partly explained by differences in accumulation due to pH 
trapping, then it is interesting that the latter should play such a comparatively important 
role, though constituting a relatively small proportion of total accumulation (Kaschula, 
2002).  Another explanation might be that accumulation is related not only to heme 
binding but to hemozoin inhibition as well, such that for some reason compounds that 
inhibit hemozoin formation accumulate more strongly; however, if so, this has not been 




The compounds in the study described above were substituted only in the 7-
position of the 4-aminoquinoline ring system, so it was not clear from that study whether 
the results would be the same for other substitution patterns.  Additionally, as observed 
by Kaschula and coworkers, the impact of the quinoline ring system substitution upon the 
pKa of the 4-aminoquinoline side chain nitrogen may partially depend on side chain 
length, and this may help explain why the antiplasmodial activity of compounds with a 
longer side chain is relatively less impacted by quinoline ring system substitution than 
shorter chain compounds.  It is therefore of interest that in many cases, compounds 
substituted in the 2- and 8- position seem to have the same strong, negative effect on 
activity regardless of side chain length and type, including the reversed chloroquine-type 
antiplasmodials in the present study.  If the deleterious effect of this substitution pattern 
on activity were due to a change in the pKa of the side chain nitrogen, leading to reduced 
accumulation by pH trapping, then it would be anticipated that 2- and 8- substituted 
compounds with a longer side chain would be more active relative to those with a shorter 
side chain.  If one assumes that the conclusions made by Kaschula and coworkers are 
correct, a possible explanation might be that 2- and 8- substituted compounds are so poor 
at inhibiting the formation of hemozoin that accumulation is irrelevant.  If this is true, it 
would be interesting to learn whether the effect of the 2- or 8-substituent is primarily a 
steric or an electronic one.  Based on the results in the present work, it appears that in 
position 8 the effect is at least partially a steric one, as the 8-methoxy and one of the 8-
methyl substituted compounds performed as poorly as 8-trifluoromethyl substituted 




moiety did not perform as poorly (see Figure 23).  Comparing the two compounds in the 
present study with a 2-methyl versus a 2-trifluoromethyl group (Figure 24), it was seen 
that the 7-chloro-2-methyl substituted compound synthesized in the present study had 
weak but improved activity relative to its 2-trifluoromethyl analogue.  However, this does 
not necessarily mean that the effect of the substituent in position 2 is an electronic one, 
since the trifluoromethyl group is also more sterically demanding than the methyl group 
(Bégué, 2008).  Synthesis and testing of a compound with a smaller electron-withdrawing 
group or a larger electron-donating group in position 2 might help to decide this question.   
 
It seems probable that neither an effect on accumulation nor an effect on the 
ability to inhibit the formation of hemozoin can be the sole reason for the importance of 
the quinoline ring system substitution pattern.  Rather, it appears that both accumulation 
and hemozoin inhibitory activity are likely to be involved.   
2.2.5. Modulation of resistance 
 
In the literature it has often been observed that modification of the chloroquine 
side chain has a powerful effect on the resistance profile of chloroquine analogues (De, 
1996; Stocks, 2002).  Changes in chain length and bulk generally confer improved 
activity against chloroquine resistant parasites relative to activity against chloroquine 
sensitive parasites (referred to as resistance index).5  The chloroquine resistance 
                                                
5 Effect on resistant parasites, or cross resistance, is often discussed in terms of the resistance 




transporter or transporters seem to have evolved in such a way that they are able to 
specifically recognize the side chain of chloroquine.  This has been exploited in the 
development of AQ-13 (De, 1996), F2Bu (Stocks, 2002), and ferroquine (Brocard, 1995; 





















IC50 = 5.5 nMHB3 (CQS),
           9.8 nMK1(CQR)
IC50 = 7 nM3D7 (CQS), 
          19 nMDd2 (CQR)
IC50 = 7 nMHaiti 135 (CQS), 
           5 nMDd2(CQR)  
Figure 42: Altering side chain length of chloroquine analogues restores activity against chloroquine 
resistant parasites. 
 
In contrast, it has generally been observed in the literature that modifications of the 
quinoline ring system itself have a negative impact on activity without enhancing the 
resistance index.  As stated above in the review of previous work, exceptions to this are 
known.  For the substitution pattern of sontoquine (Vippagunta, 1999; Pou, 2012), and 
for compounds with a larger quinoline ring substituent such as an iodo, phenoxy, or 
trifluoromethoxyphenyl group (De, 1998; Madrid, 2005; Pou, 2012), an improved 
resistance index has been observed.  Additionally, for some smaller substituents (nitro, 
cyano) some improvement in the resistance index has been observed also (Nsumiwa, 
2013).  Therefore it appears that the assumption that the quinoline ring system has no 
impact on resistance is not entirely correct – the chloroquine resistance transporter may 
have some ability to recognize the 7-chloroquinoline moiety of chloroquine as well as its 
                                                                                                                                            
strains.  Thus, a drug with lower overall activity than chloroquine may still show an improved 




side chain.  For the bulkier ring substituents at least, it is also possible that the compound 
simply does not fit the transporter – perhaps the compound is pushed into a less favorable 
conformation for binding (Pou, 2012). 
For the compounds in the present study, it was not possible to observe the impact 
of the quinoline ring system substitution pattern on the resistance index, since a 
resistance-reversing side-chain was already in place.  Enhancement of activity against 
resistant parasites relative to sensitive parasites was not observed upon modification of 
the quinoline ring system.  However, it occasionally appeared that modification of the 
quinoline ring system decreased activity against chloroquine resistant parasites relative to 





































IC50 = 20 nMD6, >250 nMDd2


















Figure 43: Apparent cross-resistance with chloroquine was observed for some ring-modified reversed 
chloroquine-type compounds 
 
Significantly lower activity against chloroquine resistant parasites than against 
chloroquine sensitive parasites was most commonly observed in the case of 8-substituted 
compounds.  The causes of this phenomenon are unclear at the present time.  It is 
possible that this modification to the quinoline ring system somehow negates the effect of 
the reversal agent in preventing efflux (although this seems far fetched), or perhaps it is 
related to non-resistance-related mutations in the resistant parasites which somehow 




informative to determine whether this apparent cross-resistance is reversed by a reversal 
agent, such as verapamil.  
Nevertheless, it appears that in many cases the 7-chloro substituent of reversed 
chloroquine-type compounds can be altered without adversely affecting either activity or 
resistance profile.  If reversed chloroquine-type compounds were to be used as drugs, it is 
possible that modification of the quinoline ring system might serve as an additional 
protection against the development of resistance.    
 
2.3: Summary of the present work, and future directions  
 
 Fifty three reversed chloroquine-type compounds have been synthesized in which 
the 7-chloro substituent is changed to another electron-withdrawing substituent in the 2-, 
5-, 6-, 7-, and 8- positions of the quinoline ring system, to a methyl substituent in position 
2-, 6- or 8-, or to a methoxy substituent in position 7- or 8- (see Table B1, Appendix B).  
For this class of compounds, 2-, 5-, and 8- substituents appear to decrease in vitro 
antiplasmodial activity against P. falciparum relative to 7-chloro substitution, whereas 6- 
and 7- substituted compounds have similar activity to that of 7-chloro substituted 
compounds except in the case of nitro-, fluoro-, and methoxy-substituted compounds.  
These effects on activity are directionally similar to those observed for chloroquine 
analogues without an attached reversal agent, but the magnitude of the effect is smaller.  
The results of this study support and extend the conclusions of Coatney and others that 




may be smaller for chloroquine analogues with a longer side chain.  Furthermore, the 
results obtained for 2-and 8- substituted compounds may indicate that the deleterious 
effect of these substituent positions on the antiplasmodial activity of 4-aminoquinoline 
compounds may be primarily a steric rather than an electronic one. 
 To complete this series, 7-fluoro, 7-nitro, 7-methyl and 6-methoxy substituted 
compounds should be made.  The 3-position is of particular interest by analogy to 
sontoquine, which Andersag reported as having similar activity to chloroquine, and for 
which Vippagunta (1999) and Pou (2012) have found evidence of resistance reversal 
relative to chloroquine.  Additionally, bulky electron-donating substituents would be of 
interest (such as phenoxy, tert-butoxy, trifluoromethoxy, or pentafluorosulfanyloxy (-
OSF5), as would the bulky, lipophilic, electron-withdrawing pentafluorosulfanyl group (-
SF5).  As far as is known, the pentafluorosulfanyl group is of a metabolic stability 
comparable to the trifluoromethyl group, and is analogous in its electron-withdrawing 
effect, but its larger size and increased lipophilicity should offer intriguing differences in 
biological activity (Welch, 2007 and 2009; Kirsch, 2007).6  Additionally, compounds 
substituted with a bulkier substituent in position 2 or 8 would be of interest in order to 
determine whether this would decrease activity still further than has been observed with 
the study compounds.  This might indicate whether the observed effect is due to steric or 
other factors.  Finally, it would be of interest to determine pKa values for a selection of 
                                                
6 In recent years the pentafluorosulfanyl group has met with increasing interest as a new 
substituent for bioactive molecules (Stump, 2009; Welch, 2007; Micheli, 2010; Wipf, 2009), 
especially since the methods used to incorporate it into organic molecules have improved 
(although regrettably few SF5-containing organic building blocks and reagents used to introduce 
it are commercially available).  This substituent has been incorporated into the quinoline ring 





the study compounds in order to determine whether, in fact, the side chain pKa is indeed 
less strongly effected by the quinoline ring system substitution pattern than has been 
observed for chloroquine analogues without an attached reversal agent, and in order to 
determine the effect of substituents in various positions upon pKa.  If indeed the pKa of 
the side chain nitrogen is less strongly affected in these molecules than in shorter chain 
chloroquine analogues, it would also be of interest to determine the conformation adopted 
by some of these molecules as salts in acidic aqueous solution, which might be possible 
by two-dimensional NMR spectroscopy (NOESY).   
 The results of this study show that the substitution pattern of the quinoline ring 
system of reversed chloroquine type antiplasmodials is much more flexible than that 
observed for chloroquine analogs without an attached reversal agent.  In the light of 
findings by other workers that some quinoline ring system substitution patterns offer an 
improved resistance index relative to the 7-chloro substitution pattern of chloroquine, it is 
possible that modification of the quinoline ring system substitution pattern of reversed 
chloroquine-type compounds would provide enhanced protection against the emergence 
of resistance.  At present, however, it is not known whether these compounds are equally 







Asymmetrical bis-quinolines with antiplasmodial activity 
 
 In the second portion of this work, a novel type of asymmetrical bis-quinoline has 
been developed that has unusually high antiplasmodial potency.  In this chapter, the 
subject of bis-quinolines as antimalarials will first be introduced (Section 3.1, 
Background).  This will be followed by a description of the asymmetrical bis-quinolines 
made in this work, followed by a discussion of their in vitro antiplasmodial activity and 











IC50 = 0.7 nMD6, 1.5 nMDd2  
 
Figure 44: Piperaquine, a bis-quinoline antimalarial 
 
 Like the mono-(4-amino)quinoline compounds discussed in the previous chapters, 
the class of bis-(4-amino)quinolines includes many compounds with antiplasmodial 
activity. The bis-quinoline antimalarial piperaquine (above, Figure 44), is a long-acting 




therapies recommended by the World Health Organization to treat P. falciparum malaria 
(WHO Report, 2013).  Piperaquine was originally synthesized at the French chemical 
firm, Rhône-Poulenc.  In the original patents for this compound, submitted by Rhône-
Poulenc in 1962 (France, granted in 1965) and subsequently in Belgium (granted in 
1963), examples are given not only for the synthesis of piperaquine but also a variety of 

















































Figure 45: Some bis-quinolines used as examples in the original patents for piperaquine by Rhône-Poulenc. 
 
Piperaquine attracted the interest of Chinese researchers, who synthesized it in 1965.7  
Following successful clinical trials performed during the early 1970s it was widely used 
in China both as a treatment and as prophylaxis for P. falciparum and vivax malaria 
(Davis, 2005; Schlitzer, 2007; Warhurst, 2007; Chen, 2014). 
                                                
7 It has sometimes been stated that piperaquine was synthesized independently in China (Davis, 
2005, and citing authors); however, in the reference given for this information by Davis and co-





Piperaquine is believed to work by a mechanism similar to that of chloroquine 
and other 4-aminoquinolines (Warhurst, 2007); however, it retains activity against many 
chloroquine-resistant strains, perhaps because its large size prevents its being exported by 
the chloroquine resistance transporter (Vennerstrom, 1992; Basco, 2003; Davis, 2005; 
Naudé, 2005; Pascual, 2012).  However, piperaquine resistance is now common in some 
parts of Asia, particularly the areas of China in which piperaquine was heavily used 
following its introduction (Schlitzer, 2007; Chen, 2014).  The mechanism of piperaquine 
resistance is not known, and attempts to associate resistance to piperaquine with 
mutations known to confer resistance to other quinoline antimalarials have produced 
conflicting results (Muangnoicharoen, 2009; Briolant, 2010; Eastman, 2011; Hao, 2013; 
Pasual, 2013).  Disturbingly, the development of resistance to the combination 
dihydroartemisinin-piperaquine has been reported in southeast Asia (Saunders, 2014). 
 In addition to piperaquine itself, a diverse range of other bis-4-aminoquinoline 
compounds have been shown to have antiplasmodial activity (Figure 46, following page).  
Like piperaquine, these compounds tend to be active against chloroquine-resistant strains 
(Rhône-Poulenc, 1962; Elslager, 1969; Makler, 1990; Vennerstrom, 1992; Raynes, 1995; 













(data from Gunsaru, 2010)







Mouse study: 2.8 mg/kg/day 
suppressed parasitemia by 90% (P. 
berghei); 2.5 times as potent as 
chloroquine in the same study.
N NH HN N
Cl Cl
(Vennerstrom, 1992)
IC50 = 1.0 nMD6, 1.4 nMW2 (CQR)














































































3.2: A novel, asymmetrical bis-quinoline: PL241 
 
During the initial structure-activity relationship study in which reversed 
choroquine-type compounds were developed (Burgess, 2008; Burgess, 2010), the 










Figure 47: PL69, a reversed chloroquine-type antimalarial synthesized by Steven J. Burgess (2008) 
 
The original synthetic method for PL69 required the use of the following compound 








Figure 48: PL67, an intermediate originally used to produce PL69 
 
In the present work, at the suggestion of Steven Burgess, PL67 was used to 



























Figure 49: In this work, PL67 was used to produce the novel bis-quinoline, PL241. 
 
The new compound had extremely high in vitro activity against chloroquine sensitive and 
chloroquine resistant strains of P. falciparum.  With an IC50 of less than 0.1 nM for all 
strains tested, its activity was superior to any compound previously synthesized in our 

















IC50 = 0.7 nMD6, 1.5 nMDd2  
 
Figure 50: In vitro antiplasmodial activity of PL241 compared to that of piperaquine 
  
 
PL241 is noticably different from piperaquine.  Firstly, it is asymmetrical.  




aminopiperidine moiety directly attached to one of its quinoline rings.  This structural 
motif has previously been incorporated into other quinoline compounds with 
antiplasmodial activity, including a recently published bis-quinoline conjugated with 












IC50 = 9.5 nMHaiti 135 (CQS), 
















Shown to have 
activity against P. 
vivax  in man.
 
 
Figure 51: (4-Piperidyl)-4-aminoquinolines previously shown to have antiplasmodial activity. 
 
The third important difference between piperaquine and PL241 is that the 
nitrogen in position 4 of each of the quinoline ring systems of PL241 is secondary rather 
than tertiary.  This is significant in view of the frequent observation that for mono-(4-
amino)quinolines and related antiplasmodials, the presence of a tertiary rather than a 
secondary nitrogen in position 4 of the quinoline ring system lowers antiplasmodial 
potency.  This is true not only for chloroquine analogues without an attached reversal 
agent (Wiselogle, 1948; Warhurst, 2007), but for reversed chloroquine-type compounds 




















IC50 = 1.0 nMD6, 3.6 nMDd2  
 
Figure 52: A tertiary nitrogen in position 4 of the quinoline ring system lowers antiplasmodial potency. 
 
This phenomenon was originally observed in the case of 8-aminoquinoline 
antimalarials and acridines.  In the course of a mechanistic study upon the quinoline and 
acridine antimalarials atebrine (quinacrine), plasmochin (pamaquine), and certuna 
(cilional), Schönhöfer and coworkers synthesized an N,N,N-trisubstituted derivative of 
the active antimalarial, atebrine (Schönhöfer, 1942).  The N,N,N-trisubstituted compound 















Figure 53: Atebrine and its N,N,N-trisubstituted analogue (Schönhöfer, 1942). 
 
It was remarked by Schönhöfer that the introduction of a second substituent on the amino 
group para to the acridine ring nitrogen would prevent the following tautomerization 















Figure 54: Tautomerization of atebrine predicted by Schönhöfer to have significance for antimalarial 
potency (1942) 
 
In the context of this and other observations, Schönhöfer speculated that the form of the 
drug active in vivo might be that in which it has transiently rearranged to the above 
structure.   
In the case of 4-aminoquinolines, which are closely related to acridines, 
disubstitution of the amino group para to the ring nitrogen would also block 
tautomerization.  It is now believed that the site of action of quinoline (and acridine) 
antimalarials is the parasite’s acidic digestive vacuole, where the quinoline ring is 
expected to be protonated.  The tautomerization shown above has been revisited as 
resonance stabilization of positive charge on the ring nitrogen resulting from protonation 


















It has also been found by Egan (2000) that within the series including 2-, 3-, 4-, 5-
, 6-, and 8-aminoquinoline, the only quinolines able to bind strongly to heme are those for 
which the above resonance stabilization is possible, to wit, the 2- and 4-aminoquinolines.  
The ability to stabilize a positive charge on the ring nitrogen leads to increased basicity in 
the 2- and 4-aminoquinolines, and therefore presumably to increased accumulation in the 
digestive vacuole.  It is also possible that the altered electronic properties of the 
protonated, resonance-stabilized structure lead to improved heme binding ability (Egan, 
2000). 
It would at first appear that the resonance stabilization shown above would be 
equally effective for tertiary 4-aminoquinolines.  However, it has been suggested by 
Warhurst (2007) in the case of piperaquine that steric hindrance between the proton in 
position 5 of the quinoline ring system and the piperazine methylene results in twisting of 
the substituted 4-amino group out of the plane of the ring, so that resonance stabilization 
is decreased.  This would result in reduced basicity of the ring nitrogen for tertiary 
compounds, leading to reduced accumulation in the digestive vacuole.  Experimental 
determination of the pKas of piperaquine has shown that it is indeed less basic than 
chloroquine (Warhurst, 2007). 
In view of the observation for the general class of 4-aminoquinolines that the 
presence of a tertiary quinoline-4-amino group leads to reduced antiplasmodial activity, it 
is curious that piperaquine, with its two tertiary quinoline-4-amino groups, should have 
high activity.  The reason for this is unknown.  Assuming that piperaquine’s mode of 




piperaquine’s accumulation in the aqueous acidic vacuole should be somewhat less than 
that of chloroquine, its accumulation in the lipid portions of the vacuole is expected to be 
much greater (based on the empirically determined pKas and cLogP of both compounds; 
Warhurst, 2007).  This may be significant in view of the evidence that hemozoin may 
form at the surface of or inside of lipid droplets within the digestive vacuole (Warhurst, 
2007; Pisciotta, 2007; Egan, 2007).  It is also conceivable that the availability of two 
heme binding sites in piperaquine compensates in part for lower accumulation relative to 
that of chloroquine, with its single heme binding site.  Finally, if the importance of the 
mesomerism described above lies in its effect upon the electronic nature – and therefore 
binding ability – of the quinoline ring system of 4-aminoquinolines in general, then it is 
conceivable that piperaquine may be a special case in which the presence of the specific 
combination of the bulky aminoalkyl motif and second quinoline ring system results in a 
binding geometry altered in such a way that it is different from that of other 4-
aminoquinolines but provides equally strong heme binding and inhibition of hemozoin 
formation. 
Whatever the reasons behind piperaquine’s high activity, the fact that PL241 has 
improved activity over that of piperaquine may indicate that the presence of a tertiary 
amine is indeed detrimental to 4-aminoquinoline antimalarials and that piperaquine’s 
activity represents a compromise between the detriment of the tertiary 4-amino group and 
other more favorable properties.  PL241 may possess the positive features of piperaquine 
with the additional advantage of the secondary quinoline-4-amino group.  




against many chloroquine-resistant strains of P. falciparum malaria.  To explain 
piperaquine’s activity against chloroquine resistant strains, it has been suggested that due 
to the increased bulk and lipophilicity of piperaquine relative to that of chloroquine, the 
bis-quinoline is unable to be exported through the Plasmodium falciparum chloroquine 
resistance transporter, PfCRT (Warhurst, 2007).  This is similar to the explanation that 
has been advanced for the activity of reversed chloroquine-type antimalarials, and it has 
been remarked that piperaquine might be thought of as a reversed chloroquine-type 
antimalarial (Burgess, 2008).  This also applies to PL241, which is structurally similar to 
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uncertain whether the quinoline rings of PL241 are equally important to the antimalarial 
activity or whether one ring has weaker antimalarial activity and is perhaps acting 
primarily as a reversal agent (as we believe occurs with the N-(dipyridin-2-
ylmethylene)piperidin-4-amine group in the case of PL69, above).  To help determine 
this, a short mechanistic study was performed. 
 
3.3: A short mechanistic study: The effect of inactivating groups upon the activity of 
PL241 
 
To determine whether the two quinoline ring systems of PL241 are equally 
important to its antimalarial activity, several PL241 analogues were made and tested in 
vitro against Plasmodium falciparum.  In the first two analogues, the 7-chloro substituent 
of one quinoline ring system was changed to an 8-trifluoromethyl group, a substitution 
pattern that was expected to be inactivating based on the work described in Chapter 2 for 
quinoline ring-modified reversed chloroquine-type compounds.  It was anticipated that if 
one of the ring systems is more important to antimalarial activity than the other, then 
substitution of this ring with an 8-trifluoromethyl group would result in a diminuition of 
in vitro activity.  The results obtained are shown below (Figure 57; see also Appendix B, 
Table B6).  For comparison, PL69 is also shown, together with its 8-trifluoromethyl-
substituted analogue, PL269, as well as PL241:8  
                                                
8 With the exception of PL241, the bis-quinolines in this project were not tested against the 















































Figure 57: 8-trifluoromethyl-substituted PL241 analogues, shown with PL241, PL69, and its 8-
trifluoromethyl-substituted analogue, PL269. 
 
Within the range of the test, the activities of both 8-trifluoromethyl-substituted PL241 
analogues were equivalent to that of the parent drug.  These results may be interpreted to 
mean that neither quinoline ring system is of primary importance to the antimalarial 
activity of PL241.  However, whether the 8-trifluoromethyl group would in fact be 
inactivating in the context of these compounds was unknown.  Therefore, an additional 
PL241 analogue was synthesized in which both rings were substituted with an 8-












IC50 = 35 nMD6, 259 nM7G8  
Figure 58: A PL241 analog with two 8-trifluoromethyl-substituted quinoline ring systems. 
 
The activity of the bis-8-trifluoromethyl PL241 analogue was substantially decreased 
relative to that of PL241.  Therefore it seems probable that the 8-trifluoromethyl 
substitution is indeed an inactivating substitution pattern for compounds of this type, as 
with reversed chloroquine-type compounds.  Taken together with the results above for 
PL241 analogues with a single 8-trifluoromethyl substitution, these results suggest that 
either quinoline ring system is equally capable of participating in the antimalarial action 
of PL241.   
It is notable that for the bis-8-trifluoromethyl substituted PL241 analogue, PL341, 
the decrease in activity observed for the chloroquine sensitive parasites was not as great 
as that observed for other 8-substituted reversed chloroquine-type antimalarials when 
compared to their 7-substituted analogues (see PL69 and PL269, Figure 57, above).  
Possibly, this might be attributable to a slightly different binding pattern induced by the 
larger side chain of these compounds (including the second quinoline ring system).   
For the chloroquine resistant parasites, the activity of the bis-8-trifluoromethyl 
analogue of PL241 was much lower.  Regrettably, the magnitude of this effect cannot be 
compared to the effect on the activity of 8-trifluoromethyl substituted reversed 




test the latter did not test in the same range (all had IC50 >250 nM).   
Finally, it is of interest that the same phenomenon of apparent cross resistance is 
observed here as for most of the 8-substituted reversed chloroquine-type antimalarials 
(see Figure 43).  Again, it would be informative to determine whether this apparent cross-
resistance is reversible by verapamil (and thus whether it relates to increased efflux of the 
8-substituted compounds from the digestive vacuole, or to another, unknown 
mechanism). 
 
3.4: A second short mechanistic study: The effect of exchanging chlorine for 
hydrogen 
 
In Chapter 1, it was noted that the activity of chloroquine analogues without an 
attached reversal agent is detrimentally affected by removal of the 7-chloro substituent, 
but that this is not always true for reversed chloroquine-type compounds (see Figure 18).  
Previous work in Dr. Peyton’s laboratory has examined the importance of the 7-chloro 
substituent to the class of bis-quinolines.  Analogues of piperaquine and a related bis-
quinoline, PL192, have been made in which chlorine has been exchanged for hydrogen 




















































IC50 = 1.3 nMD6, 0.5nMDd2
 
 
Figure 59: Piperaquine analogues made during previous work, in which chlorine has been exchanged for 
hydrogen (Gunsaru, 2010).  Also shown is chloroquine with its 7-hydro analogue (Burgess, 2008). 
 
 Similarly to the case of reversed chloroquine-type compounds, no significant 
difference in activity was observed between piperaquine and its bis-7-hydro analogue, 
PL174 (Figure 59, above).  PL192 differs from piperaquine in the arrangement of its 
aminoalkyl motif, such that both quinoline ring systems have a secondary rather than 
tertiary 4-amino group.  In contrast to what was observed for piperaquine, and in contrast 
to what has been observed for some reversed chloroquine-type compounds, PL255 (the 
des-chloro analogue of PL192; Figure 59, above) showed a diminuition in activity 
compared to PL192 (Gunsaru, 2010).  However, it was not known whether this effect 
would generalize to other bis-quinolines containing secondary quinoline-4-amino groups.   
To help determine this, analogues of PL241 were made in which either or both 

























IC50 <2.5 nMD6, <2.5 nM7G8 IC50 <2.5 nM
D6, <2.5 nM7G8
IC50 = 0.063 nMD6, 0.014 nM7G8
PL241
IC50 = 17 nMD6, 28 nM7G8  
 
Figure 60: Analogues of PL241 in which chlorine has been exchanged for hydrogen. 
 
 As was observed in the case of the 8-trifluoromethyl substituted PL241 analogues, 
substitution of a single 7-chloroquinoline ring system with 7-hydroquinoline did not 
result in any reduction in activity within the range of the assay.  However, exchange of 
both rings for 7-hydroquinolines resulted in a reduction of activity similar to that seen for 
the bis-8-trifluoromethyl PL241 analogue, indicating that in the case of PL241, removal 
of the 7-chloro substituent is detrimental to antiplasmodial activity.  This limited study 
provides further support to the tentative conclusion from Gunsaru’s work (2010) that the 
activity of bis-quinoline compounds with secondary quinoline-4-amino groups is more 




piperaquine, with tertiary quinoline-4-amino groups.  The reasons for this remain unclear.  
It would be of interest to know whether the weak activity of other tertiary 4-
aminoquinoline antiplasmodials is insensitive to the removal of the 7-chloro group, or 
whether the effect is specific to piperaquine.  It would also be of interest to determine the 




3.5  The future of PL241: A potential antimalarial drug? 
 
The excellent in vitro antiplasmodial activity of PL241 makes this a compound of 
great interest for further development as a potential antimalarial drug, particularly if it 
were to be found that it is active against piperaquine-resistant strains of Plasmodium.  
However, for bis-quinolines as well as for other classes of compounds, high in vitro 
activity does not always predict high activity in vivo (Vennerstrom, 1998), and even a 
compound with high activity in vivo may not be a suitable drug.   Considered as a 
potential drug, PL241 has some features that are cause for concern.  Firstly, toxicity may 
be an issue.  In the course of this work, an initial in vitro test to determine the possible 
toxicity of PL241 was performed using mouse spleen lymphocytes (see Appendix B, 
Table B7).   Toxicity is given as LC50, the concentration required to kill 50% of the cells.  
PL241 was found to be substantially more toxic (LC50 = 190) than chloroquine (LC50 = 
12400), and also more toxic than the reversed chloroquine-type compounds tested 




substantially better than that of chloroquine – at least in vitro – so it is possible that could 
be administered at a much lower dose, below the threshold of toxicity.  The therapeutic 
index (ratio of activity to toxicity) of PL241 using the mouse spleen lymphocyte assay 
compares favorably to that of chloroquine (3500 versus 122).  A second concern is the 
known low water solubility of PL241, even as the phosphate salt.  Low aqueous solubility 
could present a problem in terms of biological absorption.  The use of a solubilizing 
counterion, such as mesylate or lactate (Stahl, 2003a), or a special formulation (Stahl, 
2003b) might alleviate this problem, but the former might not do enough to improve 
solubility while the latter would unacceptably increase cost.   It is possible that PL241 
might turn out to be is more absorbable in vivo than might be predicted (it may be worth 
noting that the predicted cLogP (octanol-water partition coefficient, a predictor of water 
solubility) of PL241 is 7.0 (ChemBioDraw), compared to 6.5 predicted for piperaquine).  
However, at this early stage, the best approach might be to modify the structure of PL241 
such that the drug properties would be improved without excessively compromising 
activity.  For example, in view of the easy synthetic variability of the quinoline ring 
system, together with the results shown above for ring-modified reversed chloroquine-
type compounds, it may be possible to add solubilizing substituents to the quinoline ring 







A survey of historical therapies used in Europe to treat intermittent fevers 
 
The mere treatment of this subject undoubtedly increases the admiration 
that I at least feel for the men of old; the greater the number of plants 
waiting to be described, the more one is led to revere the careful research 
of the ancients and their kindness in passing on the results.   
 
(Pliny, Natural History, Vol. VII, 1.)9 
 
4.1: Introduction to the project 
Malaria has been with us for many centuries, perhaps for all of human history 
(Hoeppli, 1959; Hay, 2004; Hawass, 2010; Fornaciari, 2010).  Its former range was much 
larger than it is today, including much of Europe (Nuttall, 1901; Russell, 1955; Hay, 
2004).  The following chapter will survey selected therapies used in Europe to treat 
malaria prior to and along with cinchona bark, from the time of Pliny the Elder (active in 
the first century A.D.) through the advent of modern malaria chemotherapy in the early 
twentieth century.  The substances utilized for treatment were primarily plant remedies 
(phytotherapies).  The remedies include what may be considered traditional or folk 
medicine, as well as official or scientific medicine.  These two categories are not distinct, 
and for the purposes of this survey they have been considered together.  
There has been much interest in the traditional phytotherapies used to treat 
                                                
9 Crescit profecto apud me certe tractatu ipso admiratio antiquitatis, quantoque maior copia 
herbarum dicenda restat, tanto magis adorare priscorum in invendiendo curam, in tradendo 




malaria in the parts of the world where malaria is currently endemic.  Thousands of 
articles and books have been published on this subject (see for example Dharani, 2010; 
Zhu, 2012; Singh, 2011; Soejarto, 2012; Koch, 2005).  However, with the exception of 
cinchona, the historical malaria therapies used in Europe prior to the development of 
modern antimalarial chemotherapy have attracted relatively little interest.  The reasons 
for this may be fourfold.  Firstly, malaria has not been considered endemic to most of 
Europe for nearly a century (Hay, 2004).  In many formerly malaria endemic regions, 
malaria has been absent for far longer, as has been discused by Nuttall, Cobbett, and 
Strangeways-Pigg (1901).  Naturally enough, the possibility that native European 
antimalarial phytotherapies might have existed is not often considered.  Secondly, 
historical phytotherapies are often dismissed as folk medicine.  Scientists, medical 
practitioners, and even historians within the European tradition have typically considered 
modern medicine to be contradictory and incompatible with folk medicine, which is often 
regarded with amusement and scorn (Cameron, 2006; De Vos, 2010).  It is no longer 
considered acceptable in scholarship to ridicule and dismiss traditional remedies used in 
other parts of the world, but this attitude is more rarely applied to the traditional medicine 
of one’s own culture.  Thirdly, in part because of the historical attitude of dismissal 
towards traditional remedies, and partly also because of the lapse in time since malaria 
has been prevalent in Europe, much of the European traditional medicine that was 
formerly used to treat malaria has been forgotten.  It is no longer part of the daily lives of 
most of the population.  Fourthly, there is a notion extremely prevalent in the literature 




cinchona bark in the 17th century.  Cinchona bark is generally thought of as having taken 
over relatively quickly as the malaria treatment of choice, as if in a vacuum.  In reality, 
this was far from true (Jarcho, 1993; Adams, 2011).  The prevalence of this belief has 
helped to obscure a large number of antimalarial remedies that existed in the past.    
The examination of early treatments for malaria and other diseases is not only of 
historical interest.  Both quinine and the artemisinins were originally discovered by 
isolation of active constituents from plants used to treat malaria.    Especially now that 
there is so much interest in finding novel scaffolds that are not yet subject to drug 
resistance, it is likely that phytochemical sources of interest could surface from a serious 
examination of the old literature.  Recently, Adams, Zimmerman and coworkers have 
screened 61 plants used in the European materia medica for in vitro antiplasmodial 
activity (Adams, 2011; Zimmerman, 2013).  Thirty-four of the plants were discovered by 
inspection of eight German language herbals from the 16th and 17th century, while the 
remainder were plants with known medicinal activity.   Of the plants mentioned in the 
Renaissance herbals, Adams, Zimmerman and coworkers found that many had some 
degree of antiplasmodial activity.  In view of this, it can no longer be assumed that 
cinchona bark was the only malaria remedy used in Europe that had antimalarial efficacy.  
Moreover, it appears likely that a search of the historical medical literature may yield 
useful leads for the treatment of drug-resistant malaria. 
 
In the present project, fifteen European primary sources have been searched for 




by a brief discussion.  The sources used begin with Pliny the Elder, whose Natural 
History was written in the first century A.D., and end with Mrs. M. Grieve, whose 
Modern Herbal was published in 1931.  When possible, these sources were read in their 
native language, but due to the inability of the author to read ancient Greek, Latin, 
Middle Welsh, or Anglo Saxon, translations were sometimes used.  The fifteen sources 
used in this project are described briefly below.  In the course of the project, several 
additional sources were examined without finding reference to any disease that could 
clearly be identified as malaria; the names of these sources are also briefly noted below.  
 
Pliny the Elder: Plinii Naturalis Historiae (1st century A.D.) 
 
Pliny the Elder, born in 23 A.D, was a Roman official and encyclopedist known 
for his love of reading and interest in the natural sciences. In 79 A.D. he was killed by 
toxic fumes from the eruption of Vesuvius, having sailed to the nearby Stabiae to observe 
the results of the eruption (Rackham, 1938).  His best-known work, Plinii Naturalis 
Historiae (Natural History by Pliny), includes sections on the treatment of various 
ailments and on the medical uses of plants.  The edition used in this project is that 
translated into English by H. Rackham, W.B.S. Jones, and D.E. Eichholz, divided into ten 





Dioscorides: Herbal (1st century A.D.) 
 
Dioscorides’ herbal describes the medical uses of herbs, animals, and minerals.  It 
was written in Greek by Pedanius Dioscorides, a Greek physician active in Rome during 
the reign of Nero, 54-68 A.D. (Gunther, 1934; Major; 1954; Grant, 1970; Cameron, 
2006); he was roughly contemporary with Pliny the Elder.  Dioscorides’ Herbal remained 
a standard medical work through the 1700s, having been translated into Latin early in its 
history (as Materia Medica).  Although its large size made it unavailable to many 
physicians due to the expense of producing a copy, excerpts and epitomes were widely 
available and it is frequently referred to in the older medical literature (Cameron, 2006).  
The English botanist John Goodyer translated the Herbal into English during the years 
1652-1655, and this translation was finally published in 1934, with amended translations 
of species names, by Robert T. Gunther.  A reprint of the 1934 edition has been used as a 
reference here. 
 
Alexander of Tralles: A work on fevers (525-605 A.D.) 
 
Alexander of Tralles (525-605) was a Byzantine physician who died in Rome.  He 
wrote several medical works in Greek, including a treatise on fevers.  In the latter he 
often gives scathing critiques of the methods of treatment used by other physicians, 
including Galen (whom, however, he greatly admired).  An augmented edition of his 




The edition used in this work is a reprint of the 1878 translation from Greek into German 
by T. Puschmann.   
 
The Herbarium of Pseudo Apuleius (Anglo Saxon version, 10th century or earlier) 
 
 In its Latin original, the Herbarium of Pseudo Apuleius (Herbarium) was a widely 
used health handbook on the European continent.  It is a collection of three works.  The 
first of these is a short work on the uses of the herb betony (probably Stachys officinalis 
(L.) Trevis.) by a Roman physician, Antonius Musa.  The second book is a series of 
herbal remedies, organized by ailment and ascribed to Apuleius Platonicus (this portion 
of the text is thought to have originated in the 6th or 7th century A.D.; Anderson, 1977).  
The final book is a Latin epitome of Dioscorides.  The Herbarium was translated into 
Anglo-Saxon from Latin at an unknown date, no later than the 10th century (Cameron, 
2006).  Together with other works, the Herbarium was translated from Anglo Saxon into 
English by the Reverend Thomas Oswald Cockayne, and published as a three volume set 
entitled Leechdoms, Wortcunning, and Starcraft of Early England (1864-1866).10  Of the 
included works, only the three books of the Herbarium include remedies for a disease 
that can be identified with relative certainty as malaria, despite the fact that malaria may 
have existed in Britain at that time (Nuttall, 1901).  Although the Herbarium is a 
translation of a work that survives in Latin and (in the case of Dioscorides) in ancient 
Greek, it is nevertheless valuable to examine the Anglo Saxon text.  Firstly, the 
                                                





translation into Anglo Saxon may reflect usage by a wider number of physicians in the 
British Isles (viz, literate physicians without knowledge of Latin or Greek; as pointed out 
by Cameron, it is significant that no fewer than four Anglo Saxon copies of the 
Herbarium of Pseudo Apuleius survive today).  Secondly, as noted above, its inclusion of 
remedies for a disease that can be identified as malaria may be unique among the 
surviving Anglo Saxon texts.    Finally, the Anglo Saxon translator or translators often 
rendered Latin plant names that he did not recognize as the names of local plants.  The 
plants selected may reflect to some extent existing local usage (Cameron, 2006). 
 
Hildegard of Bingen: Causae et Curae (12th century) 
 
Causaue et Curae is a health handbook written in Latin by Hildegard of Bingen 
(1098-1179), a Benedictine abbess at Disibodenberg and later, Rupertsberg in Rheinland-
Pfalz.  She personally attended and treated the sick, including not only members of her 
religious community but of the community at large; she also supervised the abbey’s herb 
garden.  Much of her writing and music survives today.  Although most of her writings 
are on subjects theological and mystical, Hildegard of Bingen was greatly interested in 
natural history, particularly the medicinal uses of plants (Anderson, 1977; Pawlik, 1989). 
Causae et Curae is partly based on historical medicine, partly on observation, and partly 
on Christian theology.  It was transcribed many times during the centuries after its 
composition, and influenced the writings of future German botanists (Anderson, 1977).  




The Physicians of Myddfai (Prior to 1234) 
 
The text of the Physicians of Myddfai (Meddygon Myddfai) is a compilation of 
prescriptions collected and written down in Middle Welsh by Rhiwallon of Myddfai, 
court physician to the South Welsh prince, Rhys Gryg (died 1234).  The collection is 
presumed to include much older material.  A transcription of the text was included in the 
Red Book of Hergest (Llyfr Coch Hergest), collected in 1382, and has survived in this 
form up to the present day (Henderson, 1994; Breverton, 2012).  The classic 1861 
English translation by John Pughe unfortunately could not be obtained, and therefore a 
more recent translation by Terry Breverton was used. 
 
Bartholomæus Anglicus: De proprietatibus rerum (Prior to 1283) 
 
Bartholomæus Anglicus (Bartholomew the Englishman) was a Franciscan teacher 
active in Paris and Saxony during the 13th century.  He may possibly have been the 
protégé of Albertus Magnus (Anderson, 1977).  His De proprietatibus rerum (On the 
properties of things) was written in Latin prior to 1283.   It is an early encyclopedia that 
includes a section on the medicinal uses of plants.  The work originally may have been 
intended as an educational text for evangelical friars; however, it gained wide popularity 
in the ensuing centuries and was translated into French, English, Dutch, Spanish, and 
possibly Bavarian (Anderson, 1977; Keen, 2007). The edition used in this project is a 





Otto Brunfels: Contrafayt Kreüterbůch (1532) and Ander Teyl des Teütschen 
Contrafayten Kreüterbůchs (1537)11 
 
 The Contrafayt Kreüterbůch (1532, Straßburg) is an early example of a new type 
of herbal that would become common in the ensuing centuries.  Unlike many 
contemporary medical texts, it is written in German rather than Latin (it is a translation of 
the Latin Herbarium Vivae Eicones, 1530, by the same author); in the ensuing years, 
many more herbals would be written in the native language of their country (Arber, 
1912).  The Kreüterbůch is renowned especially for its naturalistic woodcuts by Hans 
Weiditz, who based his woodcuts on drawings directly from plant specimens.  
Illustrations in earlier books were primarily copies of earlier illustrations, and tended to 
be conceptual or decorative rather than naturalistic (Arber, 1912; Collins, 2000).  Herbals 
of the years following the Contrafayt Kreüterbůch began to include illustrations based on 
observation of plant specimens (Arber, 1912).  In its text, the Kreüterbůch draws 
substantially on earlier authors, including Dioscorides and Pliny, and provides 
information about the astrological character of the plants, followed by information on 
how to find and use them.  Much effort is spent in trying to identify local plants as those 
spoken of by Dioscorides (Anderson, 1977).  The author, Otto Brunfels (circa 1489-
1534), was a former monk who subsequently converted to Protestantism; after working as 
a preacher and a schoolmaster, he studied to become a physician (Isely, 1994).  A 
                                                




facsimile reprint of the 1532 edition of the Contrafayt Kreüterbůch, including the 
posthumously published Ander Teyl des Teütschen Contrafayten Kreüterbůchs (1537), 
was used in this project. 
 
Hieronymus Bock: Kreutterbůch (1572) 
 
  In contrast to many earlier and contemporary medical works, the 1539 
Kreutterbůch of Heironymus Bock (also known as Tragus; 1498-1554) focuses on the 
empirical identification and uses of local plants, rather than on the identification of local 
plants as those described by ancient physicians (Anderson, 1977).  The book was 
originally written in German, not Latin, and the style is colloquial (Arber, 1912).  The 
author seems to take delight in relating superstitions about plants, only to disprove or 
reject them.  Hieronymus Bock studied medicine, and later supervised the gardens of the 
Count Palatine Ludwig; subsequently he became a Lutheran pastor (Anderson, 1977).   A 
facsimile of the 1572 edition of the Kreůterbuch was used in this project. 
 
John Gerard, Dr. Priest, and Thomas Johnson: The Herball or Generall Historie of 
Plantes (1597 and 1633) 
 
 The Herball or Generall History of Plantes, one of the best loved of all English 
botanical works, originated as a translation of Pemptades by the Belgian botanist 




being able to ready his translation for publication.  The publisher, John Norton, enlisted 
the assistant of the botanist John Gerard (1545-1612), a surgeon and well known 
horticulturist (Jackson, 1950).  It is possible that Gerard merely rearranged the work 
before publication (Arber, 1912; Anderson, 1977), but it is also possible that he 
substantially revised and augmented it with his own work (Isely, 1994; Jackson, 1950); in 
any case, The Herball was published in 1597 without crediting Dr. Priest.  An enlarged 
and improved edition was published in 1633 by Thomas Johnson (Arber, 1912; 
Anderson, 1977).  Facsimile versions of both editions were used in this project. 
 
Nicolas Culpepper, Peter Cole, and Joseph Blagrave: The English Physician (1677) 
 
The London physician and astrologer Nicolas Culpepper (1616-1654) was a noted 
proponent of astrological botany, wherein ailments and remedies are related to various 
planetary influences; in various forms, this doctrine was both controversial and popular 
throughout the Middle Ages and ensuing centuries, up to the present day (Anderson, 
1977).  Culpepper was also known for giving medical advice to the poor without fee 
(Lee, 1950).  In 1649, Culpepper caused dismay and outrage among the London College 
of Physicians by publishing an unauthorized English translation of their Pharmacopeia 
(as The London Physical Directory; Anderson, 1977; Arber, 1912).  Although described 
by Culpepper’s opponents as “very filthily done”, this book was terrifically popular and 
appeared in numerous editions.  In 1653, together with Peter Cole, Culpepper published 




enormous popularity and continued to appear in various editions in the decades after 
Culpepper’s death from consumption in 1654 (Lee, 1950).  The version used in this 
project is a facsimile of an enlarged 1677 edition published by Joseph Blagrave. 
 
William Coles: Adam in Eden, or, Nature’s Paradise: The History of Plants, Fruits, 
Herbs, and Flowers. (1657) 
 
 The English botanist William Coles (sometimes spelled Cole; 1626-1662) 
published his great botanical work, Adam in Eden, or, Nature’s Paradise, in 1657.  Many 
of the remedies given relate to the doctrine of signatures, the theory that the shapes of 
plants indicate their medical uses (e.g. the walnut for disorders of the brain).  
Giambattista Porta is credited with much of the formal development of this theory as it 
existed in early modern Europe (in his Phytognomonica, 1588), but the doctrine of 
signatures has existed in various forms for far longer and in many parts of the world 
(Arber, 1912; Bennet, 2007).  Coles is credited with further development of the doctrine 
of signatures in his work.  He was also the author of another work, The Art of Simpling 
(1656).  In this project, a fascimile of the 1657 edition of Adam in Eden was used. 
 
William Salmon: A Family Dictionary (1696) 
 
 William Salmon (1644-1713) practiced medicine in London, sold prescriptions, 




many medical works, including a translation of Sydenham’s Practice of Physic 
(sometimes referred to today for its descriptions of malaria), as well as works on other 
subjects including theology and travel; he had at one time traveled to New England 
(Moore, 1950).  His Family Dictionary is a domestic handbook, including medical 
advice, recipes, and instructions for making alcoholic beverages, perfumes, and various 
medicines.  Many of the prescriptions are intended for home manufacture, but others 
describe patent medicines obtainable at William Salmon’s practice.  The Family 
Dictionary is of special interest because it is avowedly directed not at medical 
practitioners but at the literate layman.  The edition used in this project was a facsimile of 
the expanded second edition, originally published in 1696. 
 
Robert John Thornton: A New Family Herbal (1814) 
 
 Robert John Thornton (1783-1837) was a physician, botanist, and lecturer on 
medical botany.  He published two botanical works, including both the New Family 
Herbal and another work called A New Illustration of the Sexual System of Linnaeus; the 
beautiful and expensive plates in the latter book unfortunately led to the financial ruin of 
the author (University of Cambridge Alumni Database, 2009-2011).  Despite its name, 
the New Family Herbal appears to be intended not only for lay people but for physicians 
as well.  Its entries generally include a botanical description, a history of medical use 




advice on dosage and administration.  A facsimile of the expanded second edition (1814) 
was used in this project. 
 
Mrs. M. Grieve: A Modern Herbal (1931) 
  
 The herbalist and historian Maude Grieve (1858-1941) published her A Modern 
Herbal in 1931.  Part primary source and part work of history, the book contains the 
following types of information on hundreds of herbs: firstly, information on historical 
usage gathered from dozens of primary sources, secondly, folklore and information on 
use by country people, and thirdly, information on current production and use by 
herbalists, including cultivation, dosage, method of administration, and chemical 
constituents when available.  A useful feature of the book is its list of many common or 
country names of plants, without which this project would have been much more 
difficult.  A service index of Latin names of plants was added in 1940, but the book lacks 
an index by usage, and does not contain a list of the works consulted (although names of 
sources are given within the text).  Neverthelesss, the Modern Herbal is frequently 
referred to by historians and herbalists, and has been reprinted many times.  In this 
project, a reprint from 1996 was used.  
 
The following is a list of works consulted in which malaria remedies were not found, or 
in which malaria could not be identified with relative certainty: 
 




Marcellus: De Medicamentus Liber (On medicaments; 4th-5th century) 
Isidore of Seville: The medical writings (d. 636; Sharpe, 1964) 
Bald’s Leechbook (circa 950 A.D.) 
Leechbook III (perhaps circa 950 A.D.) 
Lacnunga (Later than 950 A.D.; Cockayne, 1864-6; Cameron, 2006) 
Jean Fernel: De Abditis Rerum Causis (On the hidden causes of things; 1542)   
 
 
4.2: Tables of the historical remedies found in this survey 
 
 Following are the remedies for malaria that were discovered in this survey, in the 
form of two tables.  Table 4.1 provides the plants and other substances encountered, 
organized when possible by Latin name.  Plant names used are those currently 
recommended by the Royal Botanic Garden at Kew (The Plant List, 2013).  Some of the 
substances listed in Table 4.1 were part of more complex remedies; when this is true, the 
reader is referred to Table 4.2, in which complex remedies are given, organized by the 
source in which they were found. 
A significant difficulty encountered in the course of the project was the accurate 
identification of malaria in the sources.  The variety of the terminology used to describe 
different diseases and symptoms, as well as the different understanding of the causes of 
disease, often makes it difficult to determine whether the illness that is being described is 
malaria or not.   The word “malaria” was not commonly used to describe the disease 
itself until the beginning of the twentieth century, although it was associated with the 




unhealthful marsh air for centuries earlier (Russell, 1955; Jarcho, 1993)12.   For the 
purpose of this survey the following terms have been regarded as likely to refer to 
malaria: ague or cold ague, intermittent fever or intermittent, remitting fever, periodic 
fever, quartan or quartan fever, tertian or tertian fever, aestivoautumnal fever, Dreitägiges 
Fieber (three-day fever), and Viertägiges Fieber (four-day fever).  The terms fever or 
chills when taken alone were not considered likely to refer to malaria, nor was swelling 
of the spleen (although a recognized symptom of chronic malaria; Jones, 1909)13, as these 
symptoms are common to multiple ailments.  The term quotidian fever was also rejected, 
although it may also describe malaria (Jones, 1909).   Unless a hot ague was specified, 
ague was accepted as likely to refer to malaria despite the fact that the term “ague” is 
known to have been used for any acute fever during some periods (Nuttall, 1901; 
MacArthur, 1954).  The vocabularly used in a given source is provided in the table, so 
that the reader may make his own distinctions.  Naturally, there is substantial possibility 
for error in the identification of disease, particularly when dealing with translated 
materials.  Due to time and language limitations, it had to be assumed that the translator – 
in many cases a medical historian – had made his best effort to translate medical 
terminology correctly.  It is quite possible that not every remedy listed here was in fact 
used to treat malaria, and it is very likely that some remedies were rejected 
inappropriately.  
                                                
12 Russell (1955) and Jarcho (1993) provide a useful discussion of the origins of the term, 
malaria; these authors and others have shown that it does not originate with the physician 
Francesco Torti, as is sometimes stated. 
13 According to the Oxford English Dictionary (1971), the term “ague cake” was formerly used to 




The second primary difficulty encountered was the identification of the 
substances used.  Plants in particular are often difficult to identify with certainty, as they 
have changed their names and classifications many times over the course of millennia 
(Singer, 1961; De Vriend, 1984).  Some plants that are described in ancient texts may not 
exist today (Vehling, 1977).  In many cases, especially in the older texts, the 
identification provided can only be an informed suggestion.  A more complex situation 
arises when using texts that are themselves historical translations of earlier documents, 
intended for contemporary use as medical texts.  In these cases, it is extremely probable 
that many of the plants that were unknown to the translator were identified as local or 
imported plants that were not, in fact, those intended by the original author (De Vriend, 
1984; Cameron, 2006).  Nevertheless, as these mistranslated plants were presumably then 
used to treat malaria, they were considered valuable for this project in themselves; no 
attempt was made to correct false identifications made in historical translations that were 
used as medical books in their own right.  This category includes the following: the 
translation of Dioscorides by John Goodyer (1655), the De Proprietatibus Rerum of 
Bartholomæus Anglicus, translated by John Trevisa (1283), and the Herbarium of Pseudo 
Apuleius, translated into Anglo Saxon during the tenth century or earlier.  Several of the 
other sources, such as Otto Brunfels’ Contrafayt Kreüterbůch, also contain translations of 
remedies from other texts, such as Dioscorides and Pliny.   
Not all of the plants in the sources were European natives, or cultivated in the 
region of the source describing them.  Imported plants were nevertheless included here.  




nigrum L.), are used to treat malaria on other continents, and in some cases their 
antimalarial activity has been studied (Willcox, 2004; Kamaraj 2012).  The plants in 
Table 4.1 were roughly categorized as being either imported or available somewhere in 
Europe (whether native or cultivated, and not necessarily in the region of the source). 
 In the older literature, a distinction was made between tertian and quartan fevers, 
and this distinction has been preserved in the table.  The distinction may be that between 
malaria caused by Plasmodium falciparum, vivax, and ovale, leading to the occurrence of 
the fit on every other day, and malaria caused by Plasmodium malariae, leading to the 
occurrence of the fit on every third day (Hoeppli, 1959; Adams, 2011).  It is recognized 
today as in the past that not every remedy is appropriate for every form of malaria.  The 
manner in which remedies are prepared and administered is also given in Table 4.1.  The 
possible importance of this will be addressed below. 
 
KEY TO THE TABLES 
 
Abbreviations used for sources: 
 
Pl - Pliny the Elder: Plinii Naturalis Historiae (1st century A.D.) 
D - Dioscorides: Herbal (1st century A.D.) 
AvT - Alexander of Tralles: A work on fevers (525-605 A.D.) 
HAP - The Herbarium of Pseudo Apuleius (Anglo Saxon version, 10th century or earlier) 
HvB - Hildegard of Bingen: Causae et Curae (12th century) 
Myd - The Physicians of Myddfai (Prior to 1234) 
BA - Bartholomæus Anglicus: De proprietatibus rerum (Prior to 1283) 
OB - Otto Brunfels: Contrafayt Kreüterbuch (1532) and Ander Teyl des Teütschen 




HB - Hieronymus Bock: Kreutterbůch (1572) 
Co - William Coles: Adam in Eden, or, Nature’s Paradise: The History of Plants, Fruits, 
Herbs, and Flowers. (1657) 
JG - John Gerard, Dr. Priest, and Thomas Johnson: The Herball or Generall Historie of 
Plantes (1597) and (1633) 
Cu - Nicolas Culpepper, Peter Cole, and Joseph Blagrave: The English Physician (1677) 
Sa - William Salmon: A Family Dictionary (1696) 
Th - Robert John Thornton: A New Family Herbal (1814) 
Gr - Mrs. M. Grieve: A Modern Herbal (1931) 
 
A small h in parentheses after a source, e.g. Gr (h), indicates that source is not referring to a 




Afr. – Africa  
Aust. – Australia  
Boi. – Boiled  
Dec. – Decoction 
Dist. – Distillate or distilled 
Eur. – Europe (cultivated or native) 
Ext. – External or topical 
Extr. – Extract 
Inf. – Infusion 
Ingred. – Ingredients  
Int. – Internal 
Med. – Mediterranean  
Mid. E. – Middle East 
N. Afr. – North Africa 
New W. – New World 
Powd. – Powder or powdered  
Purg. – Purgative  
Tincture – tinct. 
Unsp. – unspecified 

















day fever (HvB) 
Int., dec. herb 
(Gr (h)); Int., 
HvB 1 
Aconitum napellus L. Wolfbane, Monkshood Eur. Th Intermittent fevers 




Acorus calamus L.? Bitter flag  Eur. Gr (h) Intermittent fevers Root, Gr 1 
Adiantum capillus-
veneris L. Maidenhair Eur. AvT  Int., AvT 13 
Aegopodium 
podagraria L. Herb Gerard Eur. JG Quartan agues (JG) 
Int., root 
powd. in wine 
before fit, to 
cure (JG) 
Aesculus 
hippocastanum L.  Horse chestnut Eur. Gr Intermittent fevers Int., inf. Bark 
Agrimonia eupatoria 





Int., dec. or 
juice of herb 
Ailanthus altissima 




action of the trees 
in malarial districts 
is considered to 





fevers) Int., inf. Bark 
Ajuga chamaepitys 
(L.) Schreb. Yellow bugle Eur. Gr Agues 
Int., powd. or 
inf. Leaves 
Allium 
ampeloprasum L. Leek Eur. AvT Tertians Int.,  AvT 14 
Allium sativum L. Garlic Eur. Pl, Th Quartans 
Int., one head,  
Pl 3 
Alnus glutinosa (L.) 
Gaertn. Alder Eur. Gr Agues Int., dec. bark 
Aloe vera (L.) 
Burm.f. Aloe Afr. Sa Agues 
Int.,  Sa 3 or 
Sa 4 
Alpinia galanga (L.) 
Willd., A. 
officinarum Hance 










Int., boi. in 
wine, water, or 
broth (Cu), Int.  
HvB 2 
Alstonia constricta 
F. Muell. Alstonia bark 
Aust




(L.) R. Br. Dita bark Asia Gr Malarial fever 




Pellitory of Spain, 
Spanish chamomile Eur. JG 









(L.) Lag. Bertram Eur. OB 
Longstanding 
fevers w/ shivering 
and cold 
("langwyrigen 
feberen so mit 
shauderen/ zytteren 
und kelte angond"). Int. 




Agues (cold fever) 
(HAP), Intermittent 
fevers (Mdf) 
Ext., boi.. in 
oil, before fit 
(HAP), Ext.  
Mdf 1, Int.  
Mdf 2 
Anchusa officinalis 




Alkanet, bugloss, or 
wild bugloss Eur. 
JG, D, 
Pl (h) 
Agues and diseases 
of spleen (JG), 
Tertians, quartans 
(D, Pl) 
Int. dec. root, 
w/ mead or 
honeyed water 
(JG), Herb boi. 















L. Dill Eur. AvT  Int., dec. herb 
Angelica 
archangelica L. Angelica Eur. Sa 
Agues, prevent and 
cure (Sa) 
Int., root 
powd.  Sa 5 
Angostura trifoliata 





Bark to Cinchona 
for use in fever 
cases" 
inf. of powd. 
bark 
Anthemis chia L., A. 










Int., Juice in 
syrup (JG), 
Int.,  AvT 13 
Aristolochia rotunda 




and shivering of), 
hardness of spleen 
(JG), Fevers (not 
specific) (HAP) 





serpentaria L. Snakeroot 
New 




roots (Gr), Th 
3  
Armoracia rusticana 
P.Gaertn., B.Mey. & 
Scherb. 
Horse radish, Dittander 





rinds in vinega 







Arnica montana L. Mountain arnica Eur. Th Intermittent fevers Int., flowers 
Artemisia abrotanum 
L. Southernwood Eur. 
JG, Gr 
(h) Agues 
Ext.?, with oil 
to remove 
shivering of 
fits (JG), Ext., 
annoint 
backbone to 
prevent fit (Gr, 
h) 
Artemisia absinthium 















(AvT (h)), Ext. 
(AvT), Int.  
Mdf 3, Int. 
powd. dried 
flowers (Gr 
(h)), dec. herb 
(Th), Int. dec. 
powd.,or  
juice, or inf. in 
wine (Co) 
Artemisia maritima 






Artemisia pontica L. 
Pontic wormwood, 
Roman wormwood Eur. JG 
Agues (lingering), 
Tertians  





(Gr, Mdf), Ague 
(Th) 
Int., juice and 
inf. of herb 
(Gr, Th), Ext.,  
Mdf 2 
Arum maculatum L. 
Arum, Cuckoo's Pint, 
Wake Robin Eur. Th Intermittent fevers  
Asarum europaeum 
L. 
European wild ginger 
(Asarabacca, 








agues of long 
continuance (JG), 
Agues (Gr from 
Cu, Co) 
Roots, inf. or 
boi. (purgative 
by vomiting) 
(JG), Int., Gr. 
4; Ext., Co 6; 
Int., inf. leaves 
& roots in 





Asplenon) Eur. HB Quartans (HB) 
Int., whole 
plant stewed in 
wine 
Athamanta cretensis 
L. Candy carrot Eur. AvT Quartans Int.,  AvT 15 
Athamanta 
macedonia (L.) 
Spreng. Macedonian parsely Eur. AvT Quartans Int.,  AvT 11 
Avena sativa L. Oats Eur. AvT 
Tertians, possibly 
quartans Int., gruel 
Bellis perennis L. 
Field daisy, common 
daisy, English daisy Eur. JG Agues 











Int., inner bark 





Ehrh. Birch Eur. Gr Intermittent fevers Inner bark 
Bidens tripartita L. Water agrimony Eur. 
Gr (h), 




Trifolium, trefoil, pitch 
trefoil Med. D Tertians, Quartans 
Int., leaves or 
seeds in wine 
(D) 
Blechnum sp. Blechnum Eur. HvB Three-day fever Int.  HvB 1 







plant stewed in 
wine (HB), Int.  
Mdf 2 
Calendula officinalis 
L. and others Marigold Eur. JG, Gr 
Pestilential agues 
(JG), Ague (Gr) Any (JG) 
Capparis spinosa L. Capers Eur. JG, D Quartans (JG) 
Int., w/ food 
(JG) 
Capsella bursa-
pastoris (L.) Medik. Shepherd's Purse Eur. Co 
Ague (to prevent 
the fits) 
Int., juice of 
the herb w/ 
wine 
Capsicum annuum L. 
Capsicum, Guinea 
pepper, Chilli pepper  Th Intermittent fevers Int., seeds 
Carum carvi L. Caraway Eur. Mdf Intermittent fevers Int.,  Mdf 2 
Castanea vesca 





Blessed thistle (Cardo 






Quartan (JG, HB, 
OB, Co), Ague 
(Co), Intermittent 
fevers (Gr) 
Int., hot, boi. 
in wine, extr. 
of leaves (JG), 
powd. in wine 




powd. or dec. 
of the herb in 
posset for any 








(JG), Tertians (Sa), 
Intermittent fevers 
(Gr) 
Int., dec. (JG, 
Sa), Herb and 
leaves (Gr) 
Chamaemelum 







Agues (Co), Agues 
















L. Greater celandine Eur. Th (h) Intermittent fevers Int., herb juice  
Chionanthus 
virginicus L. 
Fringe tree (Old Man's 
Beard) 
New 
W. Gr Intermittent fevers 
Int., extr. of 
dried root bark 
Cichorium endiva 
L.? Endive Eur. AvT Tertians, quartans Stalks 













Int., bark in 
wine, 
sweetened 
(Sa), Int., dec. 
of bark (Gr, 
Th) 
Cinnamomum verum 
J.Presl and C. cassia 
(L.) J.Presl Cinnamon Asia Sa Agues 
Int.,  Sa 2 or 
Sa 3 
Cistus creticus L. ? Ladanum (Labdanum) Med. Pl Tertians  
Citrullus colocynthis 







Quartans (HB,  
AvT, Pl, BA), 
Tertians (HB, Pl) 
Int., fruit  AvT 




Citrus limon (L.) 







Int., fruit juice 
w/ aqua vitae 
at approach of 
fit; Int., dist. 
Fruit; Int., dec. 
fruit (Gr), Int., 
juice, saturated 
w/ salt (Th) 




Mountain mint, lesser 
calamint Eur. 
JG, Gr 
(h), Cu Agues 
Int., alone or 




boi. in salad 
oil to remove 
shivering (JG) 
Commiphora myrrha 









Quartans (D, Cu), 
Ague or quartan 
ague (Sa) 
Int. w/ pepper 
and water (D), 
Int.  Sa 3, in 
wine for 
quartan (Sa), 
Int. two hours 












L. Hemlock Eur. AvT 
Quartans (provoke 
sleep to reduce 
severity of fit) Int., AvT 16 
Consolida regalis 
Gray? Larkspur Eur. HAP Quartans 




L. Field bindweed Eur. D Intermittent fevers Ext. w/ oil 
Convolvulus 
Scammonia L. 




Tertians (JG, AvT), 
quartans (AvT) 
 JG 3 (JG), 
Int.,  Sa 3 and 
Sa 4 (Sa), Int., 
juice as a mild 
purgative; or 
AvT 9  
Coriandrum sativum 
L. Coriander Eur. Pl, OB Tertians 




Cornus florida L. American boxwood 
New 
W.  Gr Intermittent fevers Int., root bark 




similar to those 
found in Peruvian 
bark"  
Crocus sativus L. Saffron Eur. Sa 
Agues (tertian) 
(Sa) Int.,  Sa 4 







fevers Int., bark 
Cucumis melo L. Melon Eur. AvT Quartans (some) 
Int., as part of 
cooling diet 
Cucurbitae sp. 
(various) Gourd or cucumber Eur. 
BA, 
JG (h) Agues (BA, JG) 
Int., roasted or 
fried (BA); 
Placed in bed 
w/ a sleeping 
infant sick w/ 
ague, to cure 
(JG) 
Curcuma longa L. Turmeric Asia Thr Intermittent fevers Int., powd. 
Curcuma zedoaria 
(Christm.) Roscoe Zedoary Asia Gr Antiperiodic 
Int., alone or 
w/ aloe 
Cuscuta epithymum 




Long tertians (JG), 
Quartans (JG, 
AvT), agues in 






on thyme, AvT 
7 and (Sa) 
Cydonia oblonga 
















Huds. English sundew Eur. Sa Quartans 
Ext., dist. 
water of plant 
applied to the 





Clemants American wormseed 
New 






. Gr Intermittent fever Int., extr. 
Eupatorium 
perfoliatum L. Boneset/Thoroughwort 
New 
W.  Gr Intermittent fevers Herb 
Euphorbia esula L. 
Leafy spurge, 
Wolffsmilch Eur. OB Quartans 








Agues (the shaking 
fit), Quartans (Cul) 




Bois., F. galbanifera 





Int.,  Sa 3, Int.  
AvT 1 
Ferula persica 
Willd. Ferula of Media 
Mid. 




of the meadow Eur. JG, Gr Quartans (JG, Gr) 
Int., flowers 
boi. in wine 
(JG) 
Foeniculum vulgare 






Int.,  Mdf 2 
(Mdf), Int.,  Pl 
2  
Fraxinus excelsior L. Ash Eur. Gr Intermittent fevers 
Int., dec. of 
bark 
Fumaria officinalis 






Int., dec. herb, 
syrup of juice, 
dist. water of 
herb (JG), Int.,  
Mdf 3  
Garrya fremontii 
Torr. Californian Fever Bush 
New 







W. Gr Intermittent fevers 
Int., inf. of 
root 
Gentiana lutea L., 
Gentiana purpurea 
L. 





(Gr, Th), Agues 
(Co) 
Int., root  Gr 3 
or Thr 4, Int., 
inf. herb in 
wine (Co) 
Gentiana 
quinquefolia Hill.  Five-flowered gentian Eur. Gr Intermittent fevers 
Int., tinct. of 
root 
Gentianella amarella 
(L.) Harry Sm. Autumn gentian Eur. Cu Agues 
Int. dist. water 




in liquid (Cu) 




(Gr, Th), Agues, 
esp. tertians (Sa) 
Int., dec. or 
inf. of powd. 
root or herb 
(Gr), Int., root 
or herb boi. in 
water or posset  






the-ground) Eur. Mdf Intermittent fevers Int.,  Mdf 2 
Gratiola officinalis 
L. Hedge hyssop Eur. Thr  Autumnal fevers Int.,  Thr 5 
Helianthus annuus 
L. Sunflower Eur. Gr Intermittent fevers 
Int., tinct. of 
the seed in 
ethanol 
Heliotropum 
europaeum L. ? Heliotrope Eur. Pl 
Tertians, Quartans 
(Pl) 
3 or 4 grains of 
seed in wine 




Helleborus niger L. 
Black hellebore, wild 
black hellebore, Great 
oxheel, Setterwort or 
bearfoot, "Christwurz 














(OB, Pl, Co - 
root) 
Hieracium murorum 
L. Hawkweed Eur. Gr (h) Agues Herb 
Hippurus vulgaris L. Horsetail Eur. D Intermittent fevers 
Drunk w/ wine 
one hour 
before the fit 
Hordeum distichon 




water or gruel 
[Gerstenschlei
msaft]) 









flowers, boi. in 
whey (JG),  





W. Th Intermittent fevers 
Int., a small 
amount before 
the fit OR to 
cause vomiting 
at the end of 
the cold stage. 




L., H. albus L. hyoscyamus sp. AvT 16 
Hypericum 
androsaemum L. Tutsan Eur. Mdf Intermittent fevers Ext.,  Mdf 1 
 
Hypericum coris L. 
Heath-leaved St. John's 
Wort, Aaron's beard Eur. HAP Quartans 
Pounded, and 
drunk in wine. 
Hypericum 
perforatum L. St. John's wort Eur. Sa, HB 




Int., warm dec. 
of leaves and 
seeds before 
the fit (Sa), 
Int. (HB) 
Hypericum 
tomentosum L. Woolly St. John's Wort Eur. JG 
Tertians and 
quartans 
Drink w/ wine 




barbatum Jacq. Hypericum sp. Eur. D, Pl 
Tertians, Quartans 
(D), Quartans (Pl) 
Int., w/ wine 




L. Hyssop Eur. 
AvT 
(h)  Int.,  AvT 10 
Ilex aquifolium L. Holly Eur. Gr Intermittent fevers 
Int., inf. or 
dec. of powd. 
Leaves 
Ilex verticillata (L.) 
A.Gray Black American alder 
New 
W. Gr  Intermittent fevers 










Agues (cold fever) 
(HAP), Quartans 
(AvT) 
boi. in oil and 
applied Ext. 
(HAP), Int.,  
AvT 8 
Ipomoea jalapa (L.) 
Pursh and I. 
pandurata (L.) G. 
Mey Jalap bindweed 
New 
W. Sa Agues Int.,  Sa 3 
Iris x germanica L., 
I. pallida Lam. and 
others 





Shaking fits of 
ague (Co) 
Int.,  AvT 1, 
Int., dec. of 
roots w/ honey 
(Co) 
Juglans nigra L. Walnut Eur. Co, Gr Agues (Co, Gr) 








L. Juniper Eur. Sa, BA 
Agues (Sa), 
Quartans (BA) 
Int., the extr.  
Sa 3, Taken 
every day 
(BA) 




Lactuca sativa L. Lettuce Eur. AvT Tertians, quartans Stalks 




L. Pl, Co Tertians, quartans 
(Pl) 







or silphion, or 
Narthex silphium, 





E. JG, Pl 
Agues (shaking 
and shivering of) 
(JG), Quartans (JG, 
Pl) 
Int.,  JG 2,  Pl 
3 
Laurus nobilis L. Bay Eur. Gr (h) Agues 
Int., inf. of 
berries 
Levisticum officinale 
W.D.J.Koch Lovage Eur. Gr (h) Agues 
Int., dec. of 
herb (Gr from 
Cu) 
Liquidambar 
orientalis Mill. Storax (Liquidambar) 
Mid. 
E. AvT Quartans Int.,  AvT 1 
Magnolia acuminata 
(L.) L. and M. 
virginiana L. Magnolia 
New 
W. Gr Malaria 
Int., bark of 
stem and root 
Malva sylvestris L. 
or Althaea officinalis 
L. Mallow Eur. Mdf Intermittent fevers 
Ext.,  Mdf 1, 
Int.,  Mdf 2 
Mandragora 
officinarum L. Mandrake Eur. AvT Quartans 
Int., the bark  
AvT 6 
Many sp. Balsam 
Mid. 




various) Stone liverwort Eur. JG Tertians  
Melissa officinalis L. 
Melissa, Lemon balm, 
"Muterkraut, 
Pfaffenkraut" Eur. OB Quartans Int., the herb 
Mentha  spicata L., 
Mentha x piperita L. Mint Eur. Sa 
Agues (quartan) 
(Sa) Int.,  Sa 2 







Ext., twigs in 
wool, wound 
about the head, 
for headache 





fit, or place 
under 
bedclothes 















quartans (Thr) Leaves, finely 
powd., inf. or 
extr. (Thr) 
Mercurialis perrenis 
L. Dog's mercury Eur. Gr (h) Ague 
Int., dec. in 
rooster broth 
Myristica fragrans 




Int.,  Sa 3, w/ 
other unsp. 
ingred. (Gr) 
Myrrhis odorata (L.) 
Scop. 
Hartswort or Seseli 
(Cicely?) Eur. JG Agues 
Int., seed, w/ 
wine 
Narcissus 


















W. Sa, Co 
Agues (Co), Agues 
(especially tertian) 
(Sa) 
Int., dist. water 
of herb w/ 
sugar before fit 
(Co), Ext.  Sa 
1 
Nigella sativa L, 
Nigella damascena 
L., and others Nigella, Fennel flower Eur. Co Tertians, quartans 
Int., seeds in 
wine before fit 
Oenanthe aquatica 







E. AvT Quartans Int.,  AvT 1 
Origanum vulgare L. Oregano Eur. 
AvT 
(h)  Int.,  AvT 10 
Paeonia officinalis 









(D); Ext., juice 







pains of); Provoke 
sleep to reduce 
severity of fit 
Int.,  AvT 12; 
AvT 16 (to 
provoke sleep, 
thus reducing 
severity of fit) 
Passiflora 
maliformis L. & P. 
suberosa L. Granadilla 
New 
W. Gr Intermittent fevers Int., leaf juice 
Pastinaca sativa L. Parsnip Eur. Gr Intermittent fevers Int., seeds 
Persicaria amphibia 
(L.) Delarbre Amphibious persicaria Eur. Mdf Intermittent fevers Ext.,  Mdf 1 
Persicaria bistorta 
(L.) Samp. Bistort Eur. Gr (h) Intermittent fevers Root,  Gr 1 
Petroselinum 





















and long Int., in wine 
Pimpinella anisum 
L. Anise Eur. 
AvT, 
Pl Quartans (Pl) 
Int.,  AvT 14, 
Int.,  Pl 2  







Int. or Ext. 
(D), Int.  AvT 
1 or AvT 9, 
Int., large dose 
to cure (Thr) 
Pistacia lentiscus L. Mastic 
Mid. 
E. AvT Quartans 
Int., gum, AvT 
7; Int., 
flowers, AvT 8 
Pisum sativum L., 
Cicer arietinum L., 
or Lathyrus odoratus 
L. (unlikely) 
Zyßeren erbsen (Pea, 
chick pea, or sweet 
pea?) Eur. OB Quartans, Tertians 
Int., legumes 
boi. in water 
Plantago major L. 











Tertians (HAP, D, 
OB, HB, Thr, Pl),  
Quartans (D, OB, 
HB), Intermittent 
fevers (Gr) 
Int. roots in 
wine (D), Int. 
sprouts in 
water or wine, 
fasting, before 
fit (HAP), Int. 
roots in wine 
and water; Int. 
dist.; Int. herb 
juice (OB), 
Int., roots boi. 
in wine; Int. 
root dist. (HB) 
Reported by 
others (Thr), 
Int. root juice 
or the pounded 
root in water 
or honey water 
before fit (Pl), 
Int., fluid extr. 








(D, Gr), Tertians 
(Pl) 
Int. w/ wine 
before fit (D), 












Quartans (HB, Co) 
Int., dist. water 
of roots & 
leaves (Gr, 
HB), Int., herb 




(Co);  Co 4 
Potentilla anserina 




Potentilla erecta (L.) 









wine and dist. 
(Co),  Gr 3;  
large dose 
(Thr); Thr 4 





(JG, D, Pl), 
Intermittent fevers 
(Gr [h]), Ague (Co) 
Int., root juice,  
JG 4; int., 
herb, D 1; Int., 
herb in wine or 
vinegar (Co), 
Int., leaves, 
either as D or 
in honey water 
w/ pepper (Pl) 
Prunus laurocerasus 
L. Cherry laurel Eur. Th Agues 




Flanders or Kentish 
cherries Eur. JG Agues Int., fruit 






Fleawort and Never 
dying fleawort Eur. JG, Cu Tertians (JG)  
Int.,  JG 3; 










Int., sour seeds 
(JG), Int., 
powd. rind of 
fruit (Gr) 
Quercus robur L. 
and others Common oak, Oak Eur. Th, Gr 
Intermittent fevers 
(Th, Gr) 
Int., bark (Th), 




sativus  (L.) Domin Radish Eur. HvB Three-day fever Int.  HvB 2 
Rheum rabarbarum 




(D), Agues (Sa), 
Lingering agues 
(JG) 
Int. w/ wine 
(D); Int., root 
boi. in posset 
before fit (Sa), 
Int., leaves inf. 
in ale (strong 
purgative) 
(JG); Int., 





Ricinus communis L. 
Satyrion royall, Palma 
christi, Castor bean Eur. JG Quartan 
Int., roots, 
crushed w/ 
wine before fit 
(as purgative) 
Rosa sp. Rose Eur. 
Cu, Sa, 
Gr (h) 
Agues (Cu, Sa, Gr 
(h), BA) 
Int., syrup of 
dried red roses 
(Cu, Gr); Int.  
Sa 2; Ext., oil 
(BA) 
Rubia tinctorum L. Madder Eur. HvB Four-day fever Int.  HvB 3 
Rubus sp. Brier Eur. HvB Four-day fever Int.  HvB 3 
Rumex acetosa L. 




Agues (JG), fiery 





Rumex acetosella L. 
Sorrel, Knobbed sorrel, 





Ruscus aculeatus L. Butcher's broom Eur. Mdf Intermittent fevers 
Ext.,  Mdf 1; 
Int.,  Mdf 2 









(Sa, Co),  Shaking 
of ague (Sa, Gr, 
Co) 
Int., possibly 
seed in wine 
(D); Int.  AvT 
3; dec. (Sa, Gr 




Ext.,  Sa 6; 




S. paniculata Mill. English saxifrage Eur. JG Agues 
Int., dec. in 
wine 




Int., dec. bark 
or powd. Root 
Salix caprea L. 
Great round-leaved 
willow Eur. Th Intermittent fevers Int., bark 
Salix x fragilis L. Crack willow Eur. Th Intermittent fevers Int., bark 
Salvia officinalis L. Sage Eur. Sa, Gr 
Agues (especially 
tertian) (Sa), Ague 
(Gr) Ext.,  Sa 6 








Int., flowers in 
water, spirit, or 
vinegar, & 
cover up to 
sweat (Cu); 




flower & bark 
oil, to  vomit 
(Cu);  syrup of 
the berries, 
buds, or bark 
(for children; 






salt of elder 
(Cu); Cu 4; 
Ext.  Mdf 1; 
Int. juice  OB 
2 
Sambucus nigra L. Elder Eur. Mdf 
Intermittent fevers 
(Mdf) 
Int., root bark  
Mdf 2 
Santalum album L. 
Sandalwood (white and 
yellow) India Cu Agues, hot fits of 
Ext., applied 
w/ rosewater 
to the temples 
Sassafras albidum 
(Nutt.) Nees Sassafras or Ague tree 
New 
W.  JG, Cu Tertians (JG) 
Int. wood inf., 
for days 
together (JG); 
dec. of wood ? 
(Cu) 
Saussurea costus 





(AvT), Cold fits of 
ague (Cu) 
Ext. w/ oil, 
before fit (D), 
Int.,  AvT 2, 
Ext., w/ oil to 
warm during 
cold fit (Cu) 
Scutellaria 
galericulata L. Common scullcap Eur. Gr Tertians 
Int., juice or 
herb inf. 
 
Sedum acre L. Wall pepper Eur. JG 
Quartans and other 
agues of long 
standing 
Int., extr. juice 
w/ vinegar or 




Sedum roseum (L.) 
Scop. ? Aaron Eur. Sa 
Agues (quartan) 
(Sa) Int.,  Sa 2 
Sempervivum 
tectorum L. Houseleek Eur. Co 
Quartans, lingering 
agues (Co, Th)  








Afr. Co Quartans (Co) 
Int., dec. or 











W. Gr Intermittent fevers  
Silybum marianum  
(L.) Gaertn. Milk thistle Eur. Gr, Co Ague (Gr (h), Co) 






W.  Gr 
Intermittent 
fevers/Antiperiodic 
Int., inf. of 
powd. seeds 
Sinapis alba L. White mustard Eur. D Intermittent fevers 
Int., dried, in 
beverage (D) 




(Heidnisch Wundkraut) Eur. Cu Agues, continual 
Int., herb boi. 
in wine 
Stachys officinalis 




Agues (JG, Sa), 
Quotidians, 
tertians, quartans 
(OB),  Quartans 
(Co) Tertians and 
quartans (Pl) 
Dried leaves 
(JG), Int.  Sa 2 
(Sa), Int.,  Co 
3 (Co), Int., in 
hydromel, or 
specifically for 
quartans,  Pl 1 
(Pl) 
Symphytum 
officinale L. Comfrey Eur. JG 
Agues (to temper 
the heat) Int.  JG 1 (JG) 
Syringa vulgaris L. Lilac Eur. Gr 
Antiperiodic/Malar
ia Leaves, fruit 
Syzygium 
aromaticum (L.) 
Merr. & L.M. Perry Cloves Asia 
Sa, Co, 
HvB 
Agues (Co, Sa), 
Three-day fever 
(HvB) 
Int., the oil 
(Co), Int.,  Sa 




balsamita L.? Balsam herb Eur. HvB Three-day fever Int.,  HvB 2 
Tanacetum 
parthenium (L.) 








Ext., w/ bay 
salt and powd. 
glass, wrist 
plaster (JG), 
Bound to the 
wrists (Gr), 
Int., a leaf in 
water (Pl, but 
ident. of plant 
uncertain) 
Tanacetum vulgare 
L. Tansy Eur. Gr, Co Agues 
Int., herb extr. 
(Gr), Ext., 
juice applied 
to wrists and 
soles of feet 
during hot fit 
(Co) 
Taraxacum 






(Gaertn.) Roxb., T. 
chebula Retz., T. 
citrina Roxb. ex 
Fleming, and others 
Myrobalans or 
Mirobalans Asia Co 
Tertians, quartans, 
long continued 
agues (Co) Int., fruits 
Teucrium 
chamædrys L. Wall germander Eur. Gr Intermittent fevers Int., herb 
Teucrium scordium 







Ext., tied about 
the body 
(HAP), Int., 
dried herb inf. 
(Gr) 
Thuja occidentalis L. 
Yellow cedar (arbor 





Thymus serpillum L. 
Wild thyme, Thyme 
marjorum Eur. JG Agues 
Int., boi. in 
wine 
Thymus vulgaris L. Garden thyme Eur. 
JG, 
















Int., leaves w/ 
wine or seeds 
(JG), Int., dec. 
herb (HB) 
Trigonella caerulea 
(L.) Ser.? Sweet trefoil or balsam Eur. Co Tertians, Quartans Int., dec. herb 
Trigonella caerulea 
(L.) Ser.? Sweet trefoil or balsam Eur. Co Tertians, Quartans Int., dec. herb 
Trigonella fœnum-





"Said to be equal to 
quinine in 
preventing fevers" Int., seeds 
Tussilago farfara L. 
? Coltsfoot? Eur. HvB Three-day fever Int.  HvB 2 
Urtica dioica L. Stinging nettle Eur. Gr Ague 











Agues (D), Tertian 
(Sa, OB, Co, Pl), 








(D), Int. (?), 
the herb (Sa, 
Co), Int., water 
of the leaves 
(OB); dec. 










Verbena supina L. Supine vervain Eur. D Tertians, Quartans 
Int., herb in 
beverage 
Viola lutea Huds. 
Wall flower, mountain 
pansy Eur. JG Agues 
Ext., crushed 




Viola odorata L. Violet Eur. Gr, JG Ague (Gr (h)) 
Int., syrup of 
flowers (Gr 
(h)) 




in infants & 
children) Int. 
Vitis vinifera L. Grape Eur. AvT Quartans (some) 
Int., as part of 
cooling diet 
Zanthoxylum 
americanum Mill. Prickly ash 
New 
W. Gr Agues Int., dec. bark 
Zingiber officinale 
Roscoe Ginger Asia HvB Three-day fever 
Int.  HvB 2; 
Int., Cu 3 
Ziziphus jujuba Mill. Beade Tree, Jujube tree 
Eur., 
Asia JG Agues (JG) 
Int., dec. bark  
JG 5 
      
Non-plant remedies 
and ingredients:      
Agaricus or Boletus 
sp. (various) 
Agarics or boletes 
(unsp.) Eur. D, Cu Agues 
Int. in wine 
before fit (D), 
Int., Cu 3 
Amber Amber Eur. Sa Agues Int.,  Sa 3 
Annelida sp. Earthworms Eur. D Tertians Ext., ground 
Antimony Antimony Eur. Sa Agues 
Int., dist. w/ 
sugar, give in  
wine before 
fit, 2-3 times 
to cure (Sa);  
Sa 5 
Araneae sp. Spiders Eur. D Tertians, Quartans 
Ext., paste, for 
tertian; amulet 
for quartan (D) 
Brachyura sp. Crab Eur. Sa 
Agues (quartan) 
(Sa) 
Int., the eye  
Sa 2; Int., 
powd. black 
tips of claws in 
any liquid (Sa) 
Castor fiber 
Beaver (source of 
castoreum) Eur. AvT Quartans 
Int.,  AvT 4, 
AvT 5 
Cimex lectularius ? Bed bugs Eur. D Quartans 





before the fit 
Gallus gallus Rooster Eur. D Agues (lingering) 
Int., broth,  D 
2 
Polypores growing 
on Larix sp. 






Agues (JG, Sa), 
agues (lingering) 





unsp. ingred.  







w/ oxymel or 
as Co 1, Co ) 
Sulfur Spirit of sulfur Eur. Sa 
Agues (tertian) 
(Sa) Int.,  Sa 4 
Worms (unidentified 
sp.) in Dipsacus 
fullonum L. 
Worms in the heads of 









up in a purse, 
hung at the 
neck or arm 





Table 2: Compound remedies  
 
Name of 
compound Specificity Components 
AvT 1 Quartans Storax, myrrh, opoponax, iris, pepper, galbanum, poppy juice.  
AvT 2 Quartans 
Saffron, opium, galbanum, cassia-cinnamon, storax, myrrh, 
castoreum, costus, pepper, spikenard, honey.  
AvT 3 Quartans 
Kyrenaischer saft (Cyrenian liquid, identity uncertain), pepper, 
myrrh, rue.   
AvT 4 Quartans 
Castoreum, poppy, myrrh, white pepper, Kyrenaischer saft 
(Cyrenian liquid, identity uncertain).  
AvT 5 Quartans Opoponax, opium, castoreum, henbane seeds.   
AvT 6 Quartans 
Poppy seeds and juice, white henbane, liquorice juice, storax, 
anise, saffron, castoreum, mandrake bark.   
AvT 7 Quartans 
Wormwood, colocynth, aloe, gum mastic, dodder growing on 
thyme. 
AvT 8 Quartans 
Myrrh, spikenard, saffron, castoreum, opium, amomum (exact 
species unknown), anise, Macedonian parsely, celery seed, mastic 
flowers, cassia, white pepper, black pepper, storax, Sison 
amomum, Sesel (unidentified), sage, honey. 
AvT 9 
Tertians, 
quartans Scammony, larch agaric, rosewater, honey, pepper. 
AvT 10 Quartans Pennyroyal, oregano, hyssop, and barley water 












quartans Roots of celery and maidenhair, cooked until soft 
AvT 14 
Tertians, 
quartans Anise, celeriac, leek leaves, honey, and vinegar 
AvT 15 Quartans Candy carrot seeds, with pepper, in hot water 




Sliced larch agaric, ginger, rock salt, polypodium, damask rose 




Hiera Picta (aloe juice, boiled down and powdered, with the bark 
of white cinnamon, Canella alba), larch agaric, aloe, honey, roses  
Co 3 Quartans Betony and pennyroyal in decoction, with mead  
Co 4 Quartans 
Common polypody with whey, honeyed water, barley water, or 
chicken broth with thyme, beet, and mallows  
Co 4 Agues European wild ginger, let sit in sun with laudanum 
Co 5 
Shaking fit 
of ague Decoction of rue with dried dill herb and flowers 
Cu 1 
Shaking fit 
of ague Asfoetida, myrrh, pepper and frankincense  
Cu 2 Quartan Asfoetida, pepper, ginger, and rue  
Cu 3 Ague Agaricus or boletus sp. with ginger, honey, and vinegar 





Cinquefoil drunk with hydromel or diluted wine, and a little 





Broth of an old rooster with sea colewort, mercury, cnicum 





Syrup made from comfrey, liquorice, poleroot, pinenuts, jujubes, 





Quartans Laserpitum, wine, pepper, and white frankincense 




Cinquefoil root juice drunk in mead or honeyed water, or wine 
with pepper 
JG 5 Agues Beade tree bark with fumitory and mirobalans 







Bastard rhubarb roots boiled in water of blessed thistle, with 
honey, taken before the fit on two or three separate occasions  
Gr 1 
Intermittent 
fevers Bistort root and calamus root 
Gr 2 Agues Chicory and endive (historic) 
Gr 3 
Intermittent 
fevers Gentian with astringents such as tormentil or galls 















Madder, brier bush, fallow root (unidentified), and wine, heated 




Mugwort, dwarf elder, tutsan, amphibious persicaria, pimpernel, 
butcher's broom, elder bark, mallow boiled together and added to 




Moss, ground ivy, elder or caraway, mallow, fennel, pimpernel, 
butcher's broom, borage, and young leaves of the earth nut, boiled 
together and mixed with the juice of elder root bark and fermented 
with goat's or cow's whey.  After taking, consume apple, honey, or 




Fumitory, infusion with dandelion in the morning, then 
wormwood infusion at noon 
OB 1 Quartans Hops seethed in wine, "mit hirtzzung und senet bletter" 
OB 2 Quartans The juice of dwarf elder with powdered leafy spurge 
Pl 1 Quartans 
Betony powdered with hypericum seed and panaces (an 
unidentified herb) 
Pl 2 Quartans Fennel and anise in vinegar and honey 
Pl 3 Quartans Garlic, one head with silphium (see laserpitum) in dry wine 
Sa 1 
Agues, esp. 
tertians Tobacco, rue, sage, bay salt, and vinegar (wrist plaster) 
Sa 2 Agues Betony, aaron roots, crabs' eyes, cinnamon, sugar of roses, mint  
Sa 3 Agues 
Scammony, myrrh, aloe, galbanum, jallop, white agaric, nutmeg, 
amber, cinnamon, cloves, and juniper 
Sa 4 Agues Scammony, saffron, aloe, spirit of wine, and spirit of sulfur 
Sa 5 Agues Antimony, angelica, and canary wine (as vomitory) 




Powdered chamomile flowers, salt of wormwood, and antimony 
(given as diaphoretic)  
Thr 2 
Intermittent 
fevers Dried arum root, rhubarb, and tartarus vitriolatus   
Thr 3 
Intermittent 
fevers Cinchona with snake root added to increase the efficacy  
Thr 4 
Intermittent 
fevers Gentian with astringents such as tormentil or galls 
Thr 5 
Autumnal 







 In the fifteen sources used, 251 substances were identified as having likely been 
used in the treatment of malaria.  Of these, 239 are plants; the remaining twelve include 
sulfur, antimony, unidentified fungi, and animal ingredients.   Not all of the remedies in 
the table were intended to remove disease; many were intended to palliate symptoms, 
while others may have been added to compound remedies in order to improve their taste, 
appearance, or perceived value.  It was often impossible to determine whether a given 
remedy or ingredient was intended to cure the disease or for one of these other purposes.  
Nevertheless, it is probable that a large portion of the substances in the table were 
intended to cure malaria.  Some substances appear repeatedly and may be of special 
interest from a medicinal chemistry standpoint; these will be discussed in more detail 
below. 
 From the table, it will be seen that some of the remedies are what would today be 
considered as food rather than medicine.  As in the Chinese and Ayurvedic medical 
traditions, the Greek and Roman physicians considered diet to be of paramount 
importance to the maintenance of health and prevention of disease.  It was believed that 
one of the causes of disease was an immoderate or imbalanced diet, sometimes to the 
extent that a disorder might be caused or cured by the consumption of particular food 
items (Celsus, 1960; Phillips, 1973).  The medieval physicians also held strongly to this 
belief (Major, 1954; Gottfried, 1986), and specific dietary recommendations are not 




Bartholomæus Anglicus (writing before 1283) gives the following information about the 
cucurbit: 
And it is to hem that hauen the feuer agu bothe mete an medicyne yrostid 
other fryed; for he purgeth the matiere by vryne and laxeth, and abateth 
the hetes and comforteth the sike.14 (Bartholomæus Anglicus, translated 
by John Trevisa, 1398.) 
 
It is certainly possible that some of the foods given in the dietary prescriptions may have 
contained compounds active against malaria, or may perhaps have contributed to the 
efficacy of other remedies; however, this portion of the table is perhaps of more historical 
than medicinal chemistry interest.    
Several of the remedies listed in the table are meant to be carried or worn as 
amulets against malaria.  It is not commonly believed today that amulets could have had 
other than a psychological effect in treatment or prevention of disease (Cameron, 2006).  
Indeed, the sources used in this project often describe amulets with some degree of 
skepticism.  The colorful nature of some of these remedies may have led to their 
perpetuation in the literature.  For example, the following use of the worms found in the 
heads of teasel (Dipsacum fullonum L.) appears in four of the sources examined:  
 
But ye worms of ye heads being bound up in a purse, & hanged about the 
neck or the arme, are sayd to cure such as have quartanes. (Dioscorides, 
Book III, 13.; Goodyer.) 
 
                                                
14 In the above quotation, as well as others by Bartholomæus Anglicus, the runic letter for the 




From Goodyer’s translation, Dioscorides appears to be relating this superstition at 
a slight distance.  In fact, each of the sources including this remedy evinces some degree 
of scepticism.  For example, Hieronymus Bock mentions it thus:  
 
Dioscorides writes that the worms that are sometimes found in the interior 
of this thistle are good for quartan fever, wrapped up and carried about the 
neck.  I have not tried it – I have certainly found the worms.15  
 (Hieronymus Bock, Kreutterbůch, 1572 edition) 
 
  Aside from those remedies overtly intended for use as amulets, there are ritual 
components in many of the other prescriptions found in the sources.  A frequent example 
is the instruction that for a tertian fever, one should use a plant with three stems, or take 
three leaves or roots, or cut at the third joint, and that for a quartan fever, one should use 
a plant with four stems, or take four leaves or roots, or cut at the fourth joint.  This 
appears at least four times in Pliny’s Natural History, including the following 
descriptions of the use of cinquefoil (possibly Potentilla reptans L.) and vervain 
(Verbena officinalis L.): 
Some have prescribed doses of three cinquefoil leaves for tertians, of four 
for quartans, and of more for the other fevers; others prescribe for all three 
oboli with pepper in hydromel.  Vervain in wine indeed is a remedy for 
fever even of beasts of burden, but for tertians the plant must be cut at the 
third joint, and for quartans at the fourth.  (Pliny, Book XXVI, Chapter 
LXXI., translated by W.H.S. Jones.) 16 
 
                                                
15 Dioscorides schreibet/ das die würmlin so etwann im marck diser distel funden werden/ seien 
gůt für das feber quartana eingewickelt unnd am halß getragen/ ich habs nicht erfaren/ die 
würmlin hab ich wol funden.  (Translation mine.) 
 
16 Quinquefolii folia quidam terna tertianis dedere, quaterna quartanis, plura ceteris, alii 
omnibus tres obolos cum pipere ex aqua mulsa.  Verbenaca quidem et iumentorum febribus in 




In addition to their possible magical purpose and psychological value, apparent 
ritual elements in a remedy may have contributed to the activity of the remedies in other 
ways.  As an example, the following is Hildegard of Bingen’s prescription for a four-day 
fever: 
A person who suffers from a four-day fever should take madder, the same 
weight of brier bush, and three times this combined amount of fallow root 
and boil them in wine.  Then pour clear, very good wine into a basin and 
plunge a heated, glowing-hot piece of steel into it; plunge the heated steel 
into the wine in this basin a second time.  Do it ten times with the same 
wine and the same steel.  After that, take the wine in which you boiled the 
plants, pour it into the heated wine into which you have plunged the hot 
steel bar, cause the whole thing to boil up one more time, and when the 
fever begins again, drink it immediately, and keep it up until you are 
healthy.  (Hildegard of Bingen, Translation by P. Madigan, 1994) 
 
The manner of heating is of interest.  Although at first it seems ritualistic, it would likely 
result in the presence of iron salts in the resulting liquid.  As malaria is known to cause 
anemia (Greenwood, 2005), it is possible that this method of heating might have helped 
the patient to recover more quickly. 
 However, the majority of the remedies listed are plants or combinations of plants 
intended to be of primarily medicinal rather than dietary or magical use against malaria. 
Of these, most (approximately 65%) are referred to in only a single source.  From the 
sheer number of different substances that were recommended at various times, it is hard 
to escape a conclusion that most of the remedies were not very effective (Cameron, 
2006).  However, approximately 35% of the remedies are referred to repeatedly.  A 
scientific examination of these plants for antimalarial activity might be of particular 
value.  Only a portion of the plants listed here have been examined previously for 




 Of the 251 entries in Table 4.1, 38 substances were referred to in three or more 
sources (Table 4.3, below).  Of these, at least fifteen have previously been examined for 
antiplasmodial activity; in many cases, they were found to have antiplasmodial activity in 
vitro or in vivo.  A small selection of the plants in Table 4.3 will be discussed in more 
detail below.  
 
Table 4.3: Remedies listed in three or more historical sources  
 
Scientific name Common name 
Number of 
references in 




Anchusa officinalis L.,  Alkanna 
tinctoria (L.) Tausch, Anchusa 
azurea Mill. Alkanet, bugloss 3 
Ozbilgin (2014)  
(Alkanna tinctoria) No 
Artemisia absinthium L. Wormwood 6 Zimmerman (2012) Yes 





Asarum europaeum L. European wild ginger  4 Not found  
Berberis vulgaris L. Barberry 3 Not found  
Centaurea benedicta (L.) L. Blessed thistle  5 Not found  
Centurium erythraea Rafn Centaury 3 Danzel (1948)  
Chamaemelum nobile (L.) All., 





Vaughan (1795)  
(and many others) Yes 
Citrullus colocynthis (L.) 
Schrad. Colocynth 4 Not found  
Citrus limon (L.) Osbeck Lemon 3 Not found  




Kuntze subsp.glandululosum  calamint 
Commiphora myrrha (Nees.) 
Engl. and others Myrrh 3 Not found  
Convolvulus scammonia L. Scammony  3 Not found  
Cuscuta epithymum L. and 
others Dodder, Hell weed 4 Not found  
Gentiana lutea L., Gentiana 
purpurea L. 
Yellow gentian, 
purple gentian 3 
Zimmerman (2012) 
See also Riscoe 
(2005) Yes 
Geum urbanum L. Avens 3 Zimmerman (2012) Yes 
Helleborus niger L. Black hellebore 5 Not found  
Lamium purpureum L. 
Lamium (Dead 
nettle) 3 Not found  
Mentha pulegium L. Pennyroyal  4 Not found  
Peucedanum ostruthium (L.) 
W.D.J. Koch Masterwort  3 Zimmerman (2012) Yes 
Piper nigrum L. Pepper 3 Kamaraj (2012)  





Sangian (2013) (P. 
lanceolata) Yes 
Polygonum aviculare L. Knotgrass 3 Not found  
Polypodium vulgare L. 
Common polypody 
(oak fern, Engelfuß, 
Steinfarn) 3 Not found  
Potentilla erecta (L.) Raeusch. Tormentil 3 Zimmerman (2012) Yes 
Potentilla reptans L. Cinquefoil 5 Not found  
Rheum rabarbarum L. Rhubarb 3 Not found  
Rosa sp. Rose 3 Not found  
Ruta graveolans L. Rue, Herb Grace 6 Not found  
Sambucus ebulus L. Dwarf elder 3 Zimmerman (2012) Yes 
Saussurea costus (Falc.) 
Lipsch. Costus 3 Not found  
Stachys officinalis (L.) Trevis. Betony 5 Not found  




Merr. & L.M. Perry 
Tanacetum parthenium (L.) 
Sch.Bip. Feverfew 3 Zimmerman (2012) Yes 
Verbena officinalis L. 
Vervain, verbena, 
Eisenkraut 6 Zimmerman (2012) Yes 
Polypores growing on Larix sp. Shelf fungi on larch 6 Not found  
Worms (unidentified sp.) in 
Dipsacus fullonum L. 
Worms in teasel 
heads  4 Not found  
 
 
Artemisia absinthium L. and Artemisia vulgaris L. 
 
In this survey, wormwood (Artemisia absinthium L.) and mugwort (Artemisia 
vulgaris L.) were recommended to treat intermittent fevers by six and three sources 
respectively.  These plants are widely naturalized throughout various continents, 
including the United States.  Their use to treat malaria is intriguing, since they are 
relatives of Artemisia annua (qinghao), the source of the antimalarial artemisinin 
(qinghaosu); the additional Artemisia species A. abrotanum L. (southernwood), A. 
ponticum L. (Roman wormwood), and A. maritima L. (sea wormwood) are also 
mentioned in the sources as having antimalarial acitivity.  Both A. absinthium and A. 
vulgaris have been tested for antimalarial properties, and activity has been found both in 
vitro and in vivo (Plasmodium berghei in a mouse model; Milhau, 1997; Zimmerman, 
2012; Bamunuarachchi, 2013 and others).  There has, however, been a report that a 
traveler to West Africa attempted to use Artemisia vulgaris L. as antimalarial 





Berberis vulgaris L. 
 
Barberry (probably Berberis vulgaris L.), a Eurasian shrub producing edible berries, is 
recommended to treat intermittent fevers in three of the sources surveyed.  Although it 
appears that this species of barberry may not have been screened as an antimalarial, the 
roots of this plant are known to produce berberine, a compound with antiplasmodial 
activity.  Both this and other barberries are used in natural medicine in many parts of the 
world (Duke, 1985; Hutchens, 1991; Bahar, 2014).   
 
Citrus limon (L.) Osbeck 
 
The rind or juice of lemon (perhaps Citrus limon (L.) Osbeck) was recommended to treat 
intermittent fevers by three of the sources in the survey.  Although the lemon does not 
appear to have been assayed for activity against Plasmodium, the peel and juice of other 
species of citrus have been found to have antiplasmodial activity.  In a mouse study, the 
juice of grapefruit was found to confer some degree of protection against infection by 
rodent malaria (P. berghei; Oreagba, 2008), and acridones with antimalarial activity have 
been isolated from the peel of Citrus grandis (Fujioka, 1989).  Ascorbic acid (present in 
lemon juice) has also been found to potentiate the antimalarial activity of the oxidant 





Helleborus niger L. and others: 
 
Hellebore (including Helleborus niger L., Christmas Rose) was described in nearly all of 
the sources in this survey, and is one of the few medicaments recommended by 
Hippocrates (460-370 B.C., translated by Jones, 1957) and Celsus (25 B.C. – 50 A.D., 
translated by Spencer, 1960).  Although an Old World plant, it is grown in the United 
States as an ornamental.  It was formerly used in herbal medicine as a drastic purgative, 
but at the time of Celsus it was already considered quite dangerous and not appropriate 
for all patients – its use causes nausea and diarrhea, and larger doses cause vomiting, 
narcosis and coronary arrest (Gerard, 1597; Duke, 1985; Frohne, 2005).  Five of the 
sources in this survey recommended the use of hellebore in intermittent fevers.  However, 
each author urges caution in its use.  Bartholomæus Anglicus gives the following 
warning: 
 
Dias and othre auctors meneth that it is a ful violent herbe and schal be 
ytake redily and warly, for he greueth and son[e]st ageins many yueles if it 
is vnredily ytake to ony person… he destroyeth the feuere quarteyn… 
(Bartholomæus Anglicus, translated by John Trevisa.) 
 
Gerard has the following: 
 
Blacke Hellebor purgeth downwards flegme, choler, and also blacke 
choler especially, and all melancholike humors, yet not without trouble 
and difficultie.  Therefore it is not to be giuen but to robustious and strong 
bodies, as Mesues teacheth.  A purgation of blacke Hellebor is good for 
mad and furious men, for melancholike, dull, and heauie persons, for those 
that are troubled with the falling sicknesse, for lepers, for them that are 




blacke choler, and molested with melancholie.  (John Gerard and Dr. 
Priest, 1597) 
 
Although hellebore was intended to purge disease-causing humors, it is possible that this 
plant may contain compounds that are active against Plasmodium species.  As this plant 
apparently has not been assayed for antimalarial activity, it may be another 
phytochemical source of interest. 
 
Plantago major L. and Plantago lanceolata L. 
 
The plantains (waybread, or Wegerich, and ribwort, or Spitzwegerich) are 
recommended to treat intermittent fevers in seven of the sources surveyed, more 
frequently than any other plant.  These edible plants are present on several continents, 
and both species are common in the Pacific Northwest as an introduced species.  The 
plantains are used in traditional medicine in many parts of the world (Duke, 1985).  
Sangian and coworkers (2013) have recently reported that an ethanolic extract of P. 
major had mild antiplasmodial activity in vitro (IC50 = 40 µg/mL).  Therefore, further 
examination of both P. lanceolata L. and P. major L. appears promising, particularly as 








Potentilla reptans L. 
 
Cinquefoil, tentatively identified as Potentilla reptans L., was recommended to treat 
intermittent fevers by five of the sources in this survey.  However, it does not appear to 
have been assayed for antimalarial activity.  A related species, Potentilla discolor, is used 
in Chinese medicine to treat malaria (Yang, 2010). 
 
4.4: Further notes on historical remedies, and a word of caution for medicinal 
chemists 
 
While the approach of looking for active compounds in medicinal plants is 
intriguing from the perspective of medicinal chemistry, it is attended by certain dangers 
from an anthropological or historical point of view.  There is a large difference between 
an herbal remedy administered in the recommended form within in its cultural context, 
and a purified compound given as a pharmaceutical drug.  It must not be concluded that 
because a plant extract does not have in vitro antiplasmodial activity that the remedy was 
useless.  In vitro and even in vivo testing of plant extracts may provide misleading results 
for several reasons.  Firstly, the importance of psychological factors in determining the 
efficacy of medical treatment must not be underestimated.  Secondly, whole plants may 
contain active constituents that are degraded under the conditions of the techniques used 
to extract them.  In view of this it is important to consider the recommended method of 
administration of the remedy. Thirdly, more than a single constituent may be important to 




that act either separately or synergistically, or it may be that compounds are present that 
have little antimalarial activity of their own, but potentiate the activity of the active 
constituents.  The latter may be true in the case of qinghao (sweet wormwood, Artemisia 
annua L.), the source of the antimalarial compound artemisinin (qinghaosu).  Mice fed 
whole plant Artemisia annua have been observed to have far higher levels of artemisinin 
in their blood than those fed an equivalent amount of purified artemisinin (Weathers, 
2011), and in a mouse model of malaria it has also been observed that whole-plant 
Artemisia annua has higher antimalarial activity than would be expected on the basis of 
its content of artemisinin (Elfawal, 2012).  It has therefore been suggested that other 
compounds are present in the whole plant that act synergistically with artemisinin; these 
compounds may be removed when artemisinin is purified.  Flavones isolated from 
Artemisia annua, such as artemetin and casticin (Figure 61, below), have been observed 
































Synergistic activity has also been observed in the case of cinchona alkaloids (Baranger, 
1948; Druilhe, 1988; Rasonaivo, 2011).  For the same reason, it is also important to 
remember that many of the remedies in the table were not intended to be given alone.  
Some of the compound remedies identified in the course of this project may have had 
antimalarial activity due to the synergistic action of constituents in several different 
ingredients.  
The sources used in this project generally provide the method in which a remedy 
should be prepared and administered, often in great detail.  As with modern 
pharmaceutical preparations, this may have had a significant effect on efficacy.  Some 
plants were recommended for fresh use, while others were recommended for use in a 
dried state; the state of the plant certainly would affect the constituents, but the 
determination of active constituents in fresh plant matter presents great challenges.  
Remedies intended for internal use are most often administered in liquid form.  The most 
common liquids used are water, wine (usually white wine is specified), vinegar, ale, and 
milk.  The prescriptions were sometimes heated – at times using sunlight – and other 
times not.  Heating in wine or vinegar would have a high likelihood of extracting active 
principles; it is conceivable that the prescriptions that are not meant to be heated may 
contain active constituents that would be destroyed by heat.  Honey is a frequent 
component of remedies.  It is easy to assume that this was simply added to improve the 
taste of an otherwise less palatable remedy, but the possibility that its presence increased 
the efficacy of the remedy cannot be neglected.  Writing in 1951, W.H.S. Jones has 





There is at least one ingredient of the Plinian remedies that must have 
been of great value.  Honey appears again and again in both potions and 
external applications, full use being made of its healing powers.  The 
superseding of honey by sugar has been by no means an unmixed blessing. 
(W.H.S. Jones, introduction to Pliny, volume VI, 1951.)  
 
More recently, honey has attracted considerable interest for its possible activity as an 
antibacterial, antiinflammatory, antidiabetic, and anticancer agent (Alvarez-Suarez, 2013; 
Carina, 2014; Erujawa, 2014). 
Finally, as mentioned above, some remedies are not single herbs (simples), but 
combinations of two or more herbs.  Compound medicines, sometimes including more 
than ten different substances, are often encountered.  William Coles, the author of The 
Art of Simpling, makes the following remark about compound remedies in the 
introduction to his Adam in Eden:   
 
And now let me tell the ingenious Reader, and by him others, that if those 
of these times would but be, by a joynt Concurrence, as industrious to 
search into the Secrets of the Nature of Herbs, as some of the former, and 
make tryall of them as they did, they should no doubt find the force of 
Simples many times no leße effectual, then that of the Compounds, to 
which this present Age is too too much addicted… Thus have I broken the 
Nut of Herbarisme, do thou take out the Kernel and eate it and much good 
may it do thee.  (William Coles) 
 
 
It cannot be assumed that all of the materials in a compound remedy were expected to 
have antimalarial activity of their own – some might have been intended to treat various 
symptoms or to improve the flavor and appearance of the remedy.  It must be suspected 




crab’s eyes were added for no other reason than to increase the perceived value of the 
remedy (e.g. Salmon, 1696).  A medicinal chemistry approach to the compound 
medicines might be to test the components individually, and then as the compound, to 
determine whether the components act synergistically; however, this would be quite 
laborious.   
 
4.5: Conclusions  
 
 
It may be seen from the results of this project, and those of other workers, that 
cinchona bark was far from being the only remedy for malaria used in Europe prior to the 
advent of modern antimalarial chemotherapy.  The results of antiplasmodial testing by 
other workers (Table 4.3) have shown that at least some of the treatments used may have 
been effective.  However, the majority of the phytotherapies for malaria identified in this 
project have not yet been tested against Plasmodium species.  Despite the cautions above, 
the results obtained by other workers indicate that this approach may provide valuable 
leads for medicinal chemists.  Moreover, this project has examined only a fraction of the 
surviving historical literature on the treatment of malaria.  A more comprehensive project 
might be of great historical value.  The following are the words of the historian Theodor 
Puschmann, writing in 1878: 
 
The history of a science is that science itself.  The knowledge of its past 
gives understanding of its present.  The doctor who neglects historical 
studies becomes an empiricist; he will fall into many errors, undertake 




his predecessors, and because he has become used to measuring facts by the 
narrow measuring stick of the time period to which he belongs. 
 
Theodor Puschmann, 1878 (Vorwort, Alexander 
of Tralles: Original-Text und Übersetzung.)17 
 
 




                                                
17 Die Geschichte einer Wissenschaft ist diese Wissenschaft selbst.  Die Kenntniss ihrer 
Vergangenheit gibt das Verständniss ihrer Gegenwart.  Der Arzt, welcher die 
historischen Studien vernachlässigt, wird zum Empiriker; er wird manchen Irrweg 
einschlagen, manche fruchtlose Arbeit unternehmen, weil eir nicht gelernt hat, die Fehler 
seiner Vorgänger zu vermeiden, und weil er sich gewöhnt hat, die Thatsachen mit dem 
Massstab des engen Zeitraumes zu messen, dem er angehört.  (Historical spelling 
preserved.  English translation mine.) 
18 Bartholomæus Anglicus, in On the Properties of Things. (Translation into English by 








5.1.: General synthetic methods 
 
Described below are the general synthetic methods used to make the compounds 
described in this work.  For specific synthetic details for each compound, including 
characterization data, see Appendix A: Specific synthetic methods and characterization 
data.  For in vitro antiplasmodial activity and cytotoxicity data, see Appendix B: Tables 
of in vitro antiplasmodial activity and cytotoxicity.  For sample NMR data (for PL241), 
see Appendix C: Sample NMR spectra: PL241. 
5.1.1.: Synthesis of drug candidates and intermediates: Quinoline-ring modified 
reversed chloroquine-type compounds 
 
Substituted 4-chloroquinolines with hydrogen in the 2-position were made by the Gould-
Jacobs reaction, followed by chlorination with phosphorus oxychloride (Figure 62; 






































R = H, F, Cl, Br, I, NO2, CF3, Me, OMe
Claisen, R.L.; Hasse, E., Justus Liebigs Annalen der Chemie, 1897, 297, 1-98
Gould, R.G. Jr.; Jacobs, W.A., J. Am. Chem. Soc., 1939, 61, 2890-2895
Price, C.C.; Roberts, R.M., J. Am. Chem. Soc., 1946, 1204-1208
 




 4-chloroquinolines containing a trifluoromethyl group in the 2-position were made by 
the Conrad-Limpach reaction, followed by phosphorus oxychloride chlorination (Figure 
































R = H, Cl, OMe
R' = CH3, CF3
Conrad, M.; Limpach, L., Ber., 1887, 20, 944-98; 1891, 24, 2990-2; 
Reynolds, G.A.; Hauser, C.R., Organic Syntheses 
Collective Vol 3., 1955, 374-5 and 593-4
 
Figure 63: Synthesis of 2-trifluoromethyl-4-chloroquinolines by the Conrad-Limpach reaction, followed by 
phosphorus oxychloride chlorination. 
 
 
In most cases the resulting substituted 4-chloroquinolines were then allowed to undergo 
solvolysis with 3-amino-1-propanol to give 4-amino alcohols, and the hydroxyl group 

























R = H, F, Cl, Br, I, NO2, CF3, Me, OMe
R' = H, CH3, CF3
Burgess, S. J., Kelly, J.A., Shomloo, S., Wittlin, S., Brun, R., 
Liebmann, K., Peyton, D.H., J. Med. Chem., 2010, 53, 6477-6489  
 
Figure 64: Reaction of 4-chloroquinolines with 3-amino-1-propanol, followed by activation of the resulting 
alcohol by methanesulfonyl chloride. 
 
Finally, the resulting compounds were allowed to react with an appropriate secondary 
amine to yield either the final products (Group 1, Figure 65, below) or an imine that was 
then reduced with sodium borohydride to yield the final product (Group 2, Figure 65, 
below).  The secondary amines required to produce the compounds in Figure 65, Group 
1, were purchased, but in the case of the secondary amine required to produce compounds 
shown in Figure 65, Group 2,  the secondary amine was first synthesized as shown below 

































































Burgess, S. J., Kelly, J.A., Shomloo, S., Wittlin, S., Brun, R., 
Liebmann, K., Peyton, D.H., J. Med. Chem., 2010, 53, 6477-6489
 
 
Figure 65: Reaction of mesyl alcohols with secondary amines to produce the final products. 
 
 
In one case, a different method was used to produce a final product starting from the 4-
chloroquinoline; this is detailed below (PL142, Method 2, Appendix A, p. 257).   In most 
cases, final products were purifiable by recrystallization, though column chromatography 





5.1.2: Synthesis of asymmetrical bis-quinoline type compounds 
 
The synthesis of the asymmetrical bis-quinoline compounds required the synthesis of two 
different quinoline starting materials.  One quinoline starting material was identical to 
that shown above (Figure 64, far right).  The other was produced by reaction of the 
appropriate 4-chloroquinoline with 3-carbethoxy-4-aminopiperidine in phenol (Andersag, 
1948; Surrey, 1951; De, 1998), followed by removal of the carbethoxy group by heating 






















Figure 66: Synthesis of one starting material for asymmetrical bis-quinoline compounds. 
 
Reaction of the two quinoline starting materials under the same conditions shown above 


















Figure 67: Synthesis of asymmetrical bis-quinoline compounds. 
 
A different, less satisfactory synthetic method was initially used to produce PL241.  This 




 As with the reversed chloroquine-type compounds in section 5.1.1, the bis-
quinolines could in most cases be purified by recrystallization.  However, column 
chromatography was necessary in a few cases. 
 
5.1.3: Characterization of products 
 
Final products were characterized by NMR (1H, 13C, COSY, HSQC, NOESY, and 19F if 
applicable), melting point, HPLC, and LC/MS (details of methods used below).  
Intermediates not previously reported in the literature were characterized by 1H NMR, 
melting point (for purified products), and occasionally HPLC and LC/MS.  For sample 
NMR spectral interpretations for final products, see pages 187, 193, 213, 220, 256, 262-3 
and 316.  For example NMR spectra, see Appendix C: Sample NMR data: PL241.  
Nearly all 4-chloroquinoline starting materials were synthesized from the corresponding 
aniline in several steps (only 4-chloro-2,8-(ditrifluoromethyl)quinoline and 4,7-
dichloroquinaldine were purchased).  The intermediates in these syntheses are reported as 
individual steps below, but the products generally were not characterized (NMR was 
sometimes used, and in most cases this spectral data is reported below).  As these 
reactions are well understood and ample characterization data exists in the literature for 
the 4-quinolones and 4-chloroquinolines produced, it was found convenient to limit 
characterization by NMR and melting point to the 4-chloroquinoline, which is the starting 
point for the novel compounds.   Of the 4-chloroquinoline intermediates, only two had 




(trifluoromethyl)quinoline and 4,7-dichloro(2-trifluoromethyl)quinoline.  These were 
characterized by 1H, 13C, 19F, and 2D NMR, melting point, and GC/MS. 
1H, 13C, COSY, HSQC, HMBC, and 19F, NMR experiments were run on a Bruker 
400 MHz or 600MHz spectrometer.  HPLC was performed using UV detection at 254 
and 325 nm, using a Varian ProStar 325 UV/vis dual wavelength detector.  Two HPLC 
methods were used.  For HPLC Method A, a SUPELCO Ascentis RP-Amide 5µm, 4.6 
mm x 150 mm column was used, eluting with a gradient of 95:5 to 30:70 water with 
0.1% formic acid (v/v)/acetonitrile.   For HPLC method C, a SUPELCO Ascentis C18 
5µm, 4.6 x 150 mm column was used, eluting with a gradient from 95:5 to 5:95 water 
with 0.1% formic acid (v/v)/acetonitrile.  High resolution mass spectrometry was 
performed on a Bruker micrOTOF-Q instrument.  Results were obtained using 
electrospray ionization (ESI) in the positive mode, at a flow rate of 0.4 mL/min. with 1:1 
methanol-water.  Gas chromatography-mass spectrometry (GC-MS) was performed using 
a Hewlett Packard HP5890 Series II gas chromatograph with a 30-m DB5 column.  The 
oven temperature was set at 130° for 2 minutes, and then increased to 300°C at the rate of 
30°C per minute. This instrument was used with the kind permission of Dr. Michael 
Riscoe of the Portland Veterans Affairs Medical Center. 
 
5.2: In vitro studies on inhibition of P. falciparum parasite growth  
 
The antiplasmodial activities of the compounds in this study were determined by Dr. Jane 




methods described previously (e.g. Burgess, 2010; Pou, 2012).  The following three 
strains of P. falciparum were used: 1) a chloroquine-sensitive strain, D6, 2) a chloroquine 
resistant strain, Dd2, originally isolated from southeast Asia 3) a second chloroquine 
resistant strain, 7G8, originally isolated from Brazil.  The parasites were maintained 
continueously in culture, and asynchronous cultures were used for testing.  Samples of 
the cultures were diluted to 0.2% parasitemia and 0.2% hemocrit using uninfected red 
blood cells and complete cell growth medium (RPMI-1640 with 0.5% Albumax II).  
Chloroquine was used as a positive control.  Solutions of chloroquine and the test 
compounds were made at 10mM in DMSO.  These solutions were diluted into complete 
cell growth medium.  In 96-well microplate, the stock solutions were diluted with 
complete cell growth medium to provide triplicate wells at concentrations between 0 to 
10-4 M, each having a final volume of 100µL.  A given assay was performed using 
concentrations either in the range of 0.025 nM to 250 nM, or 2.5 nM to 2500 nM.  The 
plates were then incubated under standard culture conditions for 72 hours before 
harvesting.  The SYBR Green-I fluorescence-based method (Smilkstein, 2004) was used 
to read the plates, using  a 96-well plate fluorescence reader (Gemini-EM, Molecular 
devices) with respective excitation and emission wavelengths of 497 and 520nm.  
Fluorescence was plotted against the logarithm of drug concentration.  IC50 values were 
then obtained by curve fitting by nonlinear regression analysis, using Prism (Graph Pad) 
software.  The IC50 obtained for the chloroquine positive control was then used to 
“normalize” the IC50 values obtained for the test compounds to the following chloroquine 




formula used to obtain the normalized value for the IC50 of a given test compound is 
shown here for the case of strain D6, using 6.9 nM as the control value for chloroquine’s 
IC50 against strain D6: 
 
Normalized IC50 of test compound against D6 = (6.9/IC50 of chloroquine against D6) × 
IC50 of test compound against D6. 
 
 From the variability in IC50 values obtained in different tests on the same compounds 
over a period of several years, the uncertainty in the obtained values is estimated to be 





Happy the Man, who, studying Nature's Laws, 
Thro’ known Effects can trace the secret Cause. 
 
Virgil, Georgics II, line 49019, rendered by John Dryden (1697). 
                                                
19 Note: Line 698 in Dryden’s text.  Latin text reads as follows:  Felix, qui potuit rerum 
cognoscere causas, atque metus omnis et inexorabile fatum subiecit pedibus strepitumque 
Acherontis avari. See Virgil (1999), Virgil: Eclogues, Georgics, Aenid, with an English 
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APPENDIX A:  Specific synthetic methods and characterization data 
 
The following synthetic methods are organized by quinoline ring substitution pattern (for 
the monoquinolines), followed by a separate section for bis-quinolines and their starting 
materials.  For an overview of the compounds included, see the Table of Contents, page 
vii.  For an overview of the synthetic methods used to make the compounds described 
herein, and a description of the methods used to obtain the characterization data, see 
Chapter 5, sections 5.1-2.  Again, note that characterization data has often been omitted 
for those quinolone intermediates that have been previously well characterized in the 
literature.  To find the synthetic method for a final product by its code number (PL 
number), see Table A1, below. 
Table A1: Compounds listed by code number (PL number) 
 

























255 (Method 1) 























































316 (primary method) 





















































































































































































































































































































































































































































para-Chloroaniline (10.05 g, 78.8 mmol) and diethyl ethoxymethylene malonate (17.03 
g, 78.8 mmol) were heated in refluxing Dowtherm A (70 mL) for 25 minutes.  After 
cooling, the reaction mixture was diluted with hexanes (150 mL) and vacuum filtered, 
rinsing well with additional hexanes, to recover the product as an off-white, crystalline 
solid (18.32 g, 92%).  
 
 








3-carbethoxy-6-chloro-4-quinolone (18.32 g, 72.8 mmol) in 200 mL of 10% caustic soda 
was allowed to reflux, stirring, for 3 hours.  The hot reaction mixture was poured into 500 
mL water and acidified with concentrated muriatic acid.   After cooling, vacuum filtration 
yielded a white solid.  This was allowed to air dry, and was used without further 
purification or drying. 
 
 











3-carboxy-6-chloro-4-quinolone from the above reaction (presumed to contain residual 
water) was heated in Dowtherm A (100 mL) at reflux for 40 minutes.  After cooling, the 
reaction mixture was diluted with 100 mL hexanes and vacuum filtered to yield a 
sawdust-colored solid.  NMR indicated that reaction was not complete.  The solid was 
again suspended in Dowtherm (100 mL) and returned to reflux for a further 15 minutes.  
Upon cooling, the reaction mixture was diluted with hexanes (150 mL) and vacuum 
filtered, rinsing well with additional hexanes, to recover the product as a greenish-tan, 
crystalline solid (13.93 g, used without further purification). 
 
 







6-chloro-4-quinolone from the above reaction (13.93 g of crude material) and phosphorus 
oxychloride (40 mL) were heated at a gentle reflux for 5 hours.  After cooling, the 
reaction mixture was poured gradually onto ice and then cautiously basified with 50% 
caustic soda.  This was diluted to 3.3 L with water and divided into three equal portions, 
each of which was extracted with chloroform (100 mL, followed by 3 x 30 mL).  The 
pooled chloroform layers from all extractions were dried (MgSO4) and evaporated under 
reduced pressure with warming to yield a pale tan solid (13.48 g, 86% from para-
chloroaniline, mp = 102.3-103.6°C (lit. 104°C (Tarbell, 1946)). 
 
1H NMR δ (ppm)(CHCl3-d): 8.78 (1 H, d, J = 4.71 Hz), 8.23 (1 H, d, J = 2.34 Hz), 8.07 











4,6-dichloroquinoline (5.00 g, 25.2 mmol) and 3-amino-1-propanol (12.0 mL, 157 mmol) 
were heated at 85°C for 2 days, whereupon TLC indicated that reaction was complete.  
The hot reaction mixture was then poured into water (150 mL), while stirring vigorously.  
After resting 20 minutes, the resulting precipitate was recovered by vacuum filtration, 
followed by air drying and partial recrystallization from ethyl acetate to provide the 





1H NMR δ (ppm)(DMSO-d6): 8.40 (1 H, d, J = 5.37 Hz), 8.38 (1 H, d, J = 2.38 Hz), 7.78 
(1 H, d, J = 8.95 Hz), 7.60 (1 H, dd, J = 8.95, 2.30 Hz), 7.23 (1 H, br t, J = 5.31 Hz), 6.49 
(1 H, d, J = 5.42 Hz), 4.60 (1 H, t, J = 5.06 Hz), 3.55 (2 H, m), 3.28-3.35 (water signal 
overlaps m, ~2 H), 1.79-1.87 (2 H, m). 
 
1H NMR δ (ppm)(CHCl3-d): 8.52 (1 H, d, J = 5.34 Hz), 7.90 (1 H, d, J = 8.96 Hz), 7.68 
(1 H, d, J = 2.26 Hz), 7.55 (1 H, dd, J = 8.96, 2.24 Hz), 6.42 (1 H, d, J = 5.36 Hz), 5.80 (1 
H, br s), 3.97 (2 H, t, J = 5.45 Hz), 3.47-3.48 (2 H, m), 2.00-2.08 (2 H, m). 
 
 







3-(6-chloroquinolin-4-ylamino)propanol (4.20 g, 17.7 mmol) and triethylamine (3.71 mL, 
26.6 mmol) in dry THF (100 mL) were cooled to below 0°C on ice/salt. Methanesulfonyl 
chloride (1.58 mL, 20.3 mmol) was added dropwise.  After stirring for 30 minutes on ice, 
there remained some undissolved solid that had the appearance of starting material.  An 
additional 50 mL THF were added, followed by additional triethylamine (1.2 mL, 8.6 
mmol) and methanesulfonyl chloride (0.50 mL, 6.4 mmol), and stirring was continued for 
a further 40 minutes, whereupon TLC indicated that reaction was not complete (a sample 
of the reaction mixture indicated completion, but a sample incorporating the undissolved 
solid indicated the presence of unreacted starting material). The reaction mixture was 
filtered to remove the solid material.  The filtrate was diluted with ethyl acetate (25 mL) 
and washed with 35 mL saturated sodium bicarbonate; after separating, the aqueous layer 
was extracted with ethyl acetate (3 x 10 mL).  The pooled organic layers were dried 
(MgSO4) and evaporated under reduced pressure with warming to give the desired 















3-(6-chloroquinolin-4-ylamino)propyl methanesulfonate (2.03 g, 6.45 mmol), N-
(diphenylmethyl)piperazine (1.67 g, 6.62 mmol), and triethylamine (1.32 mL, 9.57 
mmol) were heated at reflux in acetonitrile (22 mL) for 22 hours.  TLC then indicated 
that reaction was complete. The solvent was removed by evaporation under reduced 
pressure with warming.  The residue was partitioned between 100 mL chloroform and 35 
mL water; after separation, the aqueous layer was extracted with chloroform (3 x 15 mL).  
The pooled organic layers were dried (MgSO4) and evaporated under reduced pressure 
with warming.  The residue was partially recrystallized from 95% ethanol, and then fully 
recrystallized from chloroform to yield the desired product as a white, crystalline solid 
(0.21 g, 0.4%, mp = 212-214°C). 
 
1H NMR δ (ppm)(CHCl3-d): 8.49 (1 H, d, J = 5.28 Hz), 8.01 (1 H, d, J = 2.30 Hz), 7.90 
(1 H, d, J = 8.98 Hz), 7.75 (1 H, br t, J = 3.94 Hz), 7.58 (1 H, dd, J = 8.98, 2.25 Hz), 7.45-
7.49 (4 H, m), 7.27-7.28 (4 H, m), 7.16-7.18 (2 H, m), 6.31 (1 H, d, J = 5.32 Hz), 4.48 (1 
H, s), 3.34 (2 H, td, J = 5.39, 0.00 Hz), 2.64 (10 H, br s overlaps t, J = 5.16 Hz), 1.92 (2 
H, apparent p, J = 5.27 Hz). 
 
13C NMR δ (ppm)(CHCl3-d): 151.5, 150.0, 147.0, 143.1, 131.6, 129.7, 128.6, 127.9, 
127.0, 120.1, 120.0, 119.9, 98.8, 76.1, 59.3, 54.1, 52.1, 45.0, 23.2. 
 














3-(6-chloroquinolin-4-ylamino)propyl methanesulfonate (1.00 g, 3.2 mmol), 1-(2-
pyridyl)piperazine (0.65 g, 4.0 mmol), potassium carbonate (0.66 g, 4.8 mmol), and a 
catalytic amount of potassium iodide were heated at 75°C in acetonitrile (15 mL) for 28 
hours. TLC then indicated that reaction was complete. The solvent was removed under 
reduced pressure with warming, and the residue was shaken with ethyl acetate (30 mL) 
and water (20 mL).  Some material remained insoluble, and was removed by vacuum 
filtration.  The filtrate was separated, and the aqueous layer was extracted with ethyl 
acetate (3 x 10 mL).  The pooled ethyl acetate layers were dried over MgSO4 and 
evaporated under reduced pressure with warming to yield a solid.  This was combined 
with the solid material that had been removed from the extraction by filtration.  This 




to provide the desired product as large, golden crystals (0.66 g, 54%, mp = 175.6-
177.5°C). 
 
1H NMR δ (ppm)(CHCl3-d): 8.51 (1 H, d, J = 5.31 Hz, Q-C2-H), 8.23-8.23 (1 H, m, Py-
H6 (from N, counterclockwise)), 7.94 (1 H, d, J = 2.31 Hz, Q-C5-H), 7.86 (1 H, d, J = 
8.93 Hz, Q-C8-H), 7.62 (1 H, t, J = 4.05 Hz, Q-NH), 7.51 (1 H, ddd, J = 8.54, 7.15, 2.02 
Hz, Py-H4), 7.46 (1 H, dd, J = 8.93, 2.27 Hz, Q-H7), 6.70 (1 H, d, J = 8.54 Hz, Py-H3), 
6.67 (1 H, dd, J = 7.16, 4.93 Hz, Py-H5), 6.35 (1 H, d, J = 5.35 Hz, Q-C3-H), 3.78 (4 H, 
m, Pip CH2CH2-Py), 3.41 (2 H, td, J = 5.37, 0.00 Hz, QNHCH2), 2.70-2.71 (6 H, m, Pip 
CH2CH2-Py, ~2.71; QNHCH2CH2CH2, ~2.70), 2.01 (2 H, apparent p, J = 5.28 Hz,  
CH2CH2CH2). 
 
13C NMR δ (ppm)(CHCl3-d): 159.7, 151.5 (Q-C2), 149.8, 148.0 (Py-C6 from N, 
counterclockwise), 146.9, 137.5 (Py-C4), 131.5  (Q-C8), 130.0, 129.5 (Q-C7), 119.9, 
119.8 (either 119.9 or 119.8 is Q-C5), 115.4, 113.7 (Py-C5), 107.2 (Py-C3), 98.7 (Q-C3), 
59.1 (QNHCH2CH2CH2Pip), 53.6 (Pip CH2CH2-Py), 45.2 (Pip CH2CH2-Py),  44.6 
(QNHCH2CH2CH2), 23.4 (QNHCH2CH2CH2). 
 
MS (ESI): m/z 382.17990 M + H (calculated 382.17930) 
 















3-(6-chloroquinolin-4-ylamino)propyl methanesulfonate (1.00 g, 3.2 mmol), 1-(4-
fluorophenyl)piperazine (0.60 g, 3.3 mmol), potassium carbonate (0.66 g, 4.8 mmol), and 
a catalytic amount of potassium iodide were heated at 75°C in acetonitrile (15 mL) for 28 
hours. TLC then indicated that reaction was complete. The solvent was removed under 
reduced pressure with warming, and the residue was shaken with ethyl acetate (30 mL) 
and water (20 mL).  A yellow solid remained insoluble, and was removed by vacuum 
filtration.  The filtrate was separated, and the aqueous layer was extracted with ethyl 
acetate (3 x 10 mL).  The pooled ethyl acetate layers were dried over MgSO4 and 
evaporated under reduced pressure with warming to yield a golden, crystalline solid.  The 




of ethyl acetate and 95% ethanol (6:1, 20 mL) to yield a golden, crystalline solid (0.51 g, 
40%, mp = 183.4-184.8°C). 
 
1H NMR δ (ppm)(CHCl3-d): 8.51 (1 H, d, J = 5.31 Hz), 7.93 (1 H, d, J = 2.24 Hz), 7.87 
(1 H, d, J = 8.93 Hz), 7.57 (1 H, br t, J = 3.95 Hz), 7.48 (1 H, dd, J = 8.94, 2.24 Hz), 6.94-
6.99 (4 H, m), 6.34 (1 H, d, J = 5.35 Hz), 3.40 (2 H, td, J = 5.77, 4.06 Hz), 3.36 (4 H, m), 
2.77 (4 H, m), 2.72 (2 H, t, J = 5.15 Hz), 2.00 (2 H, apparent p, J = 5.36 Hz). 
 
19F NMR δ (ppm)(CHCl3-d): -124.7 (m). 
 
13C NMR δ (ppm)(CHCl3-d): 158.2, 156.6, 151.4, 149.8, 147.7 (d, JF = 2.05 Hz?), 146.9, 
131.5, 129.9, 129.5, 119.8 (d, JF = 6.08 Hz?), 118.3 (d, JF = 8.49 Hz?), 115.5 (d, JF = 
22.01 Hz?) 98.7, 59.1, 53.9, 50.2, 44.7, 23.4. 
 
MS (ESI): m/z 399.17560 M + H (calculated NUMBER) 
 















3-(6-chloroquinolin-4-ylamino)propyl methanesulfonate (1.00 g, 3.2 mmol), 1-(4-
methoxyphenyl)piperazine (0.64 g, 3.3 mmol), potassium carbonate (0.66 g, 4.8 mmol), 
and a catalytic amount of potassium iodide were heated at 75°C in acetonitrile (15 mL) 
for 28 hours. TLC then indicated that reaction was complete. The solvent was removed 
under reduced pressure with warming, and the residue was partitioned between 
chloroform (20 mL) and water (20 mL).  After separation, the aqueous layer was 
extracted with further chloroform (3 x 7 mL), and the pooled organic layers were dried 
over MgSO4 and evaporated under reduced pressure with warming.  The residue was 
recrystallized by boiling in excess 95% ethanol, followed by slow concentration to 3 mL 
at room temperature.  This afforded the desired product as tan crystals (0.40 g, 26%, mp 
= 198.5-199.0°C). 
 
1H NMR δ (ppm)(CHCl3-d): 8.51 (1 H, d, J = 5.31 Hz), 7.95 (1 H, d, J = 2.30 Hz), 7.87 




6.98 (2 H, m), 6.85-6.86 (2 H, m), 6.34 (1 H, d, J = 5.35 Hz), 3.79 (3 H, s), 3.39 (2 H, td, 
J = 5.79, 4.06 Hz), 3.33 (4 H, m), 2.76 (4 H, m), 2.71 (2 H, t, J = 5.20 Hz), 1.99 (2 H, 
apparent p, J = 5.39 Hz). 
 
13C NMR δ (ppm)(CHCl3-d): 154.1, 151.4, 149.9, 146.9, 145.5, 131.5, 130.0, 129.6, 
119.9, 119.8, 118.8, 114.4, 98.7, 59.2, 55.6, 54.0, 50.7, 44.7, 23.4. 
 
MS (ESI): m/z 411.19454 M + H (calculated 411.19462) 
 
















ortho-Chloroaniline (5.35 mL, 51.2 mmol) and diethyl ethoxymethylene malonate (10.1 
mL, 50.3 mmol) were heated in refluxing Dowtherm A (70 mL) for 30 minutes.  After 
cooling, the reaction mixture was diluted with hexanes (150 mL) and vacuum filtered, 
rinsing with further hexanes (200 mL), followed by acetone (100 mL).  The product was 
obtained as a beige, powdery solid (11.32 g, 89%). 
 
1H NMR δ (ppm)(DMSO-d6): 11.91 (1 H, br s), 8.43 (1 H, s), 8.14 (1 H, dd, J = 8.10, 
1.38 Hz), 7.91 (1 H, dd, J = 7.72, 1.38 Hz), 7.43 (1 H, t, J = 7.92 Hz), 4.24 (2 H, q, J = 















3-carbethoxy-8-chloro-4-quinolone (11.32 g, 45.0 mmol) was heated at reflux in 200 mL 
of 10% caustic soda for 1 hour.  The hot reaction mixture was poured into 300 mL water, 
then made acidic by the addition of concentrated muriatic acid. After cooling, vacuum 
filtration yielded a white solid.  This was allowed to air dry for 48 hours followed by 
drying in a vacuum oven at 50ºC for 5 hours.  The resulting cream-colored solid  (10.40 
g, containing residual water) was used without further drying in the ensuing reaction. 
 
1H NMR δ (ppm)(DMSO-d6): 14.88 (1 H, br s), 13.00 (1 H, br s), 8.67 (1 H, s), 8.28 (1 













3-carboxy-8-chloro-4-quinolone from the above reaction (10.40 g, containing residual 
water) was heated in Dowtherm A (50 mL) at reflux for 40 minutes.  After cooling, the 
reaction mixture was diluted with 100 mL hexanes and allowed to sit for 48 hours, 
followed by vacuum filtration, rinsing with further hexanes (200 mL) followed by a 
mixture of acetone and hexanes (1:1, 50 mL). This gave a beige solid (8.27 g, used 
without further purification in the following reaction).  
 
1H NMR δ (ppm)(DMSO-d6): 11.39 (1 H, s), 8.07 (1 H, dd, J = 8.10, 1.39 Hz), 7.85-7.85 














8-chloro-4-quinolone from the above reaction (7.27 g, no more than 40 mmol) and 20.0 
mL phosphorus oxychloride (220 mmol) were heated at 70ºC for 2.5 hours, followed by 
heating at 110ºC for 1 hour.  After cooling, the reaction mixture was poured cautiously 
into ice water (300 mL), stirring vigorously.  After 30 minutes, the aqueous mixture was 
made basic to litmus by the addition of concentrated sodium hydroxide.  After cooling, 
this mixture was diluted to 2 L and divided into two portions.  Each portion was extracted 
with chloroform (100 mL followed by 3 x 15 mL), and the pooled organic layers from 
both extractions were dried (MgSO4) and evaporated under reduced pressure with 
warming to yield a pale beige solid (6.83 g, 67% from ortho-chloroaniline, mp = 159.1-











4,8-dichloroquinoline (3.00 g, 15 mmol) and 3-amino-1-propanol (5.95 mL, 7.8 mmol) 
were heated in a 10 mL Biotage microwave vial at 130°C for 15 minutes, whereupon 
TLC indicated that some starting material remained; heating at 130°C was continued for 
an additional 15 minutes.  The hot reaction mixture was then poured into water (100 mL) 
with good stirring.  After standing 18 hours, the solid product was recovered by vacuum 
filtration, followed by recrystallization from a mixture of ethyl acetate and 95% ethanol 
(55 mL, approximately 10:1).  The desired product was isolated as gleaming, beige, 
crystalline flakes (2.35 g, 66%, mp = 155.0-155.7°C). 
 
1H NMR δ (ppm)(DMSO-d6): 8.47 (1 H, d, J = 5.35 Hz), 8.19 (1 H, dd, J = 8.51, 1.28 
Hz), 7.79 (1 H, dd, J = 7.44, 1.20 Hz), 7.37 (1 H, dd, J = 8.45, 7.44 Hz), 7.32 (1 H, br t, J 
= 5.38 Hz), 6.55 (1 H, d, J = 5.41 Hz), 4.61 (1 H, t, J = 5.07 Hz), 3.55 (2 H, m), 3.34-3.35 





1H NMR δ (ppm)(CHCl3-d): 8.65 (1 H, d, J = 5.34 Hz), 7.75 (1 H, dd, J = 7.47, 1.24 Hz), 
7.65 (1 H, dd, J = 8.46, 1.25 Hz), 7.30 (1 H, dd, J = 8.44, 7.48 Hz), 6.45 (1 H, d, J = 5.37 












3-(8-chloroquinolin-4-ylamino)propanol (1.00 g, 42 mmol) and triethylamine (0.88 mL, 
63 mmol) in dry THF (100 mL) were cooled to below 0°C on ice/salt. Methanesulfonyl 
chloride (0.38 mL, 49 mmol) was added dropwise.  After stirring for 1 hour on ice, 
reaction appeared complete by TLC; however, additional methanesulfonyl chloride (0.11 
mL, 0.65 mmol) was added and stirring was continued for a further 30 minutes.  The 
reaction mixture was then diluted with ethyl acetate (30 mL) and washed with saturated 
sodium bicarbonate (25 mL); after separating, the aqueous layer was extracted with ethyl 
acetate (3 x 7 mL).  The pooled organic layers were rinsed with brine (10 mL), dried 
(MgSO4) and evaporated under reduced pressure with warming to give the desired 
product as a pale yellow, waxy solid (0.72 g, 54%).   
  
 1H NMR δ (ppm)(CHCl3-d): 8.66 (1 H, d, J = 5.20 Hz), 7.73-7.80 (1 H, m), 7.36 (1 H, t, 
J = 8.01 Hz), 6.49 (1 H, d, J = 5.12 Hz), 4.42 (2 H, t, J = 5.64 Hz), 3.59 (2 H, m), 3.06 (3 
H, s), 2.19-2.20 (2 H, m).  
 
1H NMR δ (ppm)(DMSO-d6): 8.48 (1 H, d, J = 5.78 Hz), 8.29 (1 H, d, J = 8.52 Hz), 7.87-
7.90 (2 H, m), 7.47 (1 H, t, J = 8.00 Hz), 6.68 (1 H, d, J = 5.85 Hz), 4.36 (2 H, t, J = 6.16 













Cl PL271  
 
3-(8-chloroquinolin-4-ylamino)propyl methanesulfonate (0.68 g, 2.2 mmol), N-
(diphenylmethyl)piperazine (0.56 g, 2.2 mmol), potassium carbonate (0.47 g, 3.4 mmol), 
and a catalytic amount of potassium iodide were heated at reflux in acetonitrile (50 mL) 
for 20 hours.  TLC then indicated that reaction was complete. The reaction mixture was 
diluted with 5 mL water, and the solvent was removed by evaporation under reduced 
pressure with warming.  The residue thus obtained was partitioned between chloroform 
(35 mL) and water (50 mL).  After separation, the aqueous layer was extracted with 
chloroform (3 x 7 mL).  The pooled organic layers were dried (MgSO4) and concentrated 
under reduced pressure with warming, and the resulting pale yellow solid was boiled in 
50 mL 95% ethanol; the clear, yellow supernatent was decanted from a small amount of 
insoluble material.  After cooling and crystallization, the desired product was isolated by 
vacuum filtration (a shimmering, white, crystalline solid, 0.43 g, 42%, mp = 206-208°C).  
 
1H NMR δ (ppm)(CHCl3-d): 8.62 (1 H, d, J = 5.30 Hz, Q-C2-H), 7.83 (1 H, dd, J = 8.42, 
1.29 Hz, Q-C7-H or Q-C5-H, probably C7), 7.76 (1 H, dd, J = 7.40, 1.21 Hz, Q-C5-H or 
Q-C7-H, probably C5), 7.64 (1 H, br t, J = 4.00 Hz, Q-N-H), 7.42-7.46 (4 H, m, Ph-H x 
4, ortho), 7.27-7.33 (4 H, m, Ph-H x 4, meta), 7.21-7.22 (2 H, m, Ph-H x 2, para), 7.17 (1 
H, dd, 8.40, 7.40 Hz, Q-C6-H), 6.36 (1 H, d, J = 5.34 Hz, Q-C3-H), 4.36 (1 H, s, 
CH(Ph)2), 3.36 (2 H, td, J = 5.80, 4.01 Hz, Q-NHCH2CH2CH2), 2.64 (10 H, br s overlaps 
t, J = 5.41 Hz, CH2 x 4 (piperazine) and Q-NHCH2CH2CH2), 1.93 (2 H, apparent p, J = 
5.41 Hz, Q-NHCH2CH2CH2). 
 
13C NMR δ (ppm)(CHCl3-d): 151.7 (Q-C2), 150.9 (Q-C, possibly Q-C4 (HMBC to 
QNHCH2)), 144.9 (Q-C), 142.2 (Ph-C, ipso), 133.7 (Q-C), 129.1 (Q-C5 or possibly C7, 
7.76), 128.6 (Ph-C, meta), 128.1 (Ph-C, ortho), 127.1 (Ph-C, para), 123.5 (Q-C6), 120.4 
(Q-C7 or possibly C5, 7.83), 120.1 (Q-C), 98.9 (Q-C3), 76.4 (CH(Ph)2), 58.8 (Q-
NHCH2CH2CH2), 53.9 (CH2 x 2, piperazine), 51.8 (CH2 x 2, piperazine), 44.6 (Q-
NHCH2CH2CH2), 23.4 (Q-NHCH2CH2CH2). 
 
MS (ESI): m/z 471.2300 M + H (calculated 471.2310). 
 


















3-(8-chloroquinolin-4-ylamino)propyl methanesulfonate (1.65 g, 5.2 mmol), 1-(2-
pyridyl)piperazine (0.85 g, 5.2 mmol), and potassium carbonate (1.09 g, 7.9 mmol) in 
acetonitrile (15 mL) were allowed to reflux for 3 days.  Precipitation was evident, and so 
the reaction mixture was vacuum filtered, rinsing extensively with water, and then with 1 
mL 95% ethanol.  The resulting cream-colored, sparkling solid proved to be the desired 
product (0.49 g, 25%, mp = 164.5-165.7°C). 
 
1H NMR δ (ppm)(CHCl3-d): 8.65 (1 H, d, J = 5.34 Hz), 8.23-8.25 (1 H, m), 7.80 (1 H, 
dd, J = 8.44, 1.30 Hz), 7.69 (1 H, dd, J = 7.46, 1.25 Hz), 7.51-7.55 (1 H, m), 7.39 (1 H, br 
t, J = 4.22 Hz), 7.17 (1 H, dd, J = 8.42, 7.46 Hz), 6.67-6.68 (2 H, m), 6.41 (1 H, d, J = 
5.38 Hz), 3.65-3.70 (4 H, m), 3.41 (2 H, td, J = 5.95, 4.20 Hz), 2.65-2.70 (6 H, m), 2.00 
(2 H, apparent p, J = 5.59 Hz). 
 
13C NMR δ (ppm)(CHCl3-d): 159.4, 151.7, 150.8, 148.1, 145.0, 137.7, 133.8, 129.2, 
123.7, 120.4, 119.5, 113.8, 107.1, 99.1, 58.7, 53.5, 45.3, 44.4, 23.7. 
 
MS (ESI): m/z 382.18024 M + H (calculated 382.17930) 
 




















3,5-dichloroaniline (8.11 g, 50.1 mmol) and diethyl ethoxymethylene malonate (10.04 
mL, 50.1 mmol) were heated in refluxing Dowtherm A (65 mL) for 30 minutes.  After 
cooling, the reaction mixture was diluted with hexanes (100 mL) and vacuum filtered, 
rinsing with hexanes (300 mL) and acetone (75 mL), to recover the product as a 















3-carbethoxy-5,7-dichloro-4-quinolone (11.37 g, 39.7 mmol) in 500 mL of 10% caustic 
soda was allowed to reflux, stirring, for 6 days, at which point solid was still present.  
The orange reaction mixture was decanted from  the reaction solids and made acidic by 
the addition of concentrated muriatic acid.  Further 10% caustic soda was added to the 
reaction flask and reflux was continued for an additional 24 hours, whereupon it was 
found that all solid material had dissolved; this too was poured into 100 mL water and 
made acidic by the addition of concentrated muriatic acid.  The two acidified reaction 
mixtures were combined and filtered.  The resulting pale pink solid  was allowed to air 
dry, and was used in the ensuing reaction without further purification (21.23 g, containing 
residual water).   NMR indicated that this contained some decarboxylated material, 
approximately 13% of the total quinolone content. 
 
1H NMR δ (ppm)(DMSO-d6): Major peaks: 15.06 (1 H, s), 8.93 (1 H, s), 7.80 (1 H, d, J = 














3-carboxy-5,7-dichloro-4-quinolone from the above reaction (containing residual water 




for 40 minutes.  After cooling, the reaction mixture was diluted with 75 mL hexanes and 
vacuum filtered, rinsing with 150 mL additional hexanes; the resulting solid was then 
boiled in 50 mL hexanes for 1 hour.  After standing overnight, vacuum filtration of this 
mixture afforded the desired product as a faintly pink, powdery solid (8.01 g).  
 
1H NMR δ (ppm)(DMSO-d6): 7.85 (1 H, dd, J = 7.50, 5.67 Hz), 7.52 (1 H, d, J = 2.07 











Phosphorous oxychloride (20.6 mL, 221 mmol) was cautiously added to 5,7-dichloro-4-
quinolone from the above reaction (8.01 g, 37.4 mmol), followed by heating at reflux for 
21 hours.  After cooling, the reaction mixture was poured gradually onto ice, then 
gradually made basic to litmus with solid caustic potash.  This was diluted with water to 
1 L and combined with 50 mL chloroform.  Some material remained undissolved, and 
was recovered by vacuum filtration; the filtrate was separated, and the aqueous layer was 
extracted with chloroform (5 x 15 mL).  The pooled chloroform layers from all 
extractions were combined, dried (MgSO4) and evaporated under reduced pressure with 
warming to yield a caramel-colored, crystalline solid.  NMR indicated that this was the 
desired 4,5,7-trichloroquinoline (1.26 g, 15%, mp = 107.0-109.0°C (lit. 105-6°C (Surrey, 
1946)).  NMR indicated that the solid recovered from filtration (7.59 g) also contained 
the desired quinoline, together with approximately 10% of unreacted 5,7-dichloro-4-
quinolone starting material.   
 
1H NMR δ (ppm)(CHCl3-d): 8.72 (1 H, d, J = 4.69 Hz), 8.06 (1 H, d, J = 2.21 Hz), 7.66 
(1 H, d, J = 2.21 Hz), 7.51 (1 H, d, J = 4.68 Hz). 
 
1H NMR δ (ppm)(DMSO-d6): 8.87 (1 H, d, J = 4.71 Hz), 8.19 (1 H, d, J = 2.23 Hz), 7.99 














4,5,7-trichloroquinoline (3.01 g, 12.9 mmol) and 3-amino-1-propanol (5.93 mL, 77.5 
mmol) were heated in a Carius vessel at 90°C for 3 hours.  TLC then indicated that 
reaction was complete.  The hot reaction mixture was poured into 100 mL water, with 
vigorous stirring.  After standing overnight, the resulting solid was recovered by vacuum 
filtration, followed by air-drying (2.01 g, 59%, mp = 119.3-120.1°C). 
 
1H NMR δ (ppm)(DMSO-d6): 8.41 (1 H, d, J = 5.53 Hz), 7.78 (1 H, d, J = 2.30 Hz), 7.56 
(1 H, br t, J = 2.32 Hz), 6.56 (1 H, d, J = 5.59 Hz), 4.77 (1 H, t, J = 4.91 Hz), 3.59 (2 H, 











3-(5,7-dichloroquinolin-4-ylamino)propanol (2.00 g, 7.41 mmol) and triethylamine (1.5 
mL, 11 mmol) in dry THF (100 mL) were cooled to below 0°C on ice/salt. 
Methanesulfonyl chloride (0.66 mL, 8.5 mmol) was added dropwise.  After stirring for 30 
minutes, TLC indicated that reaction was complete. The reaction mixture was diluted 
with ethyl acetate (30 mL) and washed with 100 mL saturated sodium bicarbonate.  The 
aqueous layer was extracted with ethyl acetate (3 x 10 mL), and the pooled organic layers 
were dried (MgSO4) and evaporated under reduced pressure with warming to give the 
desired product as a pale yellow solid (2.65 g, containing residual solvent and 


















3-(5,7-dichloroquinolin-4-ylamino)propyl methanesulfonate (0.52 g crude material from 
the above reaction, no more than 1.5 mmol), N-(diphenylmethyl)piperazine (0.39 g, 1.5 
mmol), potassium carbonate (0.31 g, 2.2 mmol), and a catalytic amount of potassium 
iodide were heated at reflux in acetonitrile (24 mL) for 24 hours, whereupon TLC 
indicated that reaction was complete.  The solvent was removed under reduced pressure 
with warming, and the residue was partitioned between chloroform (60 mL) and water 
(40 mL).  After separation, the aqueous layer was extracted with chloroform (3 x 15 mL), 
dried (MgSO4) and evaporated under reduced pressure with warming.  The residue was 
recrystallized from 15 mL ethyl acetate to yield the desired product as pale golden 




1H NMR δ (ppm)(CHCl3-d): 8.41 (1 H, d, J = 5.51 Hz), 7.83 (1 H, d, J = 2.26 Hz), 7.39-
7.43 (5 H, m), 7.32 (1 H, d, J = 2.26 Hz), 7.25-7.27 (solvent signal overlaps m, ~4 H), 
7.17-7.19 (2 H, m), 6.37 (1 H, d, J = 5.56 Hz), 4.23 (1 H, s), 3.29 (2 H, td, J = 6.70, 4.93 
Hz), 2.49 (10 H, m), 1.90 (2 H, apparent p, J = 6.82 Hz). 
 
13C NMR δ (ppm)(CHCl3-d): 151.8, 151.3, 151.0, 142.7, 133.4, 129.1, 128.8, 128.5, 
128.0, 127.1, 127.0, 114.9, 100.1, 76.3, 56.2, 53.7, 51.9, 42.1, 25.5. 
 
MS (ESI): m/z 505.19286 M + H (calculated 505.19203) 
 


















3-(5,7-dichloroquinolin-4-ylamino)propyl methanesulfonate (1.62 g, 4.64 mmol), 1-(2-
pyridyl)piperazine (0.79 g, 4.8 mmol), potassium carbonate (0.96 g, 6.9 mmol), and a 
catalytic amount of potassium iodide were heated at reflux in acetonitrile (48 mL) for 5 
days. The solvent was then removed under reduced pressure with warming, and the 
residue was partitioned between chloroform (60 mL) and water (40 mL).  After 
separation, the aqueous layer was extracted with chloroform (3 x 15 mL), dried (MgSO4) 
and evaporated under reduced pressure with warming.  The residue was recrystallized by 
dissolution in excess boiling ethyl acetate, followed by concentration to 10 mL at room 
temperature.  Filtration afforded the desired product as a cream colored solid.  The 
mother liquor was further concentrated to yield a second crop of the same material (total 




1H NMR δ (ppm)(CHCl3-d): 8.44 (1 H, d, J = 5.50 Hz), 8.20-8.20 (1 H, m), 7.84 (1 H, d, 
J = 2.25 Hz), 7.48 (1 H, ddd, J = 8.57, 7.12, 2.01 Hz), 7.33 (2 H, br d, J = 2.30 Hz), 6.63-
6.65 (2 H, m), 6.42 (1 H, d, J = 5.55 Hz), 3.57 (4 H, m), 3.31-3.41 (2 H, m), 2.59 (4 H, 
m), 2.56 (2 H, t, J = 6.82 Hz), 1.98 (2 H, apparent p, J = 6.79 Hz). 
 
13C NMR δ (ppm)(CHCl3-d): 159.5, 151.9, 151.3, 151.0, 148.0, 137.5, 133.5, 129.1, 
128.8, 127.2, 114.9, 113.4, 107.1, 100.2, 56.2, 53.3, 45.2, 42.0, 25.5.  
 
MS (ESI): m/z 416.14101 M + H (calculated 416.14033) 
 




















3,4-dichloroaniline (6.00 g, 37.0 mmol) and diethyl ethoxymethylene malonate (7.42 mL, 
37.0 mmol) were heated in refluxing Dowtherm A (100 mL) for 30 minutes.  After 
cooling, the reaction mixture was diluted with hexanes (200 mL) and vacuum filtered to 
recover the solid product (9.11 g, 86% yield). 
 
 











3-carbethoxy-6,7-dichloro-4-quinolone (9.11 g, 31.8 mmol) in 100 mL of 10% caustic 
soda was allowed to reflux, stirring, for 20 hours.  Solid was still present, and additional 
10% caustic soda (400 mL) was added.  Reflux was continued for a further 20 hours, 
after which no solid remained in the reaction.  The hot reaction mixture was poured into 
water (200 mL) and made acidic by the addition of concentrated HCl.  After resting 
overnight, the white precipitate was recovered by vacuum filtration and allowed to air 
dry.  The resulting off-white powder appeared by NMR to contain the 6,7- and 5,6- 
dichloro regioismers in a proportion of approximately 95:5.  This material was used 
without further purification in the following reaction (9.11 g, also containing residual 
water).  
 

















3-carboxy-6,7-dichloro-4-quinolone from the above reaction (9.11 g, containing residual 
water) was heated in Dowtherm A (100 mL) at 255°C for 50 minutes.  After cooling, the 
reaction mixture was diluted with 100 mL hexanes and vacuum filtered to yield a 
sawdust-colored solid (8.16 g).  This material was used without further purification in the 
following reaction. 
 
1H NMR δ (ppm)(DMSO-d6): 8.11 (1 H, s), 7.90 (1 H, d, J = 5.94 Hz), 7.60 (1 H, s), 5.86 













Phosphorus oxychloride (50 mL, 536 mmol) was added cautiously to 6,7-dichloro-4-
quinolone from the above reaction (12.43 g of crude material).  This was equipped with 
stacked air condensers and allowed to heat, stirring, at 105°C for 24 hours.  After cooling, 
the reaction mixture was poured gradually into 700 mL ice water and then cautiously 
basified with solid caustic soda.  This was diluted to 2.3 L and combined with 400 mL 
chloroform.  Some material remained undissolved, and was recovered by vacuum 
filtration; the remaining material was separated into three equal portions, each of which 
was treated in the following manner: after separation of the layers, the aqueous layer was 
extracted with chloroform (3 x 20 mL).  The pooled chloroform layers from all 
extractions were combined, dried (MgSO4) and evaporated under reduced pressure with 
warming to yield a cream-colored solid.  NMR indicated that this was the primarily the 
desired 4,6,7-trichloroquinoline, containing 5,6,7-trichloroquinoline in a proportion of 
approximately 1:6 (see below for spectrum).  The desired compound was obtained by 
recrystallization from 1:1 chloroform:hexanes (4.48 g including 4 crops, 52% from 3,4-





1H NMR δ (ppm)(CHCl3-d), prior to recrystallization, containing both regioisomers in a 
proportion of approximately 6:1: 8.79 (6 H, d, J = 4.72 Hz), 8.72 (1 H, d, J = 4.67 Hz), 
8.35 (6 H, s), 8.26 (6 H, s), 8.01 (1 H, d, J = 9.06 Hz), 7.80 (1 H, d, J = 9.06 Hz), 7.58 (1 
H, d, J = 4.68 Hz), 7.51 (6 H, d, J = 4.71 Hz). 
 
1H NMR δ (ppm)(CHCl3-d), after recrystallization: 8.78 (1 H, d, J = 4.72 Hz), 8.34 (1 H, 
s), 8.26 (1 H, s), 7.51 (1 H, d, J = 4.72 Hz). 
 
 












90oC, 3 days  
 
4,6,7-trichloroquinoline (0.91 g, 3.9 mmol) and 3-amino-1-propanol (1.79 mL, 23.4 
mmol) were heated at 90°C for 3 days.  The hot reaction mixture was then poured into 
250 mL water, while stirring vigorously.  After standing overnight, the resulting 
precipitate was recovered by vacuum filtration, followed by air drying and partial 
recrystallization from ethyl acetate (0.62 g of a beige solid, 59%, mp = 220-222°C). 
 
1H NMR δ (ppm)(DMSO-d6): 8.61 (1 H, s), 8.41 (1 H, d, J = 5.44 Hz), 7.98 (1 H, s), 7.36 
(1 H, s), 6.51 (1 H, d, J = 5.50 Hz), 4.57 (1 H, t, J = 5.08 Hz), 3.54 (2 H, m), 3.32 (water 
signal overlaps m, ~2 H), 1.81-1.82 (2 H, m). 
 
1H NMR δ (ppm)(CHCl3-d): 8.52 (1 H, d, J = 5.36 Hz), 8.07 (1 H, s), 7.80 (1 H, s), 6.41 
(1 H, d, J = 5.39 Hz), 5.86 (1 H, br s), 3.98 (2 H, t, J = 5.41 Hz), 3.48 (2 H, td, J = 6.23, 
















130oC, 15 minutes  
 
4,6,7-trichloroquinoline (0.25 g, 1.1 mmol) and 3-amino-1-propanol (1.00 mL, 13 mmol) 




minutes, whereupon TLC indicated that reaction was complete.  The hot reaction mixture 
was poured into 50 mL water, while stirring vigorously.  After standing 20 minutes, the 
resulting precipitate was recovered by vacuum filtration, followed by air drying to 












3-(6,7-dichloroquinolin-4-ylamino)propanol (0.62 g, 2.3 mmol) and triethylamine (0.48 
mL, 3.4 mmol) in dry THF (50 mL) were cooled to below 0°C on ice/salt. 
Methanesulfonyl chloride (0.21 mL, 2.7 mmol) was added dropwise.  After stirring for 1 
hour on ice, TLC indicated that reaction was complete; nevertheless, additional 
methanesulfonyl chloride (0.02 mL, 0.3 mmol) was added and stirring was continued for 
a further 15 hours. The reaction mixture was then washed with 100 mL saturated sodium 
bicarbonate.  The aqueous layer was extracted with ethyl acetate (3 x 10 mL), and the 
pooled organic layers were rinsed with 10 mL brine, then dried (MgSO4) and evaporated 
under reduced pressure with warming to give the desired product as a tan solid (0.71 g, 
87%).   
 
1H NMR δ (ppm)(DMSO-d6): 8.61 (1 H, s), 8.44 (1 H, d, J = 5.45 Hz), 8.01 (1 H, s), 7.43 
(1 H, s), 6.55 (1 H, d, J = 5.51 Hz), 4.35 (2 H, t, J = 6.18 Hz), 3.41 (2 H, m), 3.20 (3 H, 












Cl PL 307  
 
3-(6,7-dichloroquinolin-4-ylamino)propyl methanesulfonate (0.71 g, 2.0 mmol), 1-(2-
pyridyl)piperazine (0.35 g, 2.1 mmol), potassium carbonate (0.41 g, 3.0 mmol), and a 
catalytic amount of potassium iodide were heated in refluxing acetonitrile (21 mL) for 3 




was partitioned between chloroform (30 mL) and water (30 mL).  After separation, the 
aqueous layer was extracted with further chloroform (3 x 7 mL), and the pooled organic 
layers were dried (MgSO4) and evaporated under reduced pressure with warming to yield 
a brown solid.  This was taken up in excess boiling 95% ethanol and allowed to 
concentrate slowly at room temperature.  The resulting amber crystals proved to be the 
desired product (0.27 g, 33%, mp = 221-223°C). 
 
1H NMR δ (ppm)(CHCl3-d): 8.49 (1 H, d, J = 5.36 Hz), 8.23-8.23 (1 H, m), 8.02 (2 H, d, 
J = 11.61 Hz), 7.80 (1 H, t, J = 3.94 Hz), 7.52 (1 H, ddd, J = 8.53, 7.17, 2.02 Hz), 6.71 (1 
H, d, J = 8.54 Hz), 6.68 (1 H, dd, J = 7.17, 4.93 Hz), 6.31 (1 H, d, J = 5.40 Hz), 3.77 (4 H, 
m), 3.40 (2 H, td, J = 5.36, 0.01 Hz), 2.71-2.72 (6 H, m), 1.96-2.01 (2 H, m). 
 
13C NMR δ (ppm)(CHCl3-d): 159.7, 152.4, 149.7, 148.0, 147.5, 137.6, 133.0, 133.0, 
130.8, 128.3, 121.9, 118.4, 113.9, 107.3, 98.7, 59.2, 53.6, 45.3, 44.7, 23.2. 
 
MS (ESI): m/z 416.14087 M + H (calculated 416.14033) 
 
















2,3-dichloroaniline (25.85 g, 160 mmol) and diethyl ethoxymethylene malonate (31.65 
mL, 160 mmol) were heated in refluxing Dowtherm A (100 mL) for 40 minutes.  After 
cooling, the reaction mixture was diluted with 30-60° petroleum æther (150 mL) and 
vacuum filtered, rinsing well with additional petroleum æther, to recover the product as 

















3-carbethoxy-7.8-dichloro-4-quinolone (37.10 g, 130 mmol) in 400 mL of 10% caustic 
soda was allowed to reflux, stirring, for 20 hours.  Solid was still present, and therefore 
40 mL 50% caustic soda was added to the reaction, followed by 200 mL water.  Note: 
upon cooling somewhat, the reaction mixture solidified; upon returning to reflux, much 
of the solid again dissolved.  Reflux was continued for a further 1.5 hours.  Since a small 
amount of solid still remained, the reaction was vacuum filtered while hot, rinsing with 
hot water.  The filtrate was brought to a simmer (to dissolve material that had solidified 
upon cooling), and acidified with concentrated hydrochloric acid while hot.   After 
cooling, vacuum filtration yielded a white solid, product A.  Meanwhile, the solid from 
filtration of the basic reaction mixture returned to the reaction vessel and again heated at 
reflux in a further 400 mL 10% caustic soda.  After 1.5 hours, all material had dissolved, 
and so the reaction mixture was acidified while hot by the addition of concentrated 
hydrochloric acid.  Upon cooling, filtration again yielded an off-white solid (product B).  
Product A appeared to contain a large amount of salt (by taste and flame test) and 
residual water.  Only product B, which appeared to be the desired material by NMR, was 
used in the next reaction (15.75 g, 47%). 
 
1H NMR δ (ppm)(DMSO-d6): 13.08 (1 H, br s), 8.66 (1 H, s), 8.24 (1 H, d, J = 8.80 Hz), 













3-carboxy-7,8-dichloro-4-quinolone (15.75 g, 61.0 mmol) was decarboxyated in two 
portions (I and II).  Portion I was heated in Dowtherm A (100 mL) at reflux for 1 hour. 
Upon cooling, the reaction mixture was diluted with 30-60° petroleum æther (150 mL) 
and vacuum filtered, rinsing well with additional petroleum æther.  Portion II was heated 
in Dowtherm A (100 mL) at reflux for 40 minutes; upon cooling, NMR indicated that 
decarboxylation was not complete.  The reaction was returned to reflux and inadvertently 




petroleum æther (150 mL) and vacuum filtered, rinsing well with further petroleum 
æther.  The products from decarboxylation of portions I and II were combined (a tan 
crystalline solid, 12.31 g, 94%). 
 
1H NMR δ (ppm)(DMSO-d6): 11.51 (1 H, br s), 8.06 (1 H, d, J = 8.73 Hz), 7.88 (1 H, dd, 
J = 7.56, 6.02 Hz), 7.55 (1 H, d, J = 8.73 Hz), 6.15 (1 H, dd, J = 7.54, 1.10 Hz). 
 
1H NMR δ (ppm)(DMSO-d6): 11.51 (1 H, br d, J = 5.93 Hz), 8.06 (1 H, d, J = 8.73 Hz), 












7,8-dichloro-4-quinolone (12.31 g, 57.5 mmol) was allowed to heat, stirring, in 
phosphorus oxychloride (41 mL, 440 mmol) at a gentle reflux for 24 hours.  After 
cooling, the reaction mixture was poured gradually onto ice (with good stirring) and then 
made basic with 10% caustic soda (final volume 900 mL).  This was extracted with 
chloroform (4 x 75 mL).  The combined chloroform extracts were dried (MgSO4) and 
evaporated under reduced pressure with warming to yield a cream-colored solid (9.18 g, 
69%, mp = 126.0-126.8°C (lit. 125-126°C). 
 
1H NMR δ (ppm)(CHCl3-d): 8.93 (1 H, d, J = 4.70 Hz), 8.14 (1 H, d, J = 9.09 Hz), 7.71 














4,7,8-trichloroquinoline (4.50 g, 19.4 mmol) and 3-amino-1-propanol (8.80 mL, 115 
mmol) were heated at 110°C for 24 hours.  The hot reaction mixture was then poured into 
250 mL water, while stirring vigorously.  The resulting precipitate was recovered by 
vacuum filtration, followed by air drying and partial recrystallization from ethyl acetate.  
NMR indicated that a small amount of 3-amino-1-propanol remained, and so the product 
was ground finely and again partially recrystallized from ethyl acetate to yield the desired 
product as a tan solid (4.42 g, 84%). 
 
1H NMR δ (ppm)(DMSO-d6): 8.49 (1 H, d, J = 5.44 Hz), 8.23 (1 H, d, J = 9.15 Hz), 7.60 
(1 H, d, J = 9.08 Hz), 7.46 (1 H, t, J = 5.32 Hz), 6.58 (1 H, d, J = 5.50 Hz), 4.60 (1 H, t, J 











3-(7,8-dichloroquinolin-4-ylamino)propanol (4.42 g, 16.3 mmol) and triethylamine (3.35 
mL, 24.0 mmol) in dry dichloromethane (100 mL) were cooled to below 0°C on ice/salt. 
Methanesulfonyl chloride (1.60 mL, 20.6 mmol) was added dropwise.  After stirring for 1 
hour on ice, additional triethylamine (1.0 mL, 7.2 mmol) and methanesulfonyl chloride 
(0.50 mL, 6.4 mmol) were added and stirring was continued for a further 30 minutes, 
whereupon TLC indicated that reaction was complete. The reaction mixture was washed 
with 120 mL saturated sodium bicarbonate; after separating, the aqueous layer was 
extracted with dichloromethane (3 x 15 mL).  The pooled organic layers were dried 
(MgSO4) and evaporated under reduced pressure with warming to give the desired 
product as a yellowish tan solid (4.63 g, 82%,).   
 
1H NMR δ (ppm)(DMSO-d6): 8.51 (1 H, d, J = 5.42 Hz), 8.24 (1 H, d, J = 9.17 Hz), 7.63 
(1 H, d, J = 9.09 Hz), 7.49 (1 H, t, J = 5.36 Hz), 6.62 (1 H, d, J = 5.49 Hz), 4.35 (2 H, t, J 



















3-(7,8-dichloroquinolin-4-ylamino)propyl methanesulfonate (1.80 g, 5.15 mmol), N-
(diphenylmethyl)piperazine (1.38 g, 5.47 mmol), and potassium carbonate (0.74 g, 5.4 
mmol were heated at 75°C in acetonitrile (15 mL) for 9 days.  TLC then indicated that 
reaction was complete. The solvent was removed by evaporation under reduced pressure 
with warming.  The residue was partitioned between chloroform (40 mL) and water (35 
mL); after separation, the aqueous layer was extracted with additional chloroform (3 x 10 
mL).  The aqueous layer contained a tan precipitate that remained undissolved during 
extraction; this was recovered by vacuum filtration.  NMR indicated that this was 
predominantly the desired product.  The pooled organic layers were dried (MgSO4) and 
evaporated under reduced pressure with warming to yield a miniscule quantity of 
unpromising yellow oil; this was subsequently discarded. The solid material recovered 
from extraction was recrystallized by dissolution in excess boiling ethyl acetate, followed 
by slow concentration at room temperature to yield the desired product as a tan, 
crystalline solid (1.72 g, 66%, mp = 171.5-173.2°C). 
 
1H NMR δ (ppm)(CHCl3-d): 8.60 (1 H, d, J = 5.34 Hz), 7.79 (1 H, br t, J = 3.96 Hz), 7.68 
(1 H, d, J = 9.03 Hz), 7.41-7.45 (4 H, m), 7.30-7.36 (4 H, m), 7.24-7.29 (solvent peak 
overlaps m, ~2 H), 7.15 (1 H, d, J = 8.99 Hz), 6.34 (1 H, d, J = 5.39 Hz), 4.46 (1 H, s), 
3.35 (2 H, td, J = 5.78, 3.94 Hz), 2.65 (10 H, br s overlaps t, J = 5.31 Hz), 1.93 (2 H, 
apparent p, J = 5.33 Hz). 
 
13C NMR δ (ppm)(CHCl3-d): 152.4, 151.0, 146.1, 141.7, 133.5, 131.6, 128.5, 128.3, 
127.3, 124.8, 120.3, 118.4, 99.1, 75.8, 59.0, 54.0, 51.5, 44.8, 23.1. 
 
MS (ESI): m/z 505.19271 M + H (calculated 505.19203) 
 


















3-(7,8-dichloroquinolin-4-ylamino)propyl methanesulfonate (1.80 g, 5.15 mmol), 1-(2-
pyridyl)piperazine (0.90 mL, 5.5 mmol), and potassium carbonate (0.71 g, 7.8 mmol) 
were heated at 75°C in acetonitrile (15 mL) for 3 days. TLC then indicated that reaction 
was complete. The solvent was removed under reduced pressure with warming, and the 
residue was boiled in 100 mL water for 20 minutes.  Upon cooling, the solid was 
recovered by vacuum filtration and partially recrystallized from ethyl acetate, followed 
by full recrystallization from 95% ethanol to provide the desired product as a sparkling, 
beige solid (0.53 g, 25%). 
 
1H NMR δ (ppm)(CHCl3-d): 8.64 (1 H, d, J = 5.38 Hz), 8.24-8.24 (1 H, m), 7.73 (1 H, d, 
J = 9.04 Hz), 7.54-7.54 (1 H, m), 7.50 (1 H, s), 7.31 (1 H, d, J = 9.00 Hz), 6.69-6.70 (2 H, 
m), 6.42 (1 H, d, J = 5.42 Hz), 3.68 (4 H, m), 3.43 (2 H, td, J = 5.93, 4.14 Hz), 2.69-2.70 
(6 H, m), 2.01 (2 H, apparent p, J = 5.52 Hz). 
 
13C NMR δ (ppm)(CHCl3-d): 159.3, 152.4, 150.9, 148.1, 146.1, 137.7, 133.6, 131.9, 
125.1, 119.8, 118.4, 113.9, 107.2, 99.3, 58.8, 53.5, 45.4, 44.5, 23.5. 
 
MS (ESI): m/z 416.14033 M + H (calculated 416.14061) 
 






A.2. Haloquinolines other than chlorine 
A.2.1: 6-fluoroquinolines 
 









para-Fluoroaniline (26.39 g, 0.237 mol) and diethyl ethoxymethylene malonate (48.0 
mL, 0.238 mol) in Dowtherm A (100 mL) were allowed to heat gradually, stirring, to 
255°C, at which temperature the reaction was allowed to remain for 35 minutes.  After 
cooling, the reaction mixture was diluted with 35-60° petroleum æther (200 mL) and 

























The above product (45.83 g, 0.195 mol) in 400 mL of 10% caustic soda was allowed to 
reflux, stirring, for 2 hours, at which point all solid material had dissolved.  After partial 
cooling, the reaction was poured gradually and with good stirring into 300 mL 6M 
muriatic acid. The resulting off-white precipitate was recovered by vacuum filtration.  
After air-drying, the above product was heated in Dowtherm A (100 mL) at 255°C for 40 
minutes.  After cooling, the reaction mixture was diluted with 100 mL 35-60° petroleum 
æther and vacuum filtered.  The product was obtained as a tan, powdery solid (30.11 g, 
95%). 
 
1H NMR δ (ppm)(DMSO-d6): 11.98 (1 H, br s), 7.93 (1 H, dd, J = 7.35, 5.92 Hz), 7.72 (1 
H, dd, J = 9.43, 2.99 Hz), 7.65 (1 H, dd, J = 9.00, 4.71 Hz), 7.56 (1 H, ddd, J = 9.09, 8.22, 
3.00 Hz). 
 












Phosphorus oxychloride (80 mL, 860 mmol) was cautiously added to 6-fluoro-4-
quinolone (30.11 g, 185 mmol).  The reaction was allowed to heat, stirring, at 110°C for 
18 hours.  After cooling, the reaction mixture was poured gradually onto ice and then 
made basic (pH 10) with solid caustic potash.  This resulted in formation of white 
precipitate, which was recovered by filtration and allowed to air dry (19.16 g, 57% mp = 
60.7-65.3°C (lit. 76.5-77°C).  Note: Four years elapsed between synthesis of this product 
and determination of melting point.  The product had been stored in a sealed bottle in a 
dark drawer during this time. 
 
1H NMR δ (ppm)(CHCl3-d): 8.76 (1 H, d, J = 4.71 Hz), 8.14 (1 H, dd, J = 9.24, 5.33 Hz), 
7.86 (1 H, dd, J = 9.41, 2.83 Hz), 7.54-7.55 (2 H, m). 
 













4-chloro-6-fluoroquinoline (10.01 g, 55.1 mmol) and 3-amino-1-propanol (25.29 mL, 331 
mmol) were heated at 110°C for 24 hours.  The hot reaction mixture was poured into 750 
mL water, gradually and with good stirring.  The resulting precipitate was isolated by 
vacuum filtration, and then partially recrystallized from ethyl acetate.  Filtration afforded 
the desired product as a tan solid (9.74 g, 80%, mp =159.1-160.1°C). 
 
1H NMR δ (ppm)(DMSO-d6): 8.38 (1 H, d, J = 5.32 Hz), 8.04 (1 H, dd, J = 11.15, 2.85 
Hz), 7.83 (1 H, dd, J = 9.21, 5.84 Hz), 7.49-7.50 (1 H, m), 7.04 (1 H, br t, J = 5.28 Hz), 
6.47 (1 H, d, J = 5.37 Hz), 4.58 (1 H, t, J = 5.07 Hz), 3.55 (2 H, td, J = 6.13, 5.03 Hz), 
3.33 (water signal overlaps m, ~2 H), 1.82 (2 H, apparent p, J = 6.65 Hz). 
 





1H NMR δ (ppm)(CHCl3-d): 8.52 (1 H, d, J = 5.30 Hz), 7.96 (1 H, dd, J = 9.19, 5.61 Hz), 
7.35-7.36 (2 H, m), 6.42 (1 H, d, J = 5.32 Hz), 5.70 (1 H, s), 3.97 (2 H, t, J = 5.44 Hz), 
3.48 (2 H, m), 2.04-2.06 (2 H, m). 
 
MS (ESI): m/z 221.10864 M + H (calculated 221.10847) 
 
HPLC (method A) tR = 6.98 min (86% pure).  Second peak tR = 7.77 min (13%).  Note: 
Four years elapsed between synthesis of this product and testing by HPLC.  The product 













3-(6-fluoroquinolin-4-ylamino)propanol (3.00 g, 13.6 mmol) and triethylamine (3.00 mL, 
21.5 mmol) in dry chloroform (125 mL) were cooled to below 0°C on ice/salt. 
Methanesulfonyl chloride (1.22 mL, 15.7 mmol) was added dropwise.  After stirring for 
an hour on ice, TLC indicated that reaction was complete.  The reaction mixture was 
shaken with 25 mL saturated sodium bicarbonate, followed by extraction of the aqueous 
layer with three 10 mL portions of chloroform.  The pooled organic layers were washed 
with 10 mL water, dried over anhydrous magnesium sulfate, and evaporated under 
reduced pressure with warming.  This afforded the desired product as a pale yellow, 

















3-(6-fluoro quinolin-4-ylamino)propyl methanesulfonate (1.81 g, 6.07 mmol), N-
(diphenylmethyl)piperazine (1.62 g, 6.42 mmol), and potassium carbonate (1.26 g, 9.12 
mmol) were heated in refluxing acetonitrile (22 mL) for 5 hours. The reaction mixture 
was vacuum filtered, rinsing extensively with water, and then with 1 mL 95% ethanol.  
This afforded the desired product as a sparkling, cream-colored solid (2.12 g, 77%, mp = 
201-203°C). 
 
1H NMR δ (ppm)(CHCl3-d): 8.49 (1 H, d, J3,2 = 5.26 Hz, Q-C2-H), 7.96 (1 H, dd, J7,8 = 
9.23, JF = 5.61 Hz, Q-C8-H), 7.71 (1 H, dd, JF = 10.02, J7,5 = 2.79 Hz, Q-C5-H), 7.62 (1 
H, br t, JCH2,NH = 3.94 Hz, Q-C4-NH), 7.47-7.49 (4 H, m, Ph-H, ortho), 7.43 (1 H, ddd, 
J8,7 = 9.23, JF = 8.02, J5,7 = 2.75 Hz, Q-C7-H), 7.24-7.31 (solvent signal overlaps m, ~4 
H, Ph-H, meta), 7.15-7.22 (2 H, m, Ph-H, para), 6.31 (1 H, d, J2,3 = 5.31 Hz, Q-C3-H), 
4.36 (1 H, s, CH(Ph)2), 3.35 (2 H, td, JCH2,CH2 = 5.71, JNH,CH2 = 3.98 Hz, Q-C1-
NHCH2CH2CH2), 2.58 (10 H, br s overlaps t, center at 2.64 ppm, JCH2,CH2 = 8.82 Hz, Pip-
CH2 x 4 and Q-C1-NHCH2CH2CH2), 1.92 (2 H, apparent p, JCH2 x 2, CH2 = 5.31 Hz, Q-C1-
NHCH2CH2CH2). 
 
19F NMR δ (ppm)(CHCl3-d): -117.1 (m). 
 
13C NMR δ (ppm)(CHCl3-d): 160.8, 158.3 (d, JF = 244.47 Hz , Q-C6), 150.6 (d, JF = 1.95 
Hz, Q-C2), 150.2 (d, JF = 4.19 Hz, Q), 145.4 (Q), 142.9 (Ph-C, ipso), 132.1 (d, JF = 8.91 
Hz, Q-C8), 128.6 (Ph-C, meta), 127.9 (Ph-C, ortho), 127.0 (Ph-C, para), 119.6 (d, JF = 
8.64 Hz, Q), 118.5 (d, JF = 24.30 Hz, Q-C7), 105.3 (d, JF = 21.88 Hz, Q-C5), 98.3 (Q-
C3), 76.7 (CH(Ph)2), 59.0 (Q-C1-NHCH2CH2CH2), 53.9 (Pip-C x 2, adjacent to 
NHCH2CH2CH2), 52.1 (Pip-C x 2, adjacent to CH(Ph)2), 44.8 (Q-C1-NHCH2CH2CH2), 
23.3 (Q-C1-NHCH2CH2CH2).   
 
MS (ESI): m/z 455.26087 M + H (calculated 455.26055) 
 














3-(6-fluoroquinolin-4-ylamino)propyl methanesulfonate (1.97 g, 6.60 mmol), 1-(2-
pyridyl)piperazine (1.34 g, 8.21 mmol), and potassium carbonate (1.26 g, 9.12 mmol) 




reduced pressure with warming, and the residue was partitioned between water (25 mL) 
and ethyl acetate (35 mL).  After separation the aqueous layer was extracted with 
additional ethyl acetate (3 x 10 mL), and the pooled organic layers were dried (MgSO4) 
and evaporated under reduced pressure with warming.  The residue was dissolved in 
excess boiling ethyl acetate.  This was then allowed to concentrate slowly at room 
temperature.  Filtration afforded the desired product as pale yellow needles (0.40 g, 17%, 
mp = 145.3-146.6°C). 
 
 
1H NMR δ (ppm)(CHCl3-d): 8.51 (1 H, d, J = 5.30 Hz), 8.23 (1 H, dd, J = 4.96, 1.87 Hz), 
7.94 (1 H, dd, J = 9.22, 5.58 Hz), 7.51-7.52 (2 H, m), 7.33 (1 H, ddd, J = 9.20, 7.93, 2.75 
Hz), 7.09 (1 H, br t, J = 4.20 Hz), 6.67-6.69 (2 H, m), 6.38 (1 H, d, J = 5.32 Hz), 3.72 (4 
H, m), 3.42 (2 H, td, J = 5.94, 4.30 Hz), 2.68-2.70 (6 H, m), 2.01-2.03 (2 H, m). 
 
19F NMR δ (ppm)(CHCl3-d): -116.0 (m). 
 
MS (ESI): m/z 366.20932 M + H (calculated 366.20885) 
 
HPLC (method A) tR = 2.66 min (81% pure).  (Additional peaks elute at 1.64 min, 13%, 
























meta-Fluoroaniline (11.64 g, 105 mmol) and diethyl ethoxymethylene malonate (21.04 
mL, 105 mmol) in Dowtherm A (100 mL) were allowed to heat gradually, stirring, to 
255°C, at which temperature the reaction was allowed to remain for 30 minutes.  After 
cooling, the reaction mixture was diluted with 35-60° petroleum æther (200 mL) and 
























A portion of the above product (11.80 g, 50.2 mmol) in 250 mL of 10% caustic soda was 
allowed to reflux, stirring, for 1.75 hours, at which point all solid material had dissolved.  
After cooling to room temperature, the reaction was poured into 300 mL deionized water 
and triturated with concentrated muriatic acid until no more precipitate formed. The 
resulting off-white precipitate was recovered by vacuum filtration.  The off-white solid 
obtained after air-drying (11.12 g, presumed to contain residual water) was used without 
















The above product (10.39 g, presumed to contain residual water) was heated in 
Dowtherm A (60 mL) at 255°C for 1.5 hours.  After cooling, the reaction mixture was 
diluted with 35-60° petroleum æther (100 mL) and vacuum filtered.  The product was a 















Phosphorus oxychloride (40 mL, 430 mmol) was cautiously added to 5- and 7-fluoro-4-




hour and 45 minutes.  After cooling, the reaction mixture was poured gradually onto ice 
and then made basic (pH >10) with solid caustic potash.  The resulting white precipitate 
was recovered by filtration and allowed to air dry.  NMR indicated that this product was a 
mixture of 4-chloro-5-fluoroquinoline and 4-chloro-7-fluoroquinoline, as expected.  
Separation of the 7- and 5-fluoro regioisomers by recrystallization from hexanes was not 
successful.  The regioisomers were therefore separated by chromatography on alumina, 
eluting with 98:2 hexanes:ethyl acetate followed by 93:7 hexanes:ethyl acetate.  The 
desired 4-chloro-7-fluoroquinoline was recovered as a white, crystalline solid with a 
flowery odor, similar to that of 4,7-dichloroquinoline (4.99 g, 57%, mp = 74.9-75.6°C 
(lit. 73.5-74°C (Snyder, 1947)), Rf = 0.1 (basic alumina, hexanes)). 
 
1H NMR δ (ppm)(CHCl3-d): 8.79 (1 H, d, J = 4.74 Hz), 8.26 (1 H, dd, J = 9.27, 5.91 Hz), 
7.77 (1 H, dd, J = 9.77, 2.57 Hz), 7.48 (1 H, d, J = 4.65 Hz), 7.44-7.44 (1 H, m). 
 
19F NMR δ (ppm)(CHCl3-d), 1H-decoupled: -108.30. 
 
 
Note: Reaction of the above material with 3-amino-1-propanol gave a mixture of 
products due to replacement of the 7-fluoro substituent with 3-amino-1-propanol in 
addition to the expected substitution of the 4-chloro substituent.  Replacement of the 7-
fluoro substituent of 4-chloro-7-fluoroquinoline by amines has been observed previously 
(Snyder, 1947).  In the case of the above compound, the 7-substituted product was 
removed by chromatography.  Once purified, mesylation of the 4-substituted product 
resulted in partial substitution of the 7-fluoro substituent by the triethylamine base used 
in the reaction.  Due to the small yield of both products, the project was placed on hold.  
The easy replacement of the 7-fluoro substituent by amines, even tertiary amines, 
suggested possible avenues for the synthesis of 4,7-diamino-substituted quinolines, but 














para-Bromoaniline (13.53 g, 78.7 mmol) and diethyl ethoxymethylene malonate (15.9 




255°C, at which temperature the reaction was allowed to remain for 1.25 hours.  After 
cooling, the reaction mixture was diluted with 30-60º petroleum æther and vacuum 
filtered, rinsing with additional petroleum æther, then with acetone.  This afforded a 













3-carbethoxy-6-bromo-4-quinolone (17.56 g, 59.3 mmol) in 250 mL of 10% caustic soda 
was heated at reflux, stirring, for 1.5 hours, at which point all solid material had 
dissolved.  The hot reaction mixture was poured into 500 mL water and acidified by 
addition of concentrated muriatic acid.  The resulting white precipitate was isolated by 
vacuum filtration.  After air-drying, mass of product obtained was 16.38 g (product 
presumed to contain water; yield not calculated).  The product was used without further 
drying or purification in the next step. 
 
 









The above product (16.38 g, presumed to contain water) was decarboxylated in two 
portions.  Each portion was heated in Dowtherm A (50 mL) at 255°C for 1.25 hours. 
After cooling, the reaction mixture was diluted with 35-60° petroleum æther and vacuum 
filtered to recover the solid product as a pearlescent, pale beige solid.  In both cases, 
NMR indicated that this material was the decarboxylated product (13.40 g).  
 
1H NMR δ (ppm)(DMSO-d6): 11.94 (1 H, d, J = 5.86 Hz, Q-N1-H), 8.16 (1 H, d, J = 2.43 
Hz, Q-C5-H), 7.95 (1 H, dd, J = 7.37, 5.19 Hz, Q-C2-H), 7.79 (1 H, dd, J = 8.79, 2.48 Hz, 















The above product (13.40 g, no more than 59.3 mmol) was heated at reflux in 42 mL 
phosphorus oxychloride for 2 hours.  TLC indicated that the reaction was complete, and 
the reaction was therefore poured gradually into ice water, followed by basification with 
solid caustic potash (final volume 500 mL).  After cooling, the resulting precipitate was 
collected by vacuum filtration and allowed to air dry (10.82 g, ~75%, mp = 113.3-
114.8°C (lit. 111-112°C). 
 
1H NMR δ (ppm)(CHCl3-d): 8.80 (1 H, d, J = 4.73 Hz. Q-C2-H), 8.41 (1 H, d, J = 2.19 
Hz, Q-C5-H), 8.02 (1 H, d, J = 8.96 Hz, Q-C8-H), 7.86 (1 H, dd, J = 8.96, 2.18 Hz, Q-











4-chloro-6-bromoquinoline (5.00 g, 20.6 mmol) and 3-amino-1-propanol (15.50 mL, 203 
mmol) were heated at 100°C in a Carius vessel for 3 hours, whereupon TLC indicated 
that the reaction was complete.  The hot reaction mixture was then poured into 200 mL 
water, while stirring vigorously.  After standing overnight, the resulting precipitate was 
recovered by vacuum filtration, followed by air drying and partial recrystallization from 
25 mL ethyl acetate (3.46 g of a beige solid, 60%, mp = 176.3-177.8°C). 
 
1H NMR δ (ppm)(DMSO-d6): 8.51 (1 H, s), 8.40 (1 H, d, J = 5.38 Hz), 7.71 (2 H, d, J = 
1.24 Hz), 7.24 (1 H, br t, J = 5.27 Hz), 6.49 (1 H, d, J = 5.43 Hz), 4.58 (1 H, t, J = 5.08 
Hz), 3.55 (2 H, m), 3.30-3.32 (water signal overlaps m, ~2 H), 1.82 (2 H, apparent p, J = 





1H NMR δ (ppm)(CHCl3-d): 8.54 (1 H, d, J = 5.38 Hz), 7.85-7.85 (2 H, m), 7.68 (1 H, 
dd, J = 8.95, 2.12 Hz), 7.27 (solvent signal overlaps m, ~1 H), 6.44 (1 H, d, J = 5.40 Hz), 












3-(6-bromoquinolin-4-ylamino)propanol (3.16 g, 11.2 mmol) and triethylamine (2.35 
mL, 16.8 mmol) in dry THF (100 mL) were cooled to below 0°C on ice/salt. 
Methanesulfonyl chloride (1.00 mL, 12.9 mmol) was added dropwise.  After stirring for 1 
hour on ice, TLC indicated that reaction was not complete; additional methanesulfonyl 
chloride (0.15 mL, 1.9 mmol) were therefore added.  After a further hour of stirring, TLC 
indicated that reaction was complete.  The reaction mixture was diluted with ethyl acetate 
(10 mL) and washed with saturated sodium bicarbonate (100 mL).  The aqueous layer 
was then extracted with additional ethyl acetate (3 x 10 mL), and the pooled organic 
layers were rinsed with water (10 mL), dried (MgSO4), and evaporated under reduced 
pressure with warming to give the desired product as a pale yellow solid (3.32 g, 83%). 
 
1H NMR δ (ppm)(DMSO-d6): 8.52 (1 H, s), 8.43 (1 H, d, J = 5.41 Hz), 7.73 (2 H, m), 
7.29-7.41 (1 H, m), 6.54 (1 H, d, J = 5.47 Hz), 4.35 (2 H, t, J = 6.21 Hz), 3.37-3.38 (water 













3-(6-bromoquinolin-4-ylamino)propyl methanesulfonate (1.59 g, 4.43 mmol), N-
(diphenylmethyl)piperazine (1.17 g, 4.65 mmol), potassium carbonate (0.91 g, 6.7 




(15 mL) for 24 hours, whereupon substantial precipitate was noted to have formed.  A 
further 20 mL acetonitrile was added (to improve stirring), and reflux was continued for a 
further 4 days.  TLC then indicated that reaction was complete. The solvent was then 
removed under reduced pressure with warming, and the residue was partitioned between 
chloroform (30 mL) and water (40 mL).  After separation, the aqueous layer was 
extracted with further chloroform (3 x 7 mL), and the pooled organic layers were rinsed 
with brine (10 mL), dried (MgSO4) and evaporated under reduced pressure with warming 
to yield a pale brownish yellow solid. This material was partially recrystallized from 20 
mL 95% ethanol to provide the desired product as fine, white crystals (1.58 g, 69%, mp = 
209-210°C). 
 
1H NMR δ (ppm)(CHCl3-d): 8.50 (1 H, d, J = 5.32 Hz, Q-C2-H), 8.13 (1 H, d, J = 2.15 
Hz, Q-C5-H), 7.83 (1 H, d, J = 8.97 Hz, Q-C8-H), 7.70 (2 H, br dd, J = 8.78, 2.31 Hz, Q-
C7-H overlaps Q-C4-NH), 7.46-7.48 (4 H, m, Ph-CH ortho), 7.25-7.32 (solvent signal 
overlaps m, ~4 H, Ph-CH-meta), 7.17 (2 H, m, Ph-CH para), 6.32 (1 H, d, J = 5.37 Hz, 
Q-C3-H), 4.56 (1 H, s, CH(Ph)2), 3.34 (2 H, td, J = 5.67, 3.95 Hz, Q-NH-CH2CH2CH2), 
2.63-2.65 (10 H, br s overlaps t, J = 5.23 Hz, Pip-CH2 x 4 and Q-NH-CH2CH2CH2), 1.92 
(2 H, apparent p, J = 5.26 Hz, Q-NH-CH2CH2CH2). 
 
13C NMR δ (ppm)(CHCl3-d): 151.6 (Q-C2), 149.9 (Q), 147.2 (Q), 143.1 (Ph-C ipso), 
132.2 (Q-C7), 131.7 (Q-C8), 128.6 (Ph-C meta), 127.9 (Ph-C ortho), 127.0 (Ph-C para), 
123.2 (Q-C5), 120.5 (Q), 117.8 (Q), 98.8 (Q-C3), 75.9 (CH(Ph)2), 59.4 (Q-NH-
CH2CH2CH2), 54.2 (Pip-C-C-NCH(Ph)2), 52.0 (Pip-C-C-NCH(Ph)2), 45.1 (Q-NH-
CH2CH2CH2), 23.2 (Q-NH-CH2CH2CH2). 
 
MS (ESI): m/z 515.18091 M + H (calculated 515.18049) 
 















3-(6-bromoquinolin-4-ylamino)propyl methanesulfonate (1.66 g, 4.62 mmol), 1-(2-
pyridyl)piperazine (0.78 g, 4.85 mmol), potassium carbonate (0.95 g, 6.93 mmol), and a 
catalytic amount of potassium iodide were heated in refluxing acetonitrile (15 mL) for 24 




acetonitrile was therefore added.   Reflux was continued for a further 4 days. The solvent 
was then removed under reduced pressure with warming, and the residue was partitioned 
between chloroform (30 mL) and water (40 mL).  After separation, the aqueous layer was 
extracted with further chloroform (3 x 7 mL), and the pooled organic layers were rinsed 
with brine (10 mL), dried (MgSO4) and evaporated under reduced pressure with warming 
to yield a yellowish tan solid.  This material was taken up in excess boiling 95% ethanol 
and allowed to concentrate gradually at room temperature; the resulting pale golden 
crystals were recovered by vacuum filtration (1.17 g, 57%, mp = 186.1-187.9°C). 
 
1H NMR δ (ppm)(CHCl3-d): 8.52 (1 H, d, J = 5.33 Hz), 8.22-8.22 (1 H, m), 8.10 (1 H, d, 
J = 2.18 Hz), 7.79 (1 H, d, J = 8.93 Hz), 7.71 (1 H, br t, J = 4.09 Hz), 7.59 (1 H, dd, J = 
8.92, 2.14 Hz), 7.51 (1 H, ddd, J = 8.53, 7.15, 2.04 Hz), 6.71 (1 H, d, J = 8.55 Hz), 6.66 
(1 H, ddd, J = 7.17, 4.89, 0.84 Hz), 6.34 (1 H, d, J = 5.36 Hz), 3.81 (4 H, m), 3.41 (2 H, 
td, J = 5.38, 0.01 Hz), 2.71-2.72 (6 H, m), 2.01 (2 H, apparent p, J = 5.40 Hz). 
 
13C NMR δ (ppm)(CHCl3-d): 159.7, 151.6, 149.7, 148.0, 147.1, 137.5, 132.1, 131.6, 
123.1, 120.4, 117.8, 113.7, 107.3, 98.7, 59.3, 53.6, 45.2, 44.7, 23.4. 
 
MS (ESI): m/z 426.12947 M + H (calculated 426.12878) 
 
















meta-Bromoaniline (11.92 g, 69.3 mmol) and diethyl ethoxymethylene malonate (14.00 
mL, 69.3 mmol) in Dowtherm A (60 mL) were allowed to heat gradually, stirring, to 
255°C, at which temperature the reaction was allowed to remain for 60 minutes.  After 
cooling, the reaction mixture was diluted with 30-60º petroleum æther, then vacuum 
filtered, rinsing with additional petroleum æther, followed by acetone to give an off-

















3-carbethoxy-7-bromo-4-quinolone (13.67 g, 46.2 mmol) in 130 mL of 10% caustic soda 
was heated at reflux, stirring, for 1 hour, at which point all solid material had dissolved.  
The hot reaction mixture was poured into 1.2 M muriatic acid (400 mL).  The resulting 
white precipitate was isolated by vacuum filtration.  After air-drying, 13.00 g of a white 
solid was obtained (containing residual water).  The product was used without further 













The above product (13.00 g, containing residual water) was heated in refluxing 
Dowtherm A (200 mL) for 1 hour. After cooling, the reaction mixture was diluted with 
35-60° petroleum æther and vacuum filtered to recover the solid product as a pearlescent, 
tan solid (10.94 g, containing residual solvent; yield not calculated). 
 
 







The above product (10.94 g, no more than 46.2 mmol) was heated at reflux in phosphorus 
oxychloride (45 mL) for 2 hours.  TLC indicated that the reaction was complete, and the 




caustic potash (final volume 500 mL).  After cooling, the resulting precipitate was 
collected by vacuum filtration and allowed to air dry.  NMR indicated that this material 
was 4-chloro-7-bromoquinoline containing approximately 10% 4-chloro-5-
bromoquinoline.  The pure 7-bromo regioisomer was obtained by recrystallization from 
95% ethanol (7.02 g, 42% from m-bromoaniline, mp = 107.3-108.9°C (lit. 105-106°C 
(Conroy, 1949)).   
 
1H NMR δ (ppm)(CHCl3-d): 8.78 (1 H, d, J = 4.72 Hz), 8.32 (1 H, d, J = 1.96 Hz), 8.11 











4-chloro-6-bromoquinoline (3.00 g, 12.4 mmol) and 3-amino-1-propanol (5.98 mL, 78.2 
mmol) were heated at 100°C for 4.5 hours, whereupon TLC indicated that the reaction 
was complete.  The hot reaction mixture was poured into water (200 mL), while stirring 
vigorously.  After standing overnight, the resulting precipitate was recovered by vacuum 
filtration, followed by air drying and partial recrystallization from 20 mL ethyl acetate 
(2.29 g of a tan, crystalline solid, 66%, mp = 162.3-163.2°C). 
 
1H NMR δ (ppm)(DMSO-d6): 8.39 (1 H, d, J = 5.40 Hz), 8.18 (1 H, d, J = 9.01 Hz), 7.94 
(1 H, d, J = 2.11 Hz), 7.55 (1 H, dd, J = 8.95, 2.14 Hz), 7.30 (1 H, t, J = 5.33 Hz), 6.48 (1 
H, d, J = 5.46 Hz), 4.59 (1 H, t, J = 5.01 Hz), 3.55 (2 H, m), 3.30-3.32 (2 H, m), 1.82 (2 
H, apparent p, J = 6.68 Hz).  
 
1H NMR δ (ppm)(CHCl3-d): 8.51 (1 H, d, J = 5.36 Hz), 8.12 (1 H, d, J = 2.02 Hz), 7.56 
(1 H, d, J = 8.91 Hz), 7.46 (1 H, dd, J = 8.90, 2.03 Hz), 6.40 (1 H, d, J = 5.38 Hz), 5.92 (1 














3-(7-bromoquinolin-4-ylamino)propanol (0.58 g, 2.06 mmol) and triethylamine (0.44 
mL, 3.16 mmol) in dry tetrahydrofuran (70 mL) were cooled to below 0°C on ice/salt. 
Methanesulfonyl chloride (0.18 mL, 2.32 mmol) was added dropwise.  After stirring for 
1.5 hours on ice, TLC indicated that reaction was not complete; additional 
methanesulfonyl chloride (0.03 mL, 0.4 mmol) were therefore added.  After a further 18 
hours of stirring at room temperature, TLC indicated that reaction was complete.  The 
reaction mixture was washed with saturated sodium bicarbonate (100 mL), and the 
aqueous layer was extracted with ethyl acetate (3 x 10 mL).  The pooled organic layers 
were rinsed with brine (15 mL), dried over MgSO4, and evaporated under reduced 
pressure with warming to give the desired product as a cream-colored solid (0.68 g, 
92%). 
 
1H NMR δ (ppm)(DMSO-d6): 8.41 (1 H, d, J = 5.40 Hz), 8.20 (1 H, d, J = 8.99 Hz), 7.96 
(1 H, d, J = 2.10 Hz), 7.59 (1 H, dd, J = 8.94, 2.13 Hz), 7.38 (1 H, t, J = 5.38 Hz), 6.53 (1 
H, d, J = 5.46 Hz), 4.35 (2 H, t, J = 6.19 Hz), 3.37-3.38 (water overlaps m, ~2 H), 3.20 (3 















3-(7-bromoquinolin-4-ylamino)propyl methanesulfonate (0.68 g, 1.89 mmol), N-
(diphenylmethyl)piperazine (0.50 g, 1.98 mmol), potassium carbonate (0.39 g, 2.82 
mmol), and a catalytic amount of potassium iodide were heated in refluxing acetonitrile 
(25 mL) for 24 hours, whereupon TLC indicated that reaction was complete. The solvent 
was removed under reduced pressure with warming, and the residue was partitioned 




extracted with further chloroform (3 x 7 mL), and the pooled organic layers were rinsed 
with brine (10 mL), dried (MgSO4) and evaporated under reduced pressure with warming 
to yield a tan, crystalline solid. Recrystallization from 95% ethanol provided the desired 
product as lustrous, pale yellow crystals (0.29 g, 30%, mp = 185.5-187.3°C). 
 
1H NMR δ (ppm)(CHCl3-d): 8.48 (1 H, d, J = 5.34 Hz), 8.10 (1 H, d, J = 2.03 Hz), 7.70 
(1 H, d, J = 8.93 Hz), 7.60 (1 H, br t, J = 4.05 Hz), 7.44 (4 H, d, J = 7.55 Hz), 7.29-7.37 
(4 H, m), 7.26 (solvent signal overlaps m, ~3 H), 6.29 (1 H, d, J = 5.39 Hz), 4.44 (1 H, s), 
3.34 (2 H, td, J = 5.79, 4.03 Hz), 2.64 (10 H, br s overlaps t, J = 5.58 Hz), 1.92 (2 H, m, J 
= 5.37 Hz). 
 
13C NMR δ (ppm)(CHCl3-d): 152.1, 150.6, 149.4, 141.8, 132.0, 128.5, 128.2, 127.2, 
127.1, 122.8, 122.5, 117.8, 98.5, 75.8, 59.0, 54.0, 51.5, 44.5, 23.2. 
 
MS (ESI): m/z 515.18133 M + H (calculated 515.18049) 
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3-(6-bromoquinolin-4-ylamino)propyl methanesulfonate (1.42 g, 3.95 mmol), 1-(2-
pyridyl)piperazine (0.84 g, 5.15 mmol), potassium carbonate (0.81 g, 5.86 mmol), and 
acetonitrile (16 mL) were heated at reflux for 5 days, whereupon substantial precipitate 
was noted to have formed.  The precipitate was recovered from the reaction mixture by 
vacuum filtration, rinsing with 60 mL water; this precipitate was recrystallized from 95% 
ethanol to yield the desired product as golden crystals (0.37 g, 22%, mp = 169.7-
171.4°C).   
 
1H NMR δ (ppm)(CHCl3-d): 8.51 (1 H, d, J = 5.35 Hz), 8.24-8.24 (1 H, m), 8.11 (1 H, d, 
J = 2.03 Hz), 7.72 (1 H, d, J = 8.91 Hz), 7.54-7.54 (1 H, m), 7.36 (1 H, dd, J = 8.87, 2.04 
Hz), 7.30 (1 H, br t, J = 4.21 Hz), 6.68-6.69 (2 H, m), 6.36 (1 H, d, J = 5.39 Hz), 3.67 (4 
H, m), 3.42 (2 H, td, J = 5.46, 0.02 Hz), 2.65-2.70 (6 H, m), 2.00 (2 H, apparent p, J = 





13C NMR δ (ppm)(CHCl3-d): 159.3, 152.1, 150.5, 149.4, 148.1, 137.7, 132.1, 127.4, 
122.9, 121.9, 117.8, 113.8, 107.1, 98.7, 58.6, 53.5, 45.4, 44.2, 23.7. 
 
MS (ESI): m/z 426.12955 M + H (calculated 426.12878) 
 















para-Iodoaniline (13.24 g, 60.5 mmol) and diethyl ethoxymethylene malonate (13.05 g, 
60.4 mmol) in Dowtherm A (100 mL) were allowed to heat gradually, stirring, to 255°C, 
at which temperature the reaction was allowed to remain for 25 minutes.  After cooling, 
the reaction mixture was diluted with 150 mL hexanes, then vacuum filtered, rinsing with 














3-carbethoxy-6-iodo-4-quinolone (19.37 g, 56.5 mmol) in 250 mL of 10% caustic soda 
was heated just under reflux, stirring, for 24 hours.  At the end of this time, a small 
amount of undissolved solid was removed by vacuum filtration (0.53 g after drying, this 
was presumed to be unsaponified starting material).  The filtrate was made acidic by 
addition of concentrated muriatic acid. The resulting pure white precipitate was recovered 




was obtained (containing residual water).  This material was used without further drying 
or purification in the next step. 
 
1H NMR δ (ppm)(DMSO-d6): 15.04 (1 H, br s), 13.58 (1 H, s), 8.92 (1 H, s), 8.57 (1 H, d, 













The above product (18.80 g, containing residual water) was heated in Dowtherm A (125 
mL) at 255°C for 25 minutes.  After cooling, NMR indicated that the reaction had not 
gone to completion; it was therefore heated for an additional 25 minutes at 255°C.  After 
cooling, the reaction mixture was diluted with 100 mL 35-60° petroleum æther and 
vacuum filtered to recover the solid product (15.70 g, presumed to contain residual 












The above product (15.62 g, presumed to contain residual solvent) was heated in 
phosphorus oxychloride (60 mL, 640 mmol) for 1 hour at 100ºC, followed by 20 hours at 
70ºC, and finally 2 hours at 100ºC.  TLC indicated that the reaction was complete, and 
the dark reaction mixture was therefore poured gradually onto ice, followed by 
basification with concentrated caustic soda.  After cooling, the aqueous mixture (diluted 
to 2.7 L) was divided into three portions.  Each portion was extracted with chloroform 
(50 mL, then 5 x 15 mL), and the pooled organic layers were dried (MgSO4) and 
evaporated under reduced pressure with warming to yield an off-white, powdery solid 





1H NMR δ (ppm)(CHCl3-d): 8.78 (1 H, d, J = 4.69 Hz, Q-C2-H), 8.62 (1 H, d, J = 1.96 
Hz, Q-C5-H), 8.02 (1 H, dd, J = 8.83, 1.94 Hz, Q-C7-H), 7.84 (1 H, d, J = 8.83 Hz, Q-













4-chloro-6-iodoquinoline (7.00 g, 24.2 mmol) and 3-amino-1-propanol (10.90 g, 145 
mmol) were heated at 95°C in a Carius vessel for 24 hours.  The reaction mixture still 
contained solid material.  Temperature was increased to 140°C for 1 hour, with no visible 
change, and then to 160°C.  After a further hour, no solid was visible, and TLC indicated 
that the reaction was complete.  The reaction was allowed to cool to 110°C, and the hot 
reaction mixture was then poured into 200 mL water.  After standing 1 hour, the resulting 
precipitate was recovered by vacuum filtration, followed by air-drying (7.55 g of a 
yellow solid, 95%, mp = 177.0-179.4°C). 
 
1H NMR δ (ppm)(DMSO-d6): 8.65 (1 H, d, J = 1.91 Hz), 8.38 (1 H, d, J = 5.37 Hz), 7.84 
(1 H, dd, J = 8.80, 1.87 Hz), 7.54 (1 H, d, J = 8.80 Hz), 7.24 (1 H, br t, J = 5.27 Hz), 6.47 
(1 H, d, J = 5.43 Hz), 4.58 (1 H, t, J = 5.07 Hz), 3.54 (2 H, m), 3.26-3.33 (2 H, m), 1.82 













3-(6-iodoquinolin-4-ylamino)propanol (3.50 g, 10.7 mmol) and triethylamine (2.23 mL, 
16.1 mmol) in 100 mL dry tetrahydrofuran were cooled to below 0°C on ice/salt. 
Methanesulfonyl chloride (0.96 mL, 12.3 mmol) was added dropwise.  After stirring for 3 
hours on ice, TLC indicated that reaction was not complete.  Additional methanesulfonyl 




sealed and refrigerated for 18 hours.  TLC then indicated that no quinoline starting 
material remained.  The reaction mixture was diluted with ethyl acetate (30 mL) and 
shaken with saturated NaHCO3 (45 mL).  After separation, the organic layer was washed 
with water (3 x 10 mL), then dried (MgSO4) and evaporated under reduced pressure with 
warming (extract A).  The initial aqueous layer was extracted with further ethyl acetate (3 
x 15 mL), and this ethyl acetate was pooled, dried (MgSO4), and also evaporated under 
reduced pressure with warming (extract B).  Comparison of extracts A and B indicated 
that neither contained a significant amount of triethylamine, and that extract B contained 
6% of the total yield (i.e. additional extractions of the aqueous layer increase yield 
without increasing the amount of triethylamine contamination of the product, and it is not 
worthwhile to rinse the organic layers with water to remove residual triethylamine).  
Extracts A and B were combined (a yellow solid, 3.92 g, 90%). 
 
1H NMR δ (ppm)(DMSO-d6): 8.65 (1 H, d, J = 1.91 Hz), 8.41 (1 H, d, J = 5.36 Hz), 7.86 
(1 H, dd, J = 8.80, 1.86 Hz), 7.55 (1 H, d, J = 8.80 Hz), 7.29 (1 H, s), 6.51 (1 H, d, J = 
5.42 Hz), 4.35 (2 H, t, J = 6.21 Hz), 3.33 (water overlaps m, ~2 H), 3.20 (3 H, s), 2.08 (2 











PL 317  
 
3-(6-iodo quinolin-4-ylamino)propyl methanesulfonate (1.96 g, 4.82 mmol), N-
(diphenylmethyl)piperazine (1.28 g, 5.07 mmol), potassium carbonate (1.00 g, 7.23 
mmol), and a catalytic amount of potassium iodide were heated in refluxing acetonitrile 
(50 mL) for 24 hours.  TLC then indicated that reaction was complete. The solvent was 
removed by evaporation under reduced pressure with warming, diluting with 35 mL 
water at the end.  This material was then extracted with ethyl acetate (25 mL).  Some 
material remained insoluble, and so the aqueous layer was extracted with 
dichloromethane (25 mL); residual undissolved material was removed by vacuum 
filtration.  The aqueous layer was then extracted with a further ethyl acetate (3 x 10 mL), 
and the pooled organic layers were dried (MgSO4) and evaporated under reduced 
pressure with warming to yield an ochre solid.  The insoluble material from extraction 
was dissolved in excess boiling 95% ethanol and allowed to evaporate gradually to 200 




golden crystals.  The mother liquor was further concentrated to yield a second crop of 
crystals (1.37 g in total, 51%, mp = 208-210°C ). 
 
1H NMR δ (ppm)(CHCl3-d): 8.50 (1 H, d, J = 5.34 Hz), 8.25 (1 H, d, J = 1.89 Hz), 7.87 
(1 H, dd, J = 8.87, 1.85 Hz), 7.68 (1 H, d, J = 8.87 Hz), 7.51 (1 H, br t, J = 4.04 Hz), 7.46-
7.48 (4 H, m), 7.27-7.27 (solvent peak overlaps m, ~ 4 H), 7.14-7.21 (2 H, m), 6.32 (1 H, 
d, J = 5.39 Hz), 4.68 (1 H, s), 3.34 (2 H, td, J = 5.68, 4.01 Hz), 2.63 (10 H, br s overlaps t, 
J = 5.25 Hz), 1.92 (2 H, apparent p, J = 5.29 Hz). 
 
13C NMR δ (ppm)(CHCl3-d): 151.7, 149.6, 147.6, 143.1, 137.7, 131.8, 129.2, 128.6, 
127.9, 127.0, 121.2, 99.0, 89.1, 75.5, 59.4, 54.3, 52.0, 45.1, 23.3. 
 
MS (ESI): m/z 563.16755 M + H (calculated 563.16662) 
 













PL 318  
 
3-(6-iodoquinolin-4-ylamino)propyl methanesulfonate (1.96 g, 4.82 mmol), 1-(2-
pyridyl)piperazine (0.87 g, 5.33 mmol), and potassium carbonate (1.00 g, 7.23 mmol) 
were heated in refluxing acetonitrile (50 mL) for 28 hours.  The solvent was removed 
under reduced pressure with warming, and the residue was diluted with water (35 mL) 
and filtered.  The solid material was dissolved in excess boiling solvent (25% ethanol, 
75% ethyl acetate) and allowed to concentrate slowly at room temperature to 22 mL.  
Filtration afforded the desired product as small, amber crystals (1.25 g, 55%, mp = 193.5-
194.5°C). 
 
1H NMR δ (ppm)(CHCl3-d): 8.51 (1 H, d, J = 5.34 Hz), 8.27 (1 H, d, J = 1.91 Hz), 8.20-
8.22 (1 H, m), 7.75 (1 H, dd, J = 8.85, 1.88 Hz), 7.71 (1 H, t, J = 4.02 Hz), 7.65 (1 H, d, J 
= 8.84 Hz), 7.49 (1 H, ddd, J = 8.56, 7.14, 2.02 Hz), 6.73 (1 H, d, J = 8.57 Hz), 6.64 (1 H, 
dd, J = 7.14, 4.92 Hz), 6.33 (1 H, d, J = 5.38 Hz), 3.84 (4 H, m), 3.40 (2 H, td, J = 5.73, 
4.03 Hz), 2.70-2.71 (6 H, m), 2.00 (2 H, apparent p, J = 5.35 Hz). 
 
13C NMR δ (ppm)(CHCl3-d): 159.6, 151.7, 149.5, 147.9, 147.5, 137.5, 137.4, 131.6, 





MS (ESI): m/z 474.11508 M + H (calculated 474.11492) 
 






















meta-Iodoaniline (11.14 g, 52.1 mmol) and diethyl ethoxymethylene malonate (10.28 
mL, 51.3 mmol) in Dowtherm A (125 mL) were allowed to heat gradually, stirring, to 
255°C, at which temperature the reaction was allowed to remain for 30 minutes.  After 
cooling, the reaction mixture was vacuum filtered (without dilution), rinsing with 10 mL 
Dowtherm A, then with 35-60° petroleum æther (200 mL), and finally with acetone (70 
mL) to give an off-white, powdery solid (19.25 g).  NMR indicated that the 7- and 5- 
iodo regioisomers were present in a proportion of approximately 9:1.  This material was 
used without purification in the ensuing reactions. 
 
 
















The above product (19.25 g, ≤ 52.1 mmol) in 450 mL of 10% caustic soda was allowed to 
reflux, stirring, for 3 hours, at which point all solid material had dissolved.  After cooling 
to room temperature, some solid appeared, and so the reaction was reheated before being 
poured into 450 mL deionized water and acidified with concentrated muriatic acid. After 
cooling, the resulting white precipitate was recovered by vacuum filtration (14.41 g, used 



















Without further drying, the above product (14.41 g) was heated in Dowtherm A (75 mL) 
at 255°C for 50 minutes.  After cooling, the reaction mixture was diluted with 100 mL 
35-60° petroleum æther and vacuum filtered.  The solid product was used without 
analysis in the next reaction. 
 
 







Phosphorus oxychloride (30 mL, 320 mmol) was cautiously added to the product from 
the above reaction (12.43 g).  The mixture was heated at 105°C for 4 hours, followed by 
heating at 70°C for 14 hours.  After cooling, the reaction mixture was poured gradually 
into ice water (700 mL) and then made basic (pH 10) with solid caustic soda.  The 
resulting inhomogeneous mixture was diluted with water to 1.1 L and extracted in three 
equal portions.  Each was extracted with chloroform (100 mL, followed by 3 x 30 mL), 
and the combined organic layers were dried (MgSO4) and evaporated under reduced 
pressure with warming to yield a pale brown solid (9.60 g, 64% from the aniline, mp = 
100.4-102.3°C (lit. 101-102°C (Conroy, 1949)).  NMR indicated that none of the 5-iodo 














4-chloro-7-iodoquinoline (3.00 g, 10.4 mmol) and 3-amino-1-propanol (4.76 mL, 62.2 
mmol) were heated at 85°C in a Carius vessel for 20 hours.  TLC indicated that the 
reaction was complete, and so the hot reaction mixture was poured into 100 mL water 
(stirring well).  After standing 1 hour, the resulting precipitate was recovered by vacuum 
filtration, followed by air drying (3.28 g of an ochre solid, 96%, mp = 172.1-173.9°C). 
 
1H NMR δ (ppm)(DMSO-d6): 8.36 (1 H, d, J = 5.38 Hz), 8.15 (1 H, d, J = 1.83 Hz), 8.00 
(1 H, d, J = 8.86 Hz), 7.68 (1 H, dd, J = 8.78, 1.88 Hz), 7.26 (1 H, br t, J = 5.37 Hz), 6.48 
(1 H, d, J = 5.44 Hz), 4.59 (1 H, t, J = 5.04 Hz), 3.54 (2 H, m), 3.27-3.32 (water signal 
overlaps m, ~2 H, m), 1.81 (2 H, apparent p, J = 6.66 Hz). 
 
1H NMR δ (ppm)(CHCl3-d): 8.50 (1 H, d, J = 5.35 Hz), 8.36 (1 H, d, J = 1.79 Hz), 7.64 
(1 H, dd, J = 8.78, 1.81 Hz), 7.41 (1 H, d, J = 8.81 Hz), 6.40 (1 H, d, J = 5.37 Hz), 3.96 (2 
H, t, J = 5.43 Hz), 3.47 (2 H, m), 2.04-2.04 (2 H, m). 
 
MS (ESI): m/z 329.01435 M + H (calculated 329.01496) 
 











3-(7-iodoquinolin-4-ylamino)propanol (1.00 g, 3.05 mmol) and triethylamine (0.64 mL, 
4.6 mmol) in 100 mL dry tetrahydrofuran were cooled to 5°C in an ice bath. 
Methanesulfonyl chloride (0.26 mL, 3.4 mmol) was added dropwise.  After stirring for 30 
minutes, TLC indicated that reaction was not complete.  Additional triethylamine (0.27 
mL, 1.9 mmol) and methanesulfonyl chloride (0.07 mL, 0.9 mmol) were added.  After a 
further 45 minutes, TLC indicated that reaction was complete. The reaction mixture was 
diluted with 25 mL ethyl acetate and shaken with 30 mL saturated NaHCO3.  The 
aqueous layer was diluted with 15 mL water to dissolve a small amount of precipitate that 
formed.  After separation of the layers, the aqueous layer was extracted with 3 x 10 mL 
ethyl acetate, and the pooled organic layers were dried (MgSO4) and evaporated under 
reduced pressure with warming to yield a grayish yellow solid, containing residual ethyl 






1H NMR δ (ppm)(CHCl3-d): 8.50 (1 H, d, J = 5.36 Hz), 8.38 (1 H, d, J = 1.79 Hz), 7.69 
(1 H, dd, J = 8.80, 1.80 Hz), 7.50 (1 H, d, J = 8.84 Hz), 6.44 (1 H, d, J = 5.40 Hz), 5.56 (1 
H, s), 4.41 (2 H, t, J = 5.66 Hz), 3.57 (2 H, m), 3.06 (3 H, s), 2.16-2.18 (2 H, m).  Minor 
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3-(7-iodoquinolin-4-ylamino)propyl methanesulfonate (no more than 2.2 mmol, 
containing residual triethylamine and ethyl acetate), 1-(2-pyridyl)piperazine (0.38 g, 2.3 
mmol), and potassium carbonate (0.45 g, 2.2 mmol) were heated in refluxing acetonitrile 
(25 mL) for 13 hours.  The reaction mixture was diluted with 5 mL water, and the solvent 
was removed under reduced pressure with warming; the residue was partitioned between 
chloroform (150 mL) and water (125 mL).  After separation, the aqueous layer was 
extracted with additional chloroform (3 x 10 mL), and the pooled organic layers were 
dried (MgSO4) and evaporated under reduced pressure with warming to yield a golden 
oil.  This was recrystallized from 20 mL ethyl acetate/95% ethanol (9:1) to yield the 
desired product as yellow crystals (0.58 g, 56% from 3-(7-iodoquinolin-4-
ylamino)propanol, mp = 176.5-177.1°C). 
 
1H NMR δ (ppm)(CHCl3-d): 8.50 (1 H, d, J = 5.34 Hz), 8.35 (1 H, d, J = 1.74 Hz), 8.23-
8.25 (1 H, m), 7.57 (1 H, d, J = 8.80 Hz), 7.54-7.54 (2 H, m), 7.28 (1 H, br t, J = 4.42 
Hz), 6.67-6.71 (2 H, m), 6.36 (1 H, d, J = 5.38 Hz), 3.67 (4 H, m), 3.41 (2 H, td, J = 5.97, 
4.24 Hz), 2.67-2.68 (6 H, m), 2.00 (2 H, apparent p, J = 5.61 Hz). 
 
13C NMR δ (ppm)(CHCl3-d): 159.3, 151.9, 150.5, 149.5, 148.1, 138.8, 137.7, 132.7, 
121.8, 118.3, 113.8, 107.2, 107.1, 98.8, 94.8, 58.7, 53.5, 45.4, 44.3, 23.7. 
 
MS (ESI): m/z 474.11539 M + H (calculated 474.11492) 
 




















para-Nitroaniline (5.00 g, 36.2 mmol) and diethyl ethoxymethylene malonate (7.25 mL, 
36.2 mmol) were heated on a boiling water bath for 40 minutes.  Crystallization of the 
crude reaction mixture from methanol afforded the condensation product as greenish-gray 
crystals.  This material was heated in refluxing Dowtherm A (125 mL) for 30 minutes.  
After cooling, the reaction mixture was diluted with 35-60° petroleum æther (200 mL) 














3-carbethoxy-6-nitro-4-quinolone (6.96 g, 26.5 mmol) in 55 mL of 10% caustic soda was 
allowed to reflux, stirring, for 30 minutes, at which point all solid material had dissolved.  
After partial cooling, the brilliant orange, semisolid reaction mixture was poured into 
water (200 mL); after heating to 60°C to dissolve the solid, the mixture was acidified 
with 10% muriatic acid. The resulting tan precipitate was isolated by vacuum filtration 
(the filtrate was now colorless).  After air-drying, the product was used without further 
purification in the ensuing reaction. 
 
1H NMR δ (ppm)(DMSO-d6): 14.59 (1 H, br s, COOH), 13.78 (1 H, br s, Q-N1-H), 9.05 
(1 H, s, Q-C2-H), 8.98 (1 H, d, J = 2.64 Hz, Q-C5-H), 8.63 (1 H, dd, J = 9.16, 2.66 Hz, 
















3-carboxy-6-nitro-4-quinolone from the above reaction was decarboxylated in two 
portions as follows.  Approximately half of the above product was heated in Dowtherm A 
(100 mL) at 255°C for 30 minutes.  After cooling, the reaction mixture was diluted with 
100 mL 35-60° petroleum æther and vacuum filtered.  The remaining 3-carboxy-6-nitro-
4-quinolone was treated in the same manner and the products from the two reactions were 
combined (4.77 g, 95% from 3-carbethoxy-6-nitro-4-quinolone). 
 
1H NMR δ (ppm)(DMSO-d6): 12.28 (1 H, br d, J = 5.26 Hz, Q-N1-H), 8.84 (1 H, d, J = 
2.71 Hz, Q-C5-H), 8.42 (1 H, dd, J = 9.15, 2.73 Hz, Q-C7-H), 8.05 (1 H, dd, J = 7.52, 













6-nitro-4-quinolone (4.77 g, 25.1 mmol) was heated in 25 mL phosphorus oxychloride 
for 1.5 hours at reflux.  Upon cooling to room temperature, the reaction mixture was 
poured gradually onto ice (stirring vigorously).  The aqueous mixture (400 mL) was then 
extracted (without basifying) with four 50 mL portions of DCM, and the pooled organic 
layers were rinsed with 50 mL brine.  The yellow organic layers contained a black 
precipitate.  This was removed by vacuum filtration, followed by drying of the filtrate 
over MgSO4 and evaporation under reduced pressure with warming to yield a cream 
colored powder with an odor resembling that of 4,7-dichloroquinoline (3.35 g, 64%, mp 
= 138.5-144.5°C (lit. 141-141.5°C (Baker, 1946)).  Note: It is probably that the yield 





1H NMR δ (ppm)(CHCl3-d): 9.21 (1 H, d, J = 2.52 Hz, Q-C5-H), 8.97 (1 H, d, J = 4.72 
Hz, Q-C2-H), 8.55 (1 H, dd, J = 9.23, 2.51 Hz, Q-C7-H), 8.29 (1 H, d, J = 9.22 Hz, Q-













4-chloro-6-nitroquinoline (2.82 g, 13.5 mmol) and 3-amino-1-propanol (15.0 mL, 196 
mmol) were heated at 90°C for 1.5 hours, followed by further heating at 130°C for 20 
minutes.  TLC then indicated that the reaction was complete.  The hot reaction mixture 
was poured into 200 mL water, gradually and with good stirring.  Vacuum filtration, 
followed by air-drying, afforded the desired product as a sparkling, ochre solid (2.76 g, 
83%). 
 
1H NMR δ (ppm)(DMSO-d6): 9.37 (1 H, d, J = 2.52 Hz, Q-C5-H), 8.51 (1 H, d, J = 5.56 
Hz, Q-C2-H), 8.31 (1 H, dd, J = 9.25, 2.48 Hz, Q-C7-H), 7.95 (1 H, br t, J = 5.25 Hz, Q-
C4-NH), 7.90 (1 H, d, J = 9.25 Hz, Q-C8-H), 6.61 (1 H, d, J = 5.61 Hz, Q-C3-H), 4.59 (1 
H, t, J = 5.07 Hz, OH), 3.55 (2 H, td, J = 6.13, 5.06 Hz, Q-NHCH2CH2CH2), 3.38 (2 H, 














3-(6-nitroquinolin-4-ylamino)propanol (2.76 g, 11.2 mmol) and triethylamine (2.36 mL, 
16.9 mmol) in 100 mL dry chloroform were cooled to below 0°C on ice/salt. 
Methanesulfonyl chloride (1.01 mL, 13.0 mmol) was added dropwise.  After stirring for 
an hour on ice, additional methanesulfonyl chloride (0.5 mL, 6.43 mmol) was added.  
After a further 30 minutes, TLC indicated that no quinoline starting material remained.  




with 45 mL saturated NaHCO3.  After separation, the aqueous layer was extracted with 
further chloroform (3 x 10 mL), and the pooled organic layers were washed with 10 mL 
brine, dried (MgSO4), and evaporated under reduced pressure with warming.  This 
afforded a bright yellow semisolid with the odor of triethylamine (approximately 3 g, 
yield not calculated).  This material was used without further purification.  
 
1H NMR δ (ppm)(DMSO-d6): 9.38 (1 H, d, J = 2.53 Hz, Q-C5-H), 8.55 (1 H, d, J = 5.55 
Hz, Q-C2-H), 8.33 (1 H, dd, J = 9.24, 2.48 Hz, Q-C7-H), 7.97 (1 H, t, J = 5.25 Hz, Q-C4-
NH), 7.92 (1 H, d, J = 9.24 Hz, Q-C8-H), 6.65 (1 H, d, J = 5.61 Hz, Q-C5-H), 4.37 (2 H, 
t, J = 6.20 Hz, CH2CH2CH2OMs), 3.44 (2 H, td, J = 6.90, 5.34 Hz, CH2CH2CH2OMs), 
3.21 (3 H, s, CH3), 2.11 (2 H, apparent p, J = 6.58 Hz, CH2CH2CH2OMs).  Minor peaks 















3-(6-nitroquinolin-4-ylamino)propyl methanesulfonate (0.36 g, 1.1 mmol), 1-(2-
pyridyl)piperazine (0.23 g, 1.4 mmol), and potassium carbonate (0.23 g, 1.7 mmol) in 
acetonitrile (15 mL) were allowed to reflux for 3 days.  The reaction mixture was vacuum 
filtered, rinsing extensively with water, and then with 1 mL 95% ethanol.  The canary-
yellow, crystalline solid thus obtained proved to be the desired product (0.24 g, 55%, mp 
= 175.5-177.4°C). 
 
1H NMR δ (ppm)(CHCl3-d): 8.88 (1 H, d, J = 2.48 Hz), 8.63 (1 H, d, J = 5.50 Hz), 8.21-
8.21 (1 H, m), 8.00 (1 H, d, J = 9.25 Hz), 7.92 (1 H, br t, J = 3.99 Hz), 7.52 (1 H, ddd, J = 
8.56, 7.15, 2.01 Hz), 6.70 (1 H, d, J = 8.56 Hz), 6.66 (1 H, dd, J = 7.13, 4.94 Hz), 6.46 (1 
H, d, J = 5.54 Hz), 3.80 (4 H, m), 3.47 (2 H, td, J = 5.83, 4.10 Hz), 2.72 (6 H, m), 2.05 (2 
H, apparent p, J = 5.44 Hz). 
 
13C NMR δ (ppm)(CHCl3-d): 159.5, 154.2, 152.0, 151.4, 147.9, 143.5, 137.6, 131.3, 
122.6, 118.0, 117.9, 113.6, 107.2, 99.7, 59.1, 53.8, 45.0, 44.9, 23.3. 
 
MS (ESI): m/z 393.20411M + H (calculated 393.20335) 
 
HPLC (method A) tR = 2.97 min (89% pure).  Additional peaks elute at 1.66 min, 7%, 






2-trifluoromethyl-4-quinolone (Conrad, 1887; Conrad, 1891; Reynolds, 1955; 









Ethyl-4,4,4-trifluoroacetoacetate (13.0 g, 70.6 mmol) and aniline (6.44 mL, 70.7 mmol) 
were allowed to heat at 125ºC in a retort for 1.5 hours.  TLC and NMR indicated that 
reaction was not complete. The reaction mixture was combined with benzene (100 mL) 
and a catalytic amount of para-toluenesulfonic acid and allowed to heat for 2 hours at 
reflux in a flask equipped with a Dean and Stark water separator topped with a water-
cooled Liebig condenser.  TLC then indicated that reaction was complete.  The solvent 
was therefore removed by evaporation under reduced pressure with warming.  The 
residue was allowed to heat in Dowtherm A (110 mL) to 255ºC, and allowed to remain at 
this temperature for 70 minutes.  The cooled reaction mixture was diluted with 35-60º 
petroleum æther (150 mL), and the solid product was recovered by vacuum filtration 











2-trifluoromethyl-4-quinolone (6.00 g, 22.2 mmol) and phosphorus oxychloride (45.0 
mL, 483 mmol) were allowed to heat at 110°C for 75 minutes. After cooling, the reaction 
mixture was gradually poured into ice water (200 mL, adding additional ice as needed to 
control the resulting exothermic reaction) with vigorous stirring.  After resting 18 hours, 
the aqueous mixture was made basic by the addition of solid caustic potash.  Upon 
cooling, the solid product was recovered by vacuum filtration (5.53 g).  This material was 
recrystallized from  95% ethanol (17 mL) to provide the desired product as tan crystals 






1H NMR δ (ppm)(CHCl3-d): 8.31 (1 H, dd, J = 8.45, 1.36 Hz), 8.26 (1 H, d, J = 8.51 Hz), 
7.89 (1 H, ddd, J = 8.51, 6.91, 1.44 Hz), 7.84 (1 H, s), 7.79 (1 H, ddd, J = 8.44, 6.92, 1.22 
Hz).   
 











4-chloro-2-(trifluoromethyl)quinoline (2.65 g, 11.4 mmol) and 3-amino-1-propanol (7.00 
mL, 91.5 mmol) were allowed to heat at 90°C for 1 hour.  The hot reaction mixture was 
then poured into 100 mL water, stirring vigorously.  After standing 1 hour, the resulting 
precipitate was recovered by vacuum filtration, followed by air-drying (2.99 g of a white 
powder, 97%, mp = 162.3-163.7°C). 
 
1H NMR δ (ppm)(DMSO-d6): 8.31 (1 H, d, J = 8.47 Hz), 7.89 (1 H, d, J = 8.42 Hz), 7.69-
7.77 (2 H, m), 7.56 (1 H, t, J = 7.64 Hz), 6.76 (1 H, s), 4.62 (1 H, t, J = 5.07 Hz), 3.55 (2 
H, m), 3.42 (2 H, m), 1.80-1.88 (2 H, m). 
 











3-(2-trifluoromethylquinolin-4-ylamino)propanol (2.58 g, 9.5 mmol) and triethylamine 
(1.99 mL, 14 mmol) in anhydrous tetrahydrofuran (100 mL) were cooled to below 0°C 
on ice/salt. Methanesulfonyl chloride (0.85 mL, 11 mmol) was added dropwise.  After 
stirring for 90 minutes on ice, TLC indicated that the reaction was complete.  The 




sodium bicarbonate (30 mL).  The aqueous layer was extracted with ethyl acetate (3 x 7 
mL), and the pooled organic layers were rinsed with brine (10 mL), dried (MgSO4), and 
evaporated under reduced pressure with warming to give a tan solid (2.73 g, 82%).  
 
1H NMR δ (ppm)(DMSO-d6): 8.32 (1 H, d, J = 1.63 Hz), 7.90 (1 H, d, J = 8.43 Hz), 7.73-
7.75 (2 H, m), 7.57-7.58 (1 H, m), 6.79 (1 H, s), 4.36 (2 H, t, J = 6.16 Hz), 3.48 (2 H, m), 















3-(2-trifluoromethylquinolin-4-ylamino)propyl methanesulfonate (1.36 g, 3.9 mmol), 1-
(diphenylmethyl)piperazine (1.03 g, 4.1 mmol), and potassium carbonate (0.81 g, 5.9 
mmol) were heated at reflux in anhydrous acetonitrile (22 mL) for 18 hours.  TLC then 
indicated that reaction was complete.  The solvent was removed under reduced pressure 
with warming, and the residue was partitioned between chloroform (25 mL) and water 
(25 mL).  After separation, the aqueous layer was extracted with further chloroform (3 x 
10 mL), and the pooled organic layers were dried (MgSO4) and evaporated under reduced 
pressure with warming to yield a beige solid.  This material was recrrystallized from 95% 
ethanol to provide the desired product as pale beige crystals (0.91 g, 46%, mp = 191.8-
193.7°C). 
 
1H NMR δ (ppm)(CHCl3-d): 8.06 (1 H, dd, J = 8.50, 1.15 Hz), 7.99 (1 H, br t, J = 3.96 
Hz), 7.95 (1 H, dd, J = 8.45, 1.30 Hz), 7.71 (1 H, ddd, J = 8.52, 6.82, 1.29 Hz), 7.45-7.45 
(4 H, m), 7.39 (1 H, ddd, J = 8.42, 6.82, 1.25 Hz), 7.30-7.32 (4 H, m), 7.19-7.27 (2 H, m), 
6.61 (1 H, s), 4.36 (1 H, s), 3.42 (2 H, td, J = 5.78, 3.98 Hz), 2.62-2.63 (10 H, br s 
overlaps t, J = 5.45 Hz), 1.95 (2 H, apparent p, J = 5.34 Hz). 
 





13C NMR δ (ppm)(CHCl3-d): 152.1, 149.1 (q, JF = 33.1 Hz, Q-C2-CF3), 147.5, 142.2, 
130.5, 129.8, 128.6, 128.0, 127.1, 125.6, 120.9, 120.7, 119.1, 93.6, 76.5, 58.9, 53.9, 51.8, 
44.7, 23.1. 
 
MS (ESI): m/z 505.25791 M + H (calculated 505.25736)  
 














3-(2-trifluoromethylquinolin-4-ylamino)propyl methanesulfonate (1.36 g, 3.9 mmol), 1-
(2-pyridyl)piperazine (0.75 g, 4.1 mmol), and potassium carbonate (0.81 g, 5.9 mmol) 
were heated at reflux in anhydrous acetonitrile (23 mL) for 42 hours.  The solvent was 
then removed under reduced pressure with warming to provide a thick, yellow oil that 
solidified upon standing.  This material was recrystallized from 95% ethanol to provide 
the desired product as fine, off-white crystals (0.54 g, 33%, mp = 146.2-146.8°C). 
 
1H NMR δ (ppm)(CHCl3-d): 8.24-8.24 (1 H, m), 8.06 (1 H, d, J = 8.47 Hz), 7.91 (1 H, d, 
J = 8.42 Hz), 7.72 (1 H, br t, J = 4.19 Hz), 7.64 (1 H, ddd, J = 8.49, 6.84, 1.35 Hz), 7.54 
(1 H, ddd, J = 8.52, 7.17, 2.02 Hz), 7.38-7.38 (1 H, m), 6.68-6.72 (2 H, m), 6.67 (1 H, s), 
3.71 (4 H, m), 3.50 (2 H, td, J = 5.44, 0.01 Hz), 2.70-2.71 (6 H, m), 2.04 (2 H, apparent p, 
J = 5.51 Hz). 
 
13C NMR δ (ppm)(CHCl3-d): 159.4, 152.0, 148.1, 147.5, 137.7, 130.6, 129.9, 125.9, 
120.4, 119.1, 113.8, 107.1, 93.8, 58.8, 53.5, 45.3, 44.5, 23.5.  
 
19F NMR δ (ppm)(CHCl3-d): -68.6. 
 
MS (ESI): m/z 416.20605 M + H (calculated 416.20566) 
 



















meta-Trifluoromethyl aniline (25.48 g, 160 mmol) and diethyl ethoxymethylene malonate 
(32 mL, 160 mmol) in Dowtherm A (150 mL) were allowed to heat gradually, stirring, to 
255°C, at which temperature the reaction was allowed to remain for 30 minutes.  After 
cooling, the reaction mixture was diluted with 35-60° petroleum æther (200 mL) and 
vacuum filtered, giving 38.94 g of a cream-colored, fine, crystalline solid (38.94 g, 86%). 
 
1H NMR δ (ppm)(DMSO-d6): 12.62 (1 H, d, J = 6.25 Hz), 8.66 (1 H, d, J = 6.47 Hz), 
8.41 (1 H, d, J = 2.02 Hz), 8.03 (1 H, dd, J = 8.68, 2.20 Hz), 7.83 (1 H, d, J = 8.66 Hz), 
4.24 (2 H, q, J = 7.10 Hz), 1.29 (3 H, t, J = 7.10 Hz).  
 













3-carbethoxy-6-trifluoromethyl-4-quinolone (38.94 g, 0.136 mol) in 400 mL of 10% 
caustic soda was allowed to reflux, stirring, for 1.5 hours, at which point all solid material 
had dissolved.  After cooling partially, the reaction was poured into 5 M HCl (350 mL) 
with good stirring.  The resulting off-white precipitate was recovered by vacuum 
filtration, followed by air-drying (34.72 g, containing residual water).  
 
1H NMR δ (ppm)(DMSO-d6): 8.10 (1 H, s), 7.88 (1 H, s), 7.31 (1 H, dd, J = 8.76, 2.06 
















3-carboxy-6-trifluoromethyl-4-quinolone (34.72 g, containing residual water) was heated 
in Dowtherm A (200 mL) at 255°C for 1.5 hours.  After cooling, the reaction mixture was 
diluted with 200 mL 35-60° petroleum æther and vacuum filtered.  The product was a 
tan, fine, crystalline solid, 27.01 g (94%). 
 












Phosphorus oxychloride (40 mL, 430 mmol) was cautiously added to 6-trifluoromethyl-
4-quinolone (27.01g, 127 mmol), followed by heating at 110°C for 1.5 h.  At the end of 
this time TLC indicated that the reaction had gone to completion.  After cooling, the 
reaction mixture was gradually added to 300 mL ice water.  Without basifying, this 
aqueous solution was extracted with chloroform (200mL, then 3 x 50 mL).  Upon drying 
over MgSO4 and evaporation under reduced pressure with warming, yield from this was 
8.72g.  Further extraction with dichloromethane (3 times 75 mL) followed by drying over 
MgSO4 and evaporation under reduced pressure with warming gave an additional 4.40 g 
of the product, a tan, crystalline material with a sweet and pleasing aroma, similar to that 
of 4,7-dichloroquinoline.  Total yield is 13.12 g (0.057 mol, 45% yield). 
 
1H NMR δ (ppm)(CHCl3-d): 8.94 (1 H, d, J = 4.83 Hz), 8.59 (1 H, s), 8.38 (1 H, d, J = 
8.85 Hz), 8.00 (1 H, dd, J = 8.84, 1.98 Hz), 7.68 (1 H, d, J = 4.83 Hz). 
 














4-chloro-6-(trifluoromethyl)quinoline (8.58 g, 37 mmol) and 3-amino-1-propanol (17.0 
mL, 222 mmol) were heated at 90°C for 2 hours, at the end of which time TLC indicated 
that the reaction had gone to completion.  The reaction mixture was poured into water 
(500 mL), and the resulting precipitate was recovered by vacuum filtration, followed by 
air-drying and partial recrystallization from ethyl acetate to provide the desired 
compound as an off-white powder (5.85 g, 0.0216 mol, 59% yield, mp = 165.1-167.0°C). 
 
1H NMR δ (ppm)(DMSO-d6): 8.73 (1 H, d, J = 2.03 Hz), 8.49 (1 H, d, J = 5.45 Hz), 7.93 
(1 H, d, J = 8.80 Hz), 7.83 (1 H, dd, J = 8.83, 2.00 Hz), 7.59 (1 H, br t, J = 5.36 Hz), 6.57 
(1 H, d, J = 5.50 Hz), 4.59 (1 H, t, J = 5.05 Hz), 3.56 (2 H, td, J = 6.10, 5.07 Hz), 3.34-
3.37 (solvent signal overlaps m, ~2 H), 1.84 (2 H, apparent p, J = 6.62 Hz). 
 













3-(6-(trifluoromethyl)quinolin-4-ylamino)propanol (5.85 g, 21.6 mmol) and triethylamine 
(9.1 mL, 6.5 mmol) were taken up in dry chloroform (250 mL) and cooled to below 0°C 
on ice/salt, and methanesulfonyl chloride (1.93 mL, 24.8 mmol) was gradually added.  
After stirring for 2 hours on ice, TLC indicated that the reaction had gone to completion.  
It was therefore rinsed with saturated sodium bicarbonate (150 mL), and the aqueous 
layer was extracted 3 times with 15 mL portions of chloroform.  The pooled organic 
extracts were dried over MgSO4 and evaporated under reduced pressure with warming to 
yield an off-white solid (7.57 g, ~100%).   
 
1H NMR δ (ppm)(DMSO-d6): 8.73 (1 H, d, J = 1.83 Hz), 8.52 (1 H, d, J = 5.44 Hz), 7.95 




(1 H, d, J = 5.50 Hz), 4.36 (2 H, t, J = 6.19 Hz), 3.42 (2 H, td, J = 6.93, 5.34 Hz), 3.20 (3 
H, s), 2.12 (2 H, apparent p, J = 7.03 Hz). 
 















3-(6-(trifluoromethyl)quinolin-4-ylamino)propyl methanesulfonate (0.98 g, 2.8 mmol), 1-
benzhydrylpiperazine (0.78 g, 3.1 mmol), and potassium carbonate (0.60 g, 4.3 mmol) 
were heated at reflux in anhydrous acetonitrile (15 mL) for 24 hours, whereupon TLC 
indicated that reaction was complete.  Substantial precipitate had formed in the reaction 
mixture.  This was recovered by vacuum filtration, rinsing with water, and the resulting 
solid was partially recrystallized from a mixture of 95% ethanol and ethyl acetate 
(approximately 4:1, total volume 20 mL) to give the desired product as a white, 
crystalline solid (1.07 g, 76%, mp = 213-218°C). 
 
1H NMR δ (ppm)(CHCl3-d): 8.59 (1 H, d, J = 5.36 Hz), 8.20 (1 H, s), 8.05 (1 H, d, J = 
8.84 Hz), 7.83 (1 H, dd, J = 8.85, 1.91 Hz), 7.62 (1 H, br t, J = 3.97 Hz), 7.47-7.48 (4 H, 
m), 7.24-7.29 (4 H, m), 7.16-7.18 (2 H, m), 6.39 (1 H, d, J = 5.41 Hz), 4.36 (1 H, s), 3.37 
(2 H, td, J = 5.69, 4.03 Hz), 2.64 (10 H, br s overlaps t, J = 5.17 Hz), 1.94 (2 H, apparent 
p, J = 5.32 Hz). 
 
19F NMR δ (ppm)(CHCl3-d): 0.5, -59.5. 
 
13C NMR δ (ppm)(CHCl3-d): 153.1, 151.2, 149.9, 143.1, 130.9, 128.6, 127.9, 127.0, 
125.6 (q, JF = 9.96 Hz), 124.7 (q, JF = 3.02 Hz), 119.2 (q, JF = 3.02 Hz), 118.4, 99.4, 75.7, 
59.4, 54.3, 51.8, 45.3, 23.3. 
 
HPLC (method C) tR = 11.80 min (98% pure). MS (ESI): m/z 505.2566 M + H 
(calculated 505.2574). 
 

















3-(6-(trifluoromethyl)quinolin-4-ylamino)propyl methanesulfonate (1.53 g, 4.39 mmol), 
N-(2-pyridyl)piperazine (0.79 g, 4.8 mmol), and potassium carbonate (0.95 g, 6.87 mmol) 
were heated at reflux in anhydrous acetonitrile (15 mL) for 24 hours.  TLC then indicated 
that reaction was complete. Substantial precipitate had formed in the reaction mixture.  
This was recovered by vacuum filtration, rinsing with acetonitrile (30 mL), followed by 
water (40 mL).  The resulting solid was recrystallized from 5 mL 95% ethanol to give the 
desired product as a white, crystalline solid (0.82 g, 45%, mp = 168.8-171.0°C). 
 
1H NMR δ (ppm)(CHCl3-d): 8.61 (1 H, d, J = 5.39 Hz), 8.22-8.24 (1 H, m), 8.15 (1 H, s), 
8.03 (1 H, d, J = 8.79 Hz), 7.74 (1 H, dd, J = 8.80, 1.95 Hz), 7.52-7.52 (2 H, m), 6.66-
6.67 (2 H, m), 6.44 (1 H, d, J = 5.44 Hz), 3.69 (4 H, m), 3.44 (2 H, td, J = 5.87, 4.17 Hz), 
2.69 (6 H, m), 2.02 (2 H, apparent p, J = 5.51 Hz). 
 
19F NMR δ (ppm)(CHCl3-d): -61.7. 
 
13C NMR δ (ppm)(CHCl3-d): 159.5, 153.1, 151.0, 149.9, 148.0, 147.9, 137.6, 130.9, 
126.0, 125.8 (q, JF = 32.5 Hz, Q-C6-CF3), 124.7, 118.7, 118.3, 113.6, 107.0, 99.3, 59.0, 
53.7, 45.0, 44.7, 23.6. 
 
MS (ESI): m/z 416.2050 M + H (calculated 416.2057). 
 
HPLC (method C) tR = 6.64 min (99% pure).  
 
 












In a round bottomed flask equipped with a Dean and Stark water separator, 4-aminopiperidine 
(16.82 g, 0.168 mol), di-2-pyridyl ketone (25.67g, 0.139 mol), and a catalytic amount of para-
toluenesulfonic acid were allowed to reflux for 20 hours.  TLC then indicated that the reaction 
had gone to completion, and the solvent was therefore evaporated under reduced pressure.  The 
















3-(6-(trifluoromethyl)quinolin-4-ylamino)propyl methanesulfonate (2.00 g, 5.74 mmol), 
PL190 (1.76 g, 6.61 mmol; see above), and potassium carbonate (1.19 g, 8.61 mmol) 
were heated at reflux in anhydrous acetonitrile (24 mL) for 24 hours.  TLC indicated that 
reaction was complete, and so the solvent was removed under reduced pressure with 
warming, and the residue partitioned between chloroform (50 mL) and water (50 mL).  
After separation, the aqueous layer was extracted with further chloroform (3 x 15 mL) 
and the pooled organic layers were dried (MgSO4) and evaporated under reduced 
pressure with warming.  The resulting brown solid was dissolved in a mixture of 
dichloromethane and methanol and allowed to evaporate at room temperature; the 
resulting crystals were washed with ethyl acetate, followed by 95% ethanol to provide the 
desired product as pale yellow, sparkling crystals (0.74 g, 26%, mp = 224-225°C). 
 
1H NMR δ (ppm)(CHCl3-d): 8.73 (1 H, d, J = 4.93 Hz), 8.60 (1 H, d, J = 5.39 Hz), 8.49 
(1 H, d, J = 4.85 Hz), 8.40 (1 H, d, J = 8.01 Hz), 8.18 (1 H, s), 8.05 (1 H, d, J = 8.82 Hz), 
7.77-7.82 (2 H, m), 7.58 (1 H, s), 7.31-7.37 (1 H, m), 7.24-7.27 (solvent signal overlaps 
m, ~2 H), 6.42 (1 H, d, J = 5.45 Hz), 3.37-3.43 (3 H, m), 2.99-3.04 (2 H, m), 2.60 (2 H, 
td, J = 5.10, 1.54 Hz), 2.14 (2 H, m), 1.97-1.99 (4 H, m), 1.81-1.83 (2 H, m). 
 
19F NMR δ (ppm)(CHCl3-d): -61.5. 
 
13C NMR δ (ppm)(CHCl3-d): 165.1, 157.3, 155.8, 153.0, 151.2, 149.9, 149.7, 148.6, 
136.3, 135.9, 130.8, 125.9 (q, JF = 32.1 Hz, Q-C6-CF3), 124.6, 124.0, 123.4, 123.1, 





MS (ESI): m/z 519.24868 M + H (calculated 519.24786) 
 
HPLC (method A) tR = 1.58 min (54% pure).  (Additional peaks elute at 2.01 min, 6%, 

















PL278 (0.74 g, 1.4 mmol) was taken up in anhydrous methanol (25 mL), and sodium 
borohydride (0.16 g, 4.2 mmol) was cautiously added.  After stirring 2 hours, additional 
sodium borohydride (0.06 g, 2 mmol) was added.  After 30 minutes, the solvent was 
removed by evaporation under reduced pressure and the resulting solid was allowed to 
stir for 1 hour with 15 mL water.   This was then extracted with methylene chloride (15 
mL followed by 3 x 10 mL), and the pooled organic extracts were dried over MgSO4 and 
evaporated under reduced pressure.  Recrystallization of the residue from 95% ethanol 
(10 mL) gave the product as a golden brown solid (0.34 g, 49%, mp = 128.2-129.8°C).  
 
1H NMR δ (ppm)(CHCl3-d): 8.58 (1 H, d, J = 5.40 Hz), 8.56-8.56 (2 H, m), 8.10 (1 H, s), 
8.03 (1 H, d, J = 8.82 Hz), 7.77 (1 H, dd, J = 8.82, 1.97 Hz), 7.63 (2 H, td, J = 7.66, 1.88 
Hz), 7.51 (3 H, d, J = 7.80 Hz), 7.14 (2 H, ddd, J = 7.48, 4.84, 1.23 Hz), 6.40 (1 H, d, J = 
5.43 Hz), 5.25 (1 H, s), 3.38 (2 H, td, J = 5.87, 4.06 Hz), 2.96 (2 H, d, J = 11.07 Hz), 
2.55-2.58 (3 H, m), 2.08 (2 H, br s), 1.96-2.03 (2 H, m), 1.93 (2 H, apparent p, J = 5.52 
Hz), 1.61 (2 H, m). 
 
19F NMR δ (ppm)(CHCl3-d): -61.4. 
 
13C NMR δ (ppm)(CHCl3-d): 162.3, 153.0, 151.1, 149.9, 149.1, 149.1, 136.6, 130.8, 
125.7 (q, JF = 32.5 Hz, Q-C6-CF3), 124.6, 122.3, 122.1, 118.8, 118.3, 99.3, 66.7, 58.7, 
52.9, 52.7, 44.7, 32.5, 23.9. 
 

















3-(6-(trifluoromethyl)quinolin-4-ylamino)propyl methanesulfonate (1.53 g, 4.4 mmol), 
N-(4-fluorophenyl)piperazine (0.87 g, 4.8 mmol), and potassium carbonate (0.95 g, 6.9 
mmol) were heated at reflux in anhydrous acetonitrile (15 mL) for 24 hours, at which 
time TLC indicated that reaction was complete.  A large amount of precipitate had 
formed in the reaction mixture.  This was recovered by vacuum filtration, rinsing with 
acetonitrile (30 mL), followed by water (40 mL).  The solid thus obtained was 
recrystallized from 8 mL 95% ethanol to give the desired product as a white, crystalline 
solid (1.04 g, 55%, mp = 181.6-183.2°C). 
 
1H NMR δ (ppm)(CHCl3-d): 8.61 (1 H, d, J = 5.39 Hz), 8.13 (1 H, s), 8.03 (1 H, d, J = 
8.79 Hz), 7.75 (1 H, dd, J = 8.80, 1.93 Hz), 7.38 (1 H, t, J = 4.11 Hz), 6.97-7.01 (2 H, m), 
6.89-6.90 (2 H, m), 6.43 (1 H, d, J = 5.43 Hz), 3.43 (2 H, td, J = 5.84, 4.20 Hz), 3.25 (4 
H, m), 2.73 (4 H, m), 2.70 (2 H, t, J = 5.34 Hz), 2.01 (2 H, apparent p, J = 5.48 Hz). 
 
19F NMR δ (ppm)(CHCl3-d): 0.5, -60.8, -124.5 (m). 
 
13C NMR δ (ppm)(CHCl3-d): 158.1, 156.5, 153.0, 151.0, 149.9, 147.6 (d, JF = 2.05 Hz?), 
130.9, 127.0, 125.9 (q, JF = 32.1 Hz), 125.2, 124.6, 123.4, 118.7, 118.3, 118.1 (d, JF = 
7.66 Hz?),, 115.5 (d, JF = 21.43 Hz?), 99.4, 59.0, 54.0, 50.0, 44.7, 23.6. 
 
MS (ESI): m/z 433.2001 M + H (calculated 433.2010). 
 




















3-(6-(trifluoromethyl)quinolin-4-ylamino)propyl methanesulfonate (1.53 g, 4.39 mmol), 
1-(4-methoxyphenyl)piperazine (0.92 g, 4.8 mmol), and potassium carbonate (0.95 g, 6.9 
mmol) were heated at reflux in anhydrous acetonitrile (16 mL) for 24 hours, whereupon 
TLC indicated that reaction was complete. Substantial precipitate had formed in the 
reaction mixture.  This was recovered by vacuum filtration, rinsing with acetonitrile (30 
mL), followed by water (40 mL).  The resulting solid was recrystallized from 5 mL 95% 
ethanol to give the desired product as a white, crystalline solid (0.27 g, 14%, mp = 173.7-
175.0°C). 
 
1H NMR δ (ppm)(CHCl3-d): 8.61 (1 H, d, J = 5.40 Hz), 8.14 (1 H, s), 8.04 (1 H, d, J = 
8.81 Hz), 7.76 (1 H, dd, J = 8.83, 1.92 Hz), 7.34 (1 H, t, J = 4.16 Hz), 6.92-6.93 (2 H, m), 
6.84-6.89 (2 H, m), 6.45 (1 H, d, J = 5.45 Hz), 3.80 (3 H, s), 3.44 (2 H, td, J = 5.85, 4.21 
Hz), 3.23 (4 H, m), 2.74 (4 H, m), 2.70 (2 H, t, J = 5.35 Hz), 2.02 (2 H, apparent p, J = 
5.47 Hz). 
 
13C NMR δ (ppm)(CHCl3-d): 153.9, 153.0, 151.0, 149.9, 145.3, 130.9, 125.9, 124.6, 
123.0, 118.7, 118.5, 118.3, 114.4, 99.4, 59.0, 55.6, 54.1, 50.5, 44.7, 29.7, 23.6. 
 
19F NMR δ (ppm)(CHCl3-d): -61.3. 
 




































meta-Trifluoromethyl aniline (4.5 g, 27.9 mmol) and diethyl ethoxymethylene malonate 
(6.00 mL, 27.9 mmol) in Dowtherm A (100 mL) were allowed to heat gradually, stirring, 
to 255°C, at which temperature the reaction was allowed to remain for 1 hour.  After 
cooling, the reaction mixture was diluted with 30-60º petroleum æther (100 mL) and 
vacuum filtered, rinsing with additional 30-60º petroleum æther (250 mL).  The resulting 
solid (6.64 g) was allowed to reflux in 10% caustic soda (50 mL) for 1 day.  After 
cooling, the reaction was made acidic by addition of 10% muriatic acid.  The resulting 
off-white precipitate was recovered by vacuum filtration, followed by drying in a vacuum 
dessicator for 1 hour.  Without further drying, this material was combined with 20 mL 
Dowtherm A and gradually heated to 255ºC, at which temperature it was allowed to 
remain for 60 minutes.  Upon cooling, the reaction mixture was diluted with 30-60º 
petroleum æther (50 mL), and the product was recovered by vacuum filtration (rinsing 
with additional 30-60º petroleum æther).  The product was a cream-colored, crystalline 
solid (4.65 g, 78% from starting aniline).   NMR indicated that the product was primarily 
the desired 7-trifluoromethyl-4-quinolone, containing approximately 3 % 5-
trifluoromethyl-4-quionolone.   
 
1H NMR δ (ppm)(DMSO-d6):  Major peaks: 12.01 (1 H, s), 8.28 (1 H, d, J = 8.47 Hz), 
8.05 (1 H, s), 7.92 (1 H, s), 7.59 (1 H, dd, J = 8.47, 1.70 Hz), 6.14 (1 H, d, J = 7.47 Hz).  
Minor peaks due to the 5-trifluoromethyl regioisomer are also present. 
 














Phosphorus oxychloride (25 mL, 270 mmol) was cautiously added to 7-trifluoromethyl-
4-quinolone (4.65 g, 21.8 mmol), followed by heating at 110°C for 1 h.  After cooling, 
the reaction mixture was gradually added to 300 mL ice water.  This was allowed to sit 
for 16 hours.  Without basifying, the aqueous solution was extracted with 
dichloromethane (100mL, then 3 x 75 mL).  Drying of the pooled organic layers over 
MgSO4 followed by evaporation under reduced pressure with warming gave the desired 
product as a pale pink solid (1.50 g, 30%, mp = 70.9-72.3°C (lit. 71-72°C (Snyder, 
1947)).  NMR indicated that the product contained less than 2% of 4-chloro-5-
trifluoromethylquinoline; this was not removed.   
 
1H NMR δ (ppm)(CHCl3-d): 8.91 (1 H, d, J = 4.75 Hz), 8.50 (1 H, s), 8.40 (1 H, d, J = 
8.82 Hz), 7.86 (1 H, dd, J = 8.82, 1.75 Hz), 7.65 (1 H, d, J = 4.74 Hz). 
 











4-chloro-7-(trifluoromethyl)quinoline (1.5 g, 6.9 mmol) and 3-amino-1-propanol (8.0 
mL, 105 mmol) were heated at 90°C for 18 hours.  The reaction mixture was then poured 
into water (50 mL), and the resulting precipitate was recovered by vacuum filtration, 
followed by air-drying to provide the desired compound (1.59 g, 85%, mp = 137.2-
137.9°C). 
 
1H NMR δ (ppm)(DMSO-d6): 8.51 (1 H, d, J = 5.41 Hz), 8.46 (1 H, d, J = 8.82 Hz), 8.08 
(1 H, s), 7.68 (1 H, dd, J = 8.79, 1.95 Hz), 7.45 (1 H, br t, J = 5.36 Hz), 6.59 (1 H, d, J = 
5.47 Hz), 4.61 (1 H, t, J = 5.05 Hz), 3.56 (2 H, m), 3.35 (water signal overlaps m, ~2 H), 
1.84 (2 H, m). 
 
19F NMR δ (ppm)(DMSO-d6): -61.1. 
 
1H NMR δ (ppm)(CHCl3-d): 8.57 (1 H, d, J = 5.36 Hz), 8.23 (1 H, s), 7.78 (1 H, d, J = 
8.77 Hz), 7.52 (1 H, dd, J = 8.75, 1.85 Hz), 6.44 (1 H, d, J = 5.38 Hz), 6.09 (1 H, br t, J = 
4.63 Hz), 4.00 (2 H, t, J = 5.38 Hz), 3.48 (2 H, td, J = 6.14, 4.73 Hz), 2.07 (2 H, apparent 
p, J = 5.75 Hz). 
 











3-(7-(trifluoromethyl)quinolin-4-ylamino)propanol (1.59 g, 5.9 mmol) and triethylamine 
(1.23 mL, 8.8 mmol) in dry dichloromethane (50 mL) were cooled to below 0°C on 
ice/salt, and methanesulfonyl chloride (0.53 mL, 6.8 mmol) was gradually added.  After 
stirring for 17 hours, TLC indicated that the reaction was not complete.  Therefore, the 
reaction was again cooled to 0ºC and additional triethylamine (1.2 mL, 8.6 mmol) and 
methanesulfonyl chloride (0.38 mL, 4.9 mmol) were added.  After stirring an additional 
18 hours, TLC indicated that reaction was complete.  The reaction mixture was rinsed 
with saturated sodium bicarbonate (35 mL), and the aqueous layer was extracted 3 times 
with 10 mL portions of dichloromethane.  The pooled organic extracts were dried over 
MgSO4 and evaporated under reduced pressure with warming to yield a yellow solid 
(1.96 g, 95%, containing traces of residual triethylamine).  This was used without further 
purification in the ensuing reactions.   
 
1H NMR δ (ppm)(DMSO-d6): 8.53 (1 H, d, J = 5.43 Hz), 8.47 (1 H, d, J = 8.82 Hz), 8.09 
(1 H, s), 7.72 (1 H, dd, J = 8.79, 1.96 Hz), 7.53 (1 H, s), 6.64 (1 H, d, J = 5.49 Hz), 4.36 
(2 H, t, J = 6.19 Hz), 3.42 (2 H, m), 3.20 (3 H, s), 2.08-2.10 (2 H, m).  
 

















3-(7-(trifluoromethyl)quinolin-4-ylamino)propyl methanesulfonate (0.67 g, 1.9 mmol), 1-




3.6 mmol) were heated at reflux in anhydrous acetonitrile (25 mL) for 18 hours, 
whereupon TLC indicated that reaction was complete.  The solvent was evaporated under 
reduced pressure with warming, and the residue was partitioned between chloroform (35 
mL) and water (35 mL).  After separation, the aqueous layer was extracted with further 
chloroform (3 x 10 mL), and the pooled organic layers were dried (MgSO4) followed by 
evaporation under reduced pressure with warming.  The resulting brown oil was purified 
by chromatography on alumina, eluting with 3:2 hexanes:ethyl acetate.  This provided the 
desired product as a white, crystalline solid (0.48 g, 47%, mp = 154.8-155.8°C, Rf = 0.8 
(basic alumina, 95/5 EA/MeOH v/v)). 
 
1H NMR δ (ppm)(CHCl3-d): 8.58 (1 H, d, J = 5.29 Hz), 8.24 (1 H, s), 7.95 (1 H, d, J = 
8.73 Hz), 7.56 (1 H, br t, J = 4.02 Hz), 7.42 (1 H, dd, J = 8.71, 1.84 Hz), 7.37-7.38 (4 H, 
m), 6.98-7.04 (4 H, m), 6.39 (1 H, d, J = 5.36 Hz), 4.38 (1 H, s), 3.38 (2 H, td, J = 5.82, 
4.07 Hz), 2.65 (10 H, br s overlaps t, J = 5.28 Hz), 1.95 (2 H, apparent p, J = 5.41 Hz). 
 
19F NMR δ (ppm)(CHCl3-d): -63.1, -115.8. 
 
13C NMR δ (ppm)(CHCl3-d): 162.8, 161.1, 152.5, 150.4, 147.7, 137.5, 129.5, 129.4, 
115.6, 115.4, 99.5, 74.4, 58.8, 53.9, 51.6, 44.5, 23.3. 
 
































3-(7-(trifluoromethyl)quinolin-4-ylamino)propyl methanesulfonate (1.09 g, 3.1 mmol), 1-
benzyhydrylpiperazine (0.83 g, 3.3 mmol), potassium carbonate (0.65 g, 4.7 mmol), and a 
catalytic amount of potassium iodide were heated at reflux in anhydrous acetonitrile (30 
mL) for 5 days, whereupon TLC indicated that reaction was complete.  The reaction  
mixture was diluted with 5 mL water and the solvent was removed by evaporation under 
reduced pressure with warming.  The residue was partitioned between ethyl acetate (25 
mL) and water (25 mL).  After separation, the aqueous layer was extracted with further 
ethyl acetate (3 x 7 mL), and the pooled organic layers were dried over magnesium 
sulfate, followed by evaporation and recrystallization of the residue from 95% ethanol; 
the desired product was recovered as a white, crystalline solid (0.47 g, 30%, mp = 162.0-
163.8°C).  
 
1H NMR δ (ppm)(CHCl3-d): 8.56 (1 H, d, J = 5.30 Hz, Q-C2-H), 8.23 (1 H, s, Q-C8-H?), 
7.92 (1 H, d, J = 8.74 Hz, Q-C5-H), 7.72 (1 H, br t, J = 3.96 Hz, Q-C4-NH), 7.42-7.43 (4 
H, m, Ph-H ortho), 7.32-7.34 (5 H, m, Ph-H meta overlaps Q-C6-H), 7.23-7.27 (solvent 
signal overlaps m, ~2 H, Ph-H para), 6.36 (1 H, d, J = 5.35 Hz, Q-C3-H), 4.48 (1 H, s, 
CH(Ph)2), 3.36 (2 H, td, J = 5.78, 4.02 Hz, Q-NH-CH2CH2CH2), 2.65 (10 H, br s overlaps 
t, J = 5.34 Hz, Pip-CH2 x 4 and Q-NH-CH2CH2CH2), 1.92-1.96 (2 H, apparent p, J = 5.38 
Hz, Q-NH-CH2CH2CH2). 
 
19F NMR δ (ppm)(CHCl3-d): -62.9. 
 
13C NMR δ (ppm)(CHCl3-d): 152.4 (Q-C2), 150.4, 147.6, 141.6 (Ph-C ipso), 130.5 (q, JF 
= 32.57 Hz, Q-C7), 128.5 (Ph-C meta), 128.2 (Ph-C ortho), 127.4 (q, J F = 4.25 Hz, Q-
C8), 127.2 (Ph-C para), 124.2 (q, JF = 271.81 Hz, CF3), 122.3, 120.8, 119.5 (q, JF = 3.26 
Hz, Q-C6), 99.4 (Q-C3), 75.6 (CH(Ph)2), 59.0 (Q-NH-CH2CH2CH2), 54.0 (Pip-C-C-
NCH(Ph)2), 51.4 (Pip-C-C-NCH(Ph)2), 44.6 (Q-NH-CH2CH2CH2), 23.1 (Q-NH-
CH2CH2CH2). 
 
MS (ESI): m/z 505.2563 M + H (calculated 505.2574). 
 







PL142, Method 2 (Based upon Gabriel, 1887; Ing, 1926; Leonardi, 2004; Nishikawa, 





































4-chloro-7-(trifluoromethyl)quinoline (0.37 g, 1.6 mmol) and phenol (2.11 g, 22 mmol) 
were allowed to heat at 105ºC for 1.5 hours.  PL151 (0.80 g, 2.6 mmol; see below) was 
then added, and the mixture was allowed to heat at 120ºC for 28 hours.  The cooled 
reaction mixture was diluted with dichloromethane (20 mL) and washed with 1 M caustic 
soda (6 x 10 mL), followed by brine (10 mL).  The pooled organic layers were dried 
(MgSO4) and concentrated under reduced pressure with warming to provide a reddish 
brown glass.  This material was purified by chromatography on alumina, eluting with 
30:70 hexanes:ethyl acetate, followed by 100% ethyl acetate and finally, 95:5 ethyl 
acetate:methanol.  The desired product was obtained as a tan solid (0.15 g, 19%, Rf = 0.8 




PL151: 3-(4-benzhydrylpiperazin-1-yl)propan-1-amine (Gabriel, 1887; Ing, 1926; 
Leonardi, 2004; Nishikawa, 1989) 
 
PL191 (1.47 g, 3.3 mmol; see below) and hydrazine monohydrate (0.48 mL, 9.9 mmol) 
were heated in refluxing 95% ethanol (50 mL) for 3 hours, at which time TLC indicated 
that the reaction was complete.  Upon cooling, crystallization occurred; the reaction was 
further chilled in an ice bath, followed by filtration.  The white solid obtained was rinsed 
with chilled 95% ethanol (3 x 10 mL), followed by chilled diethyl æther (2 x 10 mL). The 
filtrate was basified to pH 9 by the addition of 2 M NaOH and concentrated under 
reduced pressure with warming.  The residue was diluted with water (20 mL) and 




(MgSO4) and concentrated under reduced pressure with warming to yield a yellow oil, 
which became a waxy solid upon standing.  This proved to be the desired product (0.80 g, 
79%). 
 
1H NMR δ (ppm)(CHCl3-d): 7.40-7.42 (4 H, m), 7.22-7.30 (solvent signal overlaps m, ~4 
H), 7.14-7.19 (2 H, m), 4.21 (1 H, s), 2.73 (2 H, t, J = 6.83 Hz), 2.41-2.42 (10 H, br s 




PL191: 2-(3-(4-benzhydrylpiperazin-1-yl)propyl)phthalimide (Gabriel, 1887; Ing, 
1926; Leonardi, 2004; Nishikawa, 1989) 
 
1-(Diphenylmethyl)piperazine (11.00 g, 44 mmol), N-3-(bromopropyl)phthalimide (12.84 
g, 48 mmol), and potassium carbonate (16.07 g, 120 mmol) were allowed to heat in 
anhydrous acetonitrile (210 mL) at reflux under a nitrogen atmosphere for 18 hours, at 
which time TLC indicated that reaction was complete.  The reaction mixture was 
concentrated under reduced pressure with warming, and the residue was diluted with 
ethyl acetate (125 mL) and washed with water (75 mL, then 4 x 50 mL), then dried over 
magnesium sulfate and concentrated under reduced pressure with warming.  The amber 
oil thus obtained was divided into two equal portions, each of which was purified by 
column chromatography on alumina, eluting with 100% ethyl acetate followed by 95:5 
ethyl acetate:methanol.  The off-white solid thus obtained contained the residual N-3-
(bromopropyl)phthalimide in addition to the desired product.  This material was 
recrystallized from ethyl acetate to obtain the desired product as an off-white, crystalline 
solid (7.73 g, 56%, Rf = 0.6 (silica, 95/5 chloroform/methanol v/v)).  Note: It was also 
possible to perform the ensuing reactions without chromatographic purification of this 
material, with comparable results. 
 
1H NMR δ (ppm)(CHCl3-d): 7.82 (2 H, dd, J = 5.44, 3.05 Hz), 7.71 (2 H, dd, J = 5.46, 
3.04 Hz), 7.35-7.37 (4 H, m), 7.12-7.20 (2 H, m), 4.07 (1 H, s), 3.74 (2 H, t, J = 6.94 Hz), 

















3-(7-(trifluoromethyl)quinolin-4-ylamino)propyl methanesulfonate (3.10 g, 8.9 mmol), 1-
(2-pyridyl)piperazine (0.92 g, 5.6 mmol), and potassium carbonate (1.85 g, 13 mmol) 
were heated at reflux in anhydrous acetonitrile (24 mL) for 5 days. The solvent was 
removed by evaporation under reduced pressure with warming, and the residue was 
partitioned between dichloromethane (50 mL) and water (25 mL).  After separation, the 
aqueous layer was extracted with further dichloromethane (3 x 10 mL), and the pooled 
organic layers were dried over magnesium sulfate, followed by evaporation under 
reduced pressure with warming and recrystallization of the residue from ethyl acetate to 
obtain the desired product as beige crystals (0.72 g, 19%, mp = 172.3-173.9°C). 
 
1H NMR δ (ppm)(CHCl3-d): 8.60 (1 H, d, J = 5.34 Hz), 8.22-8.25 (2 H, m), 7.97 (1 H, d, 
J = 8.75 Hz), 7.54 (1 H, ddd, J = 8.53, 7.17, 2.02 Hz), 7.45 (1 H, dd, J = 8.75, 1.88 Hz), 
7.42 (1 H, t, J = 4.03 Hz), 6.69-6.70 (2 H, m), 6.44 (1 H, d, J = 5.38 Hz), 3.70 (4 H, m), 
3.43 (2 H, td, J = 5.96, 4.23 Hz), 2.69-2.70 (6 H, m), 2.02 (2 H, apparent p, J = 5.49 Hz). 
 
13C NMR δ (ppm)(CHCl3-d): 159.3, 152.5, 150.3, 148.1, 147.7, 137.7, 130.7 (q, JF = 32.5 
Hz, Q-C7-CF3), 127.7, 121.7, 120.8, 119.7, 113.8, 107.2, 99.6, 58.7, 53.5, 45.4, 44.3, 
23.6.   
 
MS (ESI): m/z 416.20603 M + H (calculated 416.20566) 
 














F3C PL230  
 
3-(7-trifluoromethyl-4-ylamino)propyl methanesulfonate (0.32 g, 0.92 mmol), N-
(dipyridin-2-methylene)piperidin-4-amine (0.36 g, 1.4 mmol), and potassium carbonate 
(0.18 g, 1.3 mmol) were allowed to heat at 70ºC in anhydrous acetonitrile (12 mL) for 6 
days.  TLC then indicated that the reaction was complete. The reaction mixture was 
diluted with water (30 mL) and partially evaporated under reduced pressure with 




air dry, then purified by chromatography on basic alumina, eluting with 100% ethyl 
acetate.  This provided the desired product as a white powder (0.14 g, 29%, mp = 191-
199°C, Rf = 0.1 (basic alumina, ethyl acetate)). 
 
1H NMR δ (ppm)(CHCl3-d): 8.75-8.75 (1 H, m), 8.59 (1 H, d, J = 5.34 Hz), 8.52-8.52 (1 
H, m), 8.34-8.41 (1 H, m), 8.26 (1 H, s), 8.22 (1 H, d, J = 8.73 Hz), 8.15 (1 H, t, J = 4.03 
Hz), 7.82-7.83 (2 H, m), 7.76 (1 H, dd, J = 8.70, 1.88 Hz), 7.36 (1 H, ddd, J = 7.67, 4.91, 
1.21 Hz), 7.29-7.29 (2 H, m), 6.40 (1 H, d, J = 5.38 Hz), 3.41-3.42 (3 H, m), 3.06-3.10 (2 
H, m), 2.63 (2 H, td, J = 4.98, 1.35 Hz), 2.05-2.09 (4 H, m), 1.96 (2 H, apparent p, J = 
5.32 Hz), 1.73-1.98 (2 H, m). 
 
13C NMR δ (ppm)(CHCl3-d): 165.5, 157.0, 155.6, 152.5, 150.5, 149.7, 148.7, 147.7, 
136.5, 136.0, 130.7 (q, JF = 32.1 Hz, Q-C7-CF3), 127.4, 124.2, 123.4, 123.1, 122.6, 
122.2, 121.0, 119.7, 115.6, 99.2, 59.0, 58.5, 52.1, 44.7, 32.9, 23.6.  
 
19F NMR δ (ppm)(CHCl3-d): -63.1.  (corrected to Freon 11) 
 
MS (ESI): m/z 519.24828 M + H (calculated 519.24786) 
 















F3C PL242  
 
PL 230 (0.11 g, 0.21 mmol) was dissolved in anhydrous methanol (10 mL), followed by 
the addition of sodium borohydride (0.03 g, 0.79 mmol).  After stirring at room 
temperature for one hour, equipped with an alumina drying tube, additional sodium 
borohydride (0.01 g, 0.26 mmol) was added.  After a further 30 minutes, the solvent was 
removed by evaporation under reduced pressure with warming. The residue was 
combined with water (10 mL) and allowed to stir for 1.5 hours at room temperature, 
followed by extraction with dichloromethane (8 x 5 mL).  The pooled organic layers were 
dried (MgSO4) and evaporated under reduced pressure with warming to yield the desired 





1H NMR δ (ppm)(CHCl3-d): 8.56-8.59 (3 H, m), 8.23 (1 H, s), 8.03 (1 H, d, J = 8.76 Hz), 
7.94 (1 H, t, J = 3.93 Hz), 7.63-7.64 (3 H, m), 7.48 (2 H, d, J = 7.88 Hz), 7.16-7.16 (2 H, 
m), 6.38 (1 H, d, J = 5.40 Hz), 5.25 (1 H, s), 3.37 (2 H, td, J = 5.74, 3.89 Hz), 3.00-3.04 
(2 H, m), 2.62-2.72 (1 H, m), 2.56-2.61 (2 H, m), 2.00-2.04 (4 H, m), 1.93 (2 H, apparent 
p, J = 5.34 Hz), 1.67 (2 H, m). 
 
19F NMR δ (ppm)(CHCl3-d): -63.3.  
 
13C NMR δ (ppm)(CHCl3-d): 162.2, 152.4, 150.5, 149.1, 147.7, 136.6, 130.7 (q, JF = 32.8 
Hz, Q-C7-CF3), 127.4, 122.4, 122.3, 122.2, 120.9, 119.7, 99.3, 66.5, 58.7, 53.1, 52.8, 
44.6, 33.1, 23.6.  
 
MS (ESI): m/z 521.2627 M + H (calculated 521.2635).   
 











FF3C PL315  
 
3-(7-(trifluoromethyl)quinolin-4-ylamino)propyl methanesulfonate (1.33 g, 3.8 mmol), 
N-(4-fluorophenyl)piperazine (0.72 g, 4.0 mmol), and potassium carbonate (0.79 g, 5.7 
mmol) were heated at 75ºC in anhydrous acetonitrile (15 mL) for 18 hours, whereupon 
TLC indicated that reaction was complete.  The reaction mixture was diluted with 5 mL 
water, followed by removal of the solvent under reduced pressure with warming.  The 
residue was partitioned between chloroform (20 mL) and water (20 mL).  After 
separation, the aqueous layer was extracted with additional chloroform (3 x 10 mL), and 
the pooled organic layers were dried (MgSO4) and evaporated under reduced pressure 
with warming.  The resulting brown semisolid was crystallized from chloroform, 
followed by recrystallization from ethyl acetate (5 mL) to provide the desired product as 
a cream-colored solid (0.17 g, 10%, mp = 182.1-183.3°C). 
 
1H NMR δ (ppm)(CHCl3-d): 8.60 (1 H, d, J = 5.35 Hz), 8.24 (1 H, s), 7.98 (1 H, d, J = 
8.75 Hz), 7.40-7.46 (2 H, m), 7.02-7.03 (2 H, m), 6.93-6.95 (2 H, m), 6.44 (1 H, d, J = 
5.38 Hz), 3.43 (2 H, td, J = 5.47, 0.01 Hz), 3.27 (4 H, m), 2.76 (4 H, m), 2.72 (2 H, t, J = 





19F NMR δ (ppm)(CHCl3-d): -63.2, -124.3 (m). 
 
13C NMR δ (ppm)(CHCl3-d): 158.3, 156.7, 152.5, 147.7, 130.9, 127.6, 121.8, 120.7, 
119.5, 117.9, 115.8, 115.6, 99.6, 58.5, 53.6, 50.3, 44.3, 23.5.  
 
MS (ESI): m/z 433.20099 M + H (calculated 433.20122) 
 
















3-(7-(trifluoromethyl)quinolin-4-ylamino)propyl methanesulfonate (1.04 g, 3.0 mmol), 
N-(p-methoxyphenyl)piperazine (0.29 g, 1.5 mmol), N-(p-methoxyphenyl)piperazine 
dihydrochloride (0.44 g, 1.7 mmol), potassium carbonate (1.08 g, 7.8 mmol), and a 
catalytic amount of potassium iodide were heated at reflux in anhydrous acetonitrile (25 
mL) for 5 days, whereupon TLC indicated that reaction was complete. The solvent was 
removed by evaporation under reduced pressure with warming, and the resulting golden 
brown, thick oil was partitioned between ethyl acetate (25 mL) and water (25 mL).  After 
separation, the aqueous layer was extracted with further ethyl acetate (3 x 7 mL), and the 
pooled organic layers were dried over magnesium sulfate, followed by evaporation and 
recrystallization of the residue from 95% ethanol; the desired product was recovered as 
large, colorless crystals (0.52 g, 39%, mp = 155.9-157.2°C). 
 
1H NMR δ (ppm)(CHCl3-d): 8.60 (1 H, d, J = 5.33 Hz, Q-C2-H), 8.24 (1 H, d, J = 1.70 
Hz, Q-C8-H), 8.01 (1 H, d, J = 8.73 Hz, Q-C5-H), 7.54 (1 H, br t, J = 4.19 Hz), 7.43 (1 H, 
dd, J = 8.70, 1.88 Hz, Q-C6-H), 6.94-6.97 (2 H, m, Ph-H, ortho to -OCH3), 6.89-6.92 (2 
H, m, Ph-H, meta to OCH3), 6.43 (1 H, d, J = 5.37 Hz, Q-C3-H), 3.81 (3 H, s, OCH3), 
3.43 (2 H, td, J = 5.89, 4.15 Hz, Q-NH-CH2CH2CH2), 3.24 (4 H, m, Pip-CH2 x 2, 
adjacent to Ph), 2.76 (4 H, m, Pip-CH2 x 2, not adjacent to Ph), 2.71 (2 H, t, J = 5.34 Hz, 
Q-NH-CH2CH2CH2), 2.01 (2 H, apparent p, J = 5.51 Hz, Q-NH-CH2CH2CH2). 
 





13C NMR δ (ppm)(CHCl3-d): 154.2 (Ph-C ipso to OCH3), 152.5 (Q-C2), 150.3 (Q-C4), 
147.8 (Q-C), 145.5 (Ph-C, para to OCH3), 130.7 (q, JF = 31.9 Hz, Q-C7), 127.6 (q, JF = 
4.5 Hz, Q-C8), 124.1 (q, JF =175.1 Hz, CF3), 122.0 (Q-C5), 120.8 (Q-C), 119.6 (q, JF = 
2.7 Hz, Q-C6), 118.4 (Ph-C, ortho to OCH3), 114.7 (Ph-C, meta to OCH3), 99.6 (Q-C3), 
58.7 (Q-NH-CH2CH2CH2), 55.6 (OCH3), 53.8 (Pip-CH2 x 2, not adjacent to Ph), 50.9 
(Pip-CH2 x 2, adjacent to Ph), 44.5 (Q-NH-CH2CH2CH2), 23.6 (Q-NH-CH2CH2CH2). 
 
MS (ESI): m/z 445.22082 M + H (calculated 445.22097) 
 























O 1) 10% NaOH, 







CF3 CF3  
 
ortho-Trifluoromethyl aniline (7.19 mL, 58.0 mmol) and diethyl ethoxymethylene 
malonate (11.63 mL, 58.0 mmol) in Dowtherm A (80 mL) were allowed to heat 
gradually, stirring, to 255°C, at which temperature the reaction was allowed to remain for 
20 minutes.  After cooling, the reaction mixture was diluted with hexanes (100 mL) and 
vacuum filtered, rinsing with additional hexanes (250 mL) followed by acetone (150 
mL).  The resulting solid was allowed to reflux in 10% caustic soda (200 mL) for 20 
hours.  After cooling partially, the reaction was made acidic by addition of 3 M muriatic 
acid.  The resulting off-white precipitate was recovered by vacuum filtration.  After air 
drying, yield was 7.31 g (49%, possibly containing residual water). 
 
1H NMR δ (ppm)(CH3OH-d4): 8.68 (1 H, s), 8.58 (1 H, d, J = 8.16 Hz), 8.14 (1 H, d, J = 















3-carboxy-8-trifluoromethyl-4-quinolone (7.31 g, 28.4 mmol) was heated in Dowtherm A 
(100 mL) at 255°C for 30 minutes.  After cooling, NMR indicated that reaction was not 
complete; the reaction was therefore returned to reflux for an additional 30 minutes.  
After cooling, the reaction mixture was diluted with hexanes (100 mL) and vacuum 












Phosphorus oxychloride (25 mL, 268 mmol) was cautiously added to 8-trifluoromethyl-
4-quinolone (3.76 g, 17.6 mmol), followed by heating at 110°C for 2.5 h.  After cooling, 
the reaction mixture was gradually poured into ice water with vigorous stirring.  After 
resting, and without basifying, the aqueous mixture (800 mL) was extracted with 
dichloromethane (500mL, then 5 x 100 mL) to provide the desired product as a tan, 
crystalline solid (3.80 g, 93%, mp = 79.5-81.2°C (lit. 78°C (Allais, 1969)). 
 
1H NMR δ (ppm)(CHCl3-d): 8.95 (1 H, d, J = 4.71 Hz), 8.48 (1 H, d, J = 8.55 Hz), 8.15 
(1 H, d, J = 7.33 Hz), 7.71 (1 H, t, J = 7.93 Hz), 7.61 (1 H, d, J = 4.71 Hz). 
 














4-chloro-8-(trifluoromethyl)quinoline (20.49 g, 88.5 mmol) and 3-amino-1-propanol 
(43.0 mL, 562 mmol) were allowed to heat at 110°C for 1.5 hours, at the end of which 
time TLC indicated that reaction was complete.  The hot reaction mixture was therefore 
poured into 500 mL deionized water, with vigorous agititation.  The resulting precipitate 
was recovered by vacuum filtration.  Upon drying, the product was an off-white powder 
(21.53 g, 90%, mp = 162.6-163.7°C). 
 
1H NMR δ (ppm)(DMSO-d6): 8.52 (1 H, d, J = 8.53 Hz), 8.49 (1 H, d, J = 5.43 Hz), 8.01 
(1 H, d, J = 7.29 Hz), 7.52 (1 H, t, J = 7.88 Hz), 7.42 (1 H, t, J = 5.37 Hz), 6.58 (1 H, d, J 
= 5.49 Hz), 4.60 (1 H, t, J = 5.06 Hz), 3.55 (2 H, m), 3.36-3.38 (water signal overlaps m, 
~2 H), 1.79-1.87 (2 H, m). 
 
1H NMR δ (ppm)(CHCl3-d): 8.69 (1 H, d, J = 5.37 Hz), 7.96 (2 H, m), 7.43 (1 H, t, J = 
7.89 Hz), 6.50 (1 H, d, J = 5.40 Hz), 6.05 (1 H, br s), 3.98 (2 H, t, J = 5.39 Hz), 3.49 (2 H, 
m), 2.06 (2 H, m). 
 
19F NMR δ (ppm)(DMSO-d6): -58.6. 
 
MS (ESI): m/z 271.10583 M + H (calculated 271.10527) 
 














3-(8-(trifluoromethyl)quinolin-4-ylamino)propanol (21.53 g, 79.7 mmol) and 
triethylamine (20.0 mL, 140 mmol) in anhydrous chloroform (500 mL) were cooled to  
below 0°C on ice/salt, and methanesulfonyl chloride (12.0 mL, 154 mmol) was gradually 
added.  After stirring 1.5 hours on ice, TLC indicated that reaction was not complete.  
Additional methanesulfonyl chloride (1.70 mL, 2.19 mmol) was added; after an 
additional hour of stirring, TLC indicated that reaction was complete.  The reaction 
mixture was shaken with saturated sodium bicarbonate (150 mL), and the aqueous layer 
was then extracted with 3 x 20 mL chloroform.  Upon standing, a fine, needlelike 
precipitate appeared in the pooled organic layers; this was recovered by filtration.  NMR 
indicated that this material was the desired product (a white, crystalline solid, 5.87 g, mp 
= 141.6-142.8°C).  The filtrate was dried over magnesium sulfate and evaporated under 
reduced pressure with warming to yield a tan solid.  NMR indicated that this, too, was the 
desired product (20.97 g; total yield 26.84 g, 97%). 
 
1H NMR δ (ppm)(DMSO-d6): 8.50-8.51 (2 H, m), 8.03 (1 H, d, J = 7.28 Hz), 7.54 (1 H, t, 
J = 7.88 Hz), 7.46 (1 H, t, J = 5.41 Hz), 6.62 (1 H, d, J = 5.47 Hz), 4.36 (2 H, t, J = 6.18 
Hz), 3.42 (2 H, m), 3.20 (3 H, s), 2.05-2.13 (2 H, m). 
 
19F NMR δ (ppm)(DMSO-d6): -58.6. 
 
MS (ESI): m/z 349.08340 M + H (calculated 349.08282) 
 
HPLC (method A) tR = 9.28 min (99% pure) 
 
Note: HPLC and MS data are of the precipitate, which is presumed to be of atypically 
















3-(8-(trifluoromethyl)quinolin-4-ylamino)propyl methanesulfonate (1.67 g, 4.79 mmol), 
1-benzyhydrylpiperazine (1.26 g, 4.99 mmol), and potassium carbonate (0.82 g, 5.9 
mmol) were heated at reflux in anhydrous acetonitrile (22 mL) for 24 hours, whereupon 




under reduced pressure with warming, and the residue was partitioned between 
dichloromethane (35 mL) and water (35 mL).  After separation, the aqueous layer was 
extracted with further dichloromethane (3 x 10 mL), and the pooled organic layers were 
dried over magnesium sulfate followed by evaporation under reduced pressure with 
warming.  Recrystallization of the residue from 95% ethanol provided the desired product 
as a cream-colored solid (0.44 g, 18%, mp = 205-208°C).  
 
1H NMR δ (ppm)(CHCl3-d): 8.65 (1 H, d, J = 5.36 Hz), 8.10 (1 H, d, J = 8.46 Hz), 7.99 
(1 H, d, J = 7.27 Hz), 7.71 (1 H, br t, J = 3.97 Hz), 7.41-7.47 (4 H, m), 7.31 (4 H, m), 
7.22-7.27 (solvent signal overlaps m, ~3 H), 6.39 (1 H, d, J = 5.41 Hz), 4.38 (1 H, s), 3.37 
(2 H, td, J = 5.78, 4.02 Hz), 2.65 (10 H, br s overlaps t, J = 5.43 Hz), 1.94 (2 H, apparent 
p, J = 5.37 Hz).   
 
19F NMR δ (ppm)(CHCl3-d): 0.5, -60.3. 
 
13C NMR δ (ppm)(CHCl3-d): 152.0, 150.7, 145.4, 142.1, 130.5, 128.6, 128.1, 127.1, 
125.5, 122.2, 119.8, 118.4, 116.2, 98.9, 76.3, 58.9, 54.0, 51.8, 44.5, 23.3. 
 
MS (ESI): m/z 505.25751 M + H (calculated 505.25736) 
 
















3-(8-(trifluoromethyl)quinolin-4-ylamino)propyl methanesulfonate (1.67 g, 4.79 mmol), 
1-(2-pyridyl)piperazine (0.92 g, 5.6 mmol), and potassium carbonate (0.98 g, 7.1 mmol) 
were heated at reflux in anhydrous acetonitrile (24 mL) for 2 days. By analogy to other 
reactions of this type, the reaction was vacuum filtered to remove precipitated product; 
however, after water rinsing, no solid was collected. After allowing the filtrate to stand 
overnight, crystallization was noted.  These crystals were recovered by filtration, rinsing 
with a few drops of 95% ethanol and acetone.  NMR indicated that this material was the 





1H NMR δ (ppm)(CHCl3-d): 8.67 (1 H, d, J = 5.37 Hz), 8.24-8.24 (1 H, m), 8.09 (1 H, d, 
J = 8.46 Hz), 7.93 (1 H, d, J = 7.29 Hz), 7.53-7.53 (1 H, m), 7.43 (1 H, br t, J = 4.14 Hz), 
7.30 (1 H, dd, J = 8.42, 7.28 Hz), 6.68-6.69 (2 H, m), 6.45 (1 H, d, J = 5.41 Hz), 3.69 (4 
H, m), 3.43 (2 H, td, J = 5.93, 4.19 Hz), 2.69-2.70 (6 H, m), 2.02 (2 H, apparent p, J = 
5.59 Hz). 
 
13C NMR δ (ppm)(CHCl3-d): 159.4, 152.0, 150.5, 148.1, 145.4, 137.7, 127.6, 127.5, 
124.9, 122.5, 119.8, 113.8, 107.2, 99.1, 58.7, 53.5, 45.4, 44.3, 23.6.   
 
MS (ESI): m/z 416.20568 M + H (calculated 416.20566) 
 



















3-(8-trifluoromethyl-4-ylamino)propyl methanesulfonate (9.50 g, 27 mmol), N-
(dipyridin-2-methylene)piperidin-4-amine (7.60 g, 29 mmol), and triethylamine (5.70 
mL, 41 mmol) were heated in anhydrous acetonitrile (50 mL) at reflux for 2 days, at the 
end of which time TLC indicated that the reaction had gone to completion.  The solvent 
was then removed under reduced pressure with warming and the resulting 
inhomogeneous brown solid was then partitioned between chloroform (250 mL) and 
saturated sodium bicarbonate (50 mL).  The aqueous layer was extracted with additional 
chloroform (3 x 50 mL), and the pooled chloroform layers were dried over MgSO4 and 
evaporated under reduced pressure with warming.  The resulting heterogeneous semisolid 
was twice recrystallized from 95% ethanol, yielding a sparkling off-white solid (3.52 g, 
25%, mp = 185.5-186.6°C).  
 
1H NMR δ (ppm)(CHCl3-d): 8.74-8.74 (1 H, m), 8.67 (1 H, d, J = 5.33 Hz), 8.51-8.53 (1 
H, m), 8.31-8.33 (1 H, m), 8.25 (1 H, d, J = 8.44 Hz), 8.01 (1 H, d, J = 7.24 Hz), 7.95 (1 




7.69, 4.93, 1.20 Hz), 7.29-7.29 (2 H, m), 6.41 (1 H, d, J = 5.39 Hz), 3.38-3.39 (3 H, m), 
3.05-3.08 (2 H, m), 2.60 (2 H, t, J = 5.05 Hz), 2.01-2.13 (4 H, m), 1.95 (2 H, apparent p, J 
= 5.35 Hz), 1.77-1.93 (2 H, m). 
 
19F NMR δ (ppm)(CHCl3-d): -60.7. 
 
13C NMR δ (ppm)(CHCl3-d): 165.5, 157.1, 155.7, 152.0, 150.8, 149.8, 148.8, 145.4, 
136.4, 136.0, 127.5, 125.6, 124.2, 123.4, 123.1, 122.5, 122.2, 120.0, 118.4, 116.2, 98.9, 
59.0, 55.8, 52.2, 44.7, 33.0, 23.6.   
 
MS (ESI): m/z 519.24853 M + H (calculated 519.24786) 
 



















PL 268 (3.44g, 6.63 mmol) was dissolved in anhydrous methanol (40 mL) to which 
sodium borohydride (0.70g, 19 mmol) was then cautiously added.  After stirring at room 
temperature for one hour, TLC indicated that the reaction had not gone to completion, 
and so additional sodium borohydride was added in several portions (in total an 
additional 0.70 g, 19 mmol) until TLC indicated that the reaction had gone to completion 
(after a further hour).  After removal of methanol by evaporation under reduced pressure 
with warming, 25 mL water was added and stirring was continued 1 hour.  The aqueous 
mixture was then extracted with chloroform (20 mL followed by three additional 10 mL 
portions), and the chloroform layers were dried (MgSO4) and evaporated under reduced 
pressure to yield a pale yellow glass (2.88 g, 83%, mp = 157.5-159.7°C).   
 
1H NMR δ (ppm)(CHCl3-d): 8.64 (1 H, d, J = 5.38 Hz), 8.56-8.59 (2 H, m), 8.12 (1 H, d, 
J = 8.49 Hz), 7.97 (1 H, d, J = 7.29 Hz), 7.80 (1 H, br t, J = 3.93 Hz), 7.63 (2 H, td, J = 




H, s), 3.35-3.36 (2 H, m), 2.98-3.01 (2 H, m), 2.62-2.62 (1 H, m), 2.53-2.60 (2 H, m), 
1.98-2.01 (4 H, m), 1.91 (2 H, apparent p, J = 5.37 Hz), 1.63-1.64 (2 H, m). 
 
13C NMR δ (ppm)(CHCl3-d): 162.1, 151.9, 150.7, 149.1, 145.4, 136.7, 127.4 (q, JF = 30.3 
Hz, Q-C8-CF3), 125.4, 123.6, 122.5, 122.4, 122.2, 119.9, 98.8, 66.6, 62.5, 58.6, 52.8, 
44.5, 33.0, 23.7, 23.7.   
 
19F NMR δ (ppm)(CHCl3-d): -60.7. 
 


















3-(8-trifluoromethyl-4-ylamino)propyl methanesulfonate (4.81 g, 13.8 mmol) 1-(4-
trifluoromethylphenylpiperazine (3.19 g, 1.4 mmol), and triethylamine (3 mL, 2.2 mmol) 
were heated in refluxing acetonitrile (24 mL) for 2 days.  TLC indicated that reaction was 
complete.  The solvent was removed under reduced pressure with warming, and the 
residue was partitioned between chloroform (100 mL) and saturated NaHCO3 (100 mL).  
After separation of the organic layer, the aqueous layer was extracted with further 
chloroform (3 x 50 mL), and the pooled organic layers were dried (MgSO4) and 
evaporated under reduced pressure with warming to yield a brown oil.  Partial 
recrystallization from 95% ethanol followed by recrystallization from chloroform yielded 
the desired product as a white, crystalline solid (0.70 g, 11%, mp = 168.8-170.3°C).   
 
1H NMR δ (ppm)(CHCl3-d): 8.67 (1 H, d, J = 5.36 Hz), 8.04 (1 H, d, J = 8.46 Hz), 7.93 
(1 H, d, J = 7.30 Hz), 7.53 (2 H, d, J = 8.57 Hz), 7.29 (1 H, t, J = 4.21 Hz), 7.26 (1 H, t, J 
= 7.90 Hz), 6.97 (2 H, d, J = 8.57 Hz), 6.44 (1 H, d, J = 5.41 Hz), 3.38-3.43 (6 H, m), 
2.74 (4 H, m), 2.70 (2 H, t, J = 5.45 Hz), 2.01 (2 H, apparent p, J = 5.60 Hz). 
 





13C NMR δ (ppm)(CHCl3-d): 153.1, 152.0, 150.4, 145.4, 127.7 (q, JF = 30.6 Hz, C-CF3), 
126.6, 124.8, 122.4, 121.1 (q, JF = 32.9 Hz, C-CF3), 119.7, 114.7, 114.7, 99.1, 58.5, 53.3, 
48.2, 44.2, 23.7.   
 
MS (ESI): m/z 483.1976 M + H (calculated 483.1978). 
 
















3-(8-(trifluoromethyl)quinolin-4-ylamino)propyl methanesulfonate (1.29 g, 3.70 mmol), 
N-(p-methoxyphenyl)piperazine dihydrochloride (1.04 g, 3.92 mmol), and potassium 
carbonate (1.29 g, 11.5 mmol) were heated at reflux in anhydrous acetonitrile (25 mL) for 
5 days, whereupon TLC indicated that reaction was complete. The solvent was removed 
by evaporation under reduced pressure with warming, and the residue was partitioned 
between water (35 mL) and dichloromethane (30 mL).  After separation, the aqueous 
layer was extracted with further dichloromethane (3 x 10 mL), and the pooled organic 
layers were rinsed with brine (10 mL), then dried over magnesium sulfate and evaporated 
under reduced pressure with warming.  The residue was purified by column 
chromatography on basic alumina, eluting with 3:2 hexanes:ethyl acetate, followed by 
recrystallization from ethyl acetate to give the desired product as a cream-colored solid 
(0.42 g, 26%, mp = 123-125°C, Rf = 0.7 (basic alumina, 95/5 EA/MeOH v/v)). 
 
1H NMR δ (ppm)(CHCl3-d): 8.67 (1 H, d, J = 5.36 Hz), 8.13 (1 H, d, J = 8.45 Hz), 7.93 
(1 H, d, J = 7.28 Hz), 7.60 (1 H, t, J = 4.08 Hz), 7.28 (1 H, t, J = 7.86 Hz), 6.95-6.96 (2 H, 
m), 6.88-6.91 (2 H, m), 6.43 (1 H, d, J = 5.41 Hz), 3.81 (3 H, s), 3.42 (2 H, td, J = 5.84, 
4.10 Hz), 3.24 (4 H, m), 2.76 (4 H, m), 2.71 (2 H, t, J = 5.29 Hz), 2.00 (2 H, apparent p, J 
= 5.47 Hz). 
 





13C NMR δ (ppm)(CHCl3-d): 154.2, 152.0, 150.6, 145.5, 145.4, 127.5, 125.3, 122.4, 
119.8, 118.3, 114.6, 99.0, 58.8, 55.6, 53.8, 50.9, 44.5, 23.5, 23.5. 
 
MS (ESI): m/z 445.22102 M + H (calculated 445.22097) 
 















4-chloro-2,8-bis(trifluoromethyl)quinoline (0.96 g, 3.2 mmol, purchased from Oakwood 
Chemical Company) and 3-amino-1-propanol (2.0 mL, 2.6 mmol) were allowed to heat at 
70°C for 1.5 hours, followed by heating at 100ºC for 1 hour.  TLC then indicated that 
reaction was complete.  The hot reaction mixture was partitioned between water (50 mL) 
and ethyl acetate (15 mL, then 3 x 10 mL).  The pooled organic layers were dried 
(MgSO4) and evaporated under reduced pressure with warming to yield the desired 
product as a creamy white solid (0.97 g, 91%, mp = 130.5-131.2°C). 
 
1H NMR δ (ppm)(DMSO-d6): 8.63 (1 H, d, J = 8.57 Hz), 8.15 (1 H, d, J = 7.30 Hz), 8.00 
(1 H, t, J = 5.41 Hz), 7.68 (1 H, t, J = 7.92 Hz), 6.90 (1 H, s), 4.63 (1 H, t, J = 5.07 Hz), 
3.55 (2 H, m), 3.46 (2 H, m), 1.79-1.89 (2 H, m). 
 
















3-(2,8-bis(trifluoromethyl)quinolin-4-ylamino)propanol (1.13 g, 3.71 mmol) and 
triethylamine (0.78 mL, 5.6 mmol) in dry THF (50 mL) were cooled to below 0°C on 
ice/salt. Methanesulfonyl chloride (0.33 mL, 4.3 mmol) was added dropwise.  After 
stirring for 1 hour on ice, TLC indicated that reaction was not complete; therefore, 
additional methanesulfonyl chloride (0.02 mL, 0.3 mmol) was added and stirring was 
continued for a further 15 hours. The reaction mixture was then washed with 100 mL 
saturated sodium bicarbonate.  The aqueous layer was extracted with ethyl acetate (3 x 10 
mL), and the pooled organic layers were rinsed with 10 mL brine, then dried (MgSO4) 
and evaporated under reduced pressure with warming to give the desired product as a 
cream-colored solid (1.19 g, 84%). 
 
1H NMR δ (ppm)(DMSO-d6): 8.63 (1 H, d, J = 8.58 Hz), 8.17 (1 H, d, J = 7.31 Hz), 8.01 
(1 H, t, J = 5.44 Hz), 7.70 (1 H, t, J = 7.92 Hz), 6.93 (1 H, s), 4.36 (2 H, t, J = 6.14 Hz), 
3.52 (2 H, m), 3.20 (3 H, s), 2.09 (2 H, m). 
 












CF3 PL280  
 
3-(2,8-di(trifluoromethyl)quinolin-4-ylamino)propyl methanesulfonate (1.21 g, 2.91 
mmol), 1-benzyhydrylpiperazine (0.79 g, 3.1 mmol), and potassium carbonate (0.62 g, 
4.5 mmol) were heated at reflux in anhydrous acetonitrile (25 mL) for 24 hours.  TLC 
indicated that reaction was complete, and so the solvent was removed under reduced 




water (50 mL).  After separation, the aqueous layer was extracted with further chloroform 
(3 x 15 mL) and the pooled organic layers were dried (MgSO4) and evaporated under 
reduced pressure with warming.  The resulting tan solid was recrystallized from ethyl 
acetate (>20 mL) to provide the desired product as a white, crystalline solid (0.50 g, 30%, 
mp = 227-229°C). 
 
1H NMR δ (ppm)(CHCl3-d): 8.19 (1 H, br t, J = 3.90 Hz), 8.12 (1 H, d, J = 8.51 Hz), 8.04 
(1 H, d, J = 7.27 Hz), 7.41-7.47 (4 H, m), 7.30-7.33 (5 H, m), 7.23 (2 H, m), 6.65 (1 H, s), 
4.40 (1 H, s), 3.40 (2 H, td, J = 5.26, -0.00 Hz), 2.68 (10 H, br s overlaps t, J = 30.53 Hz), 
1.96 (2 H, apparent p, J = 5.26 Hz). 
 
19F NMR δ (ppm)(CHCl3-d): -59.4, -67.6. 
 
13C NMR δ (ppm)(DMSO-d6): 152.4, 143.8, 142.9, 129.0, 128.5, 127.5, 126.8, 124.4, 
119.4, 94.0, 75.2, 55.4, 53.0, 51.5, 41.0, 24.8.   
 





A.3.7: 5- and 7-chloro-2-(trifluoromethyl)-quinolines 
 
5- and 7-chloro-2-trifluoromethyl-4-quinolone (based upon Conrad, 1887; Conrad, 















Ethyl-4,4,4-trifluoroacetoacetate (11.99 g, 65.1 mmol), meta-chloroaniline (8.40 g, 65.8 
mmol), and a catalytic amount of para-toluenesulfonic acid were allowed to heat in 
refluxing benzene (75 mL) in a flask equipped with a Dean and Stark water separator 
topped with stacked Vigreux condensers.  After 18 hours, the solvent was removed by 
evaporation under reduced pressure with warming to provide a pale yellow, viscous 
liquid.  This residue was allowed to heat in Dowtherm A (100 mL) to 230ºC, followed by 
cooling to room temperature; after standing 18 hours, the reaction was heated to 255ºC 
and allowed to remain at this temperature for 45 minutes.  The cooled reaction mixture 
was filtered without dilution, rinsing with Dowtherm A followed by 35-60º petroleum 
æther.  This provided a beige powder that was used without further purification (6.61 g, 





















Phosphorus oxychloride (39 mL, 418 mmol) was cautiously added to 5- and 7-chloro-2-
trifluoromethyl-4-quinolone (6.61 g, 26.7 mmol), and the mixture was heated at 110°C 
for 1 hour.  After cooling, the reaction mixture was gradually poured into ice water with 
vigorous stirring.  After resting, the aqueous mixture was basified with solid caustic 
potash and diluted with water to 1 L.  This mixture was extracted with chloroform (200 
mL, then 3 x 20 mL), dried (MgSO4), and concentrated under reduced pressure with 
warming to yield a dark, olive green liquid.  NMR indicated that this contained both 4,5-
dichloro-2-(trifluoromethyl)quinoline and 4,7-dichloro-2-(trifluoromethyl)quinoline in a 
ratio of approximately 2:3.  Crystallization from hexanes afforded 4,5-dichloro-2-
(trifluoromethyl)quinoline alone.  Concentration of the mother liquor yielded a second 
crop of the same material (1.09 g from both crystallizations, a white, crystalline solid 
having a strong odor similar to that of 4,7-dichloroquinoline, 15%, mp = 95.1-97.1°C).  
The mother liquor was further concentrated to yield an additional three crops of 4,5-
dichloro-2-(trifluoromethyl)quinoline.  The remaining mother liquor was then allowed to 
evaporate to a brown solid.  Upon recrystallizing a portion of this material from hexanes, 
a mixture of regioiosomers crystallized (approximately 1:9 4,7-dichloro:4,5-dichloro-2-
(trifluoromethyl)quinoline).  A similar result was obtained by crystallizing a second 
portion from ethyl acetate.  Automated flash chromatography on alumina, eluting with 
100% hexanes, achieved only partial separation.  The fractions containing more than 50% 
of the 4,7-dichloro-2-(trifluoromethyl)quinoline were further purified by automated flash 
chromatography on silica, eluting with 100% hexanes.  4,7-dichloro-2-
(trifluoromethyl)quinoline was obtained as a viscous, colorless liquid; this was allowed to 
stand for several days.  After disturbance of the liquid by removal of a sample, abrupt 
crystallization occurred.  The product, a white, crystalline solid (2.00 g, 28%, mp = 40.9-
41.9ºC), had a faint odor like that of 4,7-dichloroquinoline, but this was far less 
pronounced than that of the 4,5-dichloro regioisomer.    
 













White crystals, mp = 95.1-97.1°C 
 
Rf = 0.2 (silica, hexanes), 0.3 (basic alumina, hexanes) 
 
1H NMR δ (ppm)(CHCl3-d): 8.17 (1 H, dd, J = 8.43, 1.34 Hz, Q-C6-H or Q-C8-H), 7.83 
(1 H, s, Q-C3-H), 7.78 (1 H, dd, J = 7.58, 1.35 Hz, Q-C8-H or Q-C6-H), 7.71 (1 H, dd, J 
= 8.44, 7.58 Hz, Q-C7-H). 
 
19F NMR δ (ppm)(CHCl3-d): -68.5. 
 
13C NMR δ (ppm)(CHCl3-d): 150.1, 147.81 (q, JF = 23.14 Hz), 144.0, 132.8 (Q-C8?) 
130.8 (Q-C6?), 130.7 (Q-C7), 130.3, 124.6, 120.8 (q, JF = 1.01 Hz), 120.7 (q, JF = 183.82 
Hz?), 118.5, 116.2 (if these last two weak peaks are the center of a quartet, 117.4, J = 
231 Hz). 
 
GC/MS: tR = 5.32 min, 265 M+ (35Cl2), 100 %, 196 (M-CF3)+, 42%, 161 (M-CF3-Cl)+,          
28%, 99 (C8H3)+, 31%, 69 (CF3)+, 11%. 
 
 







White crystals, mp = 40.9-41.9ºC 
 
Rf = 0.3 (silica, hexanes), 0.5 (alumina, hexanes) 
 
1H NMR δ (ppm)(CHCl3-d): 8.26 (1 H, d, J6,8 ~ 1.62 Hz, Q C8-H) 8.24 (1 H, d, J6,5 ~ 
8.71 Hz, Q C5-H), 7.82 (1 H, s, Q C3-H), 7.73 (1 H, dd, J5,6 = 8.99, J8,6 = 2.10 Hz, Q C6-
H).  Note: Peaks at 8.26 and 8.24 overlap.  The estimated peak positions and coupling 
constants are provided. 
 





13C NMR δ (ppm)(CHCl3-d): 148.92 (q, JF = 35.2 Hz), 148.3, 144.8, 138.1, 130.8, 129.5, 
125.6, 125.6, 120.79 (q, JF = 275.73 Hz?), 119.0, 117.5 (q, JF = 2.37 Hz), 115.7 (if the 
last two weak peaks, 117.5 and 119.0, are part of a quartet, J would be 337.11 Hz). 
 
GC/MS: tR = 5.08 min, 265 M+ (35Cl2), 100 %, 196 (M-CF3)+, 42%, 161 (M-CF3-Cl)+,          













4,5-dichloro-2-(trifluoromethyl)quinoline (1.09 g, 4.08 mmol) and 3-amino-1-propanol 
(1.87 mL, 24.4 mmol) were allowed to heat at 80°C for 17 hours, at the end of which 
time TLC indicated that reaction was complete.  The hot reaction mixture was therefore 
poured into 100 mL water, stirring vigorously.  After standing 45 minutes, the resulting 
precipitate was recovered by vacuum filtration.  Upon drying, the product was an off-
white powder (1.13 g, 91%). 
 
1H NMR δ (ppm)(DMSO-d6): 8.01 (1 H, br t, J = 4.87 Hz), 7.87 (1 H, dd, J = 8.28, 1.48 
Hz), 7.66 (1 H, dd, J = 8.25, 7.68 Hz), 7.60 (1 H, dd, J = 7.55, 1.48 Hz), 6.82 (1 H, s), 
4.84 (1 H, t, J = 4.87 Hz), 3.61 (2 H, td, J = 5.74, 4.77 Hz), 3.43 (2 H, td, J = 6.57, 4.92 
Hz), 1.87 (2 H, apparent p, J = 6.13 Hz). 
 













3-(5-chloro-2-trifluoromethylquinolin-4-ylamino)propanol (1.13 g, 3.71 mmol) and 




ice/salt. Methanesulfonyl chloride (0.33 mL, 4.3 mmol) was added dropwise.  After 
stirring for 1 hour on ice, TLC indicated that reaction was not complete; therefore, 
additional methanesulfonyl chloride (0.02 mL, 0.3 mmol) was added and stirring was 
continued for a further 15 hours. The reaction mixture was then washed with 100 mL 
saturated sodium bicarbonate.  The aqueous layer was extracted with ethyl acetate (3 x 10 
mL), and the pooled organic layers were rinsed with 10 mL brine, then dried (MgSO4) 
and evaporated under reduced pressure with warming to give the desired product as a 
cream-colored solid (1.19 g, 84%). 
 
1H NMR δ (ppm)(DMSO-d6): 7.89 (2 H, br t overlaps dd, J = 8.29, 1.65 Hz), 7.68 (1 H, 
dd, J = 8.21, 7.70 Hz), 7.63 (1 H, dd, J = 7.55, 1.51 Hz), 6.88 (1 H, s), 4.37 (2 H, t, J = 


















3-(5-chloro-2-trifluoromethylquinolin-4-ylamino)propyl methanesulfonate (1.19 g, 3.1 
mmol), potassium carbonate (0.64 g, 4.6 mmol), 1-(diphenylmethyl)piperazine (0.82 g, 
3.2 mmol), and a catalytic amount of potassium iodide were allowed to reflux in 
anhydrous acetonitrile (22 mL) for 3 days.  TLC then indicated that reaction was 
complete.  The solvent was removed under reduced pressure with warming, and the 
residue was partitioned between chloroform (30 mL) and water (30 mL).  After 
separation, the aqueous layer was extracted with further chloroform (3 x 7 mL), and the 
pooled organic layers were dried (MgSO4) and evaporated under reduced pressure with 
warming to yield an amber oil.  This material was crystallized from 95% ethanol to yield 
the desired product as a white, crystalline solid (1.06 g, 65%, mp = 146.5-147.9°C). 
 
1H NMR δ (ppm)(CHCl3-d): 7.96 (1 H, dd, J = 8.40, 1.39 Hz), 7.65 (1 H, br t, J = 4.80 
Hz), 7.51 (1 H, t, J = 8.02 Hz), 7.40-7.44 (5 H, m), 7.25-7.26 (solvent signal overlaps m, 
~4 H), 7.13-7.20 (2 H, m), 6.68 (1 H, s), 4.23 (1 H, s), 3.36 (2 H, m), 2.52 (10 H, br s 





19F NMR δ (ppm)(CHCl3-d): 0.5, -68.5. 
 
13C NMR δ (ppm)(CHCl3-d): 152.7, 150.3, 142.7, 130.5, 129.3, 128.7, 128.5, 128.0, 
127.0, 126.9,  121.2, 116.4, 116.2, 95.3, 76.3, 56.1, 53.7, 51.8, 42.2, 25.4.  
 
MS (ESI): m/z 539.22023 M + H (calculated 539.21839) 
 











4,7-dichloro(2-trifluoromethyl)quinoline (1.00 g, 3.8 mmol) and 3-amino-1-propanol 
(1.72 mL, 23 mmol) were combined in a 2-5 mL Biotage microwave vial and heated at 
130°C for 20 minutes, whereupon TLC indicated that reaction was complete.  The 
colorless, semi-solid reaction mixture was stirred vigorously in water (100 mL), followed 
by standing for 30 minutes.  Filtration yielded a white, crystalline solid, which was 
partially recrystallized from a mixture of 95% ethanol and ethyl acetate (~2:3, 30 mL) to 
provide the desired product (a white, crystalline solid, 0.91g, 79% ). 
 
1H NMR δ (ppm)(DMSO-d6): 8.37 (1 H, d, J = 9.07 Hz), 7.93 (1 H, d, J = 2.22 Hz), 7.88 
(1 H, br t, J = 5.39 Hz, NH), 7.61 (1 H, dd, J = 9.00, 2.28 Hz), 6.79 (1 H, s), 4.63 (1 H, t, 
J = 5.06 Hz, OH), 3.55 (2 H, td, J = 6.01, 5.09 Hz), 3.42 (2 H, td, J = 7.06, 5.41 Hz), 1.83 
(2 H, apparent p, J = 6.58 Hz). 
 















3-(7-chloro-2-trifluoromethylquinolin-4-ylamino)propanol (0.50 g, 1.6 mmol) and 
triethylamine (0.33 mL, 2.4 mmol) in dry THF (100 mL) were cooled to 5°C in an ice 
bath. Methanesulfonyl chloride (0.15 mL, 1.9 mmol) was added dropwise.  After stirring 
for 45 minutes on ice, additional methanesulfonyl chloride (0.05 mL, 0.6 mmol) was 
added.  After a further 20 minutes, TLC indicated that reaction was not complete; 
therefore, additional triethylamine (0.20 mL, 1.4 mmol) and methanesulfonyl chloride 
(0.03 mL, 0.4 mmol) were added and stirring was continued for a further 20 minutes. The 
reaction mixture was then washed with 35 mL saturated sodium bicarbonate.  The 
aqueous layer was extracted with ethyl acetate (3 x 10 mL), and the pooled organic layers 
were rinsed with 15 mL brine, then dried (MgSO4) and evaporated under reduced 
pressure with warming to give the desired product as a white solid (0.63 g, ~100%). 
 
1H NMR δ (ppm)(DMSO-d6): 8.38 (1 H, d, J = 9.07 Hz), 7.95 (1 H, d, J = 2.22 Hz), 7.90 
(1 H, t, J = 5.40 Hz), 7.64 (1 H, dd, J = 8.99, 2.26 Hz), 6.82 (1 H, s), 4.36 (2 H, t, J = 6.12 
Hz), 3.48 (2 H, td, J = 7.02, 5.42 Hz), 3.19 (3 H, s), 2.09 (2 H, apparent p, J = 6.54 Hz). 
 















3-(7-chloro-2-trifluoromethylquinolin-4-ylamino)propyl methanesulfonate (0.61 g, 1.6 
mmol), 1-(2-pyridyl)piperazine (0.27 g, 1.6 mmol), potassium carbonate (0.33 g, 2.4 
mmol), and a catalytic  amount of potassium iodide were heated at reflux in anhydrous 
acetonitrile (24 mL) for 18 hours.  The reaction mixture was diluted with water (5 mL), 
and the solvent was removed under reduced pressure with warming.  The residue was 
partitioned between chloroform (35 mL) and water (30 mL).  After separation, the 
aqueous layer was extracted with chloroform (3 x 5 mL), and the pooled organic layers 
were dried over magnesium sulfate and evaporated under reduced pressure with warming.  
The resulting beige solid was recrystallized from 3 mL ethyl acetate to provide the 





1H NMR δ (ppm)(CHCl3-d): 8.24 (1 H, m), 8.03 (1 H, d, J = 2.14 Hz), 7.86 (1 H, t, J = 
4.11 Hz), 7.82 (1 H, d, J = 8.97 Hz), 7.55 (1 H, ddd, J = 8.47, 7.25, 2.02 Hz), 7.29 (1 H, 
dd, J = 8.94, 2.16 Hz), 6.70-6.70 (2 H, m), 6.63 (1 H, s), 3.68-3.69 (4 H, m), 3.47 (2 H, 
td, J = 5.87, 4.08 Hz), 2.70-2.71 (6 H, m), 1.97-2.06 (2 H, m). 
 
13C NMR δ (ppm)(CHCl3-d): 159.3, 152.0, 150.0 (q, JF = 33.1 Hz), 148.2, 148.1, 137.7, 
135.9, 129.4, 126.5, 121.9, 121.8 (q, JF = 275 Hz), 117.4, 113.9, 107.2, 94.1 (q, JF = 2.2 
Hz), 58.8, 53.5, 45.3, 44.6, 23.2. 
 
19F NMR δ (ppm)(CHCl3-d): -68.8. 
 














4,7-dichloro(2-methyl)quinoline (0.50 g, 2.4 mmol, purchased from Sigma Aldrich) and 
3-amino-1-propanol (1.7 mL, 22 mmol) were combined in a 2-5 mL Biotage microwave 
vial and heated at 130°C for 20 minutes, whereupon TLC indicated that reaction was 
complete.  The strawberry-colored reaction mixture was poured into water (100 mL) with 
vigorous stirring, followed by standing for 20 minutes.  Filtration yielded a pale pink 
solid, which was partially recrystallized from a mixture of 95% ethanol and ethyl acetate 
(~1:9, 5 mL) to provide the desired product (a pinkish mauve, granular solid, 0.32g, 
53%). 
 
1H NMR δ (ppm)(DMSO-d6): 8.18 (1 H, d, J = 8.98 Hz), 7.68 (1 H, d, J = 2.24 Hz), 7.36 
(1 H, dd, J = 8.92, 2.27 Hz), 7.14 (1 H, br t, J = 5.30 Hz), 6.38 (1 H, s), 4.58 (1 H, t, J = 
5.06 Hz), 3.54 (2 H, td, J = 6.12, 5.04 Hz), 3.31 (water signal overlaps m, ~2 H), 2.45 (3 














3-(7-chloro-2-methylquinolin-4-ylamino)propanol (0.27 g, 1.1 mmol) and triethylamine 
(0.23 mL, 1.6 mmol) in dry THF (100 mL) were cooled to 5°C in an ice bath. 
Methanesulfonyl chloride (0.10 mL, 1.3 mmol) was added dropwise.  After stirring for 45 
minutes on ice, additional methanesulfonyl chloride (0.03 mL, 0.4 mmol) was added.  
After a further 20 minutes, TLC indicated that reaction was complete.  The reaction 
mixture was washed with 35 mL saturated sodium bicarbonate.  The aqueous layer was 
extracted with ethyl acetate (3 x 10 mL), and the pooled organic layers were dried 
(MgSO4) and evaporated under reduced pressure with warming to give the desired 
product as a white solid (0.24 g, 72%). 
 
1H NMR δ (ppm)(DMSO-d6): 9.17 (1 H, br t, J = 5.52 Hz), 8.52 (1 H, d, J = 9.09 Hz), 
7.91 (1 H, d, J = 2.12 Hz), 7.75 (1 H, dd, J = 9.01, 2.12 Hz), 6.83 (1 H, s), 4.35 (2 H, t, J 
= 6.08 Hz), 3.60 (2 H, td, J = 6.98, 5.48 Hz), 3.21 (3 H, s), 2.65 (3 H, s), 2.12 (2 H, 














3-(7-chloro-2-methylquinolin-4-ylamino)propyl methanesulfonate (0.24 g, 0.73 mmol), 
1-(2-pyridyl)piperazine (0.12 g, 0.73 mmol), potassium carbonate (0.15 g, 1.1 mmol), 
and a catalytic amount of potassium iodide were heated at reflux in anhydrous 
acetonitrile (24 mL) for 18 hours.  After dilution of the reaction mixture with water (5 
mL), the solvent was removed under reduced pressure with warming; the residue was 
partitioned between chloroform (25 mL) and water (20 mL) and separated.  The aqueous 
layer was then extracted with chloroform (3 x 5 mL), and the pooled organic layers were 
dried over magnesium sulfate and evaporated under reduced pressure with warming.  The 




crystallization occurred; vacuum filtration provided the desired product as white crystals 
(0.07 g, 24%). 
 
1H NMR δ (ppm)(CHCl3-d): 8.24 (1 H, m), 7.86 (1 H, d, J = 2.14 Hz), 7.73 (1 H, d, J = 
8.89 Hz), 7.52-7.53 (1 H, m), 7.18 (1 H, dd, J = 8.86, 2.16 Hz), 7.11 (1 H, t, J = 4.21 Hz), 
6.69 (2 H, m), 6.26 (1 H, s), 3.67 (4 H, m), 3.41 (2 H, td, J = 5.96, 4.30 Hz), 2.65-2.70 (6 
H, m), 2.59 (3 H, s), 1.99 (2 H, apparent p, J = 5.64 Hz). 
 
13C NMR δ (ppm)(CHCl3-d): 160.9, 159.4, 150.4, 149.0, 148.1, 137.7, 134.7, 128.0, 
124.1, 121.6, 116.1, 113.8, 107.1, 98.8, 58.6, 53.5, 45.3, 44.2, 25.8, 23.8. 
 















Aniline (10.0 mL, 110 mmol) and diethyl ethoxymethylene malonate (21.99 mL, 110 
mmol) were heated in refluxing Dowtherm A (100 mL) for 30 minutes.  After cooling, 
the reaction mixture was diluted with hexanes (150 mL) and vacuum filtered, rinsing with 
further hexanes (200 mL), followed by acetone (100 mL).  The product was obtained as 
grayish beige, powdery solid (13.87 g, 58%). 
 
1H NMR δ (ppm)(DMSO-d6): 12.31 (1 H, s), 8.54 (1 H, s), 8.16 (1 H, dd, J = 8.09, 1.47 
Hz), 7.71 (1 H, ddd, J = 8.27, 6.99, 1.54 Hz), 7.62 (1 H, dd, J = 8.24, 1.07 Hz), 7.42 (1 H, 

















3-carbethoxy-4-quinolone (13.87 g, 63.9 mmol) was heated at reflux in 200 mL of 10% 
caustic soda for 18 hours.  The hot reaction mixture was poured into 300 mL water, then 
made acidic by the addition of concentrated muriatic acid. After cooling, vacuum 
filtration followed by air-drying provided the desired product as a white solid (12.20 g, 
containing residual water).  This material was used without further drying in the ensuing 
reaction. 
 
1H NMR δ (ppm)(DMSO-d6): 15.36 (1 H, br s), 13.48 (1 H, br s), 8.90 (1 H, s), 8.31 (1 












3-carboxy-4-quinolone from the above reaction (12.06 g, containing residual water) was 
heated in Dowtherm A (100 mL) at reflux for 40 minutes.  After cooling, the reaction 
mixture was diluted with 100 mL hexanes and allowed to sit for 48 hours, followed by 
vacuum filtration, rinsing with further hexanes (300 mL) to provide the product as an off-
white, powdery solid (9.28 g, ~100% from 3-carbethoxy-4-quinolone). 
 
1H NMR δ (ppm)(DMSO-d6): 11.74 (1 H, s), 8.09 (1 H, dd, J = 8.08, 1.47 Hz), 7.89 (1 H, 
dd, J = 7.39, 5.89 Hz), 7.64 (1 H, ddd, J = 8.34, 6.94, 1.56 Hz), 7.54 (1 H, d, J = 8.31 Hz), 














4-quinolone (9.28 g, 63.9 mmol) and phosphorus oxychloride (35 mL, 375 mmol) were 
heated at 110ºC for 2.5 hours, whereupon TLC indicated that the reaction was complete.  
After cooling, the reaction mixture was poured cautiously onto ice, stirring vigorously.  
After resting, the aqueous mixture was made basic to litmus by the addition of solid 
caustic potash (final volume 800 mL).  After cooling, this mixture was extracted with 
chloroform (200 mL followed by 3 x 20 mL), and the pooled organic layers were dried 
(MgSO4) and evaporated under reduced pressure with warming to yield the desired 
product as a viscous, aromatic liquid.  After offgassing for several days, followed by 
storage for several years in a closed vial, this became a beige solid (9.42 g, 90%, mp = 
25.9-28.1°C (lit. 34-35°C; Hauser, 1950)). 
 
1H NMR δ (ppm)(CHCl3-d): 8.80 (1 H, d, J = 4.70 Hz), 8.25 (1 H, dd, J = 8.42, 1.38 Hz), 
8.14 (1 H, dd, J = 8.48, 1.11 Hz), 7.79 (1 H, ddd, J = 8.49, 6.89, 1.44 Hz), 7.66 (1 H, ddd, 











4-chloroquinoline (3.00 g, 18.3 mmol) and 3-amino-1-propanol (8.42 mL, 110 mmol) 
were heated at 70°C in a Carius vessel for 24 hours.  TLC indicated that the reaction was 
not complete.  The temperature was increased to 90°C, and heating was continued for a 
further 6 days.  Reaction was found to be complete by TLC, and the thick reaction 
mixture was poured without cooling into water (300 mL).  After resting for 20 minutes, 
the resulting precipitate was recovered by vacuum filtration to give the desired product as 
a creamy white, sparkling solid (3.60 g, 97%, mp = 148.7-149.7°C).  
 
1H NMR δ (ppm)(DMSO-d6): 8.38 (1 H, d, J = 5.30 Hz), 8.18 (1 H, dd, J = 8.42, 1.33 
Hz), 7.76 (1 H, dd, J = 8.37, 1.26 Hz), 7.59 (1 H, ddd, J = 8.39, 6.77, 1.37 Hz), 7.40 (1 H, 




(1 H, t, J = 5.06 Hz), 3.55 (2 H, m), 3.32-3.36 (water signal overlaps m, ~2 H), 1.83 (2 H, 
apparent p, J = 6.65 Hz). 
 
MS (ESI): m/z 203.11814 M + H (calculated 203.11789) 
 











3-(quinolin-4-ylamino)propanol (0.50 g, 2.5 mol) and triethylamine (0.52 mL, 3.7 mmol) 
were taken up in 50 mL anhydrous dichloromethane and chilled to below 0°C in an ice-
salt bath.  Methanesulfonyl chloride (0.22 mL, 2.8 mmol) was gradually added and 
stirring on ice was continued for 1 hour.  TLC indicated that the reaction was not 
complete.  The flask was sealed and stored at 5°C for 18 hours.  Further triethylamine 
(1.00 mL, 7.2 mmol) and methanesulfonyl chloride (0.12 mL, 1.5 mmol) were then 
added.  After thirty minutes, TLC indicated that reaction was complete. The reaction 
mixture was washed with saturated NaHCO3 (25 mL), and the aqueous layer was then 
extracted with dichloromethane (3 x 7 mL).  The pooled organic layers were dried over 
magnesium sulfate and evaporated under reduced pressure with warming to yield a cream 
colored solid (0.61 g, 88%). 
 
1H NMR δ (ppm)(DMSO-d6): 8.40 (1 H, d, J = 5.31 Hz), 8.20 (1 H, dd, J = 8.45, 1.31 
Hz), 7.78 (1 H, dd, J = 8.39, 1.25 Hz), 7.61 (1 H, ddd, J = 8.42, 6.78, 1.31 Hz), 7.42 (1 H, 
ddd, J = 8.42, 6.78, 1.33 Hz), 7.17 (1 H, br t, J = 5.45 Hz), 6.48 (1 H, d, J = 5.36 Hz), 




















3-(quinolin-4-ylamino)propyl methanesulfonate (1.17 g, 4.2 mmol), PL190 (1.28 g, 4.8 
mmol), potassium carbonate (0.87 g, 6.3 mol), and a catalytic amount of potassium iodide 
were allowed to reflux in anhydrous acetonitrile (50 mL) for 24 hours, at which time TLC 
indicated that reaction was complete.  The reaction mixture was diluted with water (5 
mL) and evaporated under reduced pressure with warming.  The residue was partitioned 
between water (25 mL) and chloroform (50 mL).  After separation, the aqueous layer was 
further extracted with chloroform (3 x 10 mL).  The pooled organic layers were dried 
(MgSO4) and evaporated under reduced pressure with warming.  The resulting thick, 
amber oil was purified by flash chromatography on basic alumina, eluting with a gradient 
of 100% hexanes to 3/2 hexanes/ethyl acetate (v/v).  The resulting tan solid was taken up 
in boiling ethyl acetate (40 mL) and the solution was allowed to evaporate at room 
temperature to 10 mL.  Filtration afforded the desired product as tan crystals (0.63 g, 
34%, mp = 171.0-172.5°C). 
 
1H NMR δ (ppm)(CHCl3-d): 8.73-8.75 (1 H, m), 8.54 (1 H, d, J = 5.26 Hz), 8.51 (1 H, 
m), 8.34 (1 H, m), 8.01 (1 H, d, J = 8.37 Hz), 7.97 (1 H, m), 7.81 (2 H, m), 7.63 (1 H, m), 
7.57 (1 H, t, J = 4.11 Hz), 7.52 (1 H, m), 7.35 (1 H, m), 7.28 (2 H, m) , 6.35 (1 H, d, J = 
5.31 Hz), 3.39 (3 H, m), 3.06 (2 H, m), 2.58 (2 H, td, J = 5.25, 1.20 Hz), 2.13 (2 H, m), 
2.03 (2 H, br m), 1.94 (2 H, apparent p, J = 5.39 Hz), 1.83 (2 H, m). 
 
13C NMR δ (ppm)(CHCl3-d): 165.4, 157.2, 155.8, 151.3, 150.6, 149.7, 148.7, 148.5, 
136.4, 136.0, 129.8, 128.9, 124.2, 124.1, 123.4, 123.0, 122.2, 120.8, 119.2, 98.2, 59.0, 
58.8, 52.2, 44.4, 33.0, 24.0. 
 
MS (ESI): m/z 451.26047 M + H (calculated 451.26102) 
 


















PL374 (0.58 g, 1.3 mol) was dissolved in anhydrous methanol (40 mL).  Sodium 
borohydride (0.18 g, 4.8 mmol) was added and the reaction was allowed to stir at room 
temperature, equipped with a calcium chloride drying tube, for 1 hour.  Additional 
sodium borohydride was then added (0.09 g, 2.4 mmol), and stirring was continued for 14 
hours, whereupon TLC indicated that the reaction was complete.  After removal of the 
solvent under reduced pressure with warming, the residue was stirred with water (35 
mL), then shaken with 35 mL dichloromethane.  After separation, the aqueous layer was 
extracted with further dichloromethane (3 x 10 mL), dried (MgSO4), and evaporated 
under reduced pressure with warming to yield a pale yellow glass.  This material was 
allowed to stand overnight, followed by heating at 50ºC in the vacuum oven for 1 hour to 
remove residual solvent.  The desired product was obtained as a pale yellow glass (0.57 
g, 96%, mp = 93.0-98.8°C). 
 
1H NMR δ (ppm)(CHCl3-d): 8.57-8.57 (2 H, m), 8.52 (1 H, d, J = 5.32 Hz), 7.95 (1 H, 
dd, J = 8.43, 1.20 Hz), 7.89 (1 H, dd, J = 8.40, 1.32 Hz), 7.63-7.63 (3 H, m), 7.46-7.48 (4 
H, m), 7.15 (2 H, ddd, J = 7.46, 4.88, 1.19 Hz), 6.33 (1 H, d, J = 5.37 Hz), 5.25 (1 H, s), 
3.37 (2 H, td, J = 5.88, 4.16 Hz), 2.93-3.05 (2 H, m), 2.54-2.59 (3 H, m), 1.94-1.96 (6 H, 
m), 1.66-1.68 (2 H, m). 
 
13C NMR δ (ppm)(CHCl3-d): 162.1, 151.1, 150.6, 149.1, 148.3, 136.6, 129.6, 128.9, 
124.3, 122.4, 122.2, 120.6, 119.1, 98.1, 66.6, 60.4, 58.6, 52.8, 44.3, 33.0, 24.0. 
 
MS (ESI): m/z 453.27612 M + H (calculated 453.27655) 
 






















para-Toluidine (4.97 g, 46 mmol) and diethyl ethoxymethylene malonate (10.04 g, 46 
mmol) were allowed to heat in Dowtherm A (80 mL) to 255ºC.  After 20 minutes at this 
temperature, the reaction was removed from the heat.  Upon cooling, the reaction mixture 
was diluted with hexanes (100 mL), and the solid was recovered by vacuum filtration, 
rinsing with hexanes (200 mL) followed by acetone (100 mL) to provide the product as a 
















3-carbethoxy-6-methyl-4-quinolone from the above reaction (5.79 g, 25 mmol) was 
allowed to heat in 10% sodium hydroxide (200 mL) at reflux for 46 hours.  After cooling, 
the reaction mixture was diluted to 500 mL and made acidic by the addition of 
concentrated muriatic acid.  The resulting precipitate was recovered by vacuum filtration 
















3-carboxy-6-methyl-4-quinolone from the above reaction (7.25 g, presumed to contain 
residual water) was allowed to heat in Dowtherm A (30 mL) to 255ºC, at which 
temperature it was allowed to remain for 30 minutes.  Upon cooling, the reaction mixture 
was diluted with hexanes and the solid material was recovered by vacuum filtration (an 
off-white powder, 6.00 g).  The product was used without purification in the ensuing 
reaction. 
 
1H NMR δ (ppm)(DMSO-d6): 11.74 (1 H, s), 7.84-7.90 (2 H, m), 7.45-7.47 (2 H, m), 












6-methyl-4-quinolone (6.00 g) and phosphorus oxychloride (40 mL, 430 mmol) were 
allowed to heat at 110ºC for 3 days.  After cooling, the reaction mixture was poured 
cautiously onto ice (final volume 1.4 L).  After resting, the mixture was made basic by 
the addition of solid caustic potash, followed by extraction with chloroform (100 mL, 
followed by 3 x 50 mL).  The pooled chloroform layers were dried over magnesium 
sulfate and evaporated under reduced pressure with warming to provide the desired 
product as a golden brown, crystalline solid (3.90 g, 48% from para-toluidine, mp = 















4-chloro-6-methylquinoline (1.96 g, 11 mmol) and 3-amino-1-propanol (5.07 mL, 66 
mmol) were heated at 90°C for 24 hours in a Carius vessel, at the end of which time TLC 
indicated that the reaction had gone to completion.  The hot reaction mixture was poured 
into water (200 mL), and after standing 1 hour the resulting precipitate was recovered by 
vacuum filtration, followed by air-drying to provide the desired compound (2.20 g, 92%). 
 
1H NMR δ (ppm)(DMSO-d6): 8.32 (1 H, d, J = 5.27 Hz), 7.98 (1 H, s), 7.66 (1 H, d, J = 
8.49 Hz), 7.43 (1 H, dd, J = 8.50, 1.80 Hz), 6.99 (1 H, br t, J = 5.35 Hz), 6.40 (1 H, d, J = 












3-(6-methylquinolin-4-ylamino)propanol (2.20 g, 10 mmol) and triethylamine (1.54 g, 15 
mmol) in dry tetrahydrofuran (100 mL) were cooled to below 0°C on ice/salt, and 
methanesulfonyl chloride (0.91 mL, 12 mmol) was gradually added.  After stirring for 2 
hours on ice, TLC indicated that the reaction had not gone to completion.  Additional 
triethylamine (0.51 g, 5.0 mmol) and methanesulfonyl chloride (0.39 mL, 5.0 mmol) 
were therefore added.  The reaction was sealed and stored at 5ºC for three days, then 
diluted with ethyl acetate (50 mL) and rinsed with saturated sodium bicarbonate (50 mL). 
The aqueous layer was extracted with further ethyl acetate (3 x 10 mL), and the pooled 
organic extracts were washed with brine (10 mL), dried over magnesium sulfate, and 
evaporated under reduced pressure with warming to yield the desired product (2.08 g, 
containing residual ethyl acetate and triethylamine).  This material was used without 

















3-(6-quinolin-4-ylamino)propyl methanesulfonate (1.04 g, 3.5 mmol), 1-
benzhydrylpiperazine (0.88 g, 3.5 mmol), potassium carbonate (0.73 g, 5.3 mmol), and a 
catalytic amount of potassium iodide were heated at reflux in anhydrous acetonitrile (50 
mL) for 4 days, whereupon TLC indicated that reaction was complete.  The solvent was 
removed under reduced pressure with warming, and the residue was partitioned between 
chloroform (50 mL) and water (50 mL), followed by extraction of the aqueous layer with 
additional chloroform (3 x 10 mL).  The pooled organic layers were dried over 
magnesium sulfate and evaporated under reduced pressure with warming.  The solid 
residue was recrystallized from ethyl acetate/95% ethanol (approximately 9:1). The 
desired product was obtained as small, beige crystals (0.34 g, 7.5% from 3-(6-
methylquinolin-4-ylamino)propanol, mp = 168.9-171.3°C). 
 
1H NMR δ (ppm)(CHCl3-d): 8.46 (1 H, d, J = 5.24 Hz), 7.87 (1 H, d, J = 8.55 Hz), 7.70 
(1 H, s), 7.47 (1 H, dd, J = 8.59, 1.82 Hz), 7.44 (4 H, m), 7.28 (4 H, m), 7.18 (2 H, m), 
7.15 (1 H, br t, J = 4.15 Hz), 6.30 (1 H, d, J = 5.29 Hz), 4.31 (1 H, s), 3.35 (2 H, td, J = 
5.43, 0.01 Hz), 2.58-2.69 (13 H, br s overlaps s, 2.69 ppm, and t, 2.61 ppm, J = 5.51 Hz), 
1.92 (2 H, apparent p, J = 5.49 Hz). 
 
13C NMR δ (ppm)(CHCl3-d): 150.4, 150.1, 146.9, 142.8, 133.6, 130.9, 129.6, 128.6, 
127.8, 127.1, 119.5, 119.0, 98.4, 76.7, 58.9, 54.0, 52.2, 44.5, 23.8, 22.1. 
 
MS (ESI): m/z 451.28603 M + H (calculated 451.28562) 
 
HPLC (method A) tR = 10.40 min (89% pure).  (Additional peaks elute at 9.58 minutes, 



















ortho-Toluidine (9.78 mL, 92 mmol) and diethyl ethoxymethylene malonate (18.53 mL, 
92 mmol) were allowed to heat in Dowtherm A (200 mL) to 255ºC.  After 20 minutes at 
this temperature, the reaction was removed from the heat.  Upon cooling, the reaction 
mixture was diluted with hexanes, and the solid was recovered by vacuum filtration, 














3-carbethoxy-8-methyl-4-quinolone from the above reaction (19.53 g) was allowed to 
heat in 10% sodium hydroxide (215 mL) at reflux for 18 hours.  After cooling, the 
reaction mixture was diluted to 600 mL and made acidic by the addition of concentrated 
muriatic acid.  The resulting precipitate was recovered by vacuum filtration and allowed 















3-carboxy-8-methyl-4-quinolone from the above reaction (15.77 g, presumed to contain 
residual water) was allowed to heat in Dowtherm A (175 mL) to 255ºC, at which 
temperature it was allowed to remain for 25 minutes.  Upon cooling, the reaction mixture 
was diluted with hexanes and the solid material was recovered by vacuum filtration (a 
gray powder, 13.82 g).  This material was used without purification in the ensuing 
reaction. 
 
1H NMR δ (ppm)(DMSO-d6): 11.09 (1 H, s), 7.96 (1 H, d, J = 8.12 Hz), 7.82 (1 H, dd, J 
= 7.41, 6.09 Hz), 7.49 (1 H, d, J = 7.13 Hz), 7.21 (1 H, t, J = 7.61 Hz), 6.06 (1 H, d, J = 











8-methyl-4-quinolone (13.82 g, no more than 84 mmol) and phosphorus oxychloride (40 
mL, 430 mmol) were allowed to heat at 110ºC for 3 hours.  After cooling, the reaction 
mixture was poured cautiously onto ice.  After resting, the mixture was made basic by the 
addition of solid caustic potash (end volume 1.4 L), followed by extraction with 
chloroform (100 mL, followed by 3 x 50 mL).  The pooled chloroform layers were dried 
over magnesium sulfate and evaporated under reduced pressure with warming to provide 
a cream-colored solid (12.35 g, 76% from para-toluidine, mp = 96.3-97.2°C (lit. 99°C; 
Burckhalter, 1948). 
 
1H NMR δ (ppm)(CHCl3-d): 8.80 (1 H, d, J = 4.66 Hz), 8.11 (1 H, dd, J = 8.43, 1.35 Hz), 
7.63 (1 H, dd, J = 7.02, 1.33 Hz), 7.54 (1 H, dd, J = 8.40, 7.06 Hz), 7.50 (1 H, d, J = 4.66 














4-chloro-8-methylquinoline (4.00 g, 1.9 mmol) and 3-amino-1-propanol (10.33 mL, 140 
mmol) were heated at 90°C for 9 days in a Carius vessel, at the end of which time TLC 
indicated that the reaction had gone to completion.  The hot reaction mixture was poured 
into water (200 mL), and after standing 1 hour the resulting precipitate was recovered by 
vacuum filtration, followed by air-drying and recrystallization from ethyl acetate to 
provide the desired compound as golden tan crystals (4.58 g, 92%). 
 
1H NMR δ (ppm)(DMSO-d6): 8.41 (1 H, d, J = 5.28 Hz), 8.01 (1 H, d, J = 8.46 Hz), 7.46 
(1 H, d, J = 6.93 Hz), 7.28 (1 H, dd, J = 8.44, 6.93 Hz), 7.05 (1 H, br t, J = 5.39 Hz), 6.46 
(1 H, d, J = 5.34 Hz), 4.59 (1 H, t, J = 5.05 Hz), 3.55 (2 H, m), 3.32 (water signal 











3-(8-methylquinolin-4-ylamino)propanol (1.00 g, 4.6 mmol) and triethylamine (1.0 mL, 
7.2 mmol) in dry tetrahydrofuran (100 mL) were cooled to below 0°C on ice/salt, and 
methanesulfonyl chloride (0.42 mL, 5.4 mmol) was gradually added.  After stirring for 2 
hours on ice, TLC indicated that the reaction had not gone to completion.  Additional 
triethylamine (0.40 mL, 2.9 mmol) and methanesulfonyl chloride (0.20 mL, 2.6 mmol) 
were therefore added.  After stirring for a further hour, TLC indicated that reaction was 
complete.  The reaction mixture was diluted with ethyl acetate (50 mL) and rinsed with 
saturated sodium bicarbonate (50 mL), followed by extraction of the aqueous layer by 




(10 mL), dried over magnesium sulfate, and evaporated under reduced pressure with 
warming to yield an off-white, crystalline solid (1.00 g, 74%). 
 
1H NMR δ (ppm)(DMSO-d6): 8.43 (1 H, d, J = 5.27 Hz), 8.03 (1 H, d, J = 8.49 Hz), 7.48 
(1 H, d, J = 6.92 Hz), 7.30 (1 H, dd, J = 8.45, 6.93 Hz), 7.10 (1 H, br t, J = 5.43 Hz), 6.50 
(1 H, d, J = 5.32 Hz), 4.35 (2 H, t, J = 6.20 Hz), 3.39-3.41 (water signal overlaps m, ~2 














3-(8-quinolin-4-ylamino)propyl methanesulfonate (0.50 g, 1.7 mmol), 1-
benzyhydrylpiperazine (0.44 g, 1.7 mmol), potassium carbonate (0.35 g, 2.5 mmol), and a 
catalytic amount of potassium iodide were heated at reflux in anhydrous acetonitrile (50 
mL) for 24 hours, whereupon TLC indicated that reaction was complete.  The solvent 
was removed under reduced pressure with warming, and the residue was partitioned 
between chloroform (50 mL) and water (50 mL), followed by extraction of the aqueous 
layer with additional chloroform (3 x 10 mL).  The pooled organic layers were dried over 
magnesium sulfate and evaporated under reduced pressure with warming.  The resulting 
amber oil was crystallized from ethyl acetate (initially taken up in 20 mL, then allowed to 
evaporate to 10 mL at room temperature).  The desired product was obtained as glittering, 
colorless crystals (0.55 g, 72%, mp = 154.3-156.0°C). 
 
1H NMR δ (ppm)(CHCl3-d): 8.56 (1 H, d, J = 5.26 Hz), 7.76 (1 H, d, J = 8.44 Hz), 7.50 
(1 H, d, J = 6.98 Hz), 7.42-7.47 (4 H, m), 7.26-7.34 (5 H, m), 7.18-7.26 (3 H, m), 6.34 (1 
H, d, J = 5.31 Hz), 4.33 (1 H, s), 3.35 (2 H, td, J = 5.87, 4.20 Hz), 2.77 (3 H, s), 2.53-2.62 
(10 H, br s overlaps t, J = 5.84 Hz), 1.92 (2 H, apparent p, J = 5.55 Hz). 
 
13C NMR δ (ppm)(CHCl3-d): 150.8, 150.0, 147.4, 142.4, 137.2, 129.1, 128.5, 128.0, 
127.0, 123.6, 118.8, 118.8, 98.2, 76.5, 58.7, 53.9, 51.9, 44.4, 23.7, 18.9. 
 
 
MS (ESI): m/z 451.28600 M + H (calculated 451.28562) 
 
















3-(8-quinolin-4-ylamino)propyl methanesulfonate (0.50 g, 1.7 mmol), N-(2-
pyridyl)piperazine (0.32 g, 1.9 mmol), potassium carbonate (0.35 g, 2.5 mmol), and a 
catalytic amount of potassium iodide were heated at reflux in anhydrous acetonitrile (50 
mL) for 5 days.  TLC then indicated that reaction was complete. The reaction mixture 
was diluted with water (5 mL) followed by evaporation of the solvent under reduced 
pressure with heating, and the residue was partitioned between chloroform (50 mL) and 
water (50 mL), followed by extraction of the aqueous layer with additional chloroform (3 
x 10 mL).  The pooled organic layers were dried over magnesium sulfate and evaporated 
under reduced pressure with warming.  The residue was taken up in boiling ethyl acetate 
(30 mL) and allowed to evaporate gradually to 10 mL at room temperature.  Vacuum 
filtration afforded the desired product as large, colorless crystals (0.37 g, 60%, mp = 
175.5-177.5°C). 
 
1H NMR δ (ppm)(CHCl3-d): 8.59 (1 H, d, J = 5.26 Hz), 8.23-8.23 (1 H, m), 7.73 (1 H, d, 
J = 8.44 Hz), 7.52 (1 H, ddd, J = 8.54, 7.16, 2.02 Hz), 7.44 (1 H, d, J = 6.98 Hz), 7.20 (1 
H, dd, J = 8.40, 6.97 Hz), 7.05 (1 H, t, J = 4.29 Hz), 6.66-6.67 (2 H, m), 6.39 (1 H, d, J = 
5.30 Hz), 3.68 (4 H, m), 3.41 (2 H, td, J = 6.01, 4.37 Hz), 2.75 (3 H, s), 2.65-2.66 (6 H, 
m), 1.99 (2 H, apparent p, J = 5.75 Hz). 
 
13C NMR δ (ppm)(CHCl3-d): 159.5, 150.7, 150.0, 148.1, 147.5, 137.6, 137.3, 129.2, 
123.9, 118.8, 118.2, 113.6, 107.1, 98.4, 58.6, 53.5, 45.3, 44.1, 24.0, 18.9. 
 
MS (ESI): m/z 362.23440 M + H (calculated 362.23392) 
 
















para-Anisidine (12.32 g, 100 mmol), diethyl ethoxymethylene malonate (21.68 g, 100 
mmol), and Dowtherm A (100 mL) were heated to reflux, at which temperature the 
reaction was allowed to remain for 30 minutes.  Upon cooling, the reaction mixture was 
diluted with hexanes and vacuum filtered, rinsing with further hexanes, followed by 













3-carboxy-6-methoxy-4-quinolone (15.08 g, 61 mmol) was heated for 5 hours in 
refluxing 10% caustic soda (250 mL).  The hot reaction mixture was poured into 300 mL 
water and made acidic by the addition of concentrated muriatic acid.  After standing 20 
hours, vacuum filtration afforded 3-carboxy-6-methoxy-4-quinolone as a white, powdery 
solid (13.30 g, ~100%).   
 
1H NMR δ (ppm)(DMSO-d6): 15.55 (1 H, s), 13.43 (1 H, s), 8.83 (1 H, s), 7.80 (1 H, d, J 
















3-carbethoxy-6-methoxy-4-quinolone (13.30 g, 61 mmol) was heated in 100 mL 
refluxing Dowtherm A for 40 minutes. Upon cooling, the reaction mixture was diluted 
with 100 mL hexanes and vacuum filtered, rinsing with additional hexanes followed by 












6-methoxy-4-quinolone (10.30 g, 59 mmol) was heated in phosphorus oxychloride (40 
mL, 43 mmol) at 110°C for 2.5 hours.  After cooling, the dark reaction mixture was 
poured gradually onto ice with vigorous stirring.  After standing overnight, the mixture 
was made basic by the gradual addition of solid caustic potash.  The resulting aqueous 
mixture was extracted with chloroform (150 mL, followed by 5 x 20 mL), and the pooled 
organic layers were dried (MgSO4) and evaporated under reduced pressure with warming 
to yield a dark brown, crystalline solid with a pronounced odor of Dowtherm A.  This 
was taken up in boiling hexanes and decanted from an insoluble black residue, which was 
twice rinsed with boiling hexanes; the pooled hexanes were returned to a boil and 
concentrated to 50 mL.  Upon cooling, the product was recovered as gleaming, pale 















6-methoxy-4-chloroquinoline (2.94 g, 15 mmol) and 3-amino-1-propanol (6.97 mL, 91 
mmol) were heated at 80°C in a Carius vessel for 48 hours.  TLC indicated that the 
reaction was not complete.  The temperature was increased to 120°C and heating was 
continued for one hour, following which the reaction was poured without cooling into 
water (100 mL), stirring well.  An oil separated.  After standing 24 hours, the resulting 
mixture was extracted with dichloromethane (200 mL).  The dichloromethane layer was 
washed with water (3 x 20 mL).  After drying over MgSO4 and evaporation under 
reduced pressure with warming, the resulting yellow oil was taken up in boiling ethyl 
acetate and allowed to evaporate slowly at room temperature for several days.  Filtration 
afforded the desired product as tan crystals (0.42 g, 12%, mp = 140.2-141.6°C). 
 
1H NMR δ (ppm)(DMSO-d6): 8.26 (1 H, d, J = 5.25 Hz), 7.69 (1 H, d, J = 9.11 Hz), 7.54 
(1 H, d, J = 2.76 Hz), 7.24 (1 H, dd, J = 9.11, 2.71 Hz), 6.97 (1 H, t, J = 5.43 Hz), 6.41 (1 
H, d, J = 5.32 Hz), 4.60 (1 H, t, J = 5.03 Hz), 3.88 (3 H, s), 3.56 (2 H, q, J = 5.61 Hz), 
3.34 (water overlaps m, ~2 H), 1.83 (2 H, apparent p, J = 6.73 Hz). 
 
1H NMR δ (ppm)(CHCl3-d): 8.43 (1 H, d, J = 5.25 Hz), 7.89 (1 H, d, J = 9.17 Hz), 7.26 
(solvent signal may overlap s, ~1 H), 6.94 (1 H, d, J = 2.71 Hz), 6.39 (1 H, d, J = 5.28 
Hz), 5.59 (1 H, s), 3.96 (2 H, t, J = 5.50 Hz), 3.89 (3 H, s), 3.48 (2 H, td, J = 6.26, 4.93 
Hz), 2.05 (2 H, apparent p, J = 5.84 Hz).  
 
Note: No further compounds were successfully made from this material.  For the 3-
(quinolin-4-ylamino)propanol compounds containing a methoxy substituent, the 
mesylation reaction that had been used successfully with other compounds of this type 
did not work well.   After many attempts using various solvents, temperatures, and 
repeated additions of methanesulfonyl chloride and triethylamine, it was discovered that 
the optimal method was to work up the partially complete reaction and use the crude 
mixture in the next step.  The unreacted  3-(quinolin-4-ylamino)propanol could then be 
removed by chromatography.  Reversed chloroquine type compounds were made from the 
7- and 8-methoxy substituted 3-(quinolin-4-ylamino)propanol using this method, but time 




















meta-Anisidine (9.05 g, 74 mmol), diethyl ethoxymethylene malonate (14.73 mL, 74 
mmol), and 75 mL Dowtherm A were heated to 255ºC.  After remaining at this 
temperature for 25 minutes, the reaction was removed from the heat.  Upon cooling, the 
reaction mixture was filtered, rinsing with 3 small portions of Dowtherm A, followed by 
hexanes and finally, acetone. This afforded the desired product as a tan, powdery solid, 
with no trace of the 5-methoxy regioisomer (10.57 g, 58%).  The absence of the 5-
methoxy regioisomer in the product of this reaction has been reported previously (Lauer, 
1946). 
 
1H NMR δ (ppm)(DMSO-d6): 12.10 (1 H, s), 8.48 (1 H, s), 8.05 (1 H, dd, J = 8.13, 1.66 















3-carbethoxy-7-methoxy-4-quinolone (10.57g, 43 mmol) in 20% caustic soda (250 mL) 
was heated at 80ºC for 18 hours, followed by 1 hour at reflux.  Upon cooling to room 
temperature, the reaction mixture was poured into water (300 mL) and acidified by the 
addition of concentrated muriatic acid.  After cooling, the resulting white solid was 
recovered by vacuum filtration, followed by air-drying.  This material was used without 















3-carboxy-7-methoxy-4-quinolone (containing residual water) was heated for 25 minutes 
at 255ºC in Dowtherm A.  Upon cooling, the reaction mixture was diluted with hexanes 
(100 mL) and vacuum filtered, rinsing with further hexanes; the resulting solid was then 
allowed to reflux in hexanes (100 mL) for 1 hour.  Filtration afforded the desired product 
as a beige solid (7.56 g).  
 
1H NMR δ (ppm)(DMSO-d6): 11.60 (1 H, s), 7.98 (1 H, d, J = 8.82 Hz), 7.80 (1 H, t, J = 











7-methoxy-4-quinolone (7.56 g, 43 mmol) was heated at 100°C for 2.5 hours in 
phosphorus oxychloride (50 mL, 540 mmol).  TLC then indicated that reaction was 
complete.  After cooling, the reaction mixture was poured gradually onto ice with 
vigorous stirring.  After standing, the mixture was basified by the gradual addition of 
50% caustic soda.  The resulting aqueous mixture was diluted to 800 mL with water and 
divided into three portions, each of which was extracted with chloroform (100 mL, 
followed by 5 x 20 mL).  The pooled organic layers from all three extractions were dried 
(MgSO4) and evaporated under reduced pressure with warming to yield the desired 
product as a beige solid (6.58 g, 79%, mp = 87.1-88.4°C (lit. 82-83°C; Lauer, 1946)). 
 
1H NMR δ (ppm)(CHCl3-d): 8.70 (1 H, d, J = 4.79 Hz), 8.12 (1 H, d, J = 9.22 Hz), 7.43 
(1 H, d, J = 2.55 Hz), 7.35 (1 H, d, J = 4.79 Hz), 7.29 (1 H, dd, J = 9.23, 2.55 Hz), 3.97 (3 














7-methoxy-4-chloroquinoline (3.25 g, 16.8 mmol) and 3-amino-1-propanol (7.73 mL, 
101 mmol) were heated at 90°C in a Carius tube for 3 days.  TLC indicated that no 
quinoline starting material remained, and the reaction was therefore poured without 
cooling into 200 mL water, stirring well.  After standing for 30 minutes, the resulting 
precipitate was isolated by vacuum filtration as a beige, sparkling solid.  This material 
was recrystallized from 9:1 ethyl acetate:ethanol (20 mL) to give a beige, crystalline solid 
(3.32 g, 85%, mp =147.8-148.5°C). 
 
1H NMR δ (ppm)(CHCl3-d): 8.45 (1 H, d, J = 5.39 Hz), 7.59 (1 H, d, J = 9.17 Hz), 7.30 
(1 H, d, J = 2.64 Hz), 7.03 (1 H, dd, J = 9.15, 2.64 Hz), 6.31 (1 H, d, J = 5.41 Hz), 5.74 (1 











3-(7-methoxyquinolin-4-ylamino)propanol (0.60 g, 2.6 mmol) was dissolved in 
anhydrous THF (100 mL), and triethylamine (0.36 mL, 2.6 mmol) was added.  The 
solution was cooled to 10 ºC, and methanesulfonyl chloride (0.20 mL, 2.6 mmol) was 
added dropwise.  After 50 minutes, the reaction mixture was diluted with ethyl acetate 
(50 mL) and washed with saturated sodium bicarbonate (100 mL).  The aqueous layer 
was extracted with additional ethyl acetate (3 x 10 mL), and the pooled organic layers 
were rinsed with brine (15 mL), dried over magnesium sulfate, and evaporated under 
reduced pressure with warming to yield a yellow oil.  This material contained 
approximately 50% unreacted starting material by NMR, but was used without further 















NMeO PL391  
 
3-(7-methoxyquinolin-4-ylamino)propyl methanesulfonate (impure product from the 
above reaction, containing no more than 2.6 mmol quinoline material), 1-(2-
pyridyl)piperazine (0.44 g, 2.7 mmol), potassium carbonate (0.53 g, 3.9 mmol), and a 
catalytic amount of potassium iodide were heated at reflux in acetonitrile (22 mL) for 18 
hours. The solvent was then removed under reduced pressure with warming, and the 
residue was partitioned between chloroform (40 mL) and water (40 mL).  After 
separation, the aqueous layer was extracted with additional chloroform (3 x 10 mL), and 
the pooled organic layers were rinsed with brine (10 mL) and dried over magnesium 
sulfate.  The dried solution was partially evaporated under reduced pressure with 
warming, followed by adsorption onto basic alumina.  Flash chromatography was 
performed with basic alumina as the stationary phase, eluting with a gradient of 100% 
hexanes to 35/65 hexanes/ethyl acetate (v/v) over 55 minutes; NMR indicated that the 
product-containing fractions also contained unreacted 1-(2-pyridyl)piperazine.  Flash 
chromatography on basic alumina was repeated, with a gradient of 100% hexanes to 80% 
hexanes/20% ethyl acetate (v/v) over 45 minutes, increasing the proportion of ethyl 
acetate to 60% over an additional 55 minutes.  The desired product was then obtained as 
a colorless solid (0.06 g, 6% yield from 3-(7-methoxyquinolin-4-ylamino)propanol, mp = 
114.5-118.6°C, Rf = 0.4 (basic alumina, 9/1 MeOH/EtOAc v/v)). 
 
1H NMR δ (ppm)(CHCl3-d): 8.46 (1 H, d, J = 5.37 Hz), 8.23-8.23 (1 H, m), 7.75 (1 H, d, 
J = 9.17 Hz), 7.52-7.52 (1 H, m), 7.30 (1 H, d, J = 2.62 Hz), 7.01 (1 H, br t, J = 4.36 Hz), 
6.94 (1 H, dd, J = 9.13, 2.63 Hz), 6.67-6.68 (2 H, m), 6.29 (1 H, d, J = 5.41 Hz), 3.89 (3 
H, s), 3.67 (4 H, m), 3.42 (2 H, td, J = 6.01, 4.36 Hz), 2.64-2.70 (6 H, m), 1.96-2.01 (2 H, 
m). 
 
13C NMR δ (ppm)(CHCl3-d): 160.2, 159.4, 151.6, 150.5, 150.3, 148.1, 137.7, 121.6, 
116.6, 113.7, 113.5, 108.2, 107.1, 97.4, 58.5, 55.4, 53.5, 45.4, 44.0, 24.0. 
 
MS (ESI): m/z 378.22946 M + H (calculated 378.22884) 
 


















ortho-Anisidine (11.30 g, 92 mmol), diethyl ethoxymethylene malonate (18.40 mL, 92 
mmol), and 75 mL Dowtherm A were heated to reflux.  After remaining at reflux for 20 
minutes, the reaction was removed from the heat.  Upon cooling, the reaction mixture 
was diluted with 75 mL hexanes and filtered, rinsing with further hexanes (200 mL) and 
acetone (75 mL).  This afforded the desired product as a creamy white, crystalline solid. 
 
1H NMR δ (ppm)(DMSO-d6): 11.92 (1 H, s), 8.34 (1 H, s), 7.71 (1 H, dd, J = 7.36, 2.00 
Hz), 7.31-7.37 (2 H, m), 4.21 (2 H, q, J = 7.10 Hz), 4.01 (3 H, s), 1.27 (3 H, t, J = 7.09 













The above product was heated for 72 hours in 250 mL refluxing 10% caustic soda.  The 
hot reaction mixture was poured into 300 mL water and acidified by the addition of 
concentrated hydrochloric acid.  Vacuum filtration of the cooled solution afforded the 
















3-carboxy-8-methoxy-4-quinolone (11.17 g, 51 mmol) was heated for 1 hour in refluxing 
Dowtherm A.  Upon cooling, a small sample was analyzed by NMR and it was 
determined that the reaction was no more than 50% complete.  The reaction was therefore 
heated again at reflux for an additional hour.  Upon cooling, dilution with 100 mL 
hexanes, and resting for 20 hours, the reaction mixture became a tarry, intractable block.  
Samples analyzed by NMR and GC/MS indicated that reaction was complete.  The 
reaction mixture was briefly heated to 130°C, whereupon it became liquid; after cooling 
to 50°C, this was poured into a beaker and diluted with additional hexanes.  After again 











8-methoxy-4-quinolone (8.68 g, 50 mmol) was heated at 95°C for 20 hours in phosphorus 
oxychloride (30 mL, 320 mmol).  After cooling, the dark reaction mixture was poured 
gradually onto ice with vigorous stirring.  The mixture was allowed to stand for 30 
minutes, then made basic by the gradual addition of solid caustic potash.  The resulting 
aqueous mixture was extracted with chloroform (150 mL, followed by 5 x 20 mL), and 
the pooled organic layers were dried (MgSO4) and evaporated under reduced pressure 
with warming to yield a golden brown liquid that crystallized upon standing.  This was 
recrystallized from a mixture of ethyl acetate and hexanes to yield a tan, crystalline solid 
(3.30 g, 0.0170 mol, 34%, mp = 81.8-82.6°C (lit. 79-80°C; Lauer, 1946)). 
 
1H NMR δ (ppm)(CHCl3-d): 8.79 (1 H, d, J = 4.65 Hz), 7.81 (1 H, dd, J = 8.54, 1.13 Hz), 
7.57 (1 H, dd, J = 8.53, 7.80 Hz), 7.53 (1 H, d, J = 4.65 Hz), 7.12 (1 H, dd, J = 7.80, 1.08 















8-methoxy-4-chloroquinoline (2.03 g, 0.0105 mol) and 3-amino-1-propanol (4.81 mL, 
0.0629 mol) were heated at 90°C in a Carius tube for 48 hours.  TLC indicated that no 
quinoline starting material remained, and the reaction was therefore poured without 
cooling into 150 mL water, stirring well.  After standing for 24 hours, the resulting 
precipitate was isolated by vacuum filtration (water rinsing) as a dull yellow, sparkling 
solid; partial recrystallization from 95% ethyl acetate, 5% ethanol yielded the product as 
a sparkling, ochre solid (1.95 g, 78%, mp = 170.6-171.4°C). 
 
1H NMR δ (ppm)(CHCl3-d): 8.57 (1 H, d, J = 5.25 Hz), 7.30-7.33 (2 H, m), 7.27 (solvent 
signal may overlap compound signal, ~1 H, see DMSO-d6 spectrum below), 6.99 (1 H, d, 
J = 7.48 Hz), 6.46 (1 H, d, J = 5.27 Hz), 5.73 (1 H, t, J = 4.73 Hz), 4.05 (3 H, s), 3.94 (2 
H, t, J = 5.51 Hz), 3.47 (2 H, td, J = 6.29, 4.82 Hz), 2.04 (2 H, apparent p, J = 5.87 Hz). 
 
1H NMR δ (ppm)(DMSO-d6): 8.33 (1 H, d, J = 5.25 Hz), 7.69 (1 H, d, J = 8.52 Hz), 7.31 
(1 H, t, J = 8.10 Hz), 7.05 (1 H, d, J = 7.70 Hz), 7.00 (1 H, t, J = 5.37 Hz), 6.47 (1 H, d, J 
= 5.31 Hz), 4.61 (1 H, s), 3.89 (3 H, s), 3.55 (2 H, m), 3.30-3.32 (water signal overlaps m, 
~2 H), 1.82 (2 H, apparent p, J = 6.64 Hz). 
 
MS (ESI): m/z 233.12869 M + H (calculated 233.12845) 
 














3-(8-methoxyquinolin-4-ylamino)propanol (0.40 g, 1.7 mmol) was dissolved in 
anhydrous THF (100 mL) by warming at 50ºC in a flask equipped with a Vigreux 
condenser and calcium chloride drying tube.  This solution was allowed to cool to room 
temperature, whereupon precipitation was observed.  Triethylamine (0.24 mL, 1.7 mmol) 
was added, followed by cooling to 7ºC and addition of methanesulfonyl chloride (0.13 
mL, 1.7 mmol).  After 1 hour, TLC indicated that starting material remained; further 
methanesulfonyl chloride was added (0.40 mL, 5.1 mmol).  After a further hour, the 
reaction was sealed and stored at 8ºC for 18 hours.  The reaction mixture was then 
washed with saturated sodium bicarbonate (75 mL), followed by extraction of the 
aqueous layer with ethyl acetate (3 x 15 mL).  The pooled organic layers were rinsed with 
brine (20 mL), dried over magnesium sulfate, and evaporated under reduced pressure 
with warming to yield a yellow oil.  This contained approximately 20% unreacted starting 
material by NMR.  This material was used without further purification in the ensuing 













OMe PL390  
 
3-(8-methoxyquinolin-4-ylamino)propyl methanesulfonate (impure product from the 
above reaction, containing no more than 1.7 mmol quinoline material), 1-(2-
pyridyl)piperazine (0.30 g, 1.8 mmol), potassium carbonate (0.36 g, 2.6 mmol), and a 
catalytic amount of potassium iodide were heated at reflux in acetonitrile (25 mL) for 18 
hours. The solvent was then removed under reduced pressure with warming, and an 
attempt was made to partition the residue between ethyl acetate (50 mL) and water (30 
mL).  Some material remained undissolved and was left in the reaction flask.  After 
separation of the ethyl acetate and water layers, the aqueous layer was extracted with 
additional ethyl acetate (3 x 5 mL), and the pooled organic layers were rinsed with brine 
(10 mL) and allowed to dry over magnesium sulfate for 18 hours.  The undissolved 
material from ethyl acetate extraction was now taken up in chloroform (30 mL), in which 
it was fully soluble, and washed with the aqueous layer from the ethyl acetate extraction.  
After separation, the aqueous layer was extracted with additional chloroform (3 x 5 mL), 
and the chloroform layer was dried over magnesium sulfate.  The combined dried organic 




adsorbed onto 3.5 g basic alumina.  Flash chromatography on basic alumina was 
performed, eluting with a gradient of 100% hexanes to 100% ethyl acetate over 35 
minutes; the product-containing fractions from this also contained 1-(2-
pyridyl)piperazine.  Flash chromatography on basic alumina was repeated, with a 
gradient of 100% hexanes to 70% ethyl acetate over 30 minutes, to provide the desired 
product as a pale yellow solid (0.13 g, 20% yield from 3-(8-methoxyquinolin-4-
ylamino)propanol, mp = 147.9-150.0°C, Rf = 0.4 (Alumina, 9/1 MeOH/EtOAc v/v)). 
 
 
1H NMR δ (ppm)(CHCl3-d): 8.57 (1 H, d, J = 5.25 Hz), 8.23-8.23 (1 H, m), 7.52 (1 H, 
ddd, J = 8.58, 7.13, 2.01 Hz), 7.42 (1 H, d, J = 8.48 Hz), 7.22 (1 H, t, J = 8.10 Hz), 7.06 
(1 H, br t, J = 4.30 Hz), 6.94 (1 H, d, J = 7.72 Hz), 6.67-6.68 (2 H, m), 6.41 (1 H, d, J = 
5.29 Hz), 4.04 (3 H, s), 3.69 (4 H, m), 3.42 (2 H, td, J = 5.95, 4.26 Hz), 2.66-2.67 (6 H, 
m), 2.00 (2 H, apparent p, J = 5.68 Hz). 
 
13C NMR δ (ppm)(CHCl3-d): 159.4, 155.9, 150.3, 150.1, 148.1, 140.4, 137.6, 124.2, 
119.9, 113.6, 112.0, 107.1, 107.1, 99.1, 58.6, 55.9, 53.5, 45.3, 44.1, 23.9. 
 
MS (ESI): m/z 378.22947 M + H (calculated 378.22884) 
 




A.7: Bis-quinolines  
 
A.7.1: Bis-quinoline starting materials not described above 
 
 










PL16 was synthesized without deviating from methods previously described by Steven 







PL29: 3-(7-chloroquinolin-4-ylamino)propyl methanesulfonate (Burgess, 2006; 










PL16 (1.88 g, 7.9 mmol), triethylamine (1.66 mL, 1.2 mmol), and anhydrous THF (100 
mL) were cooled below 0°C on ice/salt, and methanesulfonyl chloride (0.71 mL, 9.1 
mmol) was added dropwise.  After stirring for an hour on ice, TLC indicated that reaction 
was not complete, and therefore additional triethylamine (0.83 mL, 6.0 mmol) and 
methanesulfonyl chloride (0.36 mL, 6.0 mmol) were added.  After a further hour, TLC 
indicated that no quinoline starting material remained.  The reaction mixture was diluted 
with ethyl acetate (30 mL) and shaken with saturated sodium bicarbonate (30 mL), 
followed by extraction of the aqueous layer with additional ethyl acetate (3 x 10 mL).  
The pooled ethyl acetate layers were washed with brine (10 mL), dried over magnesium 
sulfate, and evaporated under reduced pressure with warming to obtain a pale yellow, 
fluffy solid; this was allowed to stand overnight (1.86 g, 81%).   
 
1H NMR δ (ppm)(CHCl3-d): 8.53 (1 H, d, J = 5.37 Hz, ClQ-C2-H), 7.95 (1 H, d, J = 2.18 
Hz, ClQ-C8-H), 7.72 (1 H, d, J = 8.97 Hz, ClQ-C5-H), 7.38 (1 H, dd, J = 8.94, 2.18 Hz, 
ClQ-C6-H), 6.42 (1 H, d, J = 5.40 Hz, ClQ-C3-H), 5.55 (1 H, br t, J = 5.75 Hz, NH), 4.42 
(2 H, t, J = 5.66 Hz, CH2O), 3.58 (2 H, td, J = 6.34, 5.77 Hz, CH2N), 3.06 (3 H, s, CH3), 
2.18 (2 H, apparent p, J = 5.98 Hz, CH2). 
 
1H NMR δ (ppm)(DMSO-d6): 8.42 (1 H, d, J = 5.39 Hz, ClQ-C2-H), 8.26 (1 H, d, J = 
9.04 Hz, ClQ-C5-H), 7.79 (1 H, d, J = 2.24 Hz, ClQ-C8-H), 7.47 (1 H, dd, J = 8.98, 2.27 
Hz, ClQ-C6-H), 7.33 (1 H, br t, J = 5.39 Hz, Q-C4-NH), 6.51 (1 H, d, J = 5.45 Hz, ClQ-
C3-H), 4.35 (1 H, t, J = 6.19 Hz, HNCH2CH2CH2), 3.30-3.45 (water signal overlaps m, 




















4,7-dichloroquinoline (2.00 g, 10 mmol), ethyl-4-amino-1-piperidine carboxylate (1.83 g, 
11 mmol), and phenol (5.70 g, 61 mol) were heated at 90ºC in a sealed Carius vessel for 
48 hours.  TLC indicated that unreacted 4,7-dichloroquinoline remained, and therefore 
additional ethyl-4-amino-1-piperidine carboxylate (0.39 g, 2.3 mmol) was added.  The 
vessel was again sealed and heated for a further 7 days, whereupon TLC indicated that no 
unreacted quinoline remained.  The reaction mixture was diluted with chloroform (50 
mL) and rinsed with 10% caustic soda (6 x 10 mL), followed by further rinsing with 
brine (3 x 10 mL).  The organic layer was dried over MgSO4 and concentrated under 
reduced pressure with warming to yield a thick, tan liquid containing some solid material.  
After standing 14 hours, this was taken up in boiling solvent (50/50 ethyl acetate/95% 
ethanol (v/v)) and allowed to cool and concentrate at room temperature.  The crystals 
thus formed were recovered from the remaining 5 mL of solvent by vacuum filtration 
(off-white crystals, 1.18 g, 35%, mp =  197.3-198.8°C). 
1H NMR δ (ppm)(CHCl3-d): 8.54 (1 H, d, J = 5.36 Hz), 7.96 (1 H, d, J = 2.17 Hz), 7.66 
(1 H, d, J = 8.98 Hz), 7.37 (1 H, dd, J = 8.94, 2.19 Hz), 6.46 (1 H, d, J = 5.41 Hz), 4.92 (1 
H, br d, J = 7.25 Hz), 4.16 (4 H, br s overlaps q, J = 7.13 Hz), 3.68-3.69 (1 H, m), 3.04 (2 
H, td, J = 12.56, 2.82 Hz), 2.11-2.20 (2 H, m), 1.51-1.53 (2 H, m), 1.28 (3 H, t, J = 7.11 
Hz).  
MS (ESI): m/z 334.13271 M + H (calculated 334.13168) 
 














PL376 (2.45 g, 7.3 mmol, the product of multiple reactions), 95% ethanol (100 mL), and 
10% caustic soda (4.5 mL) were allowed to heat, stirring, at reflux for 4 days.  As TLC 
indicated that the reaction was not complete, 50% caustic soda (0.5 mL) was added, and 
reflux was continued for a further 3 days. TLC then indicated that the reaction was 
complete.  The reaction solvent was removed under reduced pressure with warming, and 
the residue was partitioned between chloroform (20 mL) and water (50 mL).  After 
separation, the aqueous layer was extracted with additional chloroform (3 x 10 mL), and 
the pooled organic layers were dried (MgSO4) and concentrated under reduced pressure 
with warming to yield a tan solid (1.05 g).  A cream colored solid was also isolated from 
the aqueous layer by vacuum filtration (1.04 g).  NMR indicated that both solids obtained 
were the desired product (total yield 1.83 g, 96%, mp = 166.3-169.4°C).  
 
1H NMR δ (ppm)(CHCl3-d): 8.52 (1 H, d, J = 5.39 Hz), 7.96 (1 H, d, J = 2.18 Hz), 7.65 
(1 H, d, J = 8.96 Hz), 7.37 (1 H, dd, J = 8.93, 2.19 Hz), 6.45 (1 H, d, J = 5.42 Hz), 4.87 (1 
H, br d, J = 7.35 Hz), 3.61-3.62 (1 H, m), 3.19 (2 H, dt, J = 12.68, 3.70 Hz), 2.79-2.81 (2 
H, m), 2.15-2.19 (2 H, m), 1.50-1.50 (2 H, m). 
 
MS (ESI): m/z 262.11116 M + H (calculated 262.11065) 
 
HPLC (method A) tR = 2.74 min (94% pure). 
 












4-chloroquinoline (2.00 g, 12 mmol), ethyl-4-amino-1-piperidine carboxylate (3.16 g, 32 
mmol), and phenol (6.90 g, 73 mmol) were heated at 90ºC in a sealed Carius vessel for 6 
days.  TLC indicated that unreacted 4,7-dichloroquinoline remained, and therefore 
additional ethyl-4-amino-1-piperidine carboxylate (1.00 g, 1.0 mmol) was added.  The 
vessel was again sealed and heated for a further 2 days, whereupon TLC indicated that 
reaction was complete.  The reaction mixture was diluted with chloroform (50 mL) and 
rinsed with 10% caustic soda (5 x 10 mL), followed by further rinsing with water (3 x 10 
mL).  The organic layer was dried over MgSO4 and concentrated under reduced pressure 
with warming to yield a brown semisolid.  This material was taken up in boiling ethyl 
acetate (70 mL) and allowed to cool and concentrate at room temperature (to 
approximately 15 mL).  Vacuum filtration provided the desired product as a sparkling, 
tan, crystalline solid (2.81 g, 77%, mp = 209-210°C). 
1H NMR δ (ppm)(CHCl3-d): 8.56 (1 H, d, J = 5.31 Hz), 7.99 (1 H, dd, J = 8.44, 1.20 Hz), 
7.72 (1 H, dd, J = 8.43, 1.25 Hz), 7.64 (1 H, ddd, J = 8.46, 6.85, 1.31 Hz), 7.44 (1 H, ddd, 
J = 8.40, 6.86, 1.29 Hz), 6.47 (1 H, d, J = 5.35 Hz), 4.90 (1 H, br d, J = 7.27 Hz), 4.17 (4 
H, br s overlaps q, J = 7.11 Hz), 3.70-3.71 (1 H, m), 3.06 (2 H, td, J = 12.54, 2.73 Hz), 
2.13-2.22 (2 H, m), 1.52-1.54 (2 H, m), 1.28 (3 H, t, J = 7.11 Hz). 
MS (ESI): m/z 300.17103 M + H (calculated 300.17065) 
 









PL377 (1.77 g, 5.9 mmol), 95% ethanol (40 mL), and 50% caustic soda (2.00 mL) were 
allowed to heat, stirring, at reflux for 20 hours.  As TLC indicated that the reaction was 
not complete, additional 50% caustic soda (1.0 mL) was added, and reflux was continued 
for a further 3 days. TLC then indicated that the reaction was complete.  The reaction 
solvent was removed under reduced pressure with warming, and the residue was 
partitioned between chloroform (25 mL) and water (25 mL).  After separation, the 
aqueous layer was extracted with additional chloroform (3 x 7 mL).  The pooled organic 




concentration under reduced pressure with warming to yield the desired product as a 
white powder (0.65 g, 48%, mp = 112.5-124°C). 
1H NMR δ (ppm)(CHCl3-d): 8.55 (1 H, d, J = 5.33 Hz), 7.98 (1 H, dd, J = 8.45, 1.22 Hz), 
7.72 (1 H, dd, J = 8.42, 1.26 Hz), 7.63 (1 H, ddd, J = 8.45, 6.85, 1.33 Hz), 7.43 (1 H, ddd, 
J = 8.39, 6.85, 1.30 Hz), 6.47 (1 H, d, J = 5.36 Hz), 4.89 (1 H, br d, J = 7.32 Hz), 3.63-
3.64 (1 H, m), 3.19 (2 H, dt, J = 12.67, 3.73 Hz), 2.80-2.81 (2 H, m), 2.17-2.20 (2 H, m), 
1.44-1.56 (2 H, m). 
 
MS (ESI): m/z 228.14987 M + H (calculated 228.14952) 
 
HPLC (method A) tR = 1.58 min (78% pure).  (Second largest peak elutes at 2.00 
minutes, 17%.) 
 








4-chloro-(8-trifluoromethyl)quinoline (1.50 g, 6.5 mmol), ethyl-4-amino-1-piperidine 
carboxylate (1.02 g, 5.9 mmol), and phenol (3.04 g, 32 mol) were heated at 82ºC in a 
sealed Carius vessel for 20 hours.  Additional ethyl-4-amino-1-piperidine carboxylate 
(0.20 g, 1.2 mmol) was added.  The vessel was again sealed and heated for a further 3 
days at 100ºC. whereupon TLC indicated that no unreacted quinoline remained.  The 
reaction mixture was diluted with chloroform (25 mL) and rinsed with 10% caustic soda 
(5 x 10 mL), followed by further rinsing with brine (2 x 10 mL).  The organic layer was 
dried over MgSO4 and concentrated under reduced pressure with warming to yield a 
thick, brown oil.  This was diluted with dichloromethane and adsorbed onto silica, then 
purified by flash chromatography on silica, eluting with a gradient of 100% hexanes to 
100% ethyl acetate.  The desired product was obtained as a beige solid (0.63 g, 27%, Rf = 
0.4 (silica, ethyl acetate)).  The quinoline phenolate was also isolated from 
chromatography (a sparkling, white, crystalline solid, 0.94 g, 50%, mp = 175.4-181.0ºC, 
Rf = 0.7 (silica, ethyl acetate)). 
 





MS (ESI): m/z 368.15863 M + H (calculated 368.15804) 
 











PL332 (0.62 g, 1.7 mmol), 95% ethanol (50 mL), and 10% caustic soda (4 mL) were 
allowed to heat, stirring, at reflux for 18 hours.  As TLC indicated that the reaction was 
not complete, 50% caustic soda (0.5 mL) was added, and reflux was continued for a 
further 24 hours. TLC then indicated that the reaction was complete.  After removal of 
the solvent under reduced pressure with warming, the residue was partitioned between 
chloroform (25 mL) and water (50 mL).  After separation, the aqueous layer was 
extracted with additional chloroform (3 x 10 mL), and the pooled organic layers were 
dried (MgSO4) and concentrated under reduced pressure with warming to provide a pale 
yellow solid (0.18 g, 36%, mp = 186.8-189.6°C). 
 
1H NMR δ (ppm)(CHCl3-d): 8.69 (1 H, d, J = 5.40 Hz), 8.00 (1 H, d, J = 7.33 Hz), 7.93 
(1 H, d, J = 8.49 Hz), 7.46 (1 H, dd, J = 8.45, 7.34 Hz), 6.56 (1 H, d, J = 5.43 Hz), 4.93 (1 
H, br d, J = 7.30 Hz), 3.63-3.64 (1 H, m), 3.20 (2 H, m), 2.79-2.80 (2 H, m), 2.16-2.20 (2 
H, m), 1.49-1.50 (2 H, m).  
 
MS (ESI): m/z 296.13763 M + H (calculated 296.13691) 
 
HPLC (method A) tR = 2.85 min (92% pure).  (Additional peaks elute at 1.81 minutes, 





























PL29 (1.20 g, 3.8 mmol), PL294 (1.05 g, 4.0 mmol), potassium carbonate (5.7 mmol, 
0.79 g), a catalytic amount of potassium iodide, and 50 mL anhydrous acetonitrile were 
allowed to heat for 48 hours at reflux, whereupon TLC indicated that the reaction was 
complete.  The reaction mixture was diluted with water (50 mL) and vacuum filtered.  
The filtrate was concentrated under reduced pressure with warming, and the reaction 
mixture was partitioned between 50/50 dichloromethane/chloroform (20 mL) and 10 mL 
saturated sodium bicarbonate, followed by further extraction with three 10 mL portions 
dichloromethane.  The pooled organic layers were dried over anhydrous magnesium 
sulfate and concentrated under reduced pressure.  The resulting solid was combined with 
the material filtered from the reaction mixture and recrystallized from 95% ethanol, 
which afforded the desired product as a pale yellow, crystalline solid (1.30 g). 
Concentration of the mother liquor yielded a further crop of crystals (0.06 g, total yield 
71%, mp = 224-227°C (dec)).  
 
1H NMR δ (ppm)(CHCl3-d): 8.56 (1 H, d, J = 5.33 Hz, Q1-C2-H), 8.53 (1 H, d, J = 5.33 
Hz, Q2-C2-H), 7.99 (1 H, d, J = 2.16 Hz, Q1-C5-H), 7.97 (1 H, d, J = 2.14 Hz, Q2-C5-H), 
7.78 (1 H, d, J = 8.90 Hz, Q2-C8-H), 7.71 (1 H, d, J = 8.95 Hz, Q1-C8-H), 7.43 (1 H, dd, J 
= 8.89, 2.18 Hz, Q1-C6-H), 7.35 (1 H, dd, J = 8.87, 2.16 Hz, Q2-C6-H), 7.02 (1 H, br t, J 
= 4.27 Hz, Q1-C4-NH), 6.47 (1 H, d, J = 5.37 Hz, Q1-C3-H), 6.38 (1 H, d, J = 5.37 Hz, 
Q2-C3-H), 4.92 (1 H, br d, J = 6.78 Hz, Q2-NH), 3.65 (1 H, m, Pip-CH), 3.42 (2 H, td, 
JCH2 = 6.01, JNH = 4.35 Hz, Q1-NHCH2CH2CH2), 3.06 (2 H, m, piperidine-CH x 2 
adjacent to alkyl chain), 2.67 (2 H, t, JCH2 = 5.64 Hz, Q1-NHCH2CH2CH2), 2.33 (2 H, m, 
piperidine-CH x 2 adjacent to alkyl chain), 2.28 (2 H, m, piperidine CH x 2 adjacent to 
CH-NH-Q2), 1.99 (2 H, apparent p, JCH2x2 = 5.75 Hz, Q1-NHCH2CH2CH2), 1.75 (water 
signal overlaps m, ~2 H, piperidine CH x 2 adjacent to CH-NH-Q2). 
 
13C NMR δ (ppm)(CHCl3-d): 152.3 (Q1-C2), 152.0 (Q2-C2), 150.4, 149.4, 149.3, 148.4, 




120.7 (Q1-C8), 117.5, 117.2, 99.6 (Q1-C3), 98.8 (Q2-C3), 58.2 (Q1-NHCH2CH2CH2), 
52.5 (piperidine-C adjacent to alkyl chain), 49.5 (piperidine-CH-NH- Q2), 43.9 (Q1-
NHCH2CH2CH2), 32.0 (piperidine-C adjacent to CH-NH-Q2), 24.4 (Q1-NHCH2CH2CH2). 
 
Note: Q1 and Q2 denote respectively the quinoline ring system on the left and that on the 
right of the structure as shown above.  For the quinoline ring system numbering, see 
Figure 5, Chapter 1.  Spectra are provided in Appendix C (Example spectra: PL241). 
 
MS (ESI): m/z 480.17456 M + H (calculated 480.17163) 
 















3-(quinolin-4-ylamino)propyl methanesulfonate (0.61 g, 2.2 mol), PL294 (0.60 g, 2.3 
mol), K2CO3 (0.45 g, 3.3 mol), and a catalytic amount of potassium iodide were heated 
for 5 days in refluxing acetonitrile (25 mL), at which point TLC indicated that reaction 
was complete.  The solvent was removed under reduced pressure with warming (after 
dilution with 10 mL water), and the residue was combined with water (50 mL) and 
chloroform (80 mL).  A large amount of material remained undissolved and was 
recovered by vacuum filtration (a cream colored solid).  The filtrate was placed in a 
separatory funnel and separated, and the aqueous layer was extracted thrice with 10 mL 
portions of chloroform.  The pooled chloroform layers were dried (MgSO4) and 
evaporated under reduced pressure with warming to yield a cloudy, pale yellow oil, 0.07 
g.  NMR indicated that the oil from extraction contained both product and starting 
material, whereas the solid recovered from filtration was the desired product with very 
little impurity.  The latter was taken up in excess boiling 95% ethanol, and allowed to 
evaporate gradually (at room temperature) to ~10 mL.  Filtration afforded the desired 
product as beige crystals (0.79 g, 81%, mp = 240-250°C (dec)). 
 
1H NMR δ (ppm)(DMSO-d6): 8.37-8.41 (3 H, m), 8.19 (1 H, d, J = 8.41 Hz), 7.77-7.79 (2 
H, m), 7.61 (1 H, ddd, J = 8.43, 6.73, 1.31 Hz), 7.42-7.46 (2 H, m), 7.30 (1 H, br t, J = 




Hz), 3.50-3.53 (1 H, m), 3.41-3.46 (2 H, m), 2.95-2.98 (2 H, m), 2.46 (2 H, t, J = 6.79 
Hz), 2.06-2.12 (2 H, m), 1.98-2.01 (2 H, m), 1.85 (2 H, apparent p, J = 6.68 Hz), 1.63-
1.72 (2 H, m). 
 
13C NMR δ (ppm)(DMSO-d6): 151.8, 150.6, 149.9, 149.2, 149.1, 148.2, 133.3, 128.9, 
128.6, 127.4, 124.4, 123.8, 123.7, 121.5, 118.8, 117.4, 99.1, 98.0, 55.7, 52.3, 49.6, 40.9, 
30.9, 25.3. 
 
MS (ESI): m/z 446.21096 M + H (calculated 446.21060) 
 















PL29 (0.83 g, 0.00264 mol), PL378 (0.63 g, 0.00277 mol), K2CO3 (0.55 g, 0.00396 mol), 
and a catalytic amount of potassium iodide were heated for 24 hours in refluxing 
acetonitrile (50 mL), at which point TLC indicated that reaction was complete.  After 
dilution with 10 mL water, the solvent was removed under reduced pressure with 
warming.  The residue was combined with additional water (30 mL in total) and 
chloroform (30mL).  A cream colored solid remained undissolved, and was recovered by 
vacuum filtration.  The filtrate was separated into two layers, and the aqueous layer was 
extracted with chloroform (3 x 10 mL).  The pooled organic layers were dried (MgSO4) 
and evaporated under reduced pressure with warming to yield a waxy, yellow solid.  This 
solid, together with the solid obtained from filtration, was dissolved in excess boiling 
95% ethanol (100 mL) and allowed to evaporate gradually (at room temperature) to ~ 10 
mL.  Filtration afforded the desired product as a beige solid (0.66 g, 56%, mp = 224-
228°C). 
 
1H NMR δ (ppm)(CHCl3-d): 8.58 (1 H, d, J = 5.28 Hz), 8.54 (1 H, d, J = 5.34 Hz), 8.01 
(1 H, dd, J = 8.43, 1.20 Hz), 7.97 (1 H, d, J = 2.14 Hz), 7.77-7.81 (2 H, m), 7.68 (1 H, 
ddd, J = 8.46, 6.84, 1.29 Hz), 7.51 (1 H, ddd, J = 8.38, 6.84, 1.30 Hz), 7.37 (1 H, dd, J = 
8.88, 2.16 Hz), 7.11 (1 H, br t, J = 4.14 Hz), 6.49 (1 H, d, J = 5.35 Hz), 6.38 (1 H, d, J = 




Hz), 3.05-3.08 (2 H, m), 2.68 (2 H, t, J = 5.61 Hz), 2.30 (4 H, d, J = 14.10 Hz), 1.99 (2 H, 
apparent p, J = 5.72 Hz), 1.72-1.81 (2 H, m). 
 
13C NMR δ (ppm)(DMSO-d6): 151.9, 150.7, 150.1, 149.1, 149.0, 148.5, 133.3, 129.0, 
128.7, 127.5, 124.1, 124.0, 123.6, 122.0, 118.9, 117.4, 98.6, 98.6, 55.7, 52.4, 49.5, 41.0, 
31.1, 25.3. 
 
MS (ESI): m/z 446.21091 M + H (calculated 446.21060) 
 












3-(quinolin-4-ylamino)propyl methanesulfonate (0.76 g, 0.00271 mol), PL378 (0.65 g, 
0.00285 mol), K2CO3 (0.56 g, 0.00407 mol), and a catalytic amount of potassium iodide 
were heated for 24 hours in refluxing acetonitrile (40 mL), at which point TLC indicated 
that reaction was complete.  After dilution with 10 mL water, the acetonitrile was 
removed by evaporation under reduced pressure with warming, and the residue was 
combined with dichloromethane (30 mL) and water (30 mL).  An undissolved tan solid 
was removed by filtration, rinsing with dichloromethane and water.  The 
dichloromethane and water layers were separated, and the aqueous layer was extracted 
with dichloromethane (3 x 10 mL), followed by drying of the pooled organic layers 
(MgSO4) and evaporation under reduced pressure with warming to yield a yellow solid.  
NMR indicated that this was primarily starting material, whereas the solid from filtration 
was primarily the desired product.  The latter was dissolved in excess boiling 95% 
ethanol, and allowed to evaporate gradually (at room temperature) to approximately 10 
mL.  Filtration afforded a tan solid (0.80 g).  This material was further purified by 
automated flash chromatography on alumina, eluting with a gradient of 100% hexanes to 
100% ethyl acetate.  The desired product was obtained as a white solid (0.29 g, 26%, mp 





1H NMR δ (ppm)(CHCl3-d): 8.56-8.58 (2 H, m), 7.95-8.04 (2 H, m), 7.87 (1 H, dd, J = 
8.38, 1.31 Hz), 7.77 (1 H, dd, J = 8.41, 1.25 Hz), 7.65-7.65 (2 H, m), 7.49-7.49 (1 H, m), 
7.41-7.41 (1 H, m), 7.01 (1 H, br t, J = 4.25 Hz), 6.49 (1 H, d, J = 5.35 Hz), 6.40 (1 H, d, 
J = 5.34 Hz), 4.95 (1 H, br d, J = 6.91 Hz), 3.66-3.66 (1 H, m), 3.43 (2 H, td, J = 6.02, 
4.41 Hz), 3.04-3.10 (2 H, m), 2.66-2.68 (2 H, m), 2.22-2.35 (4 H, m), 1.99 (2 H, p, J = 
5.79 Hz), 1.77-1.80 (2 H, m). 
 
MS (ESI): m/z 412.25005 M + H (calculated 412.24957) 
 









CF3 ClPL335  
3-(8-(trifluoromethyl)quinolin-4-ylamino)propyl methanesulfonate (0.50 g, 0.00144 
mol), PL294 (0.39 g, 0.00151 mol), K2CO3 (0.20 g, 0.00145 mol), and a catalytic amount 
of potassium iodide were heated for 5 days in refluxing acetonitrile (40 mL), at which 
point TLC indicated that reaction was complete.  After dilution with 10 mL water, the 
acetonitrile was removed by evaporation under reduced pressure with warming, and the 
residue was combined with chloroform (30 mL) and water (30 mL).  A beige solid 
remained undissolved and was removed by filtration, rinsing with chloroform and water.  
After separation of the chloroform and water layers, the aqueous layer was extracted with 
chloroform (3 x 7 mL), and the pooled organic layers were dried (MgSO4) and 
evaporated under reduced pressure with warming to yield a pale yellow, waxy solid, 
0.09g.  NMR indicated that the solid from filtration was primarily the desired product.  
This was dissolved in excess boiling 95% ethanol, and allowed to evaporate gradually (at 
room temperature) to approximately 10 mL.  Filtration afforded the desired product as 
sparkling, beige crystals (0.52 g, 70%, mp = 225-233°C (dec)). 
1H NMR δ (ppm)(DMSO-d6): 8.49-8.52 (2 H, m), 8.36-8.39 (2 H, m), 8.03 (1 H, d, J = 
7.29 Hz), 7.78 (1 H, d, J = 2.25 Hz), 7.53-7.57 (2 H, m), 7.45 (1 H, dd, J = 9.01, 2.28 
Hz), 6.98 (1 H, br d, J = 7.48 Hz), 6.62 (1 H, d, J = 5.50 Hz), 6.55 (1 H, d, J = 5.57 Hz), 
3.44-3.53 (1 H, m), 3.35-3.36 (2 H, m), 2.96 (2 H, m), 2.44-2.47 (2 H, m), 2.09 (2 H, t, J 




13C NMR δ (ppm)(DMSO-d6): 151.9, 151.4, 150.3, 149.3, 149.1, 144.9, 133.4, 127.4, 
126.7, 124.4, 123.9, 123.1, 122.4, 119.4, 117.5, 99.1, 99.0, 55.6, 52.3, 49.6, 40.9, 31.0, 
25.3. 
MS (ESI): m/z 514.19866 M + H (calculated 514.19798) 
 













3-(8-(trifluoromethyl)quinolin-4-ylamino)propyl methanesulfonate (0.66 g, 1.9 mmol), 
PL368 (0.59 g, 2.0 mmol), K2CO3 (0.39 g, 2.8 mmol), and a catalytic amount of 
potassium iodide were heated for 27 hours in refluxing acetonitrile (50 mL), at which 
point TLC indicated that reaction was complete; however, heating at reflux was 
continued for an additional 18 hours. The solvent was removed by evaporation under 
reduced pressure with warming, and the resulting golden brown solid was combined with 
chloroform (30 mL) and water (30 mL).  A large amount of solid material remained 
undissolved and was removed by filtration, rinsing with chloroform and water (a white 
solid).  This material was dissolved in excess boiling ethyl acetate, followed by gradual 
evaporation at room temperature to induce crystallization.  The fine, off-white crystals 
thus obtained proved to be the desired product (0.20 g, 19%). 
 
1H NMR δ (ppm)(CHCl3-d): 8.72 (1 H, d, J = 5.35 Hz), 8.69 (1 H, d, J = 5.35 Hz), 8.03-
8.07 (2 H, m), 7.96-8.00 (2 H, m), 7.52 (1 H, dd, J = 8.41, 7.33 Hz), 7.42 (1 H, dd, J = 
8.41, 7.27 Hz), 7.09 (1 H, br t, J = 4.24 Hz), 6.58 (1 H, d, J = 5.41 Hz), 6.48 (1 H, d, J = 
5.41 Hz), 4.97 (1 H, br d, J = 6.71 Hz), 3.66-3.69 (1 H, m), 3.44 (2 H, td, J = 6.01, 4.30 
Hz), 3.06-3.09 (2 H, m), 2.68 (2 H, t, J = 5.59 Hz), 2.28-2.33 (4 H, m), 1.99-2.05 (2 H, 
apparent p, J = 5.69 Hz), 1.73-1.82 (2 H, m). 
 
13C NMR δ (ppm)(CHCl3-d): 152.0, 151.7, 150.4, 148.3, 145.6, 145.5, 127.7, 127.4, 





MS (ESI): m/z 548.22434 M + H (calculated 548.22519) 
 














PL29 (0.59 g, 1.9 mmol), PL368 (0.58 g, 2.0 mmol), K2CO3 (0.39 g, 2.8 mmol), and a 
catalytic amount of potassium iodide were heated for 24 hours in refluxing acetonitrile 
(50 mL), at which point TLC indicated that reaction was complete. The solvent was 
removed by evaporation under reduced pressure with warming, and the resulting ochre 
solid was combined with chloroform (30 mL) and water (30 mL).  A large amount of 
solid material remained undissolved and was removed by filtration, rinsing with 
chloroform and water.  The chloroform and water layers of the filtrate were separated, 
and the aqueous layer was extracted with chloroform (3 x 10 mL), dried (MgSO4), and 
evaporated under reduced pressure with warming.  This material was combined with the 
insoluble material from extraction (above), and taken up in excess boiling 95% ethanol.  
This was allowed to cool and evaporate gradually at room temperature.  The crystals that 
formed were recovered by filtration and further purified by automated flash 
chromatography on basic alumina, eluting with a gradient of 100% hexanes to 100% 
ethyl acetate.  The desired product was obtained as a beige solid (0.38 g, 40%, mp = 205-
207°C, Rf = 0.2 (alumina, EA)). 
 
1H NMR δ (ppm)(CHCl3-d): 8.72 (1 H, d, J = 5.35 Hz), 8.54 (1 H, d, J = 5.35 Hz), 8.04 
(1 H, d, J = 7.31 Hz), 7.99 (1 H, d, J = 8.53 Hz), 7.97 (1 H, d, J = 2.15 Hz), 7.78 (1 H, d, J 
= 8.92 Hz), 7.53 (1 H, dd, J = 8.44, 7.30 Hz), 7.35 (1 H, dd, J = 8.88, 2.17 Hz), 7.03 (1 H, 
br t, J = 4.28 Hz), 6.58 (1 H, d, J = 5.41 Hz), 6.38 (1 H, d, J = 5.39 Hz), 4.98 (1 H, br d, J 
= 6.79 Hz), 3.66-3.68 (1 H, m), 3.43 (2 H, td, J = 5.99, 4.32 Hz), 3.06-3.09 (2 H, m), 2.68 






13C NMR δ (ppm)(DMSO-d6): 151.9, 151.3, 150.1, 149.3, 149.0, 145.0, 133.3, 127.4, 
127.1, 125.8, 124.0, 123.9, 122.1, 119.3, 117.4, 99.5, 98.5, 55.6, 52.3, 49.6, 40.9, 30.9, 
25.3. 
 
MS (ESI): m/z 514.19879 M + H (calculated 514.19798) 
 
HPLC (method A) tR = 6.95 min (>99% pure). 
 
A.7.3: Original method used to synthesize PL241 (for primary method, see page 
316) 
 






























Methyl isobutyl ketone, 125 mL, was allowed to reflux in a round bottom flask equipped 
with a Dean and Stark water separator.  After 30 minutes, sodium carbonate (0.74 g, 7.0 
mmol) and 4-aminopiperidine (0.580 mL, 5.5 mmol) were added and reflux was 
continued for 1 hour, at the end of which time TLC indicated that no more of the amine 
starting material was present.  The reaction was allowed to cool to 85°C, and PL29 (1.45 
g, 4.6 mmol) was added.  After 16 hours had elapsed, TLC indicated that no more PL29 
was present.  The reaction mixture was washed with water (50 mL) to remove sodium 
carbonate, and the solvent was then evaporated under reduced pressure.  The resulting 
amber oil was stirred for 1.5 hours in a mixture of 50 mL isopropanol and 5 mL water, 
and the solvent was then evaporated under reduced pressure.  The resulting liquid was 
partitioned between ethyl acetate (20 mL) and saturated sodium bicarbonate (25 mL), and 
the aqueous layer was extracted with additional ethyl acetate (3 x 10 mL).  During this 
procedure, a yellow oil remained insoluble; NMR indicated that this was pure product.  
After removal of water therefrom by heating under reduced pressure, this material was 



























PL 67 (0.30 g, approximately 0.94 mmol), 4,7-dichloroquinoline (0.59g, 3.00 mmol), and 
1.3 g phenol were heated for 40 hours at 120°C.  The resulting dark brown oil was taken 
up in dichloromethane (20 mL) and washed with 1.0 M caustic soda (6 x 10 mL), 
followed by brine (10 mL).  The organic layer was dried over anhydrous magnesium 
sulfate and evaporated under reduced pressure to yield a brown oil.  This was purified by 
column chromatography on alumina, eluting with ethyl acetate and then with 95/5 ethyl 
acetate/methanol (v/v).  The resulting solid was recrystallized using a Craig tube from 4:1 
ethyl acetate:methanol, which afforded the desired product as a beige solid (0.034g, 7%, 





 APPENDIX B: Tables of antiplasmodial activity and cytotoxicity 
 
Table B1: Ring-modified Reversed Chloroquine type compounds and their in vitro 
activity against P. falciparum malaria 
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PL267 8-CF3 





























Table B2: Comparison of in vitro activity of 6- and 7- substituted compounds 
















IC50 (nM)  












7-Cl PL06 1.9 2.6 11  
6-Cl PL270 3.4 7.9 29 
7-Br PL310 1.2 <2.5 <2.5 
6-Br PL308 <2.5 <2.5 6.8 
7-CF3 PL142 1.5 3.9 5.9 









7-CF3 PL242 2.4 1.3 1.1 
6-CF3 PL279 





7-Cl PL106 3.0 6.0 6.1 
6-Cl PL283 9.2 22 25 
7-Br PL311 2.2 4.4 7.2 
6-Br PL309 8.6 18 30 
7-I PL392 <2.5 <2.5 <2.5 
6-I PL318 2.6 5.2 6 
7-CF3 PL287 2.5 11 8.6 
6-CF3 PL276 7.2 12 23 







7-Cl PL156 1.4 <0.2 <0.2  
6-Cl PL397 - 29 7 
7-CF3 PL315 <2.5 3.8 1.5 







7-Cl PL157 1 <0.2 <0.2  
6-Cl PL382 - - 5.3 
7-CF3 PL277 - - 2.6 




Table B3: Comparison of in vitro activity of chloro-, bromo-, and fluoro- substituted 
















IC50 (nM)  











7-Cl PL06 1.9 2.6 11 
7-Br PL310 





6-F PL285 10 16 23 
6-Cl PL270 3.4 7.9 29 
6-Br PL308 <2.5 <2.5 6.8 





7-Cl PL106 3.0 6.0 6.1 
7-Br PL311 2.2 4.4 7.2 













6-Cl PL283 9.2 22 25 
6-Br PL309 8.6 18 30 






Table B4: Comparison of in vitro activity of chloro-, trifluoromethyl-, and nitro- 





























7-Cl PL06 1.9 2.6 11 
7-CF3 PL142 1.5 3.9 5.9 
6-Cl PL270 3.4 7.9 29 









7-Cl PL69 0.9 2.2 1.8 
7-CF3 PL242 2.4 1.3 1.1 
6-CF3 PL279 





7-Cl PL106 3.0 6.0 6.1 
7-CF3 PL287 2.5 11 8.6 
6-Cl PL283 9.2 22 25 
6-CF3 PL276 7.2 12 23 







7-Cl PL156 1.4 <0.2 <0.2  
7-CF3 PL315 <2.5 3.8 1.5 
6-Cl PL397 - 29 7 







7-Cl PL157 1 <0.2 <0.2 
7-CF3 PL277 - - 2.6 
6-Cl PL382 - - 5.3 







Table B5: Comparison of in vitro activity of chloro-, des-chloro-, methyl, and 












































0.88 5.0 - 
6-Cl PL270 3.4 7.9 29 
6-CH3 PL383 2.5 9 4.5 
8-Cl PL271 66 >250 >250 





7-Cl PL106 3.0 6.0 6.1 
7-OCH3 PL391 21 53 58 
8-Cl PL284 465 >2500 1570 
8-CH3 PL393 350 1825 951 









































CF3 Cl  

















N Cl  










Table B7: In vitro cytotoxicity data against mouse spleen lymphocytes  






































































APPENDIX C: Sample NMR spectra: PL241 
 
The following spectra were run at 600 MHz.  The solvent used was CDCl3, except where 
noted (it was necessary to run an additional 1H spectrum in DMSO-d6 to confirm the 
suspected integration of one peak that was overlapped by the water signal in CDCl3). 
TMS was used as a reference.  The one-dimensional spectra shown here were processed 
using DataChord Spectrum Analyst 4.1.rc39, while the two-dimensional spectra were 












Spectral assignments (see also Appendix A, p. 310): 
 
 
1H NMR δ (ppm)(CHCl3-d): 8.56 (1 H, d, J = 5.33 Hz, Q1-C2-H), 8.53 (1 H, d, J = 5.33 
Hz, Q2-C2-H), 7.99 (1 H, d, J = 2.16 Hz, Q1-C8-H), 7.97 (1 H, d, J = 2.14 Hz, Q2-C8-H), 
7.78 (1 H, d, J = 8.90 Hz, Q2-C5-H), 7.71 (1 H, d, J = 8.95 Hz, Q1-C5-H), 7.43 (1 H, dd, J 
= 8.89, 2.18 Hz, Q1-C6-H), 7.35 (1 H, dd, J = 8.87, 2.16 Hz, Q2-C6-H), 7.02 (1 H, br t, J 
= 4.27 Hz, Q1-C4-NH), 6.47 (1 H, d, J = 5.37 Hz, Q1-C3-H), 6.38 (1 H, d, J = 5.37 Hz, 
Q2-C3-H), 4.92 (1 H, br d, J = 6.78 Hz, Q2-NH), 3.65 (1 H, m, Pip-CH), 3.42 (2 H, td, 
JCH2 = 6.01, JNH = 4.35 Hz, Q1-NHCH2CH2CH2), 3.06 (2 H, m, piperidine-CH x 2 
adjacent to alkyl chain), 2.67 (2 H, t, JCH2 = 5.64 Hz, Q1-NHCH2CH2CH2), 2.33 (2 H, m, 
piperidine-CH x 2 adjacent to alkyl chain), 2.28 (2 H, m, piperidine CH x 2 adjacent to 
CH-NH-Q2), 1.99 (2 H, p, JCH2x2 = 5.75 Hz, Q1-NHCH2CH2CH2), 1.75 (water signal 
overlaps m, ~2 H, piperidine CH x 2 adjacent to CH-NH-Q2). 
 
13C NMR δ (ppm)(CHCl3-d): 152.3 (Q1-C2), 152.0 (Q2-C2), 150.4, 149.4, 149.3, 148.4, 
135.1, 134.7, 129.1 (Q-C8), 129.0 (Q-C8), 125.6 (Q1-C6), 124.8 (Q2-C6), 121.7 (Q2-C5), 
120.7 (Q1-C5), 117.5, 117.2, 99.6 (Q1-C3), 98.8 (Q2-C3), 58.2 (Q1-NHCH2CH2CH2), 
52.5 (piperidine-C adjacent to alkyl chain), 49.5 (piperidine-CH-NH- Q2), 43.9 (Q1-
NHCH2CH2CH2), 32.0 (piperidine-C adjacent to CH-NH-Q2), 24.4 (Q1-NHCH2CH2CH2). 
 
Note: Q1 and Q2 denote the quinoline ring system on the left and right of the figure, 





List of spectra: 
 
Figure C1: 1H NMR spectrum of PL241 in CDCl3, full view. 
Figure C2: 1H NMR spectrum of PL241 in CDCl3, expansion 1 of 3 (aromatic region, 
part 1). 
Figure C3: 1H NMR spectrum of PL241 in CDCl3, expansion 2 of 3 (aromatic region, 
part 2). 
Figure C4: 1H NMR spectrum of PL241 in CDCl3, expansion 3 of 3 (aliphatic region, 
part 1). 
Figure C5: 13C NMR spectrum of PL241 in CDCl3, full view. 
Figure C6: 13C NMR spectrum of PL241 in CDCl3, aliphatic region only. 
Figure C7: COSY spectrum of PL241 in CDCl3. 
Figure C8: HSQC spectrum of PL241 in CDCl3. 
Figure C9: HMBC spectrum of PL241 in CDCl3. 
Figure C10: NOESY spectrum of PL241 in CDCl3. 
Figure C11: 1H NMR spectrum of PL241 in DMSO-d6. 











Figure C1: 1H NMR spectrum of PL241 in CDCl3, with integrals (see figures C2, C3, and C4 for 











































Figure C8: HSQC spectrum of PL241 in CDCl3, showing direct proton to carbon interactions 


















Figure C11: 1H NMR spectrum of PL241 in DMSO-d6, with integrals (see figure C12 for 
expanded aliphatic region).  This spectrum was used to confirm the suspected integration of a 





Figure C12: 1H NMR spectrum of PL241 in DMSO-d6, aliphatic region. 
 
